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3 
ABSTRACT 
Introduction: The clinical benefits of mesenchymal stromal/stem cells (MSC)-based therapies 
for immune disorders and degenerative diseases are based on their ability to modulate the 
immune system and secrete growth factors. However, some essential issues concerning the 
immunosuppressive properties of MSC, such as the differences among MSC derived from 
different tissues and the influence of MSC on the function of specific immune cell 
subpopulations (namely the recently described monocyte subsets, and T cell functional 
compartments) are not well elucidated. 
Aim: Here, we compared the suppressive effect of human MSC derived from bone marrow 
(BM), adipose tissue (AT), and umbilical cord matrix (UCM), on lymphocyte activation, 
proliferation, and mRNA expression of genes with an important role in T cell and NK cell 
function; investigated the influence of human BM-MSC on monocyte and myeloid dendritic cell 
(mDC) activation/maturation, and on cytokine expression by peripheral blood mDC, monocyte 
subpopulations, and the naturally occurring functional compartments of CD4+ and CD8+ T cells, 
as well as on CD4+ and/or CD8+ T cells producing IL-17, IL-9, and IL-6. 
Material and Methods: To investigate the ability of MSC to suppress immune cells, peripheral 
blood mononuclear cells (PBMC) were cultured in the presence or absence of MSC and treated 
with stimulating agents; cell cultures of non-stimulated PBMC, in the presence or absence of 
MSC, were also carried out. To compare the effect of MSC derived from BM, AT, and UCM, 
MSC were co-cultured with PHA-stimulated PBMC; T, B and NK cell activation and proliferation 
were evaluated by flow cytometry; while RT-PCR was used to quantify mRNA expression on 
purified T and NK cells’ activation compartments. To evaluate the effect of BM-MSC on mDC, 
classical, intermediate, and non-classical monocytes, BM-MSC were co-cultured with PBMC 
stimulated with LPS+IFNγ. Cell activation and cytokine production were assessed by flow 
cytometry; and cytokine mRNA expression quantified by RT-PCR in purified monocyte subsets 
and mDC. Co-culture of BM-MSC with PMA+ionomycin-stimulated PBMC was carried out to 
evaluate MSC effect on CD4+ and CD8+ T cell functional compartments: naive, central memory 
(CM), effector memory (EM), and effector. Cytokine expression within each functional 
compartment and the percentage of CD4+ and CD8+ T cells producing IL-17, IL-9, and IL-6 were 
assessed by flow cytometry; cytokine mRNA expression was quantified in purified CD4+ and 
CD8+ T cells by RT-PCR. 
4 
Results: MSC derived from BM, AT, or UCM were able to inhibit CD4+ and CD8+ T cell 
proliferation and activation; BM- and AT-MSC also prevented B cell proliferation and 
activation, and CD56dim and CD56bright NK cell activation. AT-MSC always exerted the strongest 
suppressive action. In turn, UCM-MSC hampered activation of CD56dim NK cells, but had no 
effect on CD56bright NK cell activation, B cell activation or proliferation. Moreover, MSC co-
culture reduced TNF-α and perforin mRNA levels in activated NK cells. In the purified T cell 
activation compartments, we observed increased mRNA levels of FoxP3 and T-bet by PHA-
stimulated T cells in the presence of MSC.  
BM-MSC effectively inhibited TNF-α and CCL4 protein expression in monocytes and mDC, 
without affecting CCR7 and CD83 expression. Of note, BM-MSC-driven inhibition was more 
pronounced for mDC, and the reduction of TNF-α expression was less marked for non-classical 
monocytes. MSC also decreased mRNA levels of IL-1β and IL-6 in classical monocytes, CCL3, 
CCL5, CXCL9, and CXCL10 in classical and non-classical monocytes, and IL-1β and CXCL10 in 
mDC. 
In the same line, BM-MSC reduced the percentage CD4+ and CD8+ T cells producing TNF-α, 
IFNγ, and IL-2, as well as TNF-α and IFNγ mean fluorescent intensity (MFI), among all the four 
functional compartments, except for naive CD4+IFNγ+ T cells, where MSC had no inhibitory 
effect. While BM-MSC-driven inhibition of TNF-α and IL-2 production was higher for CD4+ T 
cells, inhibition of IFNγ secretion was more pronounced for CD8+ T cells. Accordingly, a 
decreased percentage of CD4+ and CD8+ T cells expressing IL-17, IL-17 and TNF-α, and IL-9, and 
of CD4+IL-6+ T cells, was induced by MSC. Interestingly, BM-MSC also increased IL-4 and TGF-
β1, while reduced IL-10 mRNA levels, for CD4+ T cells; and enhanced IL-4, while diminished IL-
10 and TGF-β1 mRNA, for CD8+ T cells. Analyzing the functional compartments, we found that, 
for CD4+ and CD8+ T cells producing TNF-α, EM and effector compartments were the most 
resistant to MSC suppressive effect; the degree of inhibition of CD4+ T cells producing IL-2 and 
IFNγ was similar among all the compartments; and EM and effector CD8+ T cells displayed the 
lowest degree of inhibition for IL-2, and the highest for IFNγ.  
Conclusions: MSC derived from either BM, AT, or UCM were able to inhibit T cell and CD56dim 
NK cell activation, and T and B cell proliferation; however, at different extents. In turn, UCM-
MSC were unable to inhibit B cell and CD56bright NK cell activation, conversely to BM and AT-
MSC. These important differences detected should be taken into account when choosing the 
MSC source for research or therapeutic purposes. We also found that BM-MSC didn’t impair 
the expression of maturation markers in monocytes and mDC under our experimental 
5 
conditions, nevertheless, they hampered the pro-inflammatory function of monocytes and 
mDC, which may impede the development of inflammatory immune responses. Finally, we 
reported that the functional compartments of CD4+ and CD8+ T cells were differentially 
regulate by BM-MSC, which may impact the therapeutic effect of MSC in immune disorders 
with a distinct distribution of T cells among activation/differentiation compartments. Also, the 
influence of MSC on IL-9 can extend the research field of MSC in allergic inflammation. 
 
 
  
6 
RESUMO 
Introdução: Os benefícios clínicos da utilização terapêutica das células estaminais 
mesenquimais (MSC) em doenças do foro imunológico devem-se à sua capacidade de modular 
o sistema imune. Contudo, algumas questões essenciais relativas às suas propriedades 
imunossupressoras, como as diferenças entre MSC isoladas de diferentes tecidos ou a sua 
influência sobre a função de subpopulações específicas de células do sistema imune 
(nomeadamente as subpopulações de monócitos e os compartimentos funcionais das células 
T), não se encontram totalmente esclarecidas. 
Objectivo: Neste estudo, comparámos o efeito supressor de MSC humanas isoladas da medula 
óssea (BM), tecido adiposo (AT) e matriz do cordão umbilical (UCM), na activação e 
proliferação de linfócitos e na expressão de mRNA de genes com um papel relevante na função 
das células T e NK; investigámos a influência das BM-MSC na activação/maturação de 
monócitos e células dendríticas mielóides (mDC), e na expressão de citocinas em mDC, 
subpopulações de monócitos, e compartimentos funcionais das células T CD4+ e T CD8+. 
Material e Métodos: Cultivaram-se células mononucleares do sangue periférico (PBMC), na 
presença ou ausência de MSC, bem como de agentes estimuladores. Para comparar MSC 
isoladas da BM, AT e UCM, as MSC foram cultivadas com PBMC estimuladas com PHA; a 
activação e proliferação das células T, B e NK foram avaliadas por citometria de fluxo; a 
quantificação de mRNA em células purificadas dos diferentes compartimentos de activação 
das células T e NK foi feita por RT-PCR. Para avaliar o efeito das BM-MSC em mDC, monócitos 
clássicos, intermédios e não-clássicos, as BM-MSC foram cultivadas com PBMC estimuladas 
com LPS+IFNγ. A activação celular e a produção de citocinas foram avaliadas por citometria de 
fluxo; a expressão de mRNA de citocinas foi quantificada por RT-PCR em subpopulações de 
monócitos e mDC purificadas. As BM-MSC foram também cultivadas com PBMC estimuladas 
com PMA+ionomicina para se avaliar o seu efeito nos compartimentos funcionais de células T 
CD4+ e T CD8+: naive, memória central (CM), memória efectora (EM) e efector. A expressão de 
citocinas dentro de cada compartimento funcional e a percentagem de células T CD4+ e T CD8+ 
a expressar IL-17, IL-9 e IL-6 foram avaliadas por citometria de fluxo; a expressão de mRNA de 
citocinas foi quantificada por RT-PCT em células T CD4+ e T CD8+ purificadas. 
Resultados: As MSC com origem na BM, AT e UCM inibiram a proliferação das células T CD4+, T 
CD8+, bem como a activação das células T CD4+ e T CD8+, e das células NK CD56dim; as BM-MSC 
e AT-MSC inibiram igualmente a proliferação das células B e activação das células B e NK 
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CD56bright, enquanto que as UCM-MSC não tiveram qualquer efeito nestas populações 
celulares. A acção supressora das AT-MSC foi a mais elevada. Além disso, as MSC diminuíram a 
expressão de mRNA de TNF-α e perforina em células NK activadas. Nos diferentes 
compartimentos de activação das células T, observou-se um aumento dos níveis de mRNA de 
FoxP3 e T-bet após estimulação com PHA e na presença de MSC. 
As BM-MSC regulam a expressão de TNF-α e CCL4 em monócitos e mDC, sem inibirem a 
expressão de CCR7 e CD83. Esta inibição é mais acentuada nas mDC, e os monócitos não-
clássicos são os mais resistentes à regulação da produção de TNF-α. As MSC também 
diminuem a expressão de mRNA de IL-1β e IL-6 em monócitos clássicos, CCL3, CCL5, CXCL9, e 
CXCL10 em monócitos clássicos e não-clássicos, e de IL-1β e CXCL10 em mDC. 
De modo semelhante, as BM-MSC diminuem a percentagem de células T CD4+ e T CD8+ 
produtoras de TNF-α, IFNγ e IL-2, bem como a expressão de TNF-α e IFNγ, em todos os 
compartimentos funcionais, excepto nas células T naive CD4+IFNγ+, nas quais as MSC não têm 
qualquer efeito. A inibição da produção de TNF-α e IL-2 mediada pelas MSC, foi maior para as 
células T CD4+, enquanto que a inibição de IFNγ foi mais acentuada nas células T CD8+. De 
forma idêntica, observou-se que as MSC conduziam a uma redução da percentagem de células 
T CD4+ e T CD8+ a expressar IL-17, IL-17 e TNF-α, e IL-9, e de células T CD4+IL-6+. Relativamente 
à expressão de mRNA, verificou-se um aumento de IL-4 e TGF-β1, juntamente com uma 
diminuição de IL-10, em células T CD4+; e o aumento de IL-4, com a diminuição de IL-10 e TGF-
β1, em células T CD8+, na presença de MSC. Na análise dos compartimentos funcionais, 
observou-se que, para as células T CD4+ e T CD8+ produtoras de TNF-α, os compartimentos EM 
e efector eram os mais resistentes à acção supressiva das MSC; o grau de inibição das células T 
CD4+ produtoras de IL-2 e IFNγ era similar para todos os compartimentos; enquanto que os 
compartimentos EM e efector das células T CD8+ apresentavam o menor grau de inibição para 
IL-2 e o mais elevado para IFNγ. 
Conclusões: As MSC isoladas da BM, AT e UCM são capazes de inibir a activação das células T e 
NK CD56dim, assim como a proliferação de células T; mas em diferentes graus. Por outro lado, 
as UCM-MSC não inibem a activação das células B e NK CD56bright, nem a proliferação de 
células B, ao contrário das BM e AT-MSC. Estas diferenças devem ser tidas em conta aquando 
da escolha do tipo de MSC para trabalhos de investigação ou utilização clínica. Também se 
verificou que as BM-MSC não impediam a expressão de marcadores de maturação em 
monócitos e mDC sob as nossas condições experimentais; no entanto, elas inibiram a função 
pró-inflamatória dos monócitos e mDC, o que pode impedir o desenvolvimento de uma 
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resposta imune. Por fim, verificou-se que as BM-MSC regulam de forma distinta os 
compartimentos funcionais das células T CD4+ e T CD8+, o que poderá ter impacto no efeito 
terapêutico das MSC em patologias do foro imunológico em que as células T apresentem 
alterações na sua distribuição pelos compartimentos de activação/diferenciação. É ainda de 
salientar que, com base na influência das MSC sobre a IL-9 aqui descrita, se poderá ampliar o 
campo de investigação das MSC na inflamação alérgica.  
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After the identification of a plastic-adherent bone marrow (BM) stromal cell population 
in 1976 by Friedenstein and colleagues, and the first evidence of its multilineage potential [1], 
with subsequent confirmation of their stem cell nature, an increasing interest on these BM-
derived mesenchymal stem/stromal cells (MSC) has emerged, mainly because of their 
promising therapeutic applications. By definition, a stem cell is an undifferentiated cell with 
the potential ability of self-renewal and the capability of differentiation along different cell 
lineages (multipotency). However, data published so far demonstrate that only a subset of BM-
derived mesenchymal stromal cells are, in fact, multipotent [2,3]. At the present moment, 
there is no marker available to distinguish the multipotent cells from the more committed cell 
progenitors comprised in the BM-MSC population [2,3]. 
Human MSC can be isolated from adult tissues – such as BM, adipose tissue (AT), dental 
pulp, synovial membrane, lung, skin, menstrual blood, and peripheral blood, among others – 
and fetal tissues – including extra-embryonic structures of fetal origin, such as umbilical cord 
blood (UCB), umbilical cord matrix (UCM) or Wharton’s Jelly, amniotic fluid, amnion, and 
placenta (this latter comprises MSC from both fetal and maternal origin) [2,3]. The use of 
extra-embryonic fetal MSC not only circumvent ethical issues concerning the use of fetal MSC, 
because these structures are discarded after partum, but also avoid invasive procedures 
necessary to obtain these cells from adult tissues. Despite the common features shared by 
MSC from different tissues, it is now widely accepted they display different characteristics 
which are ultimately reflected in their function, namely in their immune suppressive abilities. 
And, beyond the variability ascribed to MSC origin, it is also recognized that the culture 
conditions during cell expansion can influence MSC characteristics and functional behavior, 
which is not surprising, given their high sensibility to the microenvironmental conditions 
which, in fact, can be one feature that definitely contributes to their success, either in their 
natural role in maintaining homeostasis or when used as therapy. Notwithstanding, it is also 
observed a significant inter-donor variability concerning the immune suppressive ability of 
MSC. All these factors cause difficulties in the comparison of the results yielded by different 
studies, and raise important issues concerning the optimal protocol to isolate and expand MSC 
for clinical use. 
MSC display several features that make them attractive for cell-based therapies: they 
can be found in numerous adult tissues, they are relatively easy to isolate, and have the 
capability to expand manyfold in culture without lose their stem cell properties. Moreover, 
when systemically transplanted, MSC have the ability to migrate to sites of injury and promote 
tissue repair, by producing growth factors or other soluble factors important to tissue 
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regeneration, as well as by undergoing cellular differentiation to replace the damaged cells [2-
4]; such features explain the success of MSC transfusion therapy in genetic disorders affecting 
mesenchymal tissues [2,3]. Furthermore, MSC can suppress or modulate the immune response 
of a wide variety of immune cells, including T cells, B cells and plasma cells, naturat killer (NK) 
cells, NKT cells, dendritic cells (DC), monocytes and macrophages, neutrophils, eosinophils, and 
mast cells [2-8] (focused in chapter 1, section 3); and their benefic effect in patients’ clinical 
outcome has already been proven in severe acute graft-versus-host disease (GvHD) [2]. 
The success obtained in refractory acute GvHD treatment, together with the promising 
results in animal models of distinct diseases, propelled clinical trials in a broad spectrum of 
disorders with distinct etiology and pathophysiology, such as osteogenesis imperfecta, spinal 
cord injury, multiple sclerosis, amyotrophic lateral sclerosis, myocardial infarction, cirrhosis, 
systemic lupus erythematosus, nonhealing wounds, among others [2-4] (detailed in chapter 1, 
section 2). But, when the therapeutic use of MSC is concerned, is necessary to have into accout 
all the variables that may influence MSC efficacy. Besides the variables inherent to the 
technical preparation of MSC (election of the tissue origin, isolation, expantion, and storage 
conditions), which are known to influence MSC gene expression, phenotype, and function 
(detailed in chapter 1, section 1.4), the clinical use of MSC introduce new variables which 
influence the final clinical outcome: cell dose and number of infusions, route of infusion, and 
optimal timing of administration. 
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1. CHARACTERIZATION OF MESENCHYMAL STROMAL/STEM CELLS AND FACTORS 
THAT INFLUENCE THEIR PHENOTYPE AND FUNCTION 
1.1. CHARACTERIZATION OF MESENCHYMAL STROMAL/STEM CELLS 
1.1.1. Phenotypic characteristics of mesenchymal stromal/stem cells 
The lack of a specific cell marker for the identification and purification of MSC give rise 
to a multitude of different protocols and different strategies for MSC isolation, complicating 
the integration of results from different studies and the understanding of MSC biology. In an 
attempt of standardization, in 2006, the Mesenchymal and Tissue Stem Cell Committee of the 
International Society for Cellular Therapy (ISCT) established the minimal criteria to define 
human MSC [2], as follows: 1) MSC must be plastic-adherent when maintained in standard 
culture conditions; 2) MSC must express CD105, CD73 and CD90, and lack expression of CD45, 
CD34, CD14 or CD11b, CD79α or CD19, and human leukocyte antigen (HLA)-DR surface 
molecules; 3) MSC must have the ability to differentiate into osteoblasts, adipocytes, and 
chondroblasts in vitro. 
MSC are a rare cell population in the human BM, being reported to represent 
approximately 0.01% of all nucleated BM cells [3,4], although it is assumed that their number 
declines with aging [3]. Our data point to a percentage ranging between 0.01% and 0.03% of all 
nucleated BM cells [4]. 
In a previous work, our group evaluated a panel of nineteen markers on human BM-
derived MSC (BM-MSC) from freshly collected BM samples, aiming a better characterization of 
this cell population and to explore whether there were phenotypically distinct subpopulations 
within BM-MSC [4]. As a minor BM cell population easy to expand in vitro, it is attractive to 
characterize MSC immunophenotype after cell expansion. Nevertheless, characterizing BM-
MSC directly in the freshly collected BM samples (without previous culture) enables an analysis 
closest to their physiological conditions, excluding the phenotypic alterations induced by the 
factors present in the culture medium and the number of passages. In addition, this direct 
approach allows an accurate quantification of MSC in BM. Also, this same strategy can be 
applied to MSC from other tissues. 
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Figure 1. Immunophenotypic characteristics of MSC from freshly collected BM samples. BM-MSC are 
represented as blue events, the remaining BM nucleated cells correspond to the grey events. 
 
Our study revealed that BM-MSC from freshly collected BM were uniformly positive to 
CD13, CD29, CD49e, CD90, CD106, CD146, CD73, CD271, CD105, and HLA-ABC (Figure 1); and 
negative to CD24, CD31, CD11b, CD14, CD15, CD34, CD45, CD133, and HLA-DR. Based on the 
expression profile of these markers, BM-MSC behave as one sole cell population, as all the 
studied markers were homogeneously expressed [4]. A former study from our group, carried 
out on freshly isolated human UCB samples, demonstrated that UCB-MSC express CD44, CD71, 
CD105, CD184, and CD271 [5]. 
In the literature it is described that, after cell culture expansion, human MSC derived 
from the BM, AT, UCM, UCB, and amniotic membrane stromal cells are positive for CD13, 
CD29, CD44, CD73, CD90, CD105, CD166, and HLA-ABC, and negative for CD14, CD19, CD24, 
CD34, CD36, CD38, CD45, CD49d, CD117, CD133, and HLA-DR [5-15]. Importantly, there are a 
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significant number of proteins that are not uniformly expressed by MSC: some are not express 
by all the cells comprised in the MSC population, while others display an heterogeneous 
expression, which translates a different amount of protein per cell within the MSC population. 
In vitro expanded human BM-MSC were shown to have heterogeneous expression of CD10, 
CD31, CD56, CD71, CD80, CD106, CD119, CD130, CD140a, CD146, CD173, CD271, CD273, 
CD274, Galectin 1, neural ganglioside 2 (GD2), mesenchymal stem cell antigen-1 (MSCA-1), and 
stage specific embryonic antigen-4 (SSEA-4); however, there are contradictory data published 
concerning the phenotypic characteristics of human MSC [5]. But, despite the inconsistencies 
regarding the phenotypic characterization of human MSC, there is an agreement that they do 
not constitute a homogeneous cell population but, instead, comprise phenotypically distinct 
subpopulations. Remarkably, a recent study analyzing single cell-derived clones from human 
AT-MSC proved they present different immunomodulatory properties over T cells and NK cells 
[6]. The expression of molecules with a role in MSC function, namely CD44, CD105, CD73, 
interleukin (IL)-1β, IL-4, and IL-5, was also shown to vary among the different clones analyzed 
[6]. 
Noteworthy, some phenotypical differences among MSC from the same tissue origin 
have been associated to a differential immunosuppressive ability. Accordingly, MSC expressing 
stromal-derived factor-1 (STRO-1), CD90, CD271, or are CD39+CD73+, display a higher 
immunosuppressive potential [6,7]. In the same line, other phenotypic differences are 
correlated to other MSC features: human BM-MSC preparations with higher expression, or 
higher percentage of cells expressing CD10, CD29, CD44, CD71, CD106, CD119, CD146, CD166, 
CD271, and HLA-ABC, possess a higher clonogenic potential [5]. Remarkably, it was reported 
that the subpopulation of human BM-MSC with trilineage potency present higher expression 
of CD146, have higher clonogenic potential and proliferate faster, compared their bipotent and 
unipotent counterparts [6]; nevertheless, it was also described that the proliferation capacity 
of human BM-MSC correlates negatively with the percentage of CD146+ cells among the MSC 
population [5]. 
A special attention has been given to MSC expression of chemokines, chemokine 
receptors and adhesion molecules. These molecules are involved in MSC migratory and 
homing behavior, and enable the proximity between MSC and the target cells. Thus, the ability 
of MSC to actively migrate and integrate affected tissues or organs, and the capability to 
maintain a close interaction with target cells (either immune cells or others) are determinant 
for the successful use of MSC in cell-based therapies. 
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1.1.2. Chemokine receptors and chemokines expression by mesenchymal 
stromal/stem cells  
The important role of chemokines and adhesion molecules expressed by MSC in their 
immunosuppressive action was clearly demonstrated in the studies carried out by Ren and 
colleagues [7,8] in mouse BM-MSC. These studies showed that the adhesion molecules 
intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) 
[7], and the chemokines CXCL9 (or monokine induced by gamma, MIG) and CXCL10 (or 
interferon inducible protein 10, IP-10) [7], were upregulated in MSC after exposure to 
activated splenocytes or pro-inflammatory cytokines (interferon (IFN)γ plus tumor necrosis 
factor (TNF)-α, IL-1α, or IL-1β). The chemokines mediate MSC-driven chemoattraction of T 
cells, and the blockage of their receptor (CXCR3) abolished the immunosuppressive effect of 
MSC over T cell proliferation [7]. Similarly, blocking ICAM-1 or VCAM-1 also reversed the 
suppression of T cell proliferation [7]. 
 Concerning the migratory ability of human BM-MSC, it is reported they express several 
chemokine receptors: CCR1, CCR2, CCR3, CCR4, CCR6, CCR7, CCR9, CCR10, CXCR4, CXCR5, 
CXCR6, and CX3CR1 (though contradictory data have been published). The chemotactic 
response of MSC towards chemokines and growth factors was demonstrated both in vitro and 
in vivo [7-10]. Additionally, human BM-MSC produce chemokines which can attract immune 
cells towards MSC, namely CCL2, CCL4, CCL5, CCL20, CXCL8, CXCL12, CXCL9, CXCL10, CXCL11, 
and CX3CL1 [7,8]. Of note, CXCL9, CXCL10, and CXCL11, are chemoattractant factors for T cells, 
being demonstrated that the neutralization of CXCR3 (a receptor for CXCL9, CXCL10, and 
CXCL11) reverts T cell immunosuppression mediated by MSC [7]. Human AT-MSC were shown 
to express CXCL12, CCL2, CCL5, and CCL20 [8]. Though the soluble factors released by these 
cells have been shown to be chemoattractant for B cells, CXCL12 and CCL2 do not seem to be 
essential for B cell migration towards MSC [8]. 
1.1.3. Adhesion molecules expression by mesenchymal stromal/stem cells 
Besides possess the mechanisms necessary to migrate towards (and to induce the 
migration of) immune cells, MSC also have the means to interact in close proximity with the 
target cells by the surface expression of adhesion molecules. Adhesion molecules also play a 
determinant role in the exit of cells from the peripheral circulation and tissue homing, by 
allowing the interaction with endothelial cells and extracellular matrix. 
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Human MSC express CD54 (ICAM-1), CD102 (ICAM-2), CD106 (VCAM-1), CD58 
(lymphocyte function-associated antigen 3, LFA-3), CD72, CD90 (Thy-1), CD146 (Muc18), and a 
multitude of integrins – α1-6 integrins (CD49a-f), αv integrin (CD51), β1 (CD29), β3, β4, and β7 
integrins – which allow their stable binding to immune cells [4,7-9]. CD54 (ICAM-1) is dimly 
expressed and present only in a small percentage (≈ 10%) of human BM-MSC, but strongly 
enhanced or induced after TNF-α and IFNγ treatment [9]; it is the ligand of CD11a/CD18 (LFA-
1), being demonstrated that CD54/activated LFA-1 interaction allows a stable binding between 
human BM-MSC and Th17 cells [9]. The blockage of ICAM-1 or VCAM-1 hampers MSC-
mediated suppression of T cells, though the importance of these molecules seem to be greater 
for mouse than human MSC [7,10]. In the same line, the blockage of VCAM-1 and N-cadherin 
reverses the induction of tolerogenic DC by human BM-MSC, rendering the DC able to induce 
antigen-specific T cell proliferation [11]. CD29 (integrin β1-subunit) and CD106 (VCAM-1) are 
important for the efficient adhesion of MSC to endothelial cells [12-15]; and CD29, which when 
dimerized with CD49e (integrin α5-subunit) forms a receptor that binds to fibronectin and 
invasin, is likely to promote MSC-extracellular matrix interaction [16]. CD146 (Muc18) plays an 
important role in cell-cell and cell-extracellular matrix adhesion and an increased expression of 
these marker on tumor cells is associated with an increased cell motility and 
invasiveness/metastasis capability [17,18]. The glycoprotein CD90 (Thy-1) regulates as well 
cell-cell and cell-extracellular matrix interactions, being reported its involvement in adhesion 
to endothelial cells, migration, metastasis and tissue regeneration [19,20].  
1.1.4. Other molecules expressed by mesenchymal stromal/stem cells 
CD271 (nerve growth factor receptor, NGFR) is a growth factor receptor expressed in a 
wide variety of tissues and, depending on the cell type, signaling through this receptor 
regulates nuclear factor kappa B (NF-kB) activation, apoptosis, tissue regeneration, immune 
cell activation, proliferation, and cell differentiation [21,22]. CD105 (endoglin) is one of the 
receptors for transforming growth factor (TGF)-β, a growth factor involved in the regulation of 
development, maintenance, and proliferation of MSC [14], and also known to play an 
important role in tissue repair and immunosuppression. A broad set of immunosuppressive 
molecules is also constitutively and inducibly expressed by MSC; those are thoroughly 
described in chapter 1, section 4. 
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1.2. DIFFERENCES AMONG MESENCHYMAL STROMAL/STEM CELLS ARISING 
FROM DIFFERENT TISSUES  
Despite sharing common phenotypic features and important functional characteristics, 
MSC arising from different tissues have differences. This is unequivocally demonstrated by 
studies that compared MSC isolated from different tissues of the same donor, specifically 
UCM-MSC versus UCB-MSC [23], and dental pulp versus periodontal ligament-derived MSC 
[24]. Some important differences between human fetal and adult tissue-derived MSC, and 
among human MSC isolated from different adult tissues, are described below. 
1.2.1. Proliferation potential 
Several studies demonstrated that, in human, UCM-MSC, followed by AT-MSC, had 
faster proliferation and greater expansion capabilities than BM-MSC; UCM-MSC also display 
longer survival than AT-MSC and BM-MSC [7,25-28]. Besides, as the passage number increases, 
UCM-MSC are able to maintain the rate of proliferation, while the proliferation rate of BM-
MSC diminished [25]. Likewise, UCB-MSC possess higher proliferation capacity than AT-MSC 
and BM-MSC [29]. Similarly, fetal liver-derived MSC display faster growth, greater expansion 
ability, and longer telomeres than BM-MSC [30]. In turn, BM-MSC show signals of senescence 
in a lower passage number, compared to AT-MSC [28]. 
1.2.2. Phenotype 
It was reported that, despite sharing a similar phenotype – expression of CD90, CD73, 
CD44, CD166, and HLA-ABC, and negative expression for CD34, CD31, CD45, and HLA-DR – 
human BM-MSC, AT-MSC, and UCM-MSC possess distinct phenotypic characteristics [31,32]. 
For instance, AT-MSC express lower levels of major histocompatibility complex (MHC)-I than 
BM-MSC [33], and higher levels of CD90, followed by BM-MSC and UCB-MSC, which display the 
lowest expression [29]; though contradictory results have been published for CD90 [27]. CD40 
and CD34 is consistently negative in BM-MSC and UCM-MSC, whereas AT-MSC display a 
constitutive moderate expression of CD40, and the percentage of AT-MSC positive for CD34 
increases with the number of passages [32]. Though CD105 is expressed by MSC arising from 
the BM, AT, and UCM, its expression is higher among BM-MSC [32], and the percentage of 
CD105+ cells is lower for UCB-MSC than for AT-MSC and BM-MSC [27,29]. In the same line, the 
analysis of MSC from freshly collected BM and UCB samples reveal similar expression of CD71 
and CD184 in both MSC types, whereas BM-MSC displayed a higher expression of CD105 and 
lower expression of CD44, compared to UCB-MSC [34]. The adhesion molecule CD54 is 
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constitutively expressed by UCM-MSC and AT-MSC, but not by BM-MSC; whereas CD146 is 
predominantly express by BM-MSC and at lower levels by UCM-MSC and AT-MSC [27,32,35]. 
AT-MSC express CD49d, in contrast to BM-MSC [28]; while the highest levels of CD106 
expression are found in UCB-MSC, followed by BM-MSC and, finally, AT-MSC [28,29]. 
Human MSC can also produce several cytokines. A detailed study on the expression of 
cytokines, chemokines, and growth factors by human MSC from different origins showed that 
AT-MSC produce higher amounts of Th1 and Th2 cytokines than BM-MSC [36]. 
Considering molecules directly involved in MSC immunosuppressive functions, it was 
reported that UCM-MSC display the highest constitutive levels of CD274, hepatocyte growth 
factor (HGF), and prostaglandin (PG)E2, compared to AT-MSC and BM-MSC [26,32,37]; and 
UCM-MSC and AT-MSC were shown to produced higher levels of leukemia inhibitory factor 
(LIF), compared to BM-MSC [37,38]. Nevertheless, there is controversy concerning the type of 
MSC which express higher levels of PGE2, being reported as well that AT-MSC produce the 
highest levels of PGE2, followed by BM-MSC and, finally, UCM-MSC (which secrete the lowest 
levels) [26,39]. Of note, in comparison to UCB‐MSC , BM‐MSC secreted lower levels of PGE2 
[40]. In turn, indoleamine 2,3-dioxygenase (IDO) activity is higher in human BM-MSC than 
UCM-MSC [39], and the protein expression of CD273 and TGF-β2 is higher among UCM-MSC, 
compared to BM-MSC [37]. Moreover, some authors reported that human UCM-MSC express 
higher levels of CD200 than BM-MSC [37,41], whereas other study showed that CD200 is not 
expressed by UCM-MSC, only by BM-MSC [42], making evident the influence of different 
experimental approaches in MSC phenotype and function. 
1.2.3. Immunosuppressive ability 
The results from studies concerning the differential immunosuppressive function of 
human MSC derived from different sources not always overlap. This is not surprising because, 
as MSC are highly sensitive to microenvironment, technical differences (MSC expansion 
conditions, ratio MSC:immune cells, types of cell present in MSC and immune cell co-culture, 
type of stimulus used, among others) are very likely to change the final outcome.  
By comparing fetal and adult human MSC, it was demonstrated that BM-MSC lost their 
immunosuppressive action over T cell proliferation after 6-8 passages, whereas fetal liver- 
derived MSC maintained their immunoregulatory functions for at least 25 passages. This was 
associated to the decreased expression of HLA-G verified in BM-MSC after passage 8, which did 
not occur in fetal liver-derived MSC, at least before passage 30 [30]. Also, human embryonic 
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stem cells-derived mesenchymal progenitors were shown to be more resistant to the cytotoxic 
effects of activated NK cells, to have an increased inhibitory ability over NK cells, and to 
express a higher amount of HLA-G, compared to BM-MSC [43]. In turn, placenta-derived MSC 
were described as less effective in inhibiting T cell proliferation and expanding regulatory T 
(Treg) cell population than UCB-MSC and BM-MSC [44], but there are contradictory data 
concerning this subject [45].  
Attending to the studies which aimed to compare human MSC arising from UCM, AT, 
and BM, there are contradictory results as well. Recently, our group described that, when co-
cultured with peripheral blood mononuclear cells (PBMC) stimulated with phytohemagglutinin 
(PHA), UCM-MSC inhibited the activation and proliferation of CD4+ and CD8+ T cells, B cells, 
and CD56dim and CD56bright NK cells (only activativation was assessed for NK cells) to a lesser 
extent than AT-MSC and BM-MSC, and were unable to suppress B cell and CD56bright NK cell 
activation, and B cell proliferation, conversely to AT-MSC and BM-MSC [46]. In contrast, it was 
reported by others that UCM-MSC display a stronger inhibitory effect than BM-MSC over T cell 
proliferation induced by PBMC stimulation with PHA [39], mixed lymphocyte reaction (MLR) 
[39], and CD3/CD28 plus IL-2 [37]; being also described there were no significant differences 
among the suppressive effect of UCM-MSC and BM-MSC over T cell proliferation induced by 
MLR or PHA plus IL-2 stimulation of purified T cells, but UCM-MSC inhibit T cell activation to a 
greater extent than their BM counterparts [26]. Conversely, in PHA-stimulated PBMC, UCM-
MSC have lowest ability to inhibit IFNγ secretion and CD28 expression, while induce higher 
levels of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on T cells, compared to BM-
MSC [39]. 
Notwithstanding, the studies comparing AT-MSC and BM-MSC are more consistent, 
indicating that AT-MSC display a higher immunosuppressive capacity. Indeed, AT-MSC exhibit a 
stronger inhibitory effect over CD4+ and CD8+ T cell proliferation and activation, in response to 
different stimuli, compared to BM-MSC [26,46]. Similarly, AT-MSC were more effective in 
suppressing B cell activation and proliferation, as well as CD56dim and CD56bright NK cell 
activation, than BM-MSC [46]. Remarkably, AT-MSC are also stronger inhibitors than BM-MSC 
of monocyte differentiation into DC and induce a higher secretion of IL-10 by these cells [47]. 
Besides, AT-MSC were more resistant to both NK cell lytic activity [33] and MHC-I-specific lysis 
by CD8+ T cells [48], compared to BM-MSC. The lower susceptibility to NK cell cytotoxicity may 
be associated to the lower expression of CD112 and CD155 (ligands for DNAX accessory 
molecule-1, DNAM-1) observed in AT-MSC [33]. 
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The differences among the immunsuppressive activity of human MSC derived from BM, 
AT, and UCM over lymphocytes’ proliferation and activation are discussed in more detail in 
chapter 5, section 1. 
1.2.4. Other functional differences 
Other functional differences are found among human MSC derived from different 
tissues. For instance, UCM-MSC are more skilled for neuroprotection and angiogenesis than 
BM-MSC [49], and UCM-MSC and AT-MSC have a inferior osteogenic differentiation potential 
than BM-MSC [35,50], whereas UCB-MSC exhibit a low adipogenic differentiation potential, 
conversely to AT-MSC and BM-MSC [29,51]. Notably, UCM-MSC display lower immunogenicity, 
compared to BM-MSC [37]. 
The differences among MSC from different sources impact their function. But, as 
described below, the expression pattern of factors that influence MSC immunosuppressive 
potential (chemokine, adhesion molecules, and immunosuppressive molecules) is not static. 
The in vitro experiments that subject MSC to pro-inflammatory cytokines, TLR ligands, etc, can 
give important clues about how MSC function will be conditioned after in vivo infusion, under 
non-homeostatic conditions, such as that experienced when tissue damage or infection occur. 
1.3. DONOR-DEPENDENT VARIABILITY OF THE IMMUNOSUPPRESSIVE 
POTENTIAL OF MESENCHYMAL STROMAL/STEM CELLS 
In recent years, an increasing body of evidence point to important differences among 
MSC isolated from different donors. Part of this donor-to-donor phenotypic variability among 
human BM-MSC was demonstrated by Siegel and colleagues [5] to be associated to donor age 
and gender. Importantly, the inter-individual heterogeneity underlines the utility of MSC 
potency tests prior to their clinical application. 
When the donor’s age is concerned, it was found that younger donors possess a higher 
proportion of CD71+, CD146+, and CD274+ MSC, and a higher expression of CD71, CD90, CD106, 
CD140b, CD146, CD166, and CD274, than the older ones; in addition, MSC from younger 
donors express lower levels of IL-6 after exposure to activated T cells [5]. Differences 
concerning CD44, CD73, and CD105 expression were also observed among donors [52]. It is 
worth mentioning that some of these differentially expressed proteins are adhesion molecules 
(CD44, CD90, CD106, CD166) or immunosuppressive molecules (CD73 and CD274), thus, their 
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differential expression may imply important differences in the immunosuppressive potential of 
MSC arising from different donors. 
Remarkably, concerning the immunosuppressive potential, the inter-individual 
heterogeneity is striking. A significant variability in the amounts of PGE2 secreted from human 
BM-MSC arising from different donors is described, being demonstrated a positive correlation 
between the levels of PGE2 produced and the degree of inhibition of DC differentiation by MSC 
[53]. In line with these findings, it was shown that human BM-MSC isolated from different 
donors (in co-culture with PBMC stimulated with anti-CD3/CD28) display distinct 
immunosuppressive potential over T cell proliferation and IFNγ production; interestingly, the 
immunosuppressive potential was found to be positively correlated with IDO mRNA [5,52] and 
protein [52] expression levels. Interestingly, the immunosuppressive ability over PHA-
stimulated T cell proliferation is described to be stronger for BM-MSC isolated from female, 
compared to male donors [5]; gender differences in MSC immunosuppressive potential had 
formerly been describe in mice [54]. Furthermore, there was also observed donor-to-donor 
variability regarding the degree of inhibition of immunoglobulin (Ig)M, IgG and IgA production 
by B cells in MLR [55].  
The inter-individual variability is also visible in other aspects of human MSC biology, such 
as the ability of BM-MSC to support neural growth in vivo, which is associated to the different 
amount of cytokines and growth factors that BM-MSC isolated from different donors produced 
[56]; and the potential for the formation of fibroblast colony forming units (CFU-F), and 
absolute progenitor numbers generated, which varied among menstrual fluid stem cells’ 
donors [57]. Of note, in human BM-MSC, a higher number of CFU-F is found among women 
than men, and younger donors form more CFU-F than older donors [5]. The percentage of 
CD119+ and CD130+ MSC is higher among female donors, which also have MSC with a smaller 
diameter a lower population doubling time, compared to male donors [5]. Interestingly, the 
proliferation capacity of BM-MSC (and the cell size) were not correlated to donor age [5]. 
1.4. MICROENVIRONMENT MODULATES MESENCHYMAL STROMAL/STEM CELL 
ACTION 
MSC are highly sensitive to the microenvironment, which allow them to rapidly alter 
their protein expression profile in order to adapt their functions to the physiologic needs of 
the organism, giving their important contribute to the maintenance of the homeostasis. Thus, 
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expectedly, the culture conditions during MSC expansion or in vitro assays can change the 
cells’ phenotype and function. Factors recognized to interfere with MSC phenotype and 
function include the ratio MSC:immune cells [26,58-60], the immune cells present in the cell 
culture [61], the activation status of immune cells [58,62], and the cytokines levels in the 
milieu. It is also generally recognized that hypoxia induce a higher proliferation rate, and 
upregulation of growth factors and anti-inflammatory molecules in MSC; pro-inflammatory 
conditions promote the production of immune modulating and anti-inflammatory factors; and 
three dimensional growth increases the production of anti-cancer factors and anti-
inflammatory molecules by MSC, compared to monolayer culture [63-65].  
Notwithstanding, other factors inherent to the MSC expansion procedures may exert an 
important influence over MSC phenotype and function [66]: the presence of platelet lysate 
from platelet-rich plasma in the culture medium significantly increased the intracellular levels 
of HLA-G in human BM-MSC [67], the number of passages changes MSC phenotype [68], 
wherein a high number of passages results in the loss of the surface expression of chemokine 
receptors and adhesion molecules [69], and the level of cell confluence affect MSC gene 
expression [70]. 
1.4.1. Cytokines 
TNF-α treatment increases the proliferation rate of human BM-MSC [39]. Remarkably, a 
significant number of chemokines and chemokine receptors are upregulated after human BM-
MSC exposure to TNF-α, namely CXCL8 (IL-8), CXCL9 (MIG), CXCL10 (IP-10), CCL3 (or 
macrophage inflammatory protein (MIP)-1α), and CXCR4, CCR2, CCR3, and CCR4, among many 
others [71,72]. As expected, TNF-α increases human BM-MSC migration toward CCL5 [71]. In 
turn, it is also observed an increased secretion of PGE2 in BM-MSC and UCM-MSC [39], and 
upregulation of the growth factors and immunosuppressive molecules vascular endothelial 
growth factor (VEGF), fibroblast growth factor 2 (FGF2), HGF, insulin-like growth factor (IGF)-1, 
and galectin-9 (mRNA levels for this latter) in BM-MSC, under the influence of TNF-α  [73,74]. 
Likewise, IFNγ also promotes the expression of immune suppressive molecules by 
human MSC, namely IDO [7,39,75-77], programmed death ligand 1 (PD-L1 or B7-H1) [7,78], 
PD-L2 (B7DC) [7,78], TGF-β [76], CD73 [79], and galectin-9 (at mRNA level) [7,74],while reduce 
PGE2 expression [76]. Similar results are described for murine MSC [80]. Accordingly, IFNγ-
stimulated human MSC were shown to be more resistant to NK cell lysis than non-stimulated 
MSC [76]. The chemokine receptor CXCR4 is also upregulated in human BM-MSC upon 
exposure to IFNγ [79]. Notwithstanding, low levels of IFNγ induce antigen-presenting cell 
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properties in MSC, upregulating MHC-I (including HLA-E) and MHC-II expression, and making 
MSC acquire allogeneic potential. Nevertheless, higher IFNγ levels drives to MHC-II 
downregulation and loss of T cell allostimulation potential [7,39,81-83]. 
CD54 (or ICAM-1) expression is enhanced or induced after human BM-MSC and UCM-
MSC treatment with TNF-α and IFNγ, either alone or in combination, showing a synergistic 
effect [9,39]. In the same line, the increase of adhesion molecules had been reported in mouse 
MSC under the influence of pro-inflammatory cytokines, which contribute to their efficient 
interaction with immune cells [10]. TNF-α and IFNγ, acting individually, also increase HLA-ABC 
expression in both human BM-MSC and UCM-MSC [39]. Accordingly, exposure to either TNF-α 
or IFNγ was shown to increase human BM-MSC and UCM-MSC immunogenicity [39]. Of note, 
galectin-9 and TGF-β are also induced in human MSC by IL-1α and IL-1β [7,74,84]. 
In vivo, cells are exposed to various pro-inflammatory cytokines and not to each 
cytokine individually. Interestingly, the combination of different pro-inflammatory cytokines 
frequently results in a synergistic effect over the target cells, including MSC. Therefore, many 
authors opt to use a cocktail of pro-inflammatory cytokines, instead of individual cytokines 
and, though the insight of the role of each cytokine is lost, the assays become more close to 
the physiologic conditions. Using this approach, it was reported that a cocktail of pro-
inflammatory cytokines (TNF-α, IFNγ, and IL-6) upregulates the mRNA expression of immune 
suppressive factors (HLA-G, HGF, and IDO); MHC-I and MHC-II; CD40; and several chemokines 
for lymphocytes, monocytes, DC, and granulocytes (CXCL9, CXCL10, CXCL11, CXCL1, CXCL6, 
CXCL8 or IL-8, CCL2, CCL5, CCL7, CCL8, and CCL13) in human AT-MSC [85]. These cells also 
enhanced their ability to suppress PHA-induced PBMC proliferation after exposure to pro-
inflammatory cytokines [85]. Exposure to other combination of pro-inflammatory cytokines 
(TNF-α, IFNγ, IFNα, and IL-1β) also induced HLA-DR expression, along with CD40, in human BM, 
AT, and UCM-derived MSC [32]; and upregulates the expression of the adhesion molecules 
CD54 and CD58 [32,59], and the immunosuppressive molecules, HLA-G, CD274, and PGE2, in 
MSC from the three sources, as well as HGF secreted by UCM-MSC and galectin-1 secreted by 
BM-MSC [32,59]. 
Functionally, priming with pro-inflammatory cytokines is generally associated to the 
improvement of immunosuppressive capacity of MSC [39], which is in accordance with the 
observed upregulation of the molecular mechanisms that promote a close interaction between 
MSC and immune cells – namely, increased expression of chemokines and their receptors, and 
27 
adhesion molecules – and the augmented expression of immunosuppressive molecules that 
allow MSC to modulate immune cell function. 
1.4.2. Toll-like receptors’ stimulation 
Conversely to what is found for MSC exposure to pro-inflammatory cytokines, which 
increase MSC ability to modulate the immune response, stimulation of Toll-like receptors (TLR) 
from human MSC may maintain or impair their immunosuppressive potential. It is 
hypothesized that the presence of TLR ligands is indicative of a dangerous situation, wherein 
the organism is exposed to potentially pathogenic agents; in these cases MSC assume a pro-
inflammatory role and downregulate the immune suppressive machinery. In turn, depending 
on the ligand concentration, timing, kinetics of activation, and type of MSC [63,86], MSC may 
assume an immunosuppressive function as well. For instance, the presence of pro-
inflammatory cytokines in the absence (or low level) of TLR stimulation may be perceived as a 
situation where the pathogenic agent has already been eliminated and, therefore, 
inflammation resolution should take place; or as a chronic inflammation, wherein immune cell 
activation and effector function most probably have a deleterious rather than beneficial effect 
for the organism. 
The use of the TLR2 ligand zymosan resulted in the increased expression of galectin-9 
mRNA in human BM-MSC [74]. In mice, BM-MSC stimulation through TLR2 impair their 
capacity to induce the generation of Treg cells [86]. 
Human BM-MSC stimulated with polyinosinic–polycytidylic acid (poly(I:C)), the TLR3 
ligand, display increased expression of the chemokines CCL5 (or regulated upon activation, 
normal T cell expressed and secreted, RANTES) , CXCL10 (IP-10); the cytokines IL-4, IL-10, IL-6, 
IL-8, IL-12p35, IL-23p19, IL-27p28, and interleukin-1 receptor antagonist (IL-1Ra); adhesion 
molecules CD54 and CD58; immunosuppressive molecules IDO, galectin-9, and PGE2, while 
downregulate TGF-β, Jagged-1, and galectin-1 expression [59,74,86-91]. It is worth to mention 
that human BM-MSC stimulated through TLR3 maintain the suppressive activity over 
CD3/CD28-induced T cell proliferation [87], improve their inhibitory effect over T cell 
proliferation in MLR [88], and become more resistant to IL-2-activated NK cell killing [92]. Of 
note, TLR3 stimulation increases human BM-MSC ability to enhance neutrophil survival [93]. 
Human BM-MSC treatment with lipopolysaccharide (LPS), the TLR4 agonist, increases 
the expression of the cytokines IL-1β, IL-6, IL-8, IL-23p19, IL-27p28; CCL5 and CXCL4; the 
adhesion molecules CD54 and CD58; the immunosuppressive molecules and growth factors 
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PGE2, IDO, CD73, galectin-9 (measure at mRNA level), Jagged-1, VEGF, FGF2, HGF, and IGF-1 
expression, while slightly reduce TGF-β and galectin-1 expression [31,59,73,74,79,86-92]. LPS 
exposure also increase the secretion of PGE2 and IL-8 by human AT-MSC [31]; and of IDO, 
cyclooxygenase (COX)-2, IL-1α, IL-1β, IL-6, and IL-8 in UCM-MSC, and of the two latter 
cytokines in UCB-MSC [94,95]. Remarkably, human BM-MSC stimulated through TLR4 lose 
their suppressive activity over CD3/CD28-induced T cell proliferation [87], whereas increase 
their inhibitory effect over T cell proliferation in MLR [88]. In turn, TLR4 activation of human 
UCB-MSC seem to have no effect on their suppressive ability [86,95]. Of note, TLR4 stimulation 
increases human BM-MSC ability to enhance neutrophil survival [93]. 
TLR5 activation with flagellin of human UCB-MSC results in the increase of IL-8 secretion 
and seems to have no effect on their suppressive ability [86,95]. 
The stimulation of human BM-MSC with a combination of IFNγ and LPS upregulated 
TNF-α, IL-1β, IL-6, IL-8, IDO, and inducible T-cell co-stimulator ligand (ICOSL) mRNA expression 
[79], and significantly increased neutrophil migration towards MSC, an effect mediated by IL-8 
secretion by MSC [89]. This increased ability to induce immune cell migration was confirmed in 
vivo by infusing mouse MSC pre-treated with IFNγ and LPS; treated MSC attract a higher 
number of granulocytes, T cells, NK cells, and DC compared to their non-treated counterparts 
[89]. Notwithstanding, there are contradictory data in the literature concerning the influence 
of TLR activation on the function of human MSC [7]. 
Interestingly, and taking into account the ability that MSC seem to have to hold in check 
their immunosuppressive activity when danger signals are sensed, it was demonstrated that 
human BM-MSC did not inhibit the T cell responses specific for either Epstein-Barr virus or 
cytomegalovirus, including proliferation, IFNγ secretion, and cytolytic activity against infected 
cells by cytotoxic T cells specific for the virus [96]. 
1.5. MESENCHYMAL STROMAL/STEM CELLS’ IMMUNOGENICYTY 
1.5.1. Low immunogenicity of mesenchymal stromal/stem cells  
One of the great advantages of the use of MSC in cell therapy is their low 
immunogenicity [97]. This characteristic enables the use of allogeneic MSC for cell therapy 
with a low risk of immune recognition and rejection by the recipient, increasing their window 
of action inside the host. The expression of low surface levels of MHC-I molecules contributes 
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to MSC hypoimmunogenicity and protects them from NK cell-mediated lysis; the absence of 
MHC-II and costimulatory molecules, as CD40, CD80, and CD86, prevents MSC recognition by 
CD4+ T cells [7]. Under the influence of IFNγ, the expression of MHC-I and MHC-II is 
upregulated and, in the presence of an inflammatory environment, the expression CD40 is 
induced in MSC as well [7]. In these circumstances, there are studies reporting that MSC still 
not elicit an immune response due to the absence of other costimulatory molecules and to the 
expression of proteins with a strong inhibitory effect over T cells, many of which are 
upregulated under inflammatory conditions [7]; while other studies describe that IFNγ enable 
human BM-MSC to become non-professional antigen-presenting cells [45].  In addition, MSC 
secrete Factor H, and express CD46, CD55, and CD59, thus being protected from the 
complement system action [98,99]. 
However, these concepts of low immunogenicity and inability to mediate T cell 
activation are being challenged by an increasing number of studies showing that MSC can, 
indeed, be recognized and destroyed by the recipient’s immune system. 
1.5.2. Mesenchymal stromal/stem cells as antigen-presenting cells 
As referred above, a pro-inflammatory environment (or the influence of isolated pro-
inflammatory cytokines, such as IFNγ or TNF-α) enhances MHC-I and induces MHC-II 
expression in human MSC which, under those conditions, may behave as non-professional 
antigen-presenting cells, acquiring the ability to present exogenous antigens to CD4+ T cells 
and to cross-present exogenous antigens to CD8+ T cells as well, inducing T cell activation [45]. 
Remarkably, in human BM-MSC, the induction and maintenance of MHC-II expression, as well 
as the antigen-presenting cell function, occur when they are exposed to low levels of IFNγ, and 
an increase of this cytokine’s levels results in the downregulation of MHC-II expression and loss 
of antigen presentation ability by MSC [81]. 
Human BM-MSC either pulsed or infected with viral peptides, and pre-treated with IFNγ, 
were able to elicit MHC-I restricted CD8+ T cells response, though to a lesser extent that other 
antigen-presenting cells [83]; noteworthy, contradictory results had been published 
concerning this subject [97]. However, while pulsed human BM-MSC were vulnerable to CD8+ 
cytotoxic T cells (CTL) lysis, infected MSC were resistant due to the secretion of soluble HLA-G 
[83], showing that, under some conditions, the immunosuppressive molecules produced by 
MSC may overcome the increased expression of MHC-I, MHC-II, and costimulatory molecules 
induced by a pro-inflammatory environment. 
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Cross-presentation of exogenous antigen was demonstrated both in vitro and in vivo in 
IFNγ-primed murine BM-MSC [100]. Of note, IFNγ also enhanced the expression of transporter 
associated with antigen processing-1 (TAP1) and three proteasomal subunits, in MSC: low 
molecular mass polypeptides (LMP)2, LMP7, and multicatalytic endopeptidase complex 
subunit (MECL) [100]; conversely, there are some clues that this does not occur in human MSC 
which, in fact, was present some deficiencies in the MHC-I-related antigen-processing 
machinery components, even after IFNγ stimulation [83]. 
1.5.3. Allogeneic mesenchymal stromal/stem cells can be recognized and 
destroyed by the recipients’ immune system 
As extensively described, MSC can be target of cytolytic activity by activated (but not 
resting) NK cells [43,76,92,98,101-103] and by δ2+ γδ T cells [104]. It is recognized that human 
BM-MSC express ligands for NK activating receptors: poliovirus receptor (PVR) and Nectin-2 
(ligands of DNAM-1), ULBP and MICA (ligands of NKG2D); and NK cell-mediated MSC lysis is 
mainly attributed to NKp30, DNAM-1, and NKG2D activating receptors [76,92,101,103]. 
Interestingly, prior exposure of MSC to IFNγ make them escape to NK cell cytotoxic activity, 
because this cytokine enhance the expression of classical MHC-I molecules and HLA-E in MSC 
surface, which bind to the inhibitory receptors on NK cells and override the activating signals 
received by NK cells, resulting in the non-destruction of MSC [76,101]. IFNγ also decreases 
levels of ULBP in MSC surface, avoiding the activation of NKG2D activating receptors [76]. 
Likewise, TLR3 or TLR4 stimulation decreases MICA levels on MSC surface, augmenting their 
resistance to NK cell lysis [92]. In turn, human AT-MSC were shown to be more resistant to NK 
cell-mediated lysis than BM-MSC, which may be a reflection of their lower expression of CD112 
(Nectin-2) and CD155 (PVR), ligands for DNAM-1 [33]. 
Noteworthy, it was demonstrated in vivo (in horse and rat, among other animals) that 
the infusion of allogeneic MSC was able to elicit production of antibodies against MSC after a 
single or multiple infusions [105,106]; however, the humoral response display a high inter-
individual variability [105], and other studies describe that animals do not develop antibodies 
against the MSC infused [107]. Allogeneic MSC infusion in rhesus macaques induced the 
expansion of B cells, CD8+ T cells, NK cells and NKT cells, as well as the production of antibodies 
against MSC upon a second infusion of MSC; remarkably, the extension of the immune 
response was found to be correlated with the haplotype differences between the donor and 
the recipient [108]. In the same line, a recent study showed that human allogeneic BM-MSC 
and AT-MSC can induce MHC-I-specific lysis by CD8+ T cells, in vitro [48]. Noteworthy, the 
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immunogenicity of AT-MSC was lower than that of BM-MSC [48]. Thus, similarly to what was 
observed for NK cell [33], AT-MSC were more resistant to CD8+ T cell-mediated cytotoxicity 
than BM-MSC [48]. 
In conclusion, the studies concerning the immunogenicity of MSC (in vitro and in vivo) 
yielded different, and sometimes contradictory, results. But, in fact, given the high variability 
of the experimental procedures among the studies, it is hard to compare them and to 
integrate their data. Notwithstanding, it seems clear that immune cells can recognized 
allogeneic MSC. However, the encounter between immune cells and allogeneic MSC may 
result in rejection, in suppression of the immune response, or in the induction of immune 
tolerance. But the factors that influence the fate of immune cells after the encounter with 
allogeneic MSC are still elusive. According to Griffin and colleagues [109], the analysis of in vivo 
studies points the route of MSC administration as a possible factor. Pre-treatment with IFNγ 
and in vivo MSC differentiation can potentially alter the immunogenic properties of allogeneic 
MSC [109], but their contribute for immune recognition of allogeneic MSC in vivo needs to be 
further elucidated. 
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2. THERAPEUTIC POTENTIAL OF MESENCHYMAL STROMAL/STEM CELLS 
In the last decade, MSC have emerged as a potential therapeutic approach for diseases 
involving tissue damage and exacerbated immune responses. The natural ability to home to 
injured tissue and inflammation sites, undergo differentiation into different cellular 
components of the tissues engrafted, regulate the immune response, adapt their function to 
the microenvironmental conditions, and influence the behavior of the neighbor cells, endows 
MSC with potential unique advantages in cell-based therapies. Besides, MSC are easily 
isolated, expanded and cryopreserved, and display low immunogenicity. These singular 
features have been explored in the recent years and propelled clinical trials in a broad 
spectrum of disorders diverse in etiology and pathophysiology, such as osteogenesis 
imperfecta, spinal cord injury, nonhealing wounds, amyotrophic lateral sclerosis, multiple 
sclerosis, myocardial infarction, liver cirrhosis, diabetes mellitus, systemic lupus 
erythematosus, and GvHD, among others [110-112]. 
The recognition of the potential of MSC to differentiate into several different tissue 
types urged the interest in using these cells to treat conditions characterized by mesenchymal 
tissue lesion or loss, wherein engrafted MSC could act as a source of new cells capable to 
replace the damaged or lost ones. With this regard, an important number of investigations 
were carried out in the field of regenerative medicine. Remarkably, the benefits achieved by 
MSC-based therapies in tissue regeneration were found to be more related to the release of 
growth factors by MSC, or MSC-mediated modulation of the local inflammatory response – 
both of which actively contribute to stop tissue injury, enhance tissue regeneration, and 
decrease scar formation – than to the replacement of injured cells by progenitors arising from 
the infused MSC. 
2.1. OSTEOGENESIS IMPERFECTA 
Osteogenesis imperfecta is a genetic disease characterized by the production of 
defective type I collagen with consequent retardation of bone growth, bony deformities and 
increased risk of fractures [110,113], thus MSC were seen as a suitable therapeutic approach 
for this pathological condition. In fact, the initial clinical trials in children with osteogenesis 
imperfecta achieved promising results in the few months following bone marrow 
transplantation [113] or BM-derived MSC infusion [114], being observed that MSC migrated to 
bone where they differentiate into osteoblasts [113]. The improvements reported were 
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subsequently explained by the demonstration that osteocytes and osteoblasts synergistically 
stimulate the proliferation of mouse bone marrow MSC and their differentiation into 
osteoblasts [115]; in the same line, conditioned medium from osteocytes also induce 
osteogenesis by mouse MSC, but to a lesser extent [116]. However, the improvement in 
osteogenesis is not sustained with time after transplantation and it is hypothesized that the 
osteogenic differentiation ability of the transplanted stem cells is compromised by the micro-
environmental conditions present in osteogenesis imperfecta patients [117]. 
2.2. SPINAL CORD INJURY 
Likewise, the discovery of MSC ability to differentiate into neural and glial cell lineages 
[118] encouraged the investigation of the therapeutic use of MSC in disorders affecting the 
nervous system. Indeed, MSC have the ability to replace the lost neural cells, secrete 
neurotrophic factors that prevent apoptosis and promote neural regeneration and ameliorate 
inflammation [119], which make them a suitable therapeutic approach to spinal cord injury, 
amyotrophic lateral sclerosis and multiple sclerosis. 
The loss of neural functions in spinal cord injury is due to direct mechanical insult to the 
spinal cord, responsible for the physical disruption of neural cells, and to the subsequent 
secondary delayed injury, triggered by the necrotic cells and inflammation [119]. Current 
treatment consists of administration of high dose steroids and surgical intervention to 
minimize cord edema and the secondary delayed injury, but their clinic benefits are limited. 
Animal models of spinal cord injury demonstrated that transplanted BM-derived MSC engraft 
the injured tissue and contribute to axonal growth and function recovery, being able to 
differentiate into neurons, oligodendrocytes and astrocytes in vivo, while inhibiting the 
inflammatory response and apoptosis of neurons and oligodendrocytes [56,118-120]. These 
encouraging results obtained in rat, pig and rhesus monkey models were followed by clinical 
trials in which patients experienced sensory and motor improvements after transplantation 
with autologous BM-MSC in the injury site, namely in tactile sensitivity, pain, lower limbs 
motor function, urinary and bowel function and somatosensory evoked potentials [121-124]. 
Although autologous BM cells transplantation in conjunction with the administration of 
granulocyte macrophage-colony stimulating factor (GM-CSF) had also shown clinical benefits in 
the past, in patients with spinal cord injury [121,125], the functional improvement achieved 
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with BM-MSC transplantation was more pronounced than that with BM mononuclear cells in 
rat spinal cord injury model [125]. 
2.3. AMYOTROPHIC LATERAL SCLEROSIS 
Amyotrophic lateral sclerosis is a neurodegenerative disorder characterized by 
progressive degeneration of motor neurons in the cortex, brainstem and spinal cord, leading to 
progressive a lethal paralysis [126]. Pre-clinical trials in mice demonstrated the benefits of BM-
MSC transplantation, namely in delaying the loss of motor function and increasing the lifespan 
of the animals [126].  However, after autologous BM-MSC infusion, via intrathecal or 
intravenous injection, no functional deterioration nor improvement was detected during 6 
months in patients with amyotrophic lateral sclerosis, but an increased percentage of 
peripheral blood CD4+ Treg cells and a decreased frequency of myeloid dendritic cells 
expressing maturation markers (CD40, CD83, and CD86) was observed immediately (4 hours 
and 24 hours) after MSC transplantation [127]. Likewise, Manzinni et al. [128] did not find a 
slower disease progression among patients who received autologous BM-MSC and those who 
did not in 9-years follow up. At the present, other clinical trials are in course, using BM-MSC 
differentiated into specialized neuron-supporting cells (to stably secrete neurotrophic factors) 
and using fetal spinal cord-derived neural stem cells [126]. 
2.4. MULTIPLE SCLEROSIS 
Multiple sclerosis is an inflammatory, demyelinating disease of the central nervous 
system and, at this moment, there is no treatment capable of promoting the repair of the 
neural lesions conducing to the progressive disability of the patients. An extensive preclinical 
research has been carried out in the last years in experimental autoimmune encephalitis (EAE), 
an animal model of multiple sclerosis, in which intravenous administration of MSC in mice with 
this condition resulted in reduced disease severity, reduction of demyelination (both in brain 
and spinal cord), decrease of oligodendrocyte apoptosis and of T cells and macrophage 
infiltrate in the central nervous system, associated to preservation of the axons [129-135]. 
These processes were largely mediated by soluble factors – being demonstrated that 
conditioned medium from human MSC reduces EAE severity and promotes neural cell 
development and remyelination [136] – and primarily ascribed to the immunomodulatory 
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abilities of MSC and their soluble trophic factors, namely HGF and brain-derived neurotrophic 
factor (BDNF). In fact, infusion of MSC in EAE mice compromised the ability of T cells to 
undergo activation and produce IFNγ and TNFα and, noteworthy, intravenously injected MSC 
were detected in mice lymphoid organs [129-131,136,137]. 
Recently, clinical trials using autologous MSC have been reported in the literature. 
Intrathecal or intravenous infusion of autologous BM-MSC in multiple sclerosis patients led to 
functional improvement detected in a 6 months follow-up, along with an increased percentage 
of peripheral blood CD4+ Treg cells and a decreased frequency of myeloid dendritic cells 
expressing maturation markers (CD40, CD83 and CD86) observed immediately (4 hours and 24 
hours) after MSC transplantation [127]. In another clinical trial involving 10 patients with 
secondary progressive multiple sclerosis with clinical evidence of damage of the visual 
pathways, intravenous infusion of autologous BM-MSC improved the patients visual acuity and 
increased the optic nerve area, in a 10 months follow-up [138]. 
2.5. CARDIAC DISEASES 
The recognized ability of MSC to undergo differentiation into cardiomyocytes, promote 
angiogenesis, reverse cardiac remodeling, and blunt exacerbated pro-inflammatory responses, 
make them a suitable cell therapy for distinct heart diseases, such as acute myocardial 
infarction, in which their anti-inflammatory properties would be of great value, and chronic 
infarction, wherein clinical benefits would be mainly achieved by MSC’s regenerative 
properties and anti-fibrotic potential. 
Animal models of cardiac diseases showed an overall improvement of the cardiac 
function after MSC transplantation, namely improvement of ventricular function and 
myocardial perfusion, and reduction of myocardial scar, infarct size, and ventricular 
remodeling [139-143]. In a swine model of chronic ischemic cardiomyopathy, transfused BM-
MSC were shown to engraft into the infarcted tissue and border zone and subsequently 
differentiate into cardiomyocytes, vascular smooth muscle and endothelial cells in vivo, albeit 
a significant proportion of MSC remained undifferentiated. MSC-treated animals showed 
improved global and regional cardiac function, increased myocardial blood flow, reduction of 
the infarct size, and reverse remodeling. Of note, MSC-derived vascular smooth muscle and 
endothelial cells were incorporated into new blood vessels, contributing directly to the 
recovery of cardiac perfusion, and MSC engraftment was correlated with functional recovery in 
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contractility observed in BM-MSC-treated animals [141]. In acute myocardial infarction animal 
model, BM-MSC transplant was shown to prevent cardiomyocyte apoptosis, restore cardiac 
function, and reverse ventricular remodeling [143]. Shabbir et al. [144] highlighted the 
importance of trophic factors by demonstrating that BM-MSC, or MSC-conditioned medium, 
injected in skeletal muscle of a hamster heart failure model, were able to improve cardiac 
function, reduce cardiomyocyte apoptosis and fibrosis, and increase the expression of HGF, 
IGF-2, and VEGF in the myocardium tissue. These trophic factors are known to improve cardiac 
function, prevent apoptosis of cardiomyocytes, and have pro-angiogenic function [144-146]. 
In a rat model of experimental autoimmune myocarditis, intravenous administration of 
MSC was associated to clinical improvement and, from the immunologic point of view, 
resulted in a decreased percentage of peripheral blood CD4+ T cells producing IFNγ or IL-17, as 
well as decreased number CD4+IL-17+ T cells in the myocardium [147].  
The moderate benefits of autologous BM cells or BM-MNC administration in patients 
with myocardial infarction and ischemic cardiomyopathy had been described since 2001 [139]. 
Recently, data published by Heldman et al. [148] demonstrated that, in ischemic 
cardiomyopathy patients, autologous BM-MSC delivered by transendocardial stem cell 
injection were associated to better clinical outcome than autologous BM cells. Indeed, patients 
treated with autologous or allogeneic BM-MSC presented an improved cardiac function, 
decreased scar size, attenuated cardiac remodeling, and increased viable myocardial mass, 
suggesting myocardial regeneration [148-151]. Clinical benefits of locally administrated 
autologous BM-MSC and UC-MSC were also found in patients with coronary artery disease 
[152,153]. 
2.6. ACUTE LIVER FAILURE AND CIRRHOSIS 
The potential of human MSC to differentiate into hepatocytes in vitro [154,155], along 
with their immunomodulatory properties, raised the interest in using these cells for the 
treatment of liver diseases, particularly advanced liver cirrhosis and acute liver failure, two 
conditions involving loss of functional liver cells, wherein organ infiltration by inflammatory 
cells plays an important deleterious effect, and the only effective treatment available is liver 
transplantation [154]. A preclinical study with animal model of concavalin-induced liver injury 
in mice, reported that intravenous BM-MSC infusion ameliorates liver injury and inflammation, 
both at liver and systemically. Indeed, animals treated with MSC displayed reduced 
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inflammation and lymphocyte proliferation, along with decreased numbers of activated NKT 
cells, and levels of TNF-α, IFNγ, and IL-4, in both the liver and periphery [156]. Of note, BM-
MSC were detected in the liver 24 hours after the infusion, but were undetectable after 1 
month, which supports the hypothesis that the protective effect of MSC is mainly systemic 
[156]. Similar results were obtained after infusion of BM-MSC conditioned medium in liver 
failure animal models: reduction of hepatic cell death, liver leukocyte infiltration and serum 
levels of pro-inflammatory cytokines; increased serum levels of IL-10 and hepatic cell 
proliferation [157,158]. MSC-derived IL-6 seems to play a pivotal role in liver regeneration by 
inducing the expression of fibroblast-like protein 1 gene in hepatocytes, a critical gene for liver 
regeneration, and upregulating the expression of anti-apoptotic proteins [154,159]. In liver 
cirrhosis animal models, similar encouraging results were obtained: BM-MSC infusion induced 
regeneration of the hepatic tissues and reduced fibrosis [160]; whereas in vitro studies showed 
that MSC have the ability to modulate the function, induce apoptosis, and reduce the collagen 
type I production by liver stellate cells [161]. Results from liver cirrhosis clinical trials reported 
so far, using autologous BM-MSC, almost consistently show improvement of liver function in a 
significant percentage of patients, as revised by Volarevic et al. [154]. 
2.7. DIABETES MELLITUS 
Diabetes mellitus comprises a heterogeneous group of metabolic disorders, resultant 
from impaired insulin production and/or peripheral insulin resistance, characterized by 
hyperglycemia associated to defective metabolism of carbohydrate, fat and proteins [162,163]. 
Chronic hyperglycemia ultimately causes blood vessel damage, leading to the secondary 
complications of diabetes, grouped into “macrovascular complications” and “microvascular 
complications”. Macrovascular complications occur as consequence of arteries damage and 
include accelerated cardiovascular disease, increasing the risk of coronary artery disease and 
myocardial infarction among these patients, as well as of cerebrovascular disease (strokes), 
peripheral arterial disease, and limb amputation. Microvascular complications result from the 
damage of small blood vessels in the retina (resulting in retinopathy that can lead to 
blindness), renal glomerulus (nephropathy, which can culminate in end-stage renal failure), 
and peripheral nerve (neuropathy, manifesting as pain, foot deformity, neuropathic ulceration, 
which may lead to the need of amputation). Foot ulceration, impaired bone healing, diabetic 
cardiomyopathy (defined as ventricular dysfunction in the absence of coronary artery disease, 
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valvular heart disease, or hypertension), erectile dysfunction, dementia, and depression are 
other secondary complications associated to diabetes [162,163]. 
Recent preclinical animal models demonstrated that systemic infusion of MSC reverts 
hyperglycemia in mice. In fact, human BM-MSC can differentiated into insulin-producing cells 
in vitro, expressing genes related to the development and function of pancreatic beta cells and 
secreting insulin in a glucose-dependent manner. When these cells were transferred to a type 
1 diabetes mice experimental model, the diabetic symptoms were ameliorated [164]. 
Intravenous administration of undifferentiated BM-MSC also normalizes glycemia in type 1 and 
type 2 diabetes animal models and promote regeneration of pancreatic islands [163,165-168]. 
The beneficial effects observed in type 1 diabetes animal models are likely to be the result of 
the immunomodulatory properties of MSC, which were found to engraft lymphoid organs and 
induced systemic and local reduction of auto-immune T cells, along with an increase of 
regulatory T cells, and a shift from pro-inflammatory to anti-inflammatory cytokine profile in 
the pancreatic microenvironment. Of note, MSC infusion regenerated the local expression of 
epidermal growth factor (EGF) – a pancreatic trophic factor – in the pancreas and increased 
their levels in the plasma [166]. 
Beyond controlling hyperglycemia, MSC also act directly on the secondary complications 
of diabetic patients. For instance, in animal models of retinopathy, MSC derived from the BM, 
AT and placenta (intravenously, subretinally or intravitreally transfused) home to the damaged 
areas of the retina and differentiate into retinal cells, endothelial cells and astrocytes; they 
preserve the integrity of blood-retinal barrier and the retinal and the visual functions, while 
preventing retinal cell death and abnormal neovascularization, at least in part by secreting 
neuroprotective factors, such as basic fibroblast growth factor, nerve growth factor, brain-
derived neurotrophic factor, ciliary-derived neurotrophic factor and glial-derived neurotrophic 
factor [163,169]. In the same line, diabetes mellitus animal models also proved that human AT, 
UC and BM-MSC prevented or repaired renal damage, an effect independent of the glycemic 
control. Systemically transferred MSC engrafted into the kidneys, wherein they are able to 
undergo differentiation into endothelial cells and secrete EGF and HGF; both factors prevent 
kidney injury and the latter downregulates CCL2 (or monocyte chemotactic protein 1, MCP-1) 
expression, leading to the reduction of macrophage recruitment and expression of the pro-
inflammatory cytokines TNF-α, IL-1β, and IL-6 in the renal tissue [163,165,170]. MSC’s ability to 
produce pro-angiogenic factors (e.g. VEGF-A) surpasses the peripheral nerve’s blood vessels 
damage on the basis of diabetic neuropathy which, accompanied by the production of anti-
inflammatory and neurotrophic factors (FGF, nerve growth factor (NGF), neurotrophin-3), 
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leads to the improvement of peripheral nerve’s blood supply and creates an appropriated 
microenvironment to neural cell recovery, as verified in animal models of diabetic neuropathy 
[163,171]. Concerning diabetic cardiomyopathy – a pathological condition caused by 
hyperglycemia and resulting in myocardial hypertrophy, abnormal matrix deposition, 
cardiomyocyte apoptosis and microvascular defects – preclinical studies with diabetic mouse 
showed that BM-MSC improved the cardiac function by differentiating into cardiomyocytes, 
decreasing cardiac cell apoptosis, and improving angiogenesis and cardiac remodeling; 
paracrine mediators released by MSC, such as IGF-1, HGF, CXCL12 (or stromal cell-derived 
factor 1, SDF-1), and FGF-2, possibly play an important function in these processes [163]. To 
date, the effect of MSC transplantation on diabetic retinopathy, nephropathy, neuropathy and 
cardiomyopathy has not been investigated in human. 
In turn, topically administrated BM-MSC are currently being used in the treatment of 
diabetic wounds (and non-healing wounds of other etiologies) in humans, presenting 
remarkable results. The value of MSC had been previously demonstrated in preclinical studies, 
where their local or systemic administration resulted in the improvement of wound healing by 
MSC differentiation into epidermal and dermal cells, promotion of angiogenesis and collagen 
production, and secretion of growth factors (EGF, platelet-derived growth factor (PDGF), and 
VEGF); likewise, topically administrated BM-MSC reduced the ulcer’s size and pain in diabetic 
patients, and also improved vascular regeneration and dermal matrix synthesis [111,163,172].  
2.8. SYSTEMIC LUPUS ERYTHEMATOSUS 
Systemic lupus erythematosus is an autoimmune disease, characterized by chronic 
inflammation and production of auto-antibodies and associated with multiorgan injury, 
including the renal, cardiovascular, neural, musculoskeletal, cutaneous, and hematopoietic 
systems. The organ involvement and severity of the disease are highly variable among 
patients, nevertheless lupus nephritis and cytopenias are common manifestations and 
constitute important causes of morbidity and mortality [173,174]. 
In a mouse model of systemic lupus erythematosus, intravenous infusion of mouse BM-
MSC resulted in the reduction in glomerular immune complex deposition, lymphocytic 
infiltration, and glomerular proliferation, pointing to improvements in what concerns to the 
renal function [175]. However, no effect was observed in the IgG anti-dsDNA serum levels, 
proteinuria, or survival [175]. 
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In human, the advantages of the immunomodulatory properties of MSC are currently 
being tested in clinical trials, especially in treatment-refractory patients. Allogeneic MSC 
derived from BM and UCM, infused intravenously and in combination with 
immunosuppressive drugs, were demonstrated to induce stable remission, decrease disease 
activity and the serum levels of auto-antibodies and complement, improve renal function 
(including in patients with active and refractory lupus nephritis) and blood cell count 
[173,174,176-179]. Interestingly, MSC led to an increased frequency of peripheral blood Treg 
cells and decreased percentage of Th17 cells, which was associated to the decline of disease 
activity and to the improvement of anemia, leukopenia, and thrombocytopenia [174]. 
2.9. RHEUMATOID ARTHRITIS 
Rheumatoid arthritis is an autoimmune disease triggered by an immune response 
against self collagen-rich components of the joints. This autoimmune response, mediated by 
Th1 and Th17 cells, leads to the chronic inflammation of the joints, with subsequent cartilage 
destruction and bone erosion. Pro-inflammatory cytokines, free radicals, and extracellular 
matrix-degrading enzymes, produced by inflammatory cells infiltrating the joints (Th1 and 
Th17 cells, macrophages, and neutrophils) play a critical role in joint damage [180]. 
In vitro assays show that human BM-MSC have the ability to inhibit the proliferation, 
activation, and production of TNF-α and IFNγ by peripheral blood CD4+ and CD8+ T cells from 
arthritis rheumatoid patients, stimulated with type II collagen, while increased levels of IL-4 
and IL-10 are found in the co-culture supernatant [181]. These effects were shown to be 
partially mediated by TGF-β [181]. 
In collagen-induced arthritis (CIA), an experimental model of rheumatoid arthritis, 
intravenous administration of BM-MSC resulted in the delay of the disease onset, reduction of 
the paw swelling, and diminution of the infiltration of immune cells into the joints [182]. Apart 
from the improvement of the clinical signs of arthritis, a reduction in IL-6 serum levels, along 
with a decreased IFNγ and IL-17, and increased IL-5, IL-10, and IL-13 expression in cells isolated 
from the draining lymph nodes, were also detected among MSC-treated mice [182]. 
Noteworthy, MSC’s administration schedule was shown to be of utmost importance in CIA  
[182]. In the same line of evidence, human AT-MSC treatment of CIA mice resulted in the 
abolishment of the arthritis progression or in the amelioration of CIA severity, when MSC were 
administrated at the disease onset or after CIA establishment, respectively [180]. This was 
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accompanied by the reduction of pro-inflammatory cytokines levels in the synovium (TNF-α, IL-
1β, IL-6, IL-12, IL-17, and IFNγ) and serum (TNF-α and IFNγ), and by the augment of IL-10 in the 
synovium; these data were further confirmed in in vitro co-cultures of human AT-MSC with 
synovial cells, or draining lymph node cells, stimulated with type II collagen, wherein IL-10 and 
PGE2 were shown to play an important role in MSC-derived inhibition of TNF-α and IFNγ 
production. Remarkably, type II collagen stimulation of T cells from the draining lymph node of 
AT-MSC treated mice displayed a reduced number of CD4+TNF-α+ T cells, whereas the number 
of CD4+IL-10+ T cells was increased, as well as the levels of TGF-β in the culture supernatant; 
these data are consistent with the finding that treatment with AT-MSC induced an increased 
percentage of CD4+CD25++FoxP3+ Treg cells in vivo, in both synovium and draining lymph nodes 
[180]. 
To the best of our knowledge, only one clinical trial in rheumatoid arthritis published its 
results: this study enrolled 4 patients with refractory and persistently active rheumatoid 
arthritis and showed encouraging results for allogeneic MSC transplantation in this pathology 
[183]. 
2.10. CANCER 
The observation that tumors recruit MSC, from both local (tissue-resident MSC) and 
distant sources, as well as intravenously administrated ex vivo cultured MSC [184-188], opened 
new possibilities for their use in cancer therapy as delivery vehicles of therapeutic agents. 
Although the mechanisms of MSC mobilization to tumors still largely unknown, they are likely 
to overlap with those described for inflammation sites, as a great proportion of tumors is 
associated to inflammation and recent data point out the importance of cytokines and 
chemokines (specially CXCR4/CXCL12) for MSC homing to both tumors and sites of 
inflammation [15,188-192]. After recruitment, MSC integrate the tumor stroma and undergo 
differentiation into various cellular components of the stroma (osteoblasts, adipocytes, 
pericytes, and fibroblasts, among others), subsequently interacting with malignant cells. Once 
inside the tumor, and given the complexity of the tumor microenvironment and of MSC, the 
end result of the interaction between MSC and tumor can be either pro or anti-tumorigenic. 
On the one hand, MSC were shown to have the ability of promoting tumor growth, epithelial-
mesenchymal transition, angiogenesis, and metastasis, while modulating the immune cells’ 
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function; but on the other hand, MSC have also the ability to downregulate Wnt and Akt 
signaling pathways, having an anti-tumorogenic function [188,189,193-195]. 
Despite this duality in MSC behavior regarding the tumors, an increasing number of 
studies have demonstrated that MSC engineered with specific anti-tumor genes can be an 
effective anti-tumor therapy [189]. In the same line, as MSC are easily expanded in vitro, 
poorly immunogenic, and have the ability to home to and engraft tumors, the research of the 
use of these cells as vehicles for delivery of drugs specifically to tumors has gained an 
increasing interest in recent years. In experimental glioma rat models, the intracranial 
administration of unmodified MSC, gene-modified MSC expressing IL-2, or gene-modified 
neural stem cells expressing IL-4, IL-12, or tumor necrosis factor-related apoptosis inducing 
ligand (TRAIL) was shown to have an anti-tumoral action [184]. Both IL-2-gene-modified and 
unmodified MSC retard tumor growth and prolong rat survival [184]. 
Other studies in carcinoma animal models support the efficiency of the use of 
engineered MSC, including IFN-α on melanoma, IFN-β on pancreatic cancer, IFNγ on chronic 
myeloid leukemia, IL-12 on melanoma and hepatocellular carcinoma, and TRAIL on breast 
cancer and lung cancer [189]. 
2.11. GRAFT VERSUS HOST DISEASE 
Graft versus host disease (GvHD) is an important complication of allogeneic BM 
transplantation that arises from minor human leukocyte antigen (HLA) mismatch and is 
potentially lethal. Acute GvHD occurs 21 to 28 days after BM transplantation and is triggered 
by the donor’s T cells which recognize and react against the recipient’s cells, actively homing to 
and attacking target tissues, usually skin, liver and gastrointestinal tract. In turn, chronic GvHD 
presents some features of autoimmune disease and develops later, either as an extension of 
acute GvHD or in the absence of previous acute GvHD; it affects a variable number and type of 
organs leading to organ fibrosis and dysfunction [196,197]. 
The primary therapy for acute GvHD consists on immunosuppression with 
corticosteroids, but only 35% of the patients display a durable response to the treatment, and 
the prognosis for those refractory to therapy is very poor [196]; thus, most of the clinical trials 
using MSC has been performed in steroid-refractory patients. 
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After the encouraging results obtained by Le Blanc et al. [198] with the infusion of 
haploidentical MSC in one patient with treatment-resistant grade IV acute GvHD, clinical trials 
emerged and, despite the variations observed among the studies conducted by different 
research groups, a significant percentage of acute GvHD patients responding to treatment and 
a better overall survival rate was consistently reported [199-205]. Of note, the high response 
rate to MSC treatment was observed either in patients with only skin involvement, only 
gastrointestinal tract involvement, or multiorgan involvement [202]; for MSC derived from BM, 
MSC derived from UC, or for a premanufactured universal donor commercial preparation of 
BM-derived MSC (named “Prochymal”) [205-207]; and for either BM-derived MSC from HLA-
identical sibling donors, haploidentical donors, or third-party HLA-mismatched donors [200]. 
However, the variations in the number of MSC infused, number of infusions and their timing, 
which had been shown to be of utmost importance in animal models [208,209], limit 
comparisons between the abovementioned studies. It is noteworthy that von Bahr and 
colleagues [210] reported that the use of early-passage MSC (from passage 1-2) improved 1-
year survival of therapy-resistant acute GvHD patients, compared with late-passage MSC (from 
passage 3-4). 
In the same line, allogeneic BM-MSC transfusion in chronic GvHD steroid-refractory 
patients yielded promising results, being observed a complete or partial response in the 
majority of the patients, as well as an increased 2-year survival rate [211]. Of note, MSC 
seemed to be more effective in the lesions of the oral mucosa, gastrointestinal tract, and skin, 
not showing clinical benefits in chronic GvHD with lung involvement; furthermore, as 
expected, a low response was obtained in patients with advanced chronic GvHD because of 
the extensive organ fibrosis [196,211,212]. Importantly, MSC ameliorated sclerodermatous 
lesions (in all the 4 patients enrolled in the clinical trial conducted by Zhou et al.) [213] and dry 
eye syndrome (in an important percentage of patients) [214], which are two common 
pathological manifestations of chronic GvHD. As this condition is mainly mediated by Th2 
cytokines, it is worth to mention that the infusion of MSC increases IFNγ and IL-2, and 
decreases IL-4 and IL-10, measured both at intracellular and plasma level; also, these changes 
were correlated with an increased percentage of CD8+CD28- T cells [213,214].  
Taken together, data published so far support that MSC therapy has clinical benefits in 
patients submitted to allogeneic hematopoietic stem cell (HSC) transplantation in what 
concerns to the prevention and treatment of acute and chronic GvHD [197]; nevertheless, 
despite da Silva et al. demonstrated that the use of human BM-stromal layers is efficient for 
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the ex vivo expansion/maintenance of HSC from BM and UCB [215,216], it remains unclear 
whether MSC enhance HSC engraftment in vivo [197]. 
2.12. TRANSPLANT REJECTION 
In the last 5 years a number of clinical trials, most of them in small cohorts, has been 
giving clues about the potential benefit of MSC infusion to prevent or treat transplant kidney 
rejection. Autologous BM-MSC infused intravenously at the time or few days after kidney 
transplant allowed the reduction of the immunosuppressive drugs administration to patients; 
improved renal function; and showed a tendency to induce the decrease of peripheral blood 
CD8+ T cells with memory phenotype (CD8+CD45RO+CD45RA-), increase the frequency of 
CD4+CD25++FoxP3+CD127- Treg cells, and reduce CD8+ T cell-mediated immune response 
against donor antigens in in vitro assays [217-221]. Moreover, intravenous autologous BM-
MSC administration in kidney transplanted recipients with subclinical rejection and/or an 
increase in interstitial fibrosis/tubular atrophy, showed clinical benefit, along with the 
inhibition of PBMC proliferation and expression of IFNγ and chemokines, in response to donor 
or third party antigens [222]. 
2.13. ISSUES REGARDING THE THERAPEUTIC USE OF MESENCHYMAL 
STROMAL/STEM CELLS 
Although it is mandatory to conduct more clinical trials and study larger cohorts, 
published data foresee promising benefits of MSC therapy in a broad spectrum of disorders. 
This issue becomes particularly relevant as MSC-based therapies are being tested in 
untreatable and life-threatening diseases, and whose impact in the quality of life of the 
patients is devastating. However, some crucial questions need to be answered before MSC 
therapies enter the routine clinical practice. 
The first concern is the long-term safety of MSC-based therapy, including the potential 
risk of malignant transformation or ectopic tissue formation. Despite malignant transformation 
of MSC hadn’t been described in vivo so far, some studies suggest that MSC may favor survival 
and metastasis of pre-existing tumors [188,193,194]. In turn, the formation of intramyocardial 
calcification and ossification occurred in myocardial infarction murine models [139]. 
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Other important question is whether autologous or allogeneic MSC should be used. 
Theoretically, the use of autologous MSC allows to circumvent problems related to the risk of 
transmission of infectious diseases or possible rejection of the transplanted MSC; in fact, the 
“immune-privilege” status of MSC is being challenged by an increasing body of evidence 
describing that allogeneic MSC trigger immune responses against donor antigens mediated by 
T cells and B cells [109]. But, on the other hand, the use of autologous MSC collected under 
pathological conditions may not be innocuous. For instance, in the treatment of GvHD, BM-
MSC from the patient may be part of the malignant hematopoietic clone, or may be damaged 
during the chemotherapy conditioning regimen [196]. In fact, BM-MSC isolated from B-cell 
chronic lymphocytic leukemia patients were shown to produce altered levels of cytokines that 
enable them to promote the survival of the leukemic cells [223], and there are recent clues 
pointing in the same way for myelodysplastic syndromes [224]. Importantly, MSC isolated from 
patients with myelodysplastic syndrome were shown to carry the same genetic alterations 
than hematopoietic precursor cells (HPC) [225]; whereas in some chronic lymphocytic 
leukemia and acute lymphoblastic leukemia patients, it was detected BM-MSC aneuploidy 
[226]. In turn, concerning other disorders, it is uncertain if the functional abilities of MSC are 
fully preserved, being described a decreased immunosuppressive capability of MSC isolated 
from individuals with atherosclerosis [227], type 2 diabetes mellitus [227], systemic lupus 
erythematosus [228], and systemic sclerosis [110], though contradictory data had been 
published [110]. MSC from donors age above 65 years old also display decreased 
immunossupressive function [227]. Finally, other concern is the time spent to expand 
autologous MSC to a significant number of cells for therapeutic application, and this issue can 
preclude the use of autologous MSC under certain pathological condition, such as in situations 
of acute organ failure, where a ready-to-use source of allogeneic MSC would be more 
advantageous. 
The best source of MSC to be applied in each disease is other pertinent question that is 
far from being solved. In fact, an increasing body of evidence is revealing differences among 
MSC arisen from different tissues that ultimately may impact their clinical outcome. 
The preparation techniques, route of administration, optimal timing of administration, 
cell dose and number of infusions are other issues that can influence the end result of MSC-
based therapy and need to be study in detail. In particular, the importance of timing of MSC 
administration had already been demonstrated in EAE and cirrhosis animal models [129,160]. 
Further investigation will be needed to determine the optimal protocol for each disorder that 
can benefit from MSC-based therapy.  
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3. IMMUNOSUPPRESSIVE ABILITIES OF MESENCHYMAL STROMAL/STEM CELLS 
Although the enthusiasm for the therapeutic benefits of MSC arose firstly from the 
expectations on their ability to regenerate damaged tissue, by undergoing differentiation and 
substitute injured cells, the main clinical achievements came from MSC’s ability to change the 
microenvironment surrounding the degenerating tissues, either by producing trophic factors 
or modulating inflammation, allowing a faster and efficient recovery of the damaged cells and 
tissues. Likewise, the immunomodulatory properties of MSC are of utmost importance in 
controlling the undesirable or exacerbated immune response underlying auto-immune 
diseases, inflammatory diseases, graft rejection, and GvHD. 
In the last fifteen years, an increasing number of in vitro assays clearly demonstrated the 
immunomodulatory effect of MSC over immune cells and definitly contributed to unravel the 
mechanisms underlying MSC immunosuppressive abilities. The advantages of in vitro studies 
rely on the possibility to manipulate the variables in order to better understand MSC’s function 
and mechanisms. For instance, co-culture of MSC with purified immune cells is a common 
tactic used to determine if the MSC’s effects over those cell populations are direct or not; 
neutralization of specific molecules, by blocking antibodies or RNA interference techniques, 
are simple approaches to understand the contribution of the molecule for the MSC-driven 
immune suppression. 
Nevertheless, in vitro assays cannot mimic all the complexity found in vivo. An this fact 
assume more relevance for cell populations highly sensitive to the microenvironment, as MSC 
are. As described previously in this chapter (section 1.4), MSC function is influenced by the 
presence of other cells, by the cytokine present in the milieu, and by the presence of 
pathogen-associated molecular pattern (PAMP). These factors are different in a healthy versus 
non-healthy tissue and, besides, they are not static during the course of an infection or tissue 
damage. Thus, the predictive power of in vitro assays is expected to be limited. In this setting, 
the importance of in vivo animal models becomes clear. 
In this section, the characteristics, subpopulations, and functions of the different 
immune cell populations are briefly described, followed by a literature review disclosing the 
most relevant findings concerning how MSC modulate the immune cell population, assessed 
by in vitro and in vivo studies. 
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3.1. T CELLS 
3.1.1. T cells’ characteristics, subpopulations, and functions 
The pivotal role of T cells in host defense becomes clear with the poor prognosis 
associated to the immunodeficiencies affecting this hematopoietic cell population. Beyond the 
important specific cytotoxic function against cells infected by viruses or intracellular bacteria 
and malignant cells, carried out by cytotoxic T lymphocytes (CTL), the production of cytokines 
by helper T cells (Th) is vital to the regulation of the effector functions of the innate and 
acquired immunity. After T cell receptor binding to specific MHC-II-antigen complex expressed 
by antigen-presenting cells, and depending on the microenvironmental conditions (type of 
cytokines in the milieu, concentration of antigens, costimulatory molecules and types of 
antigen-presenting cells) [229], CD4+ T cells undergo activation, clonal expansion and 
differentiation into distinct effector phenotypes, namely Th1, Th2 and Th17, and into memory 
CD4+ T cells. Each one of the effector Th cell subsets is characterized by the presence of 
distinctive transcription factors with properties of master transcriptional regulators and a 
particular expression pattern of cytokines. The cytokines produced will determine the 
recruitment and activity of the phagocytes and other immune cells, the antigen processing and 
presentation, the class of immunoglobulins produced by B cells, and will bias the immune 
system toward an inflammatory and cell-mediated response or an antibody-mediated immune 
response [230]. 
Th1 differentiation occurs in the presence of IFNγ, IL-12 and IL-27, and IFNγ induce the 
expression of the master transcriptional regulator T-box transcription factor (T-bet). The 
cytokine expression pattern associated to Th1 cells comprises IFNγ, IL-2, TNF-α and TNF-β. 
These cells promote an inflammatory immune response against intracellular bacteria or virus, 
malignant cells or grafts, which is characterized by recruitment and activation of macrophages 
and other phagocytic cells, activation of NK cells, induction of cytolytic phenotype in CD8+ T 
cells and of the expression of IgG2a by B cells [229,231]. Th2 cells are responsible for the 
immune response against extracellular parasites and differentiate under the influence of IL-4 
and IL-2. These effector T cells are characterized by the expression the master regulator GATA 
binding protein 3 (GATA3), together with the following cytokines: IL-4, IL-5, IL-9, IL-13, IL-10, IL-
25, and amphiregulin. Th2 effector response includes induction of IgE expression by B cells and 
involves activation of basophils, mast cells, and eosinophils [229,231]. Polarization towards 
Th17 cells occurs in the presence of TGF-β and IL-6, and is characterized by the expression of 
the master transcriptional regulator retinoic acid receptor-related orphan receptor C2 
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(RORC2), the human correspondent to mouse retinoic acid receptor-related orphan receptor 
gamma-T (RORγt) [232]. IL-6 binding to its receptor on mouse T cells activates the signal 
transducer and activator of transcription (STAT)3, which induces the expression of RORγt 
[233], being demonstrated that STAT3 is also implicated in the differentiation of Th17 cells in 
human [232]. Th17 cells are involved in the immune response against extracellular bacteria 
and fungi. Their effector cytokines comprise IL-17A, IL-17F, IL-21, IL-22, IFNγ, and TNF-α, 
among others; in fact, the cytokines produced by Th17 cells depend on the cytokines present 
in the milieu where their differentiation takes place. The target-cells for IL-17 are distributed 
among a great variety of tissues throughout the body (namely, hematopoietic cells, 
osteoblasts, fibroblasts, endothelial cells, and epithelial cells) and IL-17 ligation induces the 
production of inflammatory cytokines by these cells. Therefore, Th17 effector response results 
in inflammation, by the induction of inflammatory cytokines in the IL-17 target-cells and 
recruitment of inflammatory cells to the site of inflammation [229,231,232]. Conversely, TGF-β 
in the absence of IL-6 promotes the differentiation of induced CD4+ Treg cells, which 
specifically express the master regulator forkhead box P3 (FoxP3). These cells negatively 
regulate the immune response by the production of IL-10, IL-35, and TGF-β [229,231]. 
3.1.2. Mesenchymal stromal/stem cells’ modulation of T cell functions 
Given the important role of Th cells in orchestrating and regulating the immune 
response, unsurprisingly, the majority of studies conducted to assess the immunosuppression 
abilities of MSC focused on T cells. Remarkably, the immunosuppressive effect of MSC over 
CD4+ T cells and CTL had been consistently described in the literature [231]. T cell suppression 
may be achieved indirectly, by regulating the function and activity of antigen-presenting cells 
(by modulating their cytokine expression or their ability to capture, process, and present 
antigens), which will be exploited later in this chapter (sections 3.5 and 3.6); or directly, 
through the interaction of membrane proteins from MSC and T cells (cell-to-cell contact) or 
through the release of soluble factors by MSC. However, there are important topics that need 
to be further investigated, such as to determine the effect of MSC on specific effector subsets 
or functional compartments of T cells, understand how specific pathological conditions will 
affect MSC immune-modulating functions, or perceive which source of MSC could maximize 
their clinical benefit for each specific pathological condition. 
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3.1.2.1. Mesenchymal stromal/stem cells inhibit T cell activation, proliferation, and 
function 
In the last 15 years, in vitro assays extensively proved that MSC inhibit CD4+ and CD8+ T 
cells. Indeed, MSC have the ability to inhibit CD4+ and CD8+ T cell activation (evaluated by the 
expression of T cell activator markers, namely CD69, CD25, HLA-DR, CD38) and proliferation, 
upon stimulation with phytohemagglutinin (PHA) [26,31,38,46,58,234-237], IL-2 [235], anti-
CD3/CD28 [30,38,58], concavalin A [129], or in mixed lymphocyte reactions (MLR) 
[26,31,38,75,234,235,237-239]. The activation and proliferation of CD4+ and CD8+ T cells are 
also impaired in transwell systems and with conditioned medium from lymphocytes and MSC 
co-culture, indicating that the suppressive effect mediated by MSC is achieved in part through 
the action of soluble factors [75,234,235,237,240]. However, the degree of suppression is 
lower than that observed when cell contact is allowed, demonstrating that cell-cell contact 
mechanisms also participate in the immunomodulation [235,240]. It is noteworthy that the 
decrease in the proliferation rate of T cells was not due to T cell apoptosis [45,235,241]; in fact, 
it was demonstrated that MSC can prolong survival of quiescent T cells and decrease the 
expression of Fas and Fas ligand (FasL) in activated T cells, thus inhibiting the activation 
induced cell death pathway [241]. Also, the inhibition of mitogen-mediated T cell proliferation 
is a process dependent of IL-2, as the addition of exogenous IL-2 to the co-culture system 
reverts the effects of MSC, as showed with mouse and baboons MSC [129,242]. Of note, the 
presence of MSC in PHA-stimulated PBMC or lymphocytes cultures decreases IL-2 mRNA 
expression in purified CD4+ and CD8+ T cells and the soluble levels of IL-2 detected in the 
culture supernatant [46,237,243]; similarly, the percentage of CD4+ and CD8+ T cells producing 
IL-2 protein, from phorbol 12-myristate 13-acetate (PMA) plus ionomycin-stimulated PBMC, is 
also reduced in the presence of MSC [244]. Conversely, in MLR assays, MSC do not decrease 
soluble levels of IL-2 and the addition of exogenous IL-2 do not restore T cell proliferation in 
human and mouse [243,245]; instead, an augment of soluble IL-10 is detected in the culture 
supernatant and, interestingly, blocking IL-10 further enhances the suppressive effect of MSC 
on T cell proliferation in human MLR, while no effect is observed after IL-10 blocking in PHA-
stimulated lymphocytes [243]. However, in mouse MLR, inhibition of IL-10 or IDO restores T 
cell proliferation [246]. In the same line, human BM-MSC-derived IDO also suppresses T cell 
proliferation in human MLR [247]. 
Other soluble mediators produced by MSC are able to suppress T cell proliferation. It has 
been demonstrated that PGE2 plays an important role in this process, as blocking its synthesis 
partially restores T cell proliferation in PHA stimulation assays [31,236,243,248,249], though its 
50 
influence over the inhibition of alloantigen-activated T cells is controversial [26,243,248]; 
similarly, TGF-β, hepatocyte growth factor (HGF) [235], HLA-G1 and HLA-G5 [30,67,239] were 
also found to mediate the inhibition of T cell proliferation.  
In fact, MSC were shown to arrest T cells in G0/G1 phase of the cell cycle by increasing 
the protein expression of p27KIP and decreasing phospho-Rb, cyclin D2 and cyclin A, in both 
mouse [245] and human [30], an effect mediated by HLA-G1 [30]. 
Overall, the published data demonstrate that MSC effectively inhibit T cell activation and 
subsequent clonal expansion, but the effect of MSC on T cells is dependent on the T cell stimuli 
and, depending on the environmental conditions, MSC make use of different inhibitory 
mechanisms; noteworthy, the degree of T cell suppression obtained is also dependent of the 
proportion of MSC in the cell culture [61,234,235,238,243]. 
Besides interfering with T cell activation and proliferation, MSC further inhibit T cell 
function and differentiation into effector cells. In general, co-culture of MSC with mononuclear 
cells (MNC) or purified CD4+ T cells results in the decreased expression of cytokines implicated 
in the inflammatory response and characteristic of a Th1/Th17-mediated immune response, 
such as IL-1α, IL-1β, IL-2, IL-12, IL-17, IFNγ, and TNF-α, and upregulation of Th2 cytokines, 
namely IL-4, IL-5, IL-10, and IL-13 [31,39,78,182,231,236,244,250-253]. 
3.1.2.2. Effect of mesenchymal stromal/stem cells over Th2 cells 
Human BM-MSC were shown to increase IL-4 expression in purified naive T cells 
(CD45RA+) cultured under Th2 inducing conditions [236]; though the inhibition of IL-4, IL-10, 
and GATA3 mRNA expression is reported for PBMC stimulated with PHA in the presence of 
human BM-MSC [46,254], while no effect is observed for the percentage of CD4+GATA3+ T 
cells, in MLR, in the presence of conditioned medium from human amniotic MSC [255]. 
Interestingly, it seems that when MSC are in the presence of a pathological condition 
mediated by Th2 cells, they not only decrease IL-4, IL-5, and IL-13 production, but also increase 
IFNγ, IL-2, (Th1 cytokines), TGF-β, and IL-10 (Treg cytokines), and expand CD4+CD25+FoxP3+ 
Treg cells, both in vitro and in vivo [213,231,249,256,257], a process mediated by PGE2 [249]. 
Similarly, when administrated in vivo, in mouse models of allergic airways inflammation 
(a Th2/Th17-mediated disease, characterized by increased levels of IL-4 and IL-17), BM-MSC 
increase IFNγ and IL-10 expression, while decrease IL-4, IL-13, and IL-17 [258-260]. In the same 
line of evidence, in a mouse model of ragweed induced-asthma (a Th2-mediated disease), BM-
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MSC decreased IL-4, IL-5, IL-13, IgA1, and IgE protein levels and eosinophil infiltration in the 
lung, all of which are typically increased in asthma; this inhibitory effect over the Th2-mediated 
immune response is attributed to TGF-β [261]. On the other hand, in Th1/Th17-mediated 
disorders like the CIA animal model, MSC treatment increases the expression of IL-5, IL-10, and 
IL-13 in lymph node cells and splenocytes, and increases GATA3 mRNA expression in the latter 
cell subset [182], together with the clinical amelioration of the arthritis. 
3.1.2.3. Effect of mesenchymal stromal/stem cells over Th1 cells 
Concerning the MSC effect over Th1-mediated immune response, published data 
consistently describe an inhibitory effect over both Th1 differentiation and function (in human 
and mouse), associated to a decreased expression of IFNγ and TNF-α by fully-differentiated 
Th1 cells [129,231,236,251,262,263]. Nevertheless, all these studies inferred that MSC inhibit 
Th1 differentiation and function based on the decreased IFNγ levels in the culture supernatant 
or on the decreased percentage of IFNγ-producing CD4+ T cells. Accordingly, it was recently 
described that conditioned medium derived from human amniotic MSC decreased the 
percentage of CD4+T-bet+ T cells in MLR [255]. However, when considering only the activated 
compartments of T cells, an increase of T-bet mRNA levels is observed upon co-culture with 
human MSC derived from BM, AT, or UCM [46]. 
Remarkably, recent data demonstrated that MSC upregulate IL-10 expression in IFNγ-
producing CD4+ T cells, endowing these Th1 cells with the ability to suppress T cell proliferation 
in an IL-10-dependent manner [264,265]; these cells do not express FoxP3 and, accordingly to 
their CD4+IL-10+IFNγ+ phenotype, are designated as regulatory T type 1 (Tr1) cells (of note, Tr1 
cells had been classically described as IL-10+TGF-β+IL-4-IL-2-IFNγ+/-) [266,267]. The induction of 
CTLA-4 expression is also observed on T cells co-cultured with MSC [44,238]. 
Regarding the CD8+ T cells and CTL, which are activated in the course of a Th1 immune 
response, MSC have the ability to inhibit CTL-mediated alloantigen-specific cytolytic activity 
[62,195,238] and reduce the secretion of granzyme B, TNF-α and IFNγ [195,231,241,244,268], 
being also observed a lower activity of the tyrosines activated downstream T cell receptor(TCR) 
signaling in the presence of MSC [97]. In a recent study in which skin-homing CD8+ T cells 
isolated from vitiligo patients were co-cultured with autologous dermal MSC, it was detected 
decreased levels of IL-1α, IL-12, IL-13, IL-15, MIP-1δ, among others, comparatively to skin-
homing CD8+ T cell monocultures [269]. Similarly to what is reported for CD4+ T cells, MSC can 
induce a regulatory phenotype in CD8+ T cells, which acquire the ability to inhibit T cell 
proliferation and to downregulate the expression of costimulatory molecules (CD80/CD86) in 
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monocytes, by mechanisms independent of IL-10, PGE2 and TGF-β [231,268,270]. Conditioned 
medium derived from human amniotic MSC was decribed to increase the percentage of 
CD8+CD28- T cells in MLR, which are considered to have a suppressor/regulatory activity [255]. 
Remarkably, the effect of MSC over effector CD8+ T cells seems to be less efficient 
[58,62,231,244], being described in the literature that, despite of inhibiting CD8+ T cell-
mediated cytotoxicity when added at the day 0 of a 6 days MLR, if added at the day 3, or after, 
human BM-MSC were unable to inhibit CTL-mediated lysis [62]; moreover, effector CD8+ T cells 
are more resistant to MSC-mediated suppression of TNF-α production, compared to naive and 
central memory CD8+ T cells [244]. 
Accordingly, in vivo animal models of inflammatory diseases treated with MSC show a 
decreased protein expression of TNF-α, IFNγ, IL-1β, IL-2, IL-6, IL-12, IL-17, T-bet, and RORγT, 
while the protein expression of IL-4, IL-10, TGF-β, GATA3, and FoxP3 is increased [180,271-
274]. The immunomodulation mediated by MSC was observed both in the periphery and in the 
damaged tissues [180,271,272]. 
3.1.2.4. Effect of mesenchymal stromal/stem cells over Th17 cells 
Similarly to Th1 cells, most of the studies performed so far demonstrate that mouse and 
human BM-MSC impair in vitro differentiation of purified naive and memory CD4+ T toward 
Th17 effector phenotype [9,251,263,275-278], an effect shared by human UC-MSC co-cultured 
with PBMC [279], and conditioned medium derived from human amniotic MSC in MLR [255]. 
However, other studies report the opposite showing that human BM-MSC induce CD4+ T cells, 
especially memory CD45RO+CD4+ T cells, to differentiate into Th17 cells [252,254,280]. 
Likewise, there are contradictory data regarding the influence of MSC in the function of fully 
differentiated Th17 cells, being possible that, under different conditions, MSC can either 
enhance [251,262] or impair Th17 function, including the production of IL-17A, IL-17F, IL-22, 
TNF-α, and IFNγ [9,244,263,275,278,281]. This hypothesis was elegantly demonstrated by 
Svobodova and colleagues [282]: in their study they show that, when untreated or pre-treated 
with TGF-β, mouse BM-MSC favor the differentiation of splenocytes into CD4+FoxP3+ Treg cells, 
because of the high amounts of TGF-β secreted by MSC; in turn, if pre-treated with IL-1α, BM-
MSC are induced to produce TGF-β and IL-6, promoting CD4+RORγt+ Th17 cell differentiation 
and IL-17 production. 
Human and mouse BM-MSC-driven inhibition of Th17 differentiation and reduction of IL-
17A and IL-22 expression in Th17 cells have been ascribed to PGE2 [9,275], as well as the 
induction of FoxP3 and IL-10 expression, converting fully differentiated human Th17 cells in 
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functional regulatory T cells, which have suppressive effects over T cell proliferation [9]. Of 
note, IL-10 produced by mouse BM-MSC mediates the inhibition of Th17 differentiation and 
reduces the expression of RORγt, IL-17A, and IL-17F in mouse T cells [278]. Likewise, PD-L1 
expressed on mouse BM-MSC plasmatic membrane was found to have an essential role in 
MSC-derived inhibition of proliferation, RORγt and IL-17 protein expression by fully 
differentiated Th17 [263]. 
In vivo, infusion of AT-MSC was shown to inhibit Th17-mediated immune response in 
different mouse models of inflammatory diseases. AT-MSC reduced the percentage of Th17 
cells in the lymph nodes of EAE animals [283] and in a murine model of systemic lupus 
erythematosus [274], the levels of IL-17 mRNA in the skin of mice with skin allograft [277], and 
the percentage of Th17 cells and IL-17 protein levels in the synovium of mice with CIA [180].  
3.1.2.5. Effect of mesenchymal stromal/stem cells over Treg cells 
Recently, it has been described that co-culture of human UCM-MSC or BM-MSC with 
putified CD3+CD4+CD25- T cells, stimulated with anti-CD3/CD28 plus IL-2, induces the 
generation of CD3+CD4+CD25+FoxP3+ Treg cells [37]. Indeed, a great number of studies using in 
vitro assays of MSC co-cultured with activated PBMC or purified CD4+ T cells demonstrated 
that MSC favor the differentiation of CD4+CD25+FoxP3+ Treg cells and enhance their activity 
[98,195,231,236,238,239,249,250,270,283-289], a process mediated by cell-to-cell contact 
[98,249,286,287] and by the soluble mediators PGE-2 [98,286,287], TGF-β [98,195,285-287], 
heme oxygenase-1 (HO-1) [285], soluble HLA-G5 [98,239,287], and LIF [98]. In the same line of 
evidence, the culture of purified CD4+ T cells or PBMC with conditioned medium from human 
AT-MSC or BM-MSC, respectively, resulted in the augment of CD4+CD25+FoxP3+ T cells 
associated to an increased protein expression of IL-10 in the supernatant, wherein the 
induction of Treg differentiation was mediated by TGF-β [285,290]. Likewise, the presence of 
conditioned medium derived from human amniotic MSC in MLR increased the percentage of 
CD4+FoxP3+ T cells, which were also induced to express higher levels of the immune 
suppressive molecules CD39, CD73, TGF-β, CD357 (AITR/GITR), and Helios [255]. 
Remarkably, human BM-MSC are also able to induce IL-10 expression in naive CD4+ T 
cells under Th17 differentiating conditions and in fully differentiated Th17 cells (a process 
partially mediated by PGE2), in parallel with the upregulation of FoxP3 and downregulation of 
RORc [9]. Though the expansion of the Treg subset is an efficient mechanism for MSC to inhibit 
the proliferation and the effector functions of T cells, in a recent study the allogeneic 
stimulation of CD4+ T cells or PBMC, under the influence of human UCB-MSC, did not induce 
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the increase of Treg subpopulation. Nevertheless, an effective suppression of T cell function 
was observed, mediated by the induction of IL-10 expression in IFNγ-producing T cells. In this 
particular study, it was observed that UCB-MSC increase the percentage of CD4+IFNγ+IL-10+ T 
cells without changing the frequency of CD4+CD25++FoxP3+ T cells, demonstrating that MSC 
may employ alternative mechanisms to negatively regulate T cell activity [264]. 
Besides, MSC can induce regulatory properties in human and mouse CD8+ T cells, 
upregulating the expression of IL-10, TGF-β, and FoxP3 in this cell population [193,270]. And, 
finally, Treg cells can also be indirectly induced as result of MSC-derived inhibition of DC 
maturation and induction of IL-10 expression [98], as described in detail in subsection 3.5. 
In in vivo animal models, AT-MSC induced an increased percentage of CD25+FoxP3+ T 
cells [283] and upregulated the expression of FoxP3 and IL-10 mRNA [277] detected in the 
draining lymph nodes from both mouse EAE and skin allograft models, respectively. In a CIA 
mouse model, AT-MSC treatment was shown to induce de novo generation of 
CD4+CD25+FoxP3+ Treg cells, which was translated as an increased number of Treg and 
increased IL-10 and TGF-β protein expression, in both synovium and draining lymph nodes 
[180]. In the same line of evidence, in mouse model of allergen-driven airway inflammation, 
BM-MSC treatment increases the percentage of CD4+FoxP3+ Treg cells, accompanied by 
increased expression of IL-10, in both lungs and spleen [260]; and in a murine model of 
systemic lupus erythematosus administration of human AT-MSC increase the number of 
CD4+FoxP3+ Treg cells in the spleen [274]. 
3.1.2.6. Effect of mesenchymal stromal/stem cells over the distinct functional 
compartments of T cells 
In recent years, there has been an increasing effort to understand how the effect of MSC 
on specific T cell effector subsets varied; however, there are few data comparing the immune-
modulating effect mediated by MSC among the distinct T cell functional compartments: naive, 
central memory (CM), effector memory (EM) and effector compartments. In our previous 
work, we demonstrated that the capability of human BM-MSC to decrease the percentage of 
CD4+ and CD8+ T cells expressing TNF-α, IFNγ, and IL-2 is verified among all the naturally 
occurring functional compartments of T cells (naive, CM, EM and effector compartments), and 
at different extents. Of note, only a small percentage of naive CD4+ and CD8+ T cells expressed 
the abovementioned cytokines. Also, the reduction of TNF-α and IFNγ secretion is achieved not 
only by reducing the percentage of T cells expressing these cytokines, but also by diminishing 
the amount of cytokine produced per cell [244]. Interestingly, BM-MSC-mediated inhibition of 
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TNF-α expression was less effective among the effector and EM compartments, for both CD4+ 
and CD8+ T cells, and the same subsets were also the most resistant to MSC-induced inhibition 
of IFNγ expression in CD4+ T cells, and the most inhibited for CD8+ T cells producing IFNγ [244]. 
Mouse BM-MSC also exert a stronger inhibitory effect over IFNγ-producing memory CD8+ T 
cells than naive CD8+ T cells [291]. Under the influence of human BM-MSC, the inhibition of IL-
2 and IFNγ expression was similar among all CD4+ T cell functional compartments [244].  
Consistently to what was observed for TNF-α, CD4+CD45RO+ and CD8+CD45RO+ T cells 
were shown to be less susceptible to proliferation’s suppression mediated by human AT-MSC 
than their CD45RO- counterparts; interestingly, memory CD4+ and CD8+ T cells were also 
shown to be more resistant to the inhibitory effects of Treg cells over MLR-induced 
proliferation [292]. In the same line, a recent study showed that conditioned medium derived 
from human amniotic MSC inhibit MLR-induced proliferation of CD4+ and CD8+ T cells included 
in the EM, CM, and effector functional compartments. However, MLR didn’t induced naive T 
cell proliferation, therefore it is not possible to compare this compartment with the remaing. 
Interestingly, after 6 days of MLR, the presence of conditioned medium derived from human 
amniotic MSC decreased the percentage of cells within the CM compartment and increased 
the percentage of naive T cells, for both CD4+ and CD8+ T cells [255]. 
Finally, in the studies describing that human BM-MSC were able to induce IL-17 
expression by CD4+ T cells, it was found that effect was exerted on memory CD4+CD45RO+ T 
cells, rather than in CD4+CD45RA+ [280] or CD4+CD45RO- [254] T cells, isolated from healthy 
individuals or rheumatoid arthritis and osteoarthritis patients, respectively. In opposition, 
mouse BM-MSC were shown to inhibit IL-17 cytokine, which affected naive and memory CD4+ 
T cells at similar level [275]. 
3.2. OTHER T CELL SUBSETS: γδ T CELLS AND INVARIANT NATURAL KILLER T 
CELLS 
3.2.1. γδ T cells 
3.2.1.1 Characteristics and function of γδ T cells 
γδ T cells belong to the non-conventional or innate lymphocyte family. Their T cell 
receptor (TCR) is composed of a γ and a δ chain with a restricted TCR region repertoire 
wherein, in human, only three Vδ genes and six Vγ genes are expressed. In human peripheral 
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blood, γδ T cells correspond to 1%-5% of total CD3+ T cells, and Vγ9+Vδ2+ is the most 
represented subset [104,293]. One important difference to the conventional αβ TCR T 
lymphocytes is that γδ T cells are not MHC-restricted, being able to recognize small peptides, 
soluble or membrane proteins, and small non-peptidic antigens, such as phospholipids, 
pyrophosphates (including the microbe-derived metabolites of the isoprenoid biosynthesis 
pathway), phosphoantigens produced by malignant cells, sulfatides, and alkylamines 
[104,293,294]. Also, because antigen recognition by Vγ9+Vδ2+ T cells does not require prior 
antigen processing or presentation by classical MHC or non-classical antigen-presenting 
molecules (CD1a, CD1b, CD1c, or CD1d), these cells are promptly activated during the early 
phase of the immune response. Similar to NK cells, γδ T cells are activated by ligands induced 
in a stress (DNA damage, heat stress) and/or infection context, namely MHC class I-related 
chain (MIC) A and B (MICA and MICB) and UL16 binding protein (ULBP) family, through the 
binding to the activating natural killer group 2, member D receptor (NKG2D), or direct 
recognition by γδ TCR [293]. Finally, human γδ T cells also express pattern recognition 
receptors (PRR), such as TLR [293]. 
The functional plasticity of γδ T cells is now beginning to be unraveled. Despite the first 
reports concerning the function of γδ T cells claim they exhibit cytotoxic activity against 
infected and transformed cells, together with the ability to produce TNF-α and IFNγ, it is now 
recognized that, besides this Th1-like phenotype, and depending on the microenvironment 
(cytokines and type of γδ TCR stimulus), γδ T cells can also acquire Th2, Th17, follicular helper 
T cells (Tfh), or Treg-like characteristics and functions, being also reported that activated Vδ2 T 
cells can act as antigen-presenting cells for CD4+ T cell-mediated responses [104,293]. 
3.2.1.2. Effect of mesenchymal stromal/stem cells over γδ T cells 
It was recently reported that human BM-MSC were able to inhibit proliferation of 
Vγ9+Vδ2+ or Vδ2+ T cells, induced by stimulation with IL-2 plus zoledronate [295] or 
bromohydrin pyrophosphate (BrHPP) [294] for the former γδ T cell subset, or by 
isopentenylpyrophosphate (IPP) [104] for the latter. The suppression of γδ T cell proliferation 
is mediated by PGE2 signaling through EP2 and EP4 receptors (which are highly expressed at 
their cell surface), whereas IDO, TGF-β1, IL-10, and HGF seem not to participate [104,294]. 
Concerning the effect of MSC over the cytokine production and cytolytic activity of γδ T cells, 
there are conflicting data in the literature: it was reported by Prigione and colleagues [104] 
that MSC did not inhibit TNF-α nor IFNγ production by Vγ9+Vδ2+ T cells stimulated with IPP, 
whereas the expression of both cytokines were found to be suppressed when these cell subset 
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was stimulated with BrHPP [294]; likewise, MSC didn’t alter the cytotoxic activity of Vγ9+Vδ2+ T 
cells over multiple myeloma nor melanoma cell lines [295], but hamper their ability to lysis 
Daudi Burkitt’s lymphoma cell line [294]. Concerning to the antigen-presenting cell functions of 
Vδ2+ T cells, MSC affect neither the ability of Vδ2+ T cells pulsed with Candida albicans bodies 
to stimulate the proliferation of autologous CD4+ T cells, nor their expression of CD80 and 
CD86 costimulatory molecules [104]. 
3.2.2. Natural killer T cells 
3.2.2.1.Characteristics and function of natural killer T cells 
Natural killer T (NKT) cells represent a unique subset of T lymphocytes, which accounts 
for approximately 0.2% of peripheral blood T cells and is characterized by the simultaneous 
surface expression of αβ TCR with a restricted repertoire and NK cell markers, namely CD161 
(or NKR-P1) and CD94 [296]. In human, there is a subset of NKT cells that express an invariant 
TCR α chain rearrangement (Vα24-Jα18) paired with the TCR β11 chain, designated as invariant 
NKT (iNKT) cells [230,296]. iNKT cells recognize glycolipid antigens (both foreign and self-
antigens) presented in the context of CD1d, a non-classical antigen-presenting molecule 
associated to β2-microglobulin [104,230,296]. After TCR priming, these cells can produce 
either Th1 (IFNγ, TNF-α, and IL-12) or Th2 (IL-4, IL-5, and IL-13) cytokines, also possessing the 
ability to produce Th1 and Th2 cytokines simultaneously; IL-17 and IL-10 may be produced by 
iNKT cells as well [296,297]. Nevertheless, NKT cells can also act as cytotoxic cells, being able 
to kill target cells, mainly through Fas/FasL interaction [230]. The factors and mechanisms that 
govern the effector functions assumed by iNKT cells are still not fully elucidated, though is 
evident that the type of antigen, the nature of the cell that presents the antigen, the 
costimulatory signals, and the cytokines in the milieu influence the functional response of iNKT 
cells [296,297]. 
3.2.2.2. Effect of mesenchymal stromal/stem cells over natural killer T cells 
Human BM-MSC were shown to efficiently suppress the proliferation of iNKT cells upon 
α-galactosylceramide stimulation, a process mediated by PGE2 and independent of IDO and 
TGF-β1 [104]. Additionally, human BM-MSC inhibit the secretion of IFNγ by Vα24+Vβ11+ iNKT 
cells, without altering the expression of TNF-α or their cytotoxic activity [104]. In an 
experimental mouse model of metastatic breast cancer, the administration of human 
peripheral blood-derived MSC decreased the number of CD3+NKp46+ NKT-like cells in spleen, 
besides favoring tumor growth and metastasis [298]. 
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3.3. B CELLS 
3.3.1. B cells’ characteristics, subsets, and function 
Humoral adaptive immunity relies on B cells’ ability to expand and differentiate into 
specialized antibody-secreting cells, the plasma cells, in response to a specific antigen (Ag). The 
secreted antibodies have the ability to specifically bind to the Ag expressed by the pathogen 
agents and, depending on the antibody isotype, they can impede cell infection by binding and 
blocking yhe receptors used by the pathogen to enter the host cell; they can opsonize the 
pathogen, recruiting phagocytic cells and facilitating the phagocytic process; they can activate 
the complement cascade, resulting in the pathogen lysis; and they can promote antibody- 
dependent cell-mediated cytotoxicity, through binding to CD16 (or FcγRIII). After exposure to a 
foreign Ag, B cell activation may occur in a T cell-independent or T cell-dependent manner, and 
the latter usually presuppose the formation of germinal centers and the generation of both 
memory B cells and plasma cells [230].  
After completing their differentiation process, transitional (immature) and naive 
(mature) B cells leave the BM and migrate to the lymphoid follicles, following the CXCL13 
gradient produced by follicular DC, which binds to CXCR5 expressed on B cell surface; then, B 
cells follow a pattern of recirculation between blood and lymphatic systems, and lymphoid 
follicles, to maximize the chance to encounter specific foreign antigens [230]. During their 
lifespan, naive B cells are dependent of survival signals given by B-cell activation factor (BAFF) 
– which is expressed by DC, monocytes, macrophages, neutrophils, and follicular DC – binding 
to the corresponding receptors on B cells [230].  
T cell-independent antigens activate B cells by crosslinking membrane immunoglobulin 
(Ig) receptors (which, together with CD79a and CD79b, forms the B cell receptor, BCR), or by 
binding to innate immune receptors, such as pattern recognition receptors (PRR), e.g. TLR 
[230]. Indeed, human B cell activation and differentiation into IgM-producing CD138+ plasma 
cells can be achieved through TLR9 stimulation in the absence of BCR crosslinking, which was 
verified for transitional (the most immature B cell compartment in peripheral blood), naive 
(mature B cells), and memory B cell compartments [299]. Likewise, signaling through TLR7 also 
activates and induces human naive B cell differentiation into IgG-secreting plasma cells, in the 
absence of BCR crosslinking and CD40 binding [299]. 
In a T cell-dependent response, B cells encounter and bind to the specific Ag through 
BCR; the Ag is subsequently internalized and processed, being ready to be presented in context 
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of a MHC-II molecule to a cognate activated CD4+ T cell [230]. After Ag recognition, B cells 
upregulate CCR7 expression, which leads to their migration toward T cell zones of the 
secondary lymphoid organs, where CCR7 ligands, CCL19 and CCL21, are produced by stromal 
cells [230,300]. There, B cell presents the Ag to a cognate activated (by previous contact with 
DC) CD4+ T cell; CD40 (expressed on B cells) binds to CD40L (or CD154, expressed on T cells), 
and the costimulatory molecules CD80 and CD86 (on B cells) bind to CD28 (expressed on T 
cells) [230]. The signals that trigger B cell activation are mediated by (1) Ag crosslinking to BCR, 
(2) CD40 signaling, and (3) cytokines secreted by the cognate CD4+ T cell, whose expression is 
induced by CD40L and CD28 stimulation [230]. Then, activated B cells proliferate and 
downregulate CCR7, which allows them to leave the T-cell zone of the secondary lymphoid 
organ [230,300]. 
Apart from that, the initial activation of CD4+ T cells by DC expressing ICOSL induces B-
cell lymphoma 6 (Bcl-6) expression on T cells, which is necessary for follicular T cells (Tfh) 
development. Bcl-6 downregulates CCR7 and P-selectin glycoprotein ligand 1 (PSGL-1) 
expression – allowing the exit of nascent Tfh from T cell zone of the secondary lymphoid organ 
– while upregulates CXCR5 expression. In turn, ICOSL expressed by activated B cells may give 
an important contribute to maintain Bcl-6 expression on the nascent Tfh cells along the B cell 
differentiation process [301].  
At that point, both activated B cells and activated T cells enter B cell follicles, following 
CXCL13 gradient produced by follicular DC, which binds to CXCR5 on B cell and T cell surface. 
Once in the B cell follicle, B cells still need to interact with T cells (via CD40/CD40L) and go 
through further cycles of cell division, giving rise to the germinal center. Subsequently, B cells 
undergo somatic hipermutation and Ig class switching – a process regulated by the cytokines 
released by Tfh – and only those B cells which recognize Ag presented by follicular DC with 
high affinity and receive CD40L signaling through Tfh cells, are positively selected to undergo 
differentiation into memory B cells or plasma cells (this process is called affinity maturation 
process) [230,299].  
The mechanisms that determine the differentiation of germinal center B cells into 
memory B cells or plasma cells are still elusive. There is the hypothesis that the differential 
activation of STAT5 or STAT3, for memory or plasma cell differentiation, respectively, has an 
important role in B cell fate [299]. Nevertheless, the transcription factors orchestrating 
memory B cell differentiation are still unknown. In fact, naive and memory B cell 
transcriptomes are very similar [302]. 
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According to the current knowledge, Bcl-6 and paired box gene 5 (PAX-5) need to be 
downregulated to occur plasma cell differentiation [299,300]. Bcl-6 is highly expressed by 
germinal center B cells and has an essential role in promoting survival and proliferation of 
these cells [299]; PAX-5 is essential for B cell lineage commitment and maintenance of B cell 
identity, it is also vital for B cell development, being involved in VH to D Ig heavy chain 
recombination and in maintaining Bcl-6 expression in B cells [230,299,300,303]. However, both 
PAX-5 and Bcl-6 repress the expression of B-lymphocyte-induced maturation protein 1 (BLIMP-
1), an essential and sufficient transcription factor for plasma cell differentiation 
[230,299,300,303]. Recent data point the interferon regulatory factor 4 (IRF-4) as the first 
transcription factor in the induction of B cells differentiation into plasma cells, and its 
expression is induced by CD40-mediated NF-kB activation [230,303]. In fact, IRF-4 
downregulates PAX-5 and Bcl-6 [230] and induces the expression of BLIMP-1 [230,303]. 
Likewise, STAT3 activation on B cells by Tfh-derived IL-21, also induces BLIMP-1 expression and 
plasma cell differentiation (interestingly, Bcl-6 represses STAT3 transcription) [299,300]. 
BLIMP-1, in turn, represses the expression of a great number of genes involved in B cell 
proliferation, somatic hipermutation and Ig class switching, class II transactivator (CIITA, 
resulting in the suppression MHC-II expression), and Bcl-6, among others; while upregulates 
genes implicated in Ig production and secretion, such as X-box binding protein 1 (XBP1), which 
induces the transcription of genes that regulate endoplasmic reticulum stress response, to face 
the enormous protein production that characterize plasma cells [230,303]. Also, during the 
plasma cell differentiation process, BLIMP-1 downregulates CXCR5 expression (allowing the 
cells to leave the germinal center), while upregulates CXCR4 and Very late antigen 4 (VLA-4) 
expression, permitting the exit of plasma cells from the lymph node and their migration to 
peripheral tissues and specialized niches of the BM, where BM-MSC produce CXCL12 (or SDF-1, 
the CXCR4 ligand) which is essential for plasma cells entering in the BM; CXCL12 also gives 
survival signals to long-lived BM plasma cells [230,300,303]. 
Finally, it was recently described a new B cell subset, B10 cells. They are not confined to 
any specific phenotypically characterized B cell compartment and are identified by IL-10 
expression, which endows them with regulatory functions. This cell subset comprises less than 
1% of total human peripheral blood B cells [304]. B10 cells development depends on antigen 
binding to BCR and their effector function (IL-10 production) occurs in response to its specific 
antigen and with T cell help through IL-21. These factors endow B10 cells with antigen-specific 
regulatory function. Functionally, human B10 cells were demonstrated to inhibit pro-
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inflammatory cytokine production by T cells and monocytes, in vitro; and animal model assays 
show that B10 cells have a suppressive effect over autoimmune inflammation, in vivo [304]. 
3.3.2. Effect of mesenchymal stromal/stems cell over B cells 
The immunosuppressive abilities of MSC include the inhibition of B cell proliferation, 
activation, function, and differentiation into plasma cells. And, despite not being as widely 
study as T cells, the mechanisms underlying B cell suppression by MSC are now becoming 
unveiled. Noteworthy, and accordingly to what is described for other immune cell populations, 
the effect of MSC on B cells can be antagonistic, depending on external conditions and on B 
cells and MSC intrinsic factors. Among the factors known to influence the outcome of MSC 
over B cells, it can be enumerated the immune cell populations present in the culture system, 
the type of stimuli used for B cell activation and/or differentiation, the strength of the B cell 
response to the stimulus, and the MSC:B cells ratio. 
It also worth mentioning that the immunomodulatory effect of MSC over B cell immune 
function is due to their direct effect over B cells, as demonstrated by studies using purified B 
cells in co-culture with MSC [305-308], but also to MSC action over other immune cell 
populations. In fact, MSC-mediated suppression of T cell function will indirectly hamper B cells, 
which is supported by the finding that the addition of CD40 agonist to MLR can reverse the 
suppressive effect of MSC over Ig production by B cells [55], and by the recent reports showing 
that, under some experimental conditions, MSC are only able to inhibit B cells when T cells are 
present in the culture system [309,310]; it is also worth to mention the MSC-derived 
downregulation of BAFF expression by DC [311]. Moreover, the suppressive effect of MSC over 
B cell is maintained in transwell, but is more pronounced when cell contact is allowed, pointing 
to both soluble factors and cell-to-cell contact-dependent inhibitory mechanisms [55,306]. 
3.3.2.1. Effect of mesenchymal stromal/stem cells on B cell proliferation 
Inhibition of proliferation is one of the suppression mechanisms that MSC exert over B 
cells. Indeed, human BM-MSC were shown to inhibit B cell proliferation induced by PHA alone 
[46] or with CD40L [312], LPS (TLR4 agonist) [313], CpG (TLR9 agonist) alone [314] or in 
conjugation with CD40L, anti-Ig, IL-2, IL-4, and IL-10 [305,306], and phorbol ester (12-
otetradodecanoyl-phorbol-13-acetate, TPA) [315]. This feature is shared by human AT-MSC, 
which have the ability of inhibit the proliferation of PHA-activated B cells [46]; and by human 
periodontal ligament stem cells, able to impair B cell proliferation upon CpG, CD40L, anti-Ig, IL-
2, and IL-4 stimulation [306]. 
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Interestingly, and conversely to what is observed for human BM- and AT-MSC, UCM-
MSC co-cultured with PBMC activated with PHA have no effect over the proliferation of B cells 
[46], underlining the functional differences among MSC derived from different sources. 
However, one study carried out in mouse purified B cells, stimulated with CpG, CD40L, anti-
IgM, and IL-4, reports that human UCM-MSC inhibits mouse B cell proliferation [308], 
highlighting the importance of the differences among animal species, and cell culture 
conditions (e.g. cell types present in the assay and cell stimuli used). 
The suppression of B cell proliferation by human MSC is not attributed to apoptosis 
[305,306]. Instead, BM-MSC were shown to induce cell cycle arrest in G0/G1 phases [305,315]. 
Interestingly, despite of inhibiting B cell proliferation, there are evidences that human BM-MSC 
also promote B cell survival [315]. In fact, the upregulation of IL-6 production by human BM-
MSC co-cultured with purified B cells [306], also increased in the supernatant of MLR with 
human BM-MSC [55], was demonstrated to protect B cells from apoptosis [306]. The role of 
soluble factors in human BM-MSC-driven inhibition of B cell proliferation was evidenced by 
transwell assays [305,306], and by the recent report that their derived membrane vesicles, 
which constitute a pathway of intercellular communication, actively participate in the 
suppression of B proliferation and function [314]. Notwithstanding, it was demonstrated that 
the membrane-bound proteins programmed death-ligand 1 (PD-L1) and PD-L2 [306], as well as 
galectin-9 [312] are involved in the suppression of B cell proliferation by human BM-MSC. 
Likewise, PD-L1 and PD-L2 mediate the same effect for mouse BM-MSC [175,316]. 
Remarkably, and similarly to what was found for T cells [241], human BM-MSC promote 
proliferation and survival of naive and transitional B cells in the absence of stimuli [307]. But 
this effect is also observed (again for naive and transitional compartments) when B cells are 
stimulated with CpG 2006, IL-2, anti-Ig, plus CD40L, as well as for naive, transitional and 
memory B cells after CpG 2006 plus IL-2 stimulation, in the absence of BCR stimulation and T 
cell help [307]. Irradiated human UCM-MSC also promote proliferation of purified B cells 
stimulated with CpG 2006, IL-2, anti-Ig, and CD40L [317]. In turn, mouse BM-MSC do not 
interfere with proliferation of B cells isolated from mouse spleen stimulated with CpG plus IL-
2, but display a strong inhibitory effect upon CpG plus IL-2, anti-Ig, and CD40L stimulation 
[175]. 
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3.3.2.2. Effect of mesenchymal stromal/stem cells on B cell activation and function 
Besides interfering with B cell proliferation, human BM-, UCM-, and AT-MSC also 
hamper B cell activation, as demonstrated by the suppression of the acquisition of activating 
markers (CD69 and CD25) by B cells stimulated with PHA [46]. 
Therefore, if MSC induce a defective B cell activation, it is expected that B cell function 
will be impaired as well. This is confirmed by several studies reporting an inhibitory effect of 
MSC over Ig production. In fact, Ig secretion by mitogen-stimulated B cells was shown to be 
suppressed by both human BM- and AT-MSC, wherein AT-MSC display a higher degree of 
inhibition [318]. At least under the influence of human BM-MSC, this effect is transversal for 
IgM, IgG, and IgA immunoglobulin isotypes, concerning the amount of Ig production and/or 
the number of antibody-secreting B cells. More specifically, the inhibition of the secretion of 
these three Ig classes was consistently found after stimulation with CpG 2006 alone [314], or 
plus CD40L, anti-Ig, IL-2, IL-4, and IL-10 [305,306] (with similar results for human periodontal 
ligament stem cells [306]), in MLR [55], upon LPS stimulation [319], cytomegalovirus (CMV) 
[319], or varicella zoster virus (VZV) [312,319]. Interestingly, BM-MSC display a more 
pronounced inhibitory effect for IgM, followed by IgG, whereas IgA is less affected, in MLR 
assays [55]. MSC-driven suppression of Ig production is also reported in mouse [175,308,320]. 
Remarkably, depending on the intensity of the response obtained to LPS, CMV, or VZV 
stimulation (which displays inter-individual variation), human BM-MSC can yield opposing 
effects, either suppressing or promoting IgG production, for a strong versus weak degree of 
stimulation, respectively [319]. In line with this, it was reported that human BM-MSC promote 
an increased secretion of IgM by naive and transition B cells, and of IgM, IgG, and IgA by 
memory B cells, after stimulation with CpG 2006 and IL-2 (in the absence of anti-Ig and T cell 
help); as well as an increased IgG and IgA production by transitional B cells stimulated with 
CpG 2006, IL-2, anti-Ig, plus CD40L [307]. Under the influence of this latter stimuli plus 
irradiated human UCM-MSC, purified B cells also show increased IgM, IgG, and IgA, in culture 
supernatants [317]. 
There are few reports concerning whether MSC influence the antigen-presenting cell 
function of B cells, being described that human BM-MSC does not alter HLA-DR, CD40, CD80 
and CD86 expression by B cells, after activation with LPS [313], or CpG, CD40L, anti-Ig, IL-2, IL-
4, and IL-10 [305,306]. Interestingly, human BM-MSC also interfere with B cell migration to 
secondary lymphoid organs and entering into germinal centers by decreasing the percentage 
of B cells expressing the chemokine receptors CCR7, CXCR4, and CXCR5, after stimulation with 
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CpG, CD40L, anti-Ig, IL-2, and IL-4, with [305] or without [306] IL-10. These results in the 
reduction of B cell migration toward CCL19, CXCL12, and CXCL13, respectively [305,306]. Of 
note, the abovementioned chemokines receptors are constitutively expressed by B cells and 
are responsible for their homing to lymphoid organs [305]. 
Finally, human BM-MSC also reduce the percentage of B cells producing TNF-α and IFNγ, 
having no effect on IL-4 and IL-10 expression, upon stimulation with CpG 2006 plus CD40L, 
anti-Ig, IL-2, IL-4, and IL-10 [305]. Conversely, human AT-MSC were reported to expand the IL-
10-producing B cell population (known to have regulatory functions), when non-stimulated or, 
to a greater extent, after LPS exposure [274,310]. 
3.3.2.3. Effect of mesenchymal stromal/stem cells on B cell differentiation into plasma 
cells 
The demonstration of the immunosuppressive activity of MSC over B cell’s Ig production 
in response to stimulation is highly suggestive of an inhibitory effect on the differentiation 
process from B cells to plasma cells. In this sense, and attending to the phenotypic 
characteristics of the different maturation stages of B cells, Tabera and colleagues [315] 
elegantly analyzed the influence of human BM-MSC on peripheral blood B cell differentiation 
into plasma cells. Plasma cell differentiation was induced by B cell stimulation with CpG, anti-
Ig, plus pDC, and the phenotypic analyses allowed the identification and quantification of the 
following B cell maturation stages: immature B cell (CD38-), mature B cell (CD38-/+), 
lymphoplasmocytes (CD38+) and plasma cell (CD38++), based on the expression of CD38, 
CD138, CD19, CCR7 and the surface versus cytoplasmic expression of Ig. When BM-MSC where 
present in the culture system, the number of plasma cells (CD38++ CD138+) generated 
decreased significantly, confirming that BM-MSC inhibit B cell differentiation into plasma cell 
[315]. Overlapping results were achieved with purified B cells stimulated with CpG, CD40L, 
anti-Ig, IL-4, and IL-10 co-cultured with human BM-MSC or periodontal ligament stem cells 
[306,309]; and by adding human BM-MSC derived membrane vesicles to CpG-stimulated PBMC 
cultures [314]. 
Accordingly, it was reported that mouse BM-MSC [321] and human UCM-MSC [308] 
suppress terminal mouse B cell differentiation into plasma cells. This inhibitory effect is 
mediated by soluble factors [308,321], in which matrix metalloproteinase (MMP)-processed 
CCL2 may have a prominent role [320]. Despite inducing proliferation of plasmablast, MMP-
processed CCL2 was also shown to mediate the MSC-driven inhibition of STAT3 activation in 
mouse plasma cells; the activation of STAT3 is crucial for plasma cell differentiation, because it 
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induces the expression of BLIMP-1 which, in turn, suppresses the expression of PAX-5 to allow 
the production of Ig [320]. Remarkably, MSC induce decreased BLIMP-1 mRNA levels and 
increased PAX-5 mRNA and protein expression [308,320,321]; and the increased of PAX-5 
protein expression is also mediated by MMP-processed CCL2 derived from MSC [320]. Besides, 
in mouse, MSC also suppress p38 and Akt phosphorylation [308], which have an important role 
in B cell proliferation and differentiation; however, in human, it was reported that MSC are 
able to either promote or inhibit p38 phosphorylation, depending on the type or strength of B 
cell stimulation [315]. Notwithstanding, a recent report describes that irradiated human UCM-
MSC promote plasma cell differentiation when co-cultured with purified B cells stimulated 
with CpG 2006, IL-2, anti-Ig, and CD40L [317]. 
3.3.2.4. In vivo studies 
In vivo, mouse immunization with either T-dependent or T-independent antigens 
resulted in the decreased serum levels of antigen-specific IgM and IgG1, upon administration 
of conditioned medium from BM-MSC [321]. In mouse models of systemic lupus 
erythematosus, the administration of human AT-MSC [274], human BM-MSC combined with 
cyclophosphamide [107], or murine BM-MSC [311], yielded promising results, increasing 
survival and decreasing the levels of circulating anti-dsDNA IgG. MSC treatment also reduced 
the amount of activated B cells and plasma cells [274,311], while increased the percentage of 
IL-10-producing B cells [274], in vivo. However, other study using the same model, and mouse 
MSC, resulted in increased levels of circulating anti-dsDNA IgG and of IgG deposition in 
glomeruli, compared with animal subjected to cyclophosphamide treatment [107]. In turn, in 
mouse models of transplantation, MSC infusion prolong the allograft survival and reduce the 
serum levels of allospecific Ig, as well as IgG-allospecific intragraft deposits [107]. Likewise, in 
hemophilic mice (induced by FVIII immunization), MSC treatment also decreased anti-hFVIII 
IgG titer as well as the number of anti-hFVIII Ig-secreting cells [312,320]. 
3.3.2.5. Concluding remarks 
Analyzing the published data altogether, there are an increasing body of evidence 
supporting that factors such the MSC tissue source, animal species, and ratio, type and 
strength of stimuli, and the presence of other immune cells, determine whether MSC will have 
a suppressive or activating action over B cell functions and differentiation. In fact, this aspect 
had been clearly demonstrated for B cell proliferation. 
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3.4. NATURAL KILLER CELLS 
3.4.1. Natural killer cells’ characteristics, subpopulations, and function 
Natural killer (NK) cells belong to the innate arm of the immune system and have an 
important role in given a prompt response against virus, bacteria, and neoplastic cells by their 
ability to kill self altered cells without prior stimulation. Though they also possess the ability to 
produce chemokines and cytokines, thus influencing other immune cells, such as DC and T 
cells, the main function of NK cells is, in fact, to recognize infected or tumoral cells and destroy 
them [322]. And to distinguish among abnormal (infected or malignant) and normal cells, NK 
cells rely on the signals given by their inhibitory receptors – killer immunoglobulin-like 
inhibitory receptors (KIR), C-lectin-type-inhibitory receptors (CLIR), and leukocyte associated 
Ig-like receptor 1 (LAIR1 or CD305) – and activating receptors – NKp30, NKp44, and NKp46 
(known as the natural cytotoxicity receptors, NCR), NKp80, NKG2D (CD314), CD69, and 
DNAM1/CD96 [322,323]. Nevertheless, there are other receptors, such as 2B4 (CD244) that 
can either have activating or inhibiting function, depending on the adaptor proteins to which 
they are associated [323]. It is the final balance between activating and inhibiting signals that 
will dictate the NK cell decision of kill or not to kill the target cell. 
Concerning the inhibitory receptors, both KIR and CLIR bind to and recognize HLA-I 
molecules on the target cells, and the result of this interaction gives inhibitory signals to NK 
cells, because a normal level of MHC-I expression is typical of a self non-altered cell, as 
malignant transformation or viral infection are often associated to decreased expression of 
these molecules [322]. Though KIR generally give inhibiting signals to NK cells after binding to 
and recognizing HLA-B and HLA-C molecules, there are a few KIR receptors, such as KIR2DS4, 
able to interact with non-HLA proteins in tumor cells and give activating signals [230]. Finally, 
LAIR1 binding to its ligand – the Gly-Prol-Hyp common motif of collagens type I, II, III, XIII, XVII, 
and XXIII – leads to the recruitment of SHIP1 to its cytoplasmic tail, making this phosphatase 
available to dephosphorylate the immunoreceptor tyrosine-based activation motifs (ITAM) of 
activating receptors (such as CD16) and, therefore, hampering their function [322].  
Regarding the NK cell activating receptors, CD16 is responsible for antibody-dependent 
cellular-mediated cytotoxicity [230]. CD16 binds to the fragment crystallizable (Fc) region of 
IgG, therefore it will enable the binding of innate immune cells bearing CD16 (NK cells, 
monocytes, macrophages, neutrophils, and eosinophils) to target cells whose Ag had 
previously been specifically recognized by cells from the acquired immune system. Thus, this 
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cytolytic mechanism endows cells from the innate arm of the immune system with antigen 
specificity. After binding to the target cell through CD16, NK cells release the content of their 
cytolytic granules in the cell contact interface, leading to target cell apoptosis [230]. Likewise, 
NKp30 (CD337), NKp44 (CD336), and NKp46 (CD335) receptors, which belong to the 
immunoglobulin superfamily, are thought to be only able to give activating signals, thus 
inducing the killing of the target cells [230,324]. NKp30 is constitutively expressed on NK cells 
and binds to B7-H6 molecules on tumoral cells; NKp46 is expressed by resting and activated NK 
cells and is thought to recognize ligands on malignant cells, which haven’t been identified yet; 
finally, NKp44, which is only present on activated NK cells, can recognize both viral and tumor-
associated ligands [324]. In human, the majority of NKG2D receptors (lectin-like type 2 
receptors) gives activating signals upon binding to the nonpolymorphic MHC class I chain-
related protein A (MICA) and B (MICB), or to UL16 binding proteins (ULBP members), which are 
induced by cellular stress, such as infection or DNA damage [230,324]; however, CD94/NKG2A 
binding to HLA-E (a nonclassic MHC-I molecule, whose levels of expression are directly 
proportional to MHC-I surface density) results in an inhibitory signal [101,230]. DNAM-1 is an 
activating receptor that binds to poliovirus receptor (PVR) and Nectin-2 [101]. Finally, the 
receptor 2B4 (CD244) can either trigger activating or inhibitory signals, though there are 
evidences that in human NK cells it acts mainly as an activating receptor [322,323]. 2B4 binds 
to CD48, but it can also bind to MHC-I, which results in the inhibition of 2B4-mediated killing 
[323]. Accordingly, to avoid NK cell aggression, self cells express high levels of MHC-I molecules 
(which will give inhibitory signals to NK cells), and low levels of ligands to NK cell activating 
receptors [322]. 
Notwithstanding, NK cells can also be stimulated by factors secreted by other immune 
or non-immune cells, such as type I IFN, IL-12, IL-15, and IL-18 [325]. In fact, IL-12 produced by 
antigen-presenting cells induces NK cell proliferation and IFNγ production; in turn, IFNγ and 
TNF-α produced by NK cells induce DC maturation and contribute to the assembly of a Th1 
response [322,325]. 
Concerning the effector functions, NK cells induce apoptosis on target cells by FasL/Fas 
interaction, by the releasing of granzyme which enters the target cell trough the pores built by 
perforin molecules, or by antibody-dependent cell-mediated cytotoxicity, through the action of 
CD16 molecule [230]. NK cells can also have a regulatory function. In fact, NK cells are able to 
secrete TGF-β and IL-10, being described that the former cytokine is induced after KIR 
interaction with soluble HLA-I molecules, which are known to be upregulated in autoimmune 
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diseases [322]. Moreover, NK cells can secrete soluble FasL, which can bind to and induce the 
apoptosis of T cells, thus controlling the immune response [322]. 
Importantly, NK cells are far from constitute a homogeneous cell population. It is 
accepted that CD56dim NK cells (≈90% of peripheral blood NK cells) possess a more pronounced 
cytotoxic function, while the main function CD56brigth NK cells is cytokine production [322,325]. 
Nevertheless, despite representing only ≈ 10% of NK cells in the peripheral blood, CD56bright NK 
cells are the most represented NK subpopulation on secondary lymphoid tissues, and CD56bright 
CD94/NKG2A+ NK cell subset is thought to give rise to CD56dim NK cells [324]. NK cell 
heterogeneity is also patent in the type of cytokine they express and, in this line, distinct 
subpopulations of NK cells have been identified based on their cytokine expression pattern, as 
the case of NK2, NK3, NKr, and NK22: NK2 cells are characterized by producing IL-4, IL-5, and 
IL-13; NK3 cells express IL-10; NKr cells produce TGF-β and are involved in maternal-fetal 
immune tolerance; finally, NK22 cells produce IL-22 which enable these cells to limit 
inflammation and protect gut mucosal integrity [322]. 
3.4.2. Effect of mesenchymal stromal/stem cells on NK cells 
In recent years, an increasing number of studies had been made with the aim to 
understand the influence of MSC over NK cell function and the respective underlying 
mechanisms. Indeed, MSC have the ability to inhibit cytokine-induced NK cell proliferation, as 
well as NK cell effector functions. 
3.4.2.1. Mesenchymal stromal/stem cells inhibit NK cell proliferation and activation 
The inhibition of NK cell proliferation in MLR plus IL-2 [75,238] or after cytokine 
exposure [101,102,326,327] was observed in the presence of human BM-MSC, and was shown 
to be mediated by both soluble factors and cell-contact mechanisms [45,327]. While in IL-15-
stimulated NK cells TGF-β and PGE2 were identified as interveners in this process [327], the 
inhibition of proliferation by human BM-MSC over IL-2-stimulated NK cells was the result of 
the synergistic action of PGE2 and IDO, in which TGF-β did not participate [326]. The inhibition 
of proliferation is dose-dependent and more significant for CD56bright NK cells [327]. Of note, 
the inhibition of PGE2 synthesis alone does not suppress the IL-2-induced NK cell proliferation, 
whereas IDO inhibition show a partial effect, but significantly lower than the effect observed 
when both PGE2 and IDO are inhibited simultaneously [326]. It is possible that several factors 
released by MSC contribute to the inhibition of NK cell proliferation, and the absence of one 
factor could be compensated by other factors present in the cell culture; notwithstanding, it is 
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described that PGE2 induces IDO expression [266], but whether the induction of IDO is 
necessary for the inhibitory effect of PGE2 over NK cell proliferation is still elusive. 
In addition, human BM-, AT-, and UCM-MSC impair PHA-induced activation of both 
CD56dim and CD56bright NK cells (assessed by the expression of the activator markers CD69 – 
considered an early activator marker – and CD25), except for UCM-MSC that are unable to 
inhibit the activation of CD56bright NK cells subset [46]. However, there are conflicting results 
regarding the inhibitory effect of MSC over CD69 expression under the influence of BM- and 
AT-MSC, although is worth mentioning that there are important differences in the culture 
conditions of those who detected MSC-driven CD69 decrease [46,102,328] and those who did 
not [33,326]. 
3.4.2.2. Mesenchymal stromal/stem cells inhibit NK cell function  
Accordingly with the impairment of NK cell proliferation and activation, human BM-MSC 
also display an inhibitory effect over NK cell production of TNF-α, IFNγ, and IL-10 (more 
pronounced for CD56bright than CD56dim NK cells) [75,76,102,236,326,327]; over granzyme B 
protein [102] and perforin mRNA expression [46]; over the expression of the activating 
receptors NKp30, NKp44, NKG2D, DNAM-1, 2B4, CD69, and CD16 (despite some controversy 
regarding MSC effect on NKG2D expression [33]), as well as IL-2Rγ chain (CD132, the common 
γ-chain of IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors) [33,46,102,326,327]. Likewise, human 
UCM-MSC also inhibit IFNγ production by NK cells activated with IL-12 and IL-18, alone or in 
combination [329]. Conversely, no changes were detected on the NK cell expression of NKp46, 
KIR, and CD94/NKG2A upon co-culture with human BM-MSC [33,326]. 
Of note, the inhibition of IFNγ production was found to be mediated by HLA-G5 in 
allogeneic stimulated NK cells [239]; by activin A and PGE2, in IL-12 plus IL-18-activated NK 
cells [329]; and by PGE2 and IDO, in IL-2 plus IL-15-activated NK cells [76,329]. Interestingly, 
UCM-MSC also induced the inhibition of STAT4 and NF-kB activation, as well as a decrease in T-
bet expression and DNA-binding activity (T-bet is the master regulator of IFNγ production in T 
cells and NK cells) [329]. On the contrary, it was demonstrated that neither PGE2 nor TGF-β are 
involved in the downregulation of cytokines, NKG2D, and 2B4 expression in IL-15-stimulated 
NK cells [76,327]. 
Functional assays demonstrated that both human AT- and BM-MSC decrease the 
degranulation capability of NK cells (measured by CD107b expression at NK cell surface) 
[33,239], while human BM-MSC also inhibit NK cell cytotoxicity induced by allogeneic antigens 
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from KIR-ligand incompatible target cells [238], as well as against tumor cell lines (after 
stimulation with either IL-2 or IL-15) [43,75,102,326,327]; this latter process is mediated by 
cell-cell contact, PGE2, and IDO, and independent of TGF-β [326,327]. HLA-G5 also participates 
in the impairment of NK cell cytotoxic activity mediated by MSC [239]. In turn, NK cell-
mediated lysis of HLA-class I negative cell lines was not affected by MSC [62,327]. 
Remarkably, human UCM-MSC induce the expression of CD73 on NK cells. As NK cells 
constitutively express CD39, the induction of CD73 expression enable NK cells to produce 
adenosine. In fact, increased levels of adenosine are found in purified NK cells and human 
UCM-MSC co-cultures. Adenosine is known to reduce TNF-α and IFNγ production by NK cells 
and to prevent NK cell degranulation; it also has important suppressive functions over other 
immune cell populations (detailed in section 4.4 of this chapter) [330]. 
3.5. DENDRITIC CELLS 
3.5.1. Characteristics, subpopulations, and function of dendritic cells 
Dendritic cells (DC) comprise a heterogeneous population of immune cells, whose main 
function is antigen presentation to naive T cells and to influence their differentiation towards 
distinct types of effector T cells. Despite this essential function to trigger the adaptive immune 
response, DC also activate/regulate the function of other immune cells, such as B cells, 
monocytes, NK, and NKT cells. 
Different DC subpopulations can be identified based on their immunophenotype and 
localization. In the peripheral blood it is possible to distinguish myeloid DC (mDC) and 
plasmacytoid DC (pDC). Both subsets are negative for CD3, CD19, CD56, and CD14 markers. 
pDC present high expression of CD123, is positive for CD4 and CD303 (or blood dendritic cell 
antigen-2, BDCA-2) and negative for CD33 and CD11c; these cells have the ability to produce 
copious amounts of type I IFN, assuming an important role in controlling viral infections and, 
besides peripheral blood, pDC can also be found in lymphoid tissues [230,331,332]. In turn, 
peripheral blood mDC are CD33+CD13+CD11c+CD123-CD4-, and can migrate to peripheral 
tissues. Peripheral blood mDC have recently been suggested to be subdived on two 
subpopulations: CD1c (BDCA-1)+ DC and CD141 (BDCA-3)+ DC [332]. Another DC subpopulation 
identified in the peripheral blood corresponds to 6-sulfo LacNAc+ (slan) DC, formerly known as 
M-DC8+ DC [333,334]. Despite being considered a pro-inflammatory subpopulation of DC, due 
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to their ability to secrete large amounts of TNF-α and IL-12 [333,334], slanDC efficiently 
present antigen to naive T cells, can stimulate autologous T cells in MLR (which is considered a 
characteristic property of DC), induce alloantigen-specific cytotoxic CD8+ T cells and tumor-
specific cytotoxic T cells [334,335]. These cells are phenotypically characterized as positive for 
6-sulfo LacNAc, CD16, CD33, CD4, CD32, CD11b, CD11c, CD13, CD45RA, and C5aR (CD88), and 
negative for CD14, CD64, and CLA [333-335]. However, despite previously published studies 
demonstrating these cells clearly possess DC functions, slanDC were shown to be included in 
the peripheral blood myeloid CD14-/lowCD16+ cell population (comprising approximately one 
third of them) [336] recently denominated as “non-classical monocytes” by a panel of 
immunology experts (chapter 1, section 3.6) [332]. 
In the peripheral tissues, it is possible to identify Langerhans cells, which express CD1a 
(important for the presentation of non-peptide antigens) and langerin, and can be isolated 
from the basal and suprabasal layers of epidermis [331,337]; interestingly, the classification of 
Langerhans cells as DC are now being challenged by their transcriptional profiling and other 
characteristics that suggest these cells constitute a population of tissue-resident macrophages 
[338]. Interstitial DC are also found in peripheral tissues, specifically in the dermis, and express 
DC-SIGN [337]; finally, follicular DC are localized on B cell follicles, where they secrete survival 
factors for B cells within the secondary lymphoid organs and provide the contact of B cells with 
antigens, necessary for maturation of affinity and selection processes during their 
differentiation into memory B cells or plasma cells [230].  
Overall, after DC differentiation in the BM, the cells enter peripheral blood and migrate 
into peripheral tissues. At this stage, they are considered immature DC, their function is to 
monitor the body for signs of threat and capture foreign antigens, therefore they are highly 
specialized in antigen capture and possess low ability to stimulate T cells. Accordingly, the 
immature DC present a high antigen-capturing activity, being able to uptake antigens through 
phagocytosis, receptor-mediated endocytosis (using C-type lectin receptors, Fc receptors, and 
complement receptor CR3), and pinocytosis [230,331,339]. Moreover, they express a pattern 
of chemokines receptors optimized to guide them to sites of inflammation [340,341]. After the 
encounter with antigens in the presence of dangerous signals – such as pathogen invasion, 
inflammation, or cell damage – DC undergo activation and maturation. This process can be 
triggered by the signals received through DC’s PRR (which are activated by the binding of 
bacterial and viral products, or components released by damaged cells), Fc receptors (which 
bind to antibody-opsonized pathogens), or pro-inflammatory cytokines (TNF-α, IFNγ, and IL-
1β) and prostaglandins [230,340]. During the maturation process DC diminish their phagocytic 
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and endocytic activity (which is associated to the downregulation of endocytic and phagocytic 
receptors), as well as the expression of chemokine receptors for inflammatory sites, while 
increase the expression of proteins needed for antigen presentation: class I and class II MHC 
molecules, costimulatory molecules (CD40, CD80, and CD86), and cell adhesion molecules. 
Besides, the expression of CD83 (considered as an activation marker for DC) is induced during 
the maturation process, similarly to CCR7, which follow the same pattern [331,339,340]. 
Importantly, the induction of this chemokine receptor enable the mature DC to migrate into 
the T cell areas of secondary lymphoid organs, where they can present the MHC-bound 
antigens to T cells, being capable to prime naive T cells and trigger the adaptive immune 
response [331,340,341]. 
Upon activation, depending on the signals given by the pathogen (as different 
pathogenic agents will activate distinct PPR), DC will be conditioned to produce a specific 
cytokine pattern that ultimately determines the sense of T cell differentiation. Roughly, gram-
negative bacterial and viral products will stimulate TLR4/5 and TLR3/7/9, respectively, inducing 
DC to produce IL-12, which contributes to a Th1 immune response; the binding of fungi 
products to Dectin-1, stimulates the secretion of TNF-α, IL-6, and IL-23 by DC, leading to a Th17 
response; in turn, the activation of TLR2/6 by these same pathogens, induces IL-10, TGF-β, and 
retinoic acid expression by DC, conducting to Treg differentiation; finally, TLR2/1 activation by 
helminthes will stimulate IL-10 expression by DC, while induces IL-4 production by mast cells, 
which will promote naive T cell differentiation into Th2 effector cells [230,342]. As pDC do not 
express TLR2, TLR3, TLR4 and TLR5, they are unable to respond to bacteria the same way mDC 
do [341]. In fact, the more recognized function of pDC is the production of great amounts of 
type I IFN in response to virus, which occurs through TLR7/9-dependent and independent 
pathways [343]. Of note, pDC also secrete TNF-α and IL-6 in response to virus; this latter, 
together with IFN-α, contributes to B cell differentiation into plasma cells [343]. 
Notwithstanding, the production of IFN-α can further activate pDC, mDC (including the 
promotion of IL-12 expression by mDC) and other antigen-presenting cells (monocytes and B 
cells), can activate NK (improving their cytolytic activity), NKT, and CD8+ T cells, and bias T cell 
differentiation toward a Th1 phenotype [341]. 
Remarkably, the internalized and processed antigens can be presented by DC to CD8+ T 
cells, in the context of MHC-I molecules (this process is called cross-presentation), allowing an 
effective activation of naive CD8+ T cells and subsequent differentiation in CTL [230,331]. 
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Conversely, specific conditions can also dictate the development of tolerogenic DC, 
which are considered to have an immature or semi-mature phenotype, being able to present 
antigens, but lacking the expression of costimulatory molecules or cytokines needed for the 
development of a T cell-mediated immune response. In fact, these tolerogenic DC have the 
ability to delete auto-reactive T cells, render T cells anergic, or induce their differentiation into 
regulatory T cells, including CD4+ Treg and IL-10-producing suppressive CD8+ T cells. This 
process is of utmost importance for maintaining central and peripheral tolerance, and both 
mDC and pDC participate in it [337,341]. 
The low frequency of DC in peripheral blood has definitely contributed to the common 
use of in vitro generated DC in research, and the studies on the effect of MSC on DC are not 
the exception. Caux et al. (1992) [344] and Romani et al. (1994) [345] published the first 
papers describing the protocols for ex vivo generation and expansion of human DC able to 
yield a reasonable amount of cells. In these studies, DC were generated from CD34+ HPC from 
UCB or from mobilized peripheral blood, in culture with GM-CSF alone or in combination with 
TNF-α; or from peripheral blood CD34+ HPC or CD34- cells cultured with GM-CSF plus IL-4 
[344,345]. Since then, other protocols for DC generation and expansion have been developed 
(as thoroughly reviewed by Zou et al. [339]), using different precursor cells and distinct 
cytokines for either DC generation or the induction of DC maturation. Nevertheless, though DC 
can be generated from different types of hematopoietic cells, isolated from several tissues, 
and upon exposure to a vast array of cytokines, the majority of the studies uses peripheral 
blood monocytes or BM CD34+ HPC, with GM-CSF in combination with either TNF-α or IL-4, a 
protocol which generates immature DC [339]. In vitro induction of DC maturation may be 
achieved by several pro-inflammatory cytokines, namely TNF-α, IL-1β, as well as by CD40L or 
bacterial products, such as LPS [331]. However, the great diversity of techniques for ex vivo DC 
generation and expansion is associated to distinct cellular responses, which have complicated 
the comprehension of the biology of DC in the past, and might hinder the understanding of the 
influence of MSC on DC activation, maturation, and function, in the present. For this reason, 
the use of DC directly isolated from human tissues is a valuable approach. Even though, the 
investigation of the effect of MSC on naturally occurring human peripheral blood DC was 
carried out in a small number studies [79,236,333].  
3.5.2. Effect of mesenchymal stromal/stem cells on dendritic cells 
The suppressive effect of MSC over DC is evident at different stages of DC ontogeny. In 
fact, according to the majority of published data, MSC have the ability to impair both 
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monocyte and CD34+ HPC differentiation into DC; to prevent DC maturation and, as 
consequence, DC effectiveness to prime T cells; and, finally, MSC induce a tolerogenic 
phenotype on DC, which become efficient suppressors of the T cell activation and function, or 
induce T cells to have a regulatory function. 
3.5.2.1. Effect of mesenchymal stromal/stem cells on dendritic cell differentiation 
When in vitro generation of DC from either BM precursors [346,347], UCB-derived CD34+ 
HPC [348], or peripheral blood monocytes [25,47,53,348-351] is concerned, different studies 
demonstrated that human MSC prevent this differentiation process. Specifically regarding the 
in vitro differentiation of peripheral blood monocytes into DC under the influence of GM-CSF 
plus IL-4, human BM-MSC [25,47,53,348,349,352], AT-MSC [47], UCM-MSC [25], and amniotic 
mesenchymal tissue cells [351] are potent inhibitors of this process; conversely, UCB-MSC do 
not share this feature [353]. In fact, the presence of MSC prevents the downregulation of 
CD14, upregulation of CD1a, monocyte proliferation and acquisition of a typical DC 
morphology, expected during monocyte differentiation into DC. Moreover, BM-MSC, UCM-
MSC, and UCB-MSC impair the endocytic activity of immature DC [25,350,353]. Similarly, 
human BM-MSC also prevent PBMC differentiation into mDC upon allogeneic stimulation in 
MLR [238]. Evidences point to the involvement of IL-6 [348], macrophage colony-stimulating 
factor (M-CSF) [348], PGE2 [53], and Notch signaling [347] in the inhibition of DC 
differentiation driven by human BM-MSC, but contradictory results have been published 
regarding this subject. 
As expected, BM CD34+ HPC and monocyte-derived DC generated in the presence of 
either human BM-MSC [47,53,347-349], AT-MSC [47], or amniotic mesenchymal tissue cells 
[351] failed to undergo maturation triggered by LPS, CD40L, or TNF-α. In fact, after stimulation 
of DC differentiated in the presence of MSC, there were decreased expression of HLA-DR, 
CD80, CD86, CD83, and IL-12 in DC, along with a reduced ability to stimulate T cell allogeneic 
activation in MLR, namely decreased T cell proliferation, expression of activation markers, and  
production of IFNγ. Interestingly, the presence of BM-MSC or AT-MSC also induces the 
upregulation of IL-10 expression by DC [47,347]. It is worth mentioning that monocyte-derived 
DC, differentiated and maturated in the presence of human periapical lesions-derived MSC, 
express higher levels of IDO, immunoglobulin-like transcript (ILT)3 and ILT4, a feature shared 
with tolerogenic DC [354]. Besides, these DC were shown to induce either T cell anergy, or 
suppressive T cells, demonstrated by the increased percentage of CD4+CD25+FoxP3+ Treg cells, 
as well as of IL-10-producing CD4+ T cells (Tr1) [347,354]. The induction of suppressive T cells is 
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mainly attributed to IDO [354] and Notch signaling [347], but ILT3 and ILT4 participate as well 
[354]. 
3.5.2.2. Effect of mesenchymal stromal/stem cells on dendritic cell maturation 
To better understand whether MSC interfere specifically with DC maturation, a few 
working groups had investigated the influence of MSC over immature monocyte-derived DC, 
generated by GM-CSF plus IL-4 in the absence of MSC, and matured by LPS in the presence of 
MSC. 
Co-culture of BM-MSC [25,31], AT-MSC [31], or UCM-MSC [25] with human peripheral 
blood monocyte-derived mDC (generated by GM-CSF plus IL-4) and pDC (generated by IL-3), 
stimulated with LPS (as a maturation-driving factor), results in the reduction of expression of 
markers associated to DC maturation: CD80, CD86, CD83, and HLA-DR. In the same line, BM-
MSC, AT-MSC, and amniotic mesenchymal tissue cells also suppress TNF-α, IFNγ, and IL-12 
production by mDC upon LPS-stimulation [31,351], while increase IL-10 secretion by pDC, and 
this latter effect is mediated by PGE2 [31]. Likewise, for human peripheral blood monocyte-
derived mDC (generated by GM-CSF plus IL-4), in co-culture with T cells and stimulated with 
the superantigen staphylococcal enterotoxin B (SEB), the presence of human BM-MSC also 
reduces HLA-DR, TNF-α, and IL-12 expression, while have no effect neither on IL-1β nor CD86 
expression [355]. Remarkably, co-culture of human BM-MSC with mature monocyte-derived 
DC also results in the downregulation of HLA-DR, CD1a, CD80, CD86, and CD83 [349]. 
3.5.2.3. Effect of mesenchymal stromal/stem cells on dendritic cell function 
Importantly, it is consistently found that DC which undergo maturation under the 
influence of MSC display an impaired ability to present antigen and to induced allogeneic T cell 
proliferation, as well as a diminished capability to promote IFNγ expression by T cells, which is 
valid for both DC generated in the presence [348,349] and in the absence [11,31] of MSC. This 
is in accordance with the lower expression of MHC-II, costimulatory molecules and cytokines 
(such as TNF-α and IL-12) with an important function in T cell activation. Remarkably, after 
contact with MSC-treated DC, T cells become non-responsive to a second round of activation 
[11,354]. Furthermore, the effects exerted by human BM-MSC on DC (as well as on 
monocytes), endows these antigen-presenting cells with the ability to inhibit T cell response to 
the superantigen SEB, detected by the impairment of both T cell proliferation and IFNγ 
production [355]. This effect is partially dependent on IL-10 [98,355]. In fact, by the 
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maintenance of DC in an immature or semi-mature state, MSC may contribute to the induction 
of Treg cells [98,99]. 
A recent work found that the presence of human BM-MSC during monocyte-derived DC 
maturation by antigen loading, impairs DC to establish active immune synapses with T cells, 
thus hindering T cell priming [11]. This inability results from the alteration of actin distribution 
in DC, which is mediated by MSC-driven inactivation of Rac-1, a protein which participates in 
actin cytoskeleton changes and is required for a normal interaction between DC and T cells  
[11]. Similar data were previously published in murine [356]. 
Accompanying this tendency of impaired ability of DC to prime T cells, MSC also reduces 
DC ability to migrate towards CCL21, the CCR7 ligand which guides mature DC toward T cell 
areas of the secondary lymphoid organs [346]. The human BM-MSC-derived reduction of BAFF 
secretion by DC can also compromise B cell survival and function [311]. 
Similar results were found for rat and murine, wherein MSC inhibit TNF-α or LPS-induced 
maturation of DC, by preventing the upregulation of CD80, CD86, and MHC-II, and inhibiting IL-
12, TNF-α, and IL-10 secretion [356-360]. Moreover, there are direct evidences that murine 
BM-MSC actually interfere with immature DC ability to process the antigen and present it in 
the context of a MHC-II molecule, and also impair antigen cross-presentation by DC, therefore, 
reducing antigen-specific proliferation of both CD4+ and CD8+ T cells [358,360]. In turn, mouse 
mature DC co-culture with BM-MSC also results in the decrease of CD40, CD80, CD86, and IL-
12 expression, and increased expression of TGF-β, IL-10, and Jagged-2 by DC [361,362]. MSC-
treated DC not only were unable to stimulate allogeneic T cell proliferation [361,362], but also 
had the ability to suppress T cell proliferation, IFNγ, and IL-2 production in MLR (with 
lymphocytes activated by non-MSC-treated mature DC), or by concavalin A-stimulated 
lymphocytes, demonstrating that mouse BM-MSC are able to induce immunoregulatory 
functions in mature DC [361]. The immunoregulatory properties of MSC-treated mature DC 
were mediated by Jagged-2, and were demonstrated to be functional in in vivo assays, in mice 
[361]. In addition, CCR7 surface expression and DC ability to migrate towards CCL19 is 
decreased [358]; accordingly, in vivo studies demonstrated that MSC administration reduces 
the migration of antigen-loaded DC to secondary lymphoid organs [356,360]. 
In opposition, a few number of studies support the hypothesis that once differentiated 
in vitro without the influence of MSC, immature DC would undergo normal maturation 
regardless the presence of MSC. Spaggiari and colleagues [53] described there were no 
differences among LPS-induced maturation of immature monocyte-derived DC (generated by 
77 
GM-CSF plus IL-4) in the presence or absence of human BM-MSC, concerning the upregulation 
of CD80, CD86, and CD83, as well as IL-12 production and the ability to stimulate T cells in a 
MLR. Analogous results were obtained by Li and colleagues (for DC derived from BM CD34+ 
HPC cultured with GM-CSF, Flt3-L, and TNF-α) [347] and Aldinucci et al. [11], except that in this 
latter study MSC impaired DC ability to stimulate T cells. In turn, human UCB-MSC were shown 
to promote monocyte-derived DC maturation, even in the absence of a stimulator agent, and 
do not interfere with LPS-induced DC maturation, except for MSC ability to further increase IL-
12 secretion by DC [353]. UCB-MSC also increase CCR7 expression by LPS-activated DC and 
increase their migration towards CCL21 [353]. Similar observations were made for human 
periapical lesions-derived MSC, which actually slightly increased the DC expression of HLA-DR, 
CD40, CD86, CD83, CCR7, IL-23, and IL-27 (while reduced IL-12 production), as well as DC 
allostimulatory potential, upon treatment with a pro-inflammatory cytokine cocktail (TNF-α, IL-
6, IL-1β, and PGE2) [354].  
3.5.2.4. Effect of mesenchymal stromal/stem cells on naturally occuring peripheral blood 
dendritic cells 
Concerning the studies performed in naturally occurring human peripheral blood DC, an 
overall inhibition of DC pro-inflammatory functions was observed. All the studies described 
subsequently were carried out in freshly isolated peripheral blood mDC [79,236], pDC [236], 
and slanDC (or M-DC8+ DC) [333], co-cultured with human BM-MSC. 
Co-culture with human BM-MSC, in the absence of stimulating agents, was found to 
increase the percentage of CD83+ mDC and upregulate HLA-DR expression by this cell 
population [79], while decreased the percentage of CD83+ cells and the expression of HLA-DR 
in slanDC [333]. Under the same conditions, this latter DC subpopulation also displayed a 
reduced expression of CD86 and ICAM-1, while the expression of the inhibitory molecules ILT3 
and ILT4 augmented [333]. Interestingly, when activated with LPS plus IFNγ, BM-MSC 
downregulate HLA-DR expression in mDC [79]. 
A consistent MSC-induced reduction of TNF-α expression was found for LPS-stimulated 
slanDC [333] and LPS or LPS plus IFNγ-activated mDC [79,236], an effect mediated by PGE2 
[236,333]. In the same line, MSC impair the LPS-induced upregulation of the protein 
expression of CCL4 (MIP-1β), IL-6, and IL-12, and the mRNA levels of IL-1β in mDC, along with 
an increased secretion of IL-10 by pDC and mDC [79,236,333]. Again, PGE2 produced by MSC 
mediates the inhibition of IL-12 production [333]. 
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Finally, MSC-treated slanDC (without stimulation) were found to be ineffective in 
stimulating allogeneic T cell proliferation, whereas MSC contact with LPS-stimulated slanDC 
abrogated their ability to trigger a Th1 immune response [333]. 
3.5.2.5. In vivo studies  
In vivo, MSC infusion was shown to inhibit DC endocytosis, maturation, and IL-12 
production, in a pancreatic islet transplantation mouse model [363]; to decrease the 
expression of CD40 and MHC-II in spleen DC from EAE mice [129]; to induce a tolerogenic 
phenotype in DC from a rat heart transplantation model [364]; and to reduce the migration of 
activated DC to the lymph nodes [360]. 
3.6. MONOCYTES AND MACROPHAGES 
3.6.1. Characterization, subsets, and function of monocytes 
Monocytes comprise 5% to 10% of peripheral blood leukocytes. These immune cells 
migrate into tissues where they differentiate into potent phagocytic cells, macrophages. Once 
in the tissue, macrophages may integrate the tissue-resident mononuclear phagocytic cell 
population (which comprises both macrophages and DC), as is the case of osteoclasts, 
histiocytes, microglial cells, alveolar macrophages, or liver Kupffer cells [230,365]. Importantly, 
recent data strongly suggest that not all tissue-resident macrophages derive from peripheral 
blood monocytes; in fact, an important proportion of these cells has embryonic origin [338], 
though this proportion varies for different tissue types; for instance, fetal-derived 
macrophages are more represented in microglia and less represented in the gastrointestinal 
tract, in steady-state conditions [338]. Beyond the great phagocytic activity of 
monocytes/macrophages and their immune sentinel function, these cells also play other 
important roles in the immune response – as the production of cytokines (pro-inflammatory or 
anti-inflammatory) and antigen presentation – as well as in the clearance of interstitial 
environment (including the phagocytosis of cell debris, apoptotic cells, damaged and old 
erythrocytes, erythroid cells’ expelled nuclei, among others) and in tissue repair 
[230,332,365,366]. 
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3.6.1.1. Identification of peripheral blood monocyte subsets 
Recently, a group of experts from the International Union of Immunological Societies 
(IUIS), World Health Organization (WHO), Dendritic Cells for Novel Immunotherapies 
(DCTHERA) European Network of Excellence, and European Macrophage and Dendritic Cell 
Society achieved a consensus for the nomenclature of monocyte and DC populations in human 
peripheral blood [332]. This consensus is particularly important for DC subpopulations because 
their identification based on distinct markers confuses the integration of the results obtained 
by different research groups. Another cell population that benefited from this consensus was 
CD14-/lowCD16+HLA-DR+ cells (designated by the consensus as non-classical monocytes), whose 
nature of monocyte versus DC had been discussed in the last decade. In short, the consensus 
include three subpopulations of monocytes, two subpopulations of mDC and a single 
population of pDC [332]. Peripheral blood monocyte subpopulations can be distinguished by 
their distinct phenotypic signature: classical monocytes present a strong expression of CD14, 
CD33 and HLA-DR, in the absence of CD16; intermediate monocytes express high levels of 
CD14 as well, but display an increasing expression of CD16 and a slight decrease of CD33 
expression, compared to classical monocytes; non-classical monocytes express CD16 together 
with a dim to negative expression of CD14, they present the highest expression of CD45 and 
the lowest expression of CD33 among the three monocyte subpopulations [332]. All the three 
monocyte subpopulations express CD300e (or IREM-2), a marker that appears at later stages of 
monocyte differentiation and is not present in mDC [79,367]. 
3.6.1.2. Phenotypic and functional characteristics of monocytes 
Non-classical monocytes have been subject of study from two decades now and were 
primarily ascribed to the monocytic lineage due to their ability to produce reactive oxygen 
species (ROS) and to the expression of cytoplasmic esterase [368]. Though this cell population 
seems to arise from monocytes, its nature of monocyte versus DC has been extensively 
discussed. The debate was further intensified with the discovery that about one third of the 
CD14low/-CD16+ non-classical monocytes correspond to a cell population previously identified as 
peripheral blood M-DC8+ DC [335,336,368], now designated as 6-sulfo LacNac+ DC, or slanDC 
(detailed in the section 3.5 of this chapter) [333,334], which possess the ability to present 
antigens to naive T cells and are excellent stimulators of autologous MLR, features attributed 
to DC [335]. Nevertheless, recent studies on expression profiling and hierarchical clustering 
have supported the close relationship among classical and non-classical monocytes [332], 
which was further sustained by the existence of a cell subpopulation with intermediate 
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characteristics between classical and non-classical monocytes, the intermediate monocytes, 
and which describe a clear phenotypic continuum between the loss of CD14 expression and 
the acquisition of CD16 [332]. Interestingly, this phenotypic continuum is also visible by 
analyzing other markers, such as CD64, CD115, CD163, CCR2, and CX3CR [369], and 
additionally supported by the continuous increase of CD45 intensity, accompanied by the 
decrease of CD33 expression and SSC light dispersion properties, sequentially from classical to 
intermediate and to non-classical monocytes [79]. Moreover, in the course of an infection or 
after in vitro stimulation with macrophage colony-stimulating factor (M-CSF), it is verified an 
increase of intermediate monocytes proportion, followed by an increase of non-classical 
monocytes [332]. These data and the fact that non-classical monocytes can give rise to both 
DC and macrophages, made the panel of experts agreed that this myeloid CD14low/-CD16+ cell 
population would be best called monocytes instead of DC [332]. Interestingly, macrophages 
derived from non-classical monocytes display higher phagocytic capability and a different 
protein expression pattern, in relation to classical monocytes-derived macrophages [369]. 
Non-classical monocytes are also more prone to differentiate into DC than the remaining 
monocyte subpopulations [369]. 
Non-classical monocytes comprise approximately 0.7% of peripheral blood leukocytes 
from healthy individuals, being less represented in normal BM (≈0.2%) [368]. Phenotypically 
they are characterized as CD14-/lowCD16+HLA-DR+; being also positive for CD4, like the 
remaining peripheral blood monocyte subpopulations. Non-classical monocytes display a 
higher expression of HLA-DR and CD86, and lower expression of CD14, CD11b, CD33, and 
CD38, compared to classical monocytes [332,368]; and in opposition to classical monocytes, 
non-classical monocytes express CD16 and lack CD64, myeloperoxidase, lysozyme and α-
naphthyl acetate esterase expression [368]. Of note, these enzymes, with an important 
immune function in monocytes, are present from early stages of monocytic differentiation to 
macrophages [368]. 
Interestingly, the morphological analysis reveals the presence of cytoplasmic veils and 
pinocytic vesicles in non-classical monocytes, a feature shared with DC and not found in 
classical monocytes [368]. Functionally, the Ig/complement-mediated phagocytic activity and 
oxidative burst activity against E. coli of non-classical monocytes is lower compared to classical 
monocytes, and higher compared to both mDC and pDC [368]. Similarly to classical monocytes 
and mDC, non-classical monocytes have the ability to produce IL-1β, IL-6, IL-12, and IL-8 in 
response to LPS plus IFNγ, however the percentage of cells producing cytokines is lower 
compared to classical monocytes and mDC, also, the amount of cytokine produced per cell is 
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lower for non-classical than classical monocytes [368]. In contrast, in our hands, non-classical 
monocytes demonstrated to be more efficient TNF-α producers than classical monocytes, 
displaying equal percentage of producing cells but a higher amount of cytokine produced in a 
per cell basis, after the exposure to LPS plus IFNγ [79], as previously described by others 
[332,334]. 
Compared to peripheral blood mDC, non-classical monocytes express higher levels of 
CD86 and CD45, along with lower levels of HLA-DR, CD33, and lower antigen-presenting cell 
abilities [79,368]. A very complete and interesting study, with an extensive functional, 
morphologic, and phenotypical characterization of peripheral blood classical monocytes, non-
classical monocytes, and DC – comprising the expression levels of adhesion molecules, 
costimulatory molecules, Ig Fc receptors, cytokine receptors, complement receptors, and 
complement regulatory proteins – and showing the differences among these cell populations, 
was published by Almeida and colleagues in 2001 [368]. 
In turn, the few studies concerning the function of intermediate monocytes 
demonstrated this population produce the highest levels of IL-10 upon LPS or zymosan 
exposure (which stimulate TLR4 and TLR2, respectively), possess the highest ability to present 
antigen to T cell, induce the highest levels of antigen-specific production of IFNγ by T cells, as 
well as the strongest T cell proliferative response to alloantigen, compared to the remaining 
monocyte subpopulations [369]. Intermediate monocytes also have an important role in 
angiogenesis [369].  
3.6.1.3. Phenotypic and functional characteristics of macrophages 
As previously referred, once monocytes achieve the peripheral tissues and differentiate 
into macrophages, they can assume distinct phenotypes and functions, depending on the 
current tissue needs. In this sense, in an injured tissue (in the sequence of trauma, infection, 
toxicity, ischemia, or autoimmune disease), the presence of a microenvironment rich in 
damage-associated molecular patterns (DAMP), or pathogen-associated molecular patterns 
(PAMP), will promote a pro-inflammatory response by immune and non-immune cells, through 
their pattern recognition receptors (PRR), which include TLR, C-type lectin receptors (CLR), 
retinoic acid-inducible gene (RIG)-I-like receptors (RLR), scavenger receptors, and NOD-like 
receptors (NLR) [342,365,370]. These conditions (which stimulate IFNγ secretion by NK cells 
and TNF-α production by macrophages) promote macrophage polarization to classically 
activated macrophages (M1 macrophages), which are pro-inflammatory macrophages that 
support Th1 or Th17 immune responses and display high antimicrobial potential. M1 
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macrophages (which can be generated in vitro by exposure to IFNγ or GM-CSF) are 
characterized by the production of IL-1, IL-6, IL-12, IL-23, TNF-α, ROS, and reactive nitrogen 
species (RNS), expression of inducible nitric-oxide synthase (iNOS) and IL1-R, together with 
high surface levels of MHC-II [365,366,370,371]. Upon activation, M1 macrophages (along with 
other tissue resident cells: stroma cells, DC, and mast cells) secrete chemokines that attract 
neutrophils and monocytes to the site of injury [338]. When the factors underlying the tissue 
injury are controlled, the resolution of inflammation takes place, which is accompanied by the 
decrease of PAMP and DAMP and increase of apoptotic cells (to which contributes the 
neutrophils formerly recruited to the injury site that, at this stage, are undergoing apoptosis). 
Macrophage clearance of apoptotic neutrophils induces the expression of anti-inflammatory 
molecules (TGF-β and IL-10) and growth factors (TGF-β and PDGF), contributing to 
inflammation resolution and tissue repair, respectively [365,370]. These anti-inflammatory 
tissue macrophages are likely to correspond to the alternatively activated macrophages (M2c 
macrophages) obtained upon in vitro stimulation with IL-10 and TGF-β, among other factors 
[365,371]. Of note, M2 macrophages both recruit and induce Th2 and Treg cells, which further 
supports their anti-inflammatory role [370]. However, in the cases where complete tissue 
repair is compromised, there is a predominance of profibrotic cytokines in the tissue 
microenvironment, which further induces the expression of profibrotic cytokines by 
macrophages as well, accompanied by the release of fibronectin and other extracellular matrix 
components, and by the expression of mannose and scavenger receptors, IL-1R11, FIZZ, and 
YM-1, characteristic of M2a macrophages [365,366]. M2a macrophages are obtained in vitro 
after exposure to IL-4 and IL-13, but whether M2a and M2c represent two distinct populations 
in vivo remains elusive [365]. Conversely, tissue macrophages have also the ability to limit and 
reverse fibrosis through the expression of MMP and CXCL10 (this latter can inhibit fibroblast 
proliferation in bleomycin-induced pulmonary fibrosis), however, surface markers able to 
identify these MMP-secreting fibrolytic macrophages are still not identified [365]. 
Notably, M2 macrophages display and increased expression and activity of CD39 and 
CD73, generating extracellular adenosine, which possess anti-inflammatory properties [372]; 
moreover, they secrete great amounts of IL-10 and have the ability to induce de novo 
CD4+CD25+FoxP3+ Treg cells [373]. Besides M2 macrophages, other macrophage subsets with 
immunosuppressive function have been reported: regulatory macrophages (which produce 
high levels of IL-10), myeloid-derived suppressor cells, and tumor-associated macrophages 
[370]. Tumor-associated macrophages contribute to the maintenance of an 
immunosuppressive microenvironment in tumor surroundings, they express TGF-β, IDO, B7-
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H4, and ILT3, actively recruit Treg and Th2 cells, and produce growth factors, angiogenic 
factors, and MMP9, promoting tumor cell proliferation and metastasis [374]. These cells derive 
from circulating monocytes recruited into tumor which, under the conditions of tumor 
microenvironment – containing LIF, IL-6, oncostatin M (OSM), and granulocyte colony 
stimulating factor (G-CSF) – differentiate into macrophages with immunosuppressive function 
and, despite the similarities with M2a and M2c macrophages, constitute a distinct cell subset 
[370,374]. 
3.6.2. Effect of mesenchymal stromal/stem cells on monocytes 
The majority of published data regarding the effect of MSC on monocytes is more 
focused on the pro-inflammatory function of these cells, being unequivocal that MSC impede 
monocyte pro-inflammatory activity at different levels. Interestingly, MSC were also shown to 
increase monocyte survival (associated to downregulation of mRNA levels of apoptosis-related 
genes), and to augment the percentage of CD14+CD16+ monocytes [285]. 
3.6.2.1. Mesenchymal stromal/stem cells inhibit in vitro monocyte differentiation into 
dendritic cells 
As previous mentioned in “Dendritic cells” section (section 3.5.2.1), human MSC impair 
in vitro monocyte differentiation into DC [25,47,53,348-351,375], giving rise to CD14+ cells with 
impaired ability to stimulate allogeneic T cells [45,53,351,375]. MSC-derived PGE2 [53] and IL-6 
[375] contribute for these effects. 
3.6.2.2. Mesenchymal stromal/stem cells inhibit pro-inflammatory cytokine production 
by monocytes 
Clearly, human BM-MSC have a negative impact over monocytes’ ability to produce pro-
inflammatory cytokines. Specifically, human BM-MSC decreased TNF-α and CCL4 (MIP-1β) 
production by LPS-activated monocytes (observed for classical, intermediate, and non-classical 
monocytes) [79,236], and reduce TNF-α and IL-12 secretion (with no effect on IL-1β) by 
monocytes in co-culture with T cells stimulated with the superantigen staphylococcal 
enterotoxin B (SEB) [355]. Remarkably, human BM-MSC also inhibit CCL3, CCL5, CXCL9, and 
CXCL10 mRNA expression in monocytes [79]. Likewise, human MSC suppress the production of 
IL-1β and ROS by macrophages stimulated with LPS or ATP [376]. 
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3.6.2.3. Mesenchymal stromal/stem cells interfer with monocyte’s allostimulatory ability 
Human UCM-MSC also impair monocyte ability to induce proliferation in allogeneic T 
cells, which is partially due to the action of PGE2 [248]. Interestingly, mouse BM-MSC-derived 
PGE2 was reported to induce IL-10 expression by monocytes and macrophages [377], a 
cytokine with important suppressive functions over T cells. According to the impaired 
allostimulatory abilities, it was demonstrated that human BM-MSC, AT-MSC, UCM-MSC, and 
UCB-MSC hamper HLA-DR upregulation in monocytes [248,268,355], whereas human AT-MSC 
also decreased the expression of CD80 and CD86 [268]. 
3.6.2.4. Mesenchymal stromal/stem cells induce a regulatory function in monocytes and 
macrophages 
Besides the downregulation of pro-inflammatory mediators, MHC-II molecules, and 
costimulatory molecules, human MSC enhance the expression of immune regulatory factors. 
AT-MSC upregulate ILT3 and ILT4 expression by monocytes [268]; and human BM-MSC co-
cultured with either purified monocytes or PBMC induce the expression of IL-10 in monocytes 
[52,285,375], a process mediated by IDO [52] and IL-6 [375]. IL-10 induction is accompanied by 
the upregulation of CD206, CD163, and CCL18 [52,285]; these are typical markers of M2 
macrophages and, remarkably, CCL18 enables monocytes to induce Treg cells [285]. Besides 
BM-MSC, human UCM-MSC and UCB-MSC also induced CD206 upregulation in peripheral 
blood monocytes [248]. 
Accordingly, human BM-MSC were shown to have a direct effect in skewing the 
polarization of monocytes towards CD163+CD206+ M2 macrophages [285,378,379]. All these 
effects are mediated by MSC-derived M-CSF, though other soluble factors are involved in the 
process [285]. Likewise, the presence of human placental MSC during granulocyte-macrophage 
colony-stimulating factor (GM-CSF)-induced monocyte differentiation into M1 macrophage, 
results in a shift to M2 macrophages differentiation [371]. In the same line, concerning 
macrophage functions, MSC reduced the expression of pro-inflammatory cytokines (IL-1α, IL-
1β, IL-12p70, IL-17, CCL3, TNF-α, and IFNγ) and costimulatory molecules (CD40, CD80, and 
CD86), while increased the expression of IL-10, IL-6, VEGF, and co-inhibitory molecules (CD273, 
CD274, and B7-H4), and enhanced macrophage phagocytic activity over apoptotic cells 
[371,378,379]. Thus, accrding to the published data, MSC imprint a M2-like functional profile in 
macrophages. 
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Similar results were obtained in animals: in murine macrophages (RAW264.7) the 
zymosan-induced expression of TNF-α and IL-1α was hampered by TNF-α stimulated 
gene/protein 6 (TSG-6) produced by human MSC [380]; likewise, in mouse peritoneal 
macrophages stimulated with LPS, the presence of mouse BM-MSC impairs the production of 
the pro-inflammatory cytokines TNF-α, IFNγ, IL-6, and IL-12p70, and the upregulation of CD86 
and MHC-II, while increases IL-12p40 and IL-10 expression, as well as macrophages ability to 
phagocyte apoptotic cells [381]. Accordingly, the ability to activate antigen-specific T cells was 
also reduced in macrophages co-cultured with MSC [381]. Of note, the downregulation of TNF-
α, IL-6, and IL-12p70, and the promotion of IL-10 expression in LPS-stimulated mouse 
macrophages was mediated by PGE2 derived from MSC [381]. The low expression of pro-
inflammatory cytokines, associated to high expression of IL-10 and enhanced ability to 
phagocyte apoptotic cells, are features that resemble the M2 macrophages involved in the 
resolution of inflammation. And, in the same line, similar results demonstrating that BM-MSC 
favor M2 macrophage differentiation were obtained in mouse BM-derived macrophages [382]. 
3.6.2.5. In vivo studies 
Importantly, the MSC-induced decrease of TNF-α, IL-6, and IL-12p70, upregulation of IL-
10 [377,381,383], and polarization towards M2 phenotype [382,384] was confirmed in vivo. In 
a mouse model of acute myocardial infarction, infusion of either human BM-MSC or UCM-MSC 
increased the proportion of M2 macrophages in peripheral blood and infiltrating the 
myocardium, accompanied by increased IL-10 levels and decreased IL-1β and IL-6 in the 
infarcted area [383]. Accordingly, a rat model of myocardial infarction showed that M2 
macrophages were preferentially localized near MSC infiltrating the heart [382]. Moreover, 
human [384] and mouse [377] BM-MSC were shown to reduce the mortality in sepsis mouse 
models. The improved outcome was due to the increased phagocytic activity of macrophages 
against bacteria [384], and to increased IL-10 secretion by monocytes and macrophages [377] 
induced by MSC. IL-10 upregulation is mediated by PGE2 secreted by MSC, and IL-10 secretion 
by tissue macrophages seems to reduce neutrophil infiltration and organ oxidative damage 
[377]. 
3.6.2.6. Crosstalk between Mesenchymal stromal/stem cells and monocytes 
Remarkably, under certain experimental conditions, the crosstalk between human MSC 
and monocytes enhances or is essential to the inhibition of T cell responses 
[52,248,268,355,385]. If, in the one hand, it was demonstrated that IL-1β produced by 
monocytes induces the expression of mediators with immunosuppressive function (e.g. PGE2 
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and IL-6) by UCM-MSC, and PGE2 is necessary to inhibit CD3/CD28-induced CD4+ and CD8+ T 
cell proliferation and IFNγ production [385,386]; on the other hand, MSC induce IL-10 
expression by monocytes (via IL-6 and IDO) [52,285,375] which exerts suppressive effects over 
T cells [52]. Importantly, the dependence on monocytes/macrophages was also demonstrated 
in vivo, in a mouse model of sepsis, in which it was reported that depletion of monocytes and 
macrophages in the mouse made BM-MSC lose their beneficial effect on survival [377]. 
3.7. NEUTROPHILS 
3.7.1. Neutrophils’ characteristics and function 
Neutrophils are the most represented leukocyte population in the peripheral blood 
(≈50-70% of total white cells) and act as the first line of defense against pathogenic agents. 
They are the first cells to arrive to the site of injury, where they have an important role in 
phagocytosis, pathogen killing (through the production of ROS and anti-bacterial proteins), and 
secretion of chemotactic factors able to recruit monocytes/macrophages [230,325]. 
Neutrophils are also highly versatile cells and, depending on the microenvironment, they can 
functionally behave as pro-inflammatory cells (producing the pro-inflammatory cytokines TNF-
α, IL-1β, and IL-12p70), as immune suppressive and anti-inflammatory cells (associated to the 
production of IL-1Ra and TGF-β), can induce B cell class switching, or assume pro-angiogenic or 
pro-fibrogenic functions [325,387]. Remarkably, after exposure to GM-CSF, mouse BM 
neutrophils acquire morphological, phenotypic and functional properties of DC (such as the 
expression of CD11c, MHC-II, CD80, CD86, and IL-12, along with the ability to present antigen 
to naive CD4+ T cells), but retain neutrophil features (as the expression of Ly6G, CXCR2, and 
7/4, and anti-microbial properties, including neutrophil extracellular traps (NET) formation) 
[388]. 
Despite being recognized the existence of functional heterogeneity in neutrophils, the 
information on the differentiation-promoting factors, kinetics among the different neutrophil 
subsets, and assays to clearly assess the mechanisms underlying their different functions, are 
still scarce. An efficient panel of markers for the phenotypic identification of the 
abovementioned distinct functional neutrophil subsets is also still underway, namely for the 
recently described granulocyte myeloid-derived suppressor cells. This cell population is 
constituted by neutrophils with the ability to suppress the adaptive immune response. The 
mechanisms that have been suggested to be employed by this neutrophil subset are the 
87 
increased arginase activity (which hampers T cell proliferation and activation by depleting L-
arginine, and is also involved in the host defense against fungi), and the production of ROS 
(able to suppress T cell activation and proliferation, and also implicated in bacterial killing and 
immune cell chemotaxis) [387]. 
3.7.2. Mesenchymal stromal/stem cells regulate neutrophil function 
3.7.2.1. In vitro studies 
Attending to the effect of MSC on neutrophils, it is interesting to note that human BM-
MSC actively recruit neutrophils, and this chemotactic effect is further enhanced in LPS-
activated MSC [389]. Human BM-MSC and UCM-MSC inhibit apoptosis of resting and activated 
neutrophils [390,391]. Apoptosis inhibition by BM-MSC is associated to increased expression of 
the anti-apoptotic protein myeloid cell leukemia 1 (Mcl-1) and decreased levels of the pro-
apoptotic protein Bax, while no change was observed in CD95 expression [390]. Neutrophil 
protection from apoptosis is mediated by IL-6 in BM-MSC [93,390] (but not in UCM-MSC 
[391]), and improved by previous BM-MSC activation through TLR3 or TLR4 [93]. To the 
enhanced neutrophil survival observed in TLR3-stimulated MSC, besides IL-6, also contribute 
GM-CSF and IFNβ, whereas in TLR4-activated MSC is GM-CSF which mediates the protection 
from apoptosis [93]. 
Concerning neutrophil function, human BM-MSC hamper N-formyl-L-methionin-L-leucyl-
L-phenylalanine (f-MLP)-induced respiratory burst [390], which is consistent with the 
downregulation of NADPH oxidase-1 (an enzyme involved in the production of the superoxide 
anion) mRNA expression induced by human UCM-MSC (in a IL-6 and ICAM-1-dependent 
manner) [391], and the increased mRNA levels of the anti-oxidant enzyme catalase [391]. 
Conversely, poly(I:C), a specific ligand for TLR3) or LPS-activated human BM-MSC (but not non-
stimulated MSC) increase respiratory burst in response to E. coli [93,389]. Likewise, neutrophil 
phagocytosis of bacteria is also increased by BM-MSC and further enhanced after the 
activation of this latter cell population with LPS [389]. Interestingly, non-activated human BM-
MSC do not alter the expression of CD11b or CD62L (which participates in the adhesion of 
neutrophils to endothelium) in neutrophils stimulated with f-MLP [390], but after TLR3 or TLR4 
stimulation of MSC, it is observed an increase of CD11b expression in neutrophil [93]. 
Neutrophil chemotaxis to f-MLP, IL-8, or C5a also remains unchanged after co-culture with 
non-stimulated human BM-MSC [390]. In turn, LPS-activated human BM-MSC upregulate CCL4 
(MIP-1β) expression by neutrophils, an effect not shared with non-activated BM-MSC [389]; 
whereas non-activated UCM-MSC decreased CCL4 and IL-8 expression in neutrophils [391]. 
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Finally, human UCM-MSC upregulate COX-2, while downregulate HO-1 expression in 
neutrophils [391]. 
Similar results were found in mouse: MSC-derived from compact bone increase 
neutrophil phagocytosis of bacteria [392]; and the addition of neutrophils, previously co-
cultured with TNF-α-primed BM-MSC, to CD3-stimulated T cells has the ability to decrease T 
cell proliferation and activation (an effect mediated by nitric oxide, NO), whereas only a slight 
effect was observed for freshly isolated neutrophils (that did not contact with MSC) or 
neutrophils co-cultured with non-primed MSC [393]. Interestingly, freshly isolated neutrophils 
from tumor-bearing mice also inhibit T cell proliferation and activation, demonstrating that 
tumor environment conditions neutrophils to acquire an immunosuppressive phenotype [393]. 
Accordingly, an increased arginase activity, along with increased mRNA expression of iNOS, 
anti-inflammatory cytokines and their receptors (IL-10, IL-6, IL-4R, IL-10R), and a multitude of 
chemokines, occurred after neutrophil co-culture with mouse BM-MSC [393]. Remarkably, it 
was demonstrated in vivo that infusion of MSC-treated neutrophils promotes tumor 
progression [393]. 
3.7.2.2. In vivo studies 
In vivo, it is described that MSC treatment reduces neutrophil organ infiltration in animal 
models of sepsis [377,392], ventilator-induced lung injury [394], and global cerebral ischemia 
[395], among others, which protects the tissues from ROS-induced damage. Consistent with 
the reduced neutrophil infiltration, are the decreased protein levels of myeloperoxidase, 
decreased ROS production, and reduced oxidative organ damage in MSC-treated animals 
[377,394]; notwithstanding, in MSC-treated septic mouse, the phagocytic activity of 
neutrophils was enhanced, improving bacterial clearance [392]. Although the mechanisms 
underlying MSC effects are not well elucidated, it is reported that adenosine (a suppressive 
molecule produced by MSC and detailed in the section 4.4 of this chapter) decrease neutrophil 
chemotactic activity and adhesion to the vascular endothelium [372], making plausible the 
involvement of this mediator in the inhibitory effects of MSC over neutrophils. Likewise, IL-10 
has also been described to inhibit the rolling, adhesion and trans-epithelial migration of 
neutrophils [377]. 
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3.8. EOSINOPHILS, MAST CELLS, AND BASOPHILS 
Eosinophils, mast cells, and basophils are important players in allergic inflammation. In 
this condition, a Th2 immune response is triggered by an allergen, and the high levels of IL-4 
and IL-13 secreted promote immunoglobulin class switch to IgE. IgE molecules bind to high 
affinity receptors (FcεRI) on eosinophil, basophil, or mast cell surface, and subsequent IgE 
crosslinking by allergen induce cell degranulation (and release of inflammatory mediators 
contained inside them), production of cytokines (including IL-4, IL-5, IL-8, IL-13, GM-CSF, and 
TNF-α), leukotrienes, and prostaglandins [230]. The inflammatory mediators released by mast 
cells degranulation increase vascular permeability and attract eosinophils and neutrophils to 
the site of inflammation; IL-4 and IL-13 stimulate Th2 immune response, reinforcing IgE 
production; IL-4 also plays an important role in mast cell priming and increases the expression 
of FcεRI in these cells; IL-5 recruits and activates eosinophils; IL-8 attracts neutrophils and T 
cells; whereas GM-CSF activates myeloid cells [40,230,396]. The consequent accumulation and 
degranulation of eosinophils and neutrophils largely contribute to tissue damage [230]. 
3.8.1. Eosinophils 
Eosinophils comprise approximately 3% of peripheral blood leukocytes. Their main 
function is to protect the organism from parasites, which eosinophils attack by releasing the 
content of their granules. These cells also have phagocytic activity and participate in asthma 
and allergy [230]. 
The published data regarding how MSC affect eosinophil function came from in vivo 
studies using animal models of asthma/airway inflammation that consistently show clinical 
improvement and reduced eosinophil infiltration in the airways, after treatment with mouse 
MSC [260,261,396,397]. Asthma is a chronic airway inflammation, mediated by Th2 cells and 
characterized by increased levels of IL-4, IL-13, and IL-5 in the airways [396]. In mouse models 
of ovalbumin and ragweed-induced asthma, the effects of mouse BM-MSC or AT-MSC infusion 
include the reduction of inflammatory cells and eosinophil count, IL-4, IL-5, and IL-13 
expression, and increase IL-10 and TGF-β levels in bronchoalveolar lavage fluid and lung 
draining lymph nodes. MSC also increase the numbers of CD4+FoxP3+ Treg cells in lung tissue, 
lung draining lymph nodes, and spleen; and decrease antigen-specific IgG1 and IgE levels, 
along with increased PGE2 levels, in the serum [260,261,396]. Interestingly, the modulation of 
cytokine expression and IgE levels by MSC was dependent on TGF-β production and Treg 
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induction, while the reduction of eosinophilia in the bronchoalveolar lavage fluid was 
mediated by TGF-β produced by MSC [260,261]. 
3.8.2. Mast cells 
After their differentiation in the BM, wherein they represent <0.03% of BM 
hematopoietic nucleated cells, mast cells enter the blood circulation to reach different tissues. 
Once within the tissue, mast cells finish their maturation process acquiring a phenotype that is 
determined by the tissue they had integrated [230]. 
In 2011, Brown and colleagues [398] investigated the effect of mouse BM-MSC in the 
major functions of mouse mast cells. In vitro co-cultures of mouse BM-MSC with mast cells 
sensitized with IgE revealed an inhibitory effect over TNF-α secretion (mediated by PGE2) and 
mast cell degranulation; the inhibition of FcεRI-mediated mast cell degranulation was also 
confirmed in vivo [398]. Besides, mouse BM-MSC present the ability to impair mast cell 
migration to stem cell factor (SCF) as well [398]. In vitro studies made similar findings in 
human, demonstrating that gingiva-derived MSC and BM-MSC reduce TNF-α, IL-6, and IL-4 
production by mast cells stimulated with PMA and calcium ionophore, in a PGE2-dependent 
manner [399]. Likewise, human UCB-MSC exert a strong inhibition of mast cell degranulation, 
in a TGF-β1 and PGE2-dependent manner; TGF-β1 also mediates the downregulation of FcεRI 
expression in mast cells observed in the presence UCB-MSC [40]. 
Atopic dermatitis is characterized by increased IgE serum levels against environment 
allergens; the consequent IgE-mediate mast cell degranulation results in the recruitment of 
neutrophils, eosinophils, and lymphocytes to the dermis, as explained above [40]. In vivo, in a 
murine model of atopic dermatitis, treatment with human UCB-MSC resulted in clinical 
improvement, associated to the decreased mast cell (as well as eosinophil and lymphocyte) 
infiltration in the skin, decreased mast cell degranulation, along with reduced IgG1 and IgE 
serum levels [40]. Likewise, infusion of human gingiva-derived MSC in a mouse model of 
contact hypersensitivity showed clinical benefits [399]. Remarkably, besides the immune 
suppressive actions of MSC over DC and T cells, it was also shown a reduced number of mast 
cell infiltration. Interestingly, the infused MSC localized near mast cells and inhibit their 
degranulation through PGE2 [399]. 
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3.8.3. Basophils 
Basophils are non-phagocytic granulocytes which constitute a less-represented 
leukocyte population in the peripheral blood (≈0.7%). Their main function is the defense 
against parasites, particularly helminthes. Like eosinophils, basophils attack the parasites by 
releasing the bioactive factors contained in their granules, among them histamine, which 
augment blood vessel permeability and smooth muscle contractility [230]. Basophil 
degranulation occurs in response to antibody binding to FcεRI surface receptors, and these 
cells are also associated to the development of allergies [230]. No data concerning the effect 
of MSC over basophils was published until the present moment. 
3.8.4. Concluding remarks 
Despite the small number published concerning the effect of MSC on the function of 
these innate immune cells with a critical role in the development of allergic inflammation, the 
data consistently show clinical benefits in the use of MSC-based therapies in animal models. 
Also, in vitro studies demonstrated MSC exert an inhibitory effect over eosinophil and mast cell 
functions. In the same line, and attending to the relevance of IL-9 in allergic inflammation, our 
group recently described that human BM-MSC decrease the percentage of Th9 and Tc9 cells 
[244], which was confirmed by a recent study showing that human conditioned medium from 
amniotic MSC co-cultured with T cells reduced IL-9 in the culture supernatant [255]. 
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4. IMMUNOSUPPRESSIVE MECHANISMS OF MESENCHYMAL STROMAL/STEM CELLS 
As detailed in section 1.1.2 of this chapter, the surface membrane expression of 
chemokine receptors allows MSC to be attracted to and migrate into sites of tissue injury or 
inflammation. In addition, the expression of adhesion (chapter 1, section 1.1.3) molecules 
enables a stable binding and close interaction between MSC and the target immune cells. 
To inhibit the immune response, MSC rely on both soluble mediators and cell-to-cell 
contact mechanisms. For human MSC, it has been demonstrated that the modulation of the 
immune response may be accomplished by the soluble factors TGF-β, PGE2, IDO, LIF, HGF, IGF, 
HLA-G5, galectin-1, galectin-9, Jagged-1, adenosine, semaphorin-3A, IL-6, IL-10, HO-1, and TNF-
α stimulated gene/protein 6 (TSG-6) [7,45,240,281,400]; or by the plasmatic membrane 
proteins HLA-G1, PD-L1, CD200, and B7-H4 [107,401] upon interaction with the correspondent 
ligand expressed at the plasmatic membrane of the target immune cell. 
Importantly, MSC from different species may employ different immunosuppressive 
molecules, as the case of nitric oxide (NO) produced by mouse MSC and which seems to 
constitute an important immune suppressive factor employed by MSC of this specie, but not 
by human MSC. Likewise, there are evidences that, in human, distinct immunomodulatory 
factors may have a differential relevance for the immune regulatory function of MSC arising 
from different sources. This is inferred because there are important differences in the 
expression levels of immunomodulatory molecules among MSC derived from different tissues, 
and also because the inhibition of those immunomodulatory molecules in in vitro assays, 
where only the type of MSC used varies, lead to different outcomes. Thus, if the inhibition of 
the same molecule results in the abolishment of a given suppressive function for one type of 
MSC, but has no effect for another MSC type, it is likely that the latter type of MSC possesses 
other mechanisms that can surpass the deficiency of the neutralized factor, in opposition to 
the former MSC type. 
It is also worth mentioning that our group [46] and others [26,37,39,43,44,47] 
demonstrated that human MSC isolated from different tissues, and tested under the same 
conditions, present differential immunosuppressive abilities, which is described in the section 
1.2.3 of this chapter. 
Remarkably, the exposure to inflammatory cytokines increases the expression of 
immunomodulatory molecules and adhesion molecules in MSC (chapter 1, section 1.4), 
demonstrating these cells are highly sensitive to microenvironment and physiologic state of 
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the organism, and also proving their versatility to adapt their functions to the current needs of 
the individual. 
4.1. TRANSFORMING GROWTH FACTOR-β 
4.1.1. The effect of transforming growth factor-β on immune cells 
Transforming growth factor (TGF)-β is a regulatory cytokine able to influence the 
function of a broad range of cell lineages and involved in numerous physiologic processes, such 
as embryogenesis, carcinogenesis, and immune response [402]. Three isoforms of this cytokine 
(TGF-β1, TGF-β2, and TGF-β3) were identified in mammals, in which the isofrom TGF-β1 is 
predominantly expressed in the immune system [402,403]. Focusing on the role of TGF-β in 
the immune system, an increasing body of evidence supports its importance in the early T cell 
development, in the survival of naive T cells, in the generation of natural Treg cells in the 
thymus, and the induction of Treg cells in the periphery [402-404]; indeed, TGF-β has the 
ability to induce and maintain FoxP3 expression in T cells [229,287,402,404]. 
Besides the generation of Treg cells, this cytokine has an immunosuppressive effect over 
T cells, NK cells, DC, macrophages, mast cells and granulocytes [403]. TGF-β inhibits IL-2 
expression by activated T cells, through inhibition of IL-2 promoter activity; it also interferes 
with T cell proliferation and differentiation into effector Th1, Th2, or Th17 cells [402,403]. The 
ability to impair IL-2 production will consequently condition T cell proliferation; 
notwithstanding, TGF-β also arrest T cell cycle by downregulating the expression of c-myc, 
cyclin D2, cyclin-dependent kinase 2 (CDK2), and cyclin E, while upregulates the expression of 
the cyclin-dependent kinase inhibitors p15, p21 and p27 [403]. The suppression of naive T cell 
differentiation into Th1, Th2, and Th17 is achieved by downregulating the expression of T-bet, 
GATA3, and RORγt (in the absence of IL-6 and with high concentration of TGF-β), respectively 
[229,402,403,405]. In fully differentiated Th1 cells, TGF-β inhibits IFNγ expression and impairs 
IL-12 signaling, while induces IL-10 expression [403,406]; whereas in CD8+ T cells, it hampers 
cell activation and effector functions, specifically by decreasing the expression of granzyme B, 
inhibiting granule exocytosis, and cytotoxic activity [402,403]. On B cells, TGF-β inhibits 
expression of IgM and IgG, while induces IgA [407]. Moreover, TGF-β reduces IFNγ and NKG2D 
expression and cytolytic activity in NK cells [408-411]. 
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In Lagerhans cells, TGF-β, though essential to their development, blocks their 
phenotypic maturation and phagocytic activity, and impairs the production of IL-12 [412]; 
similarly, it inhibits CD80 upregulation in human peripheral blood DC and monocytes [413]; 
impairs DC maturation, LPS-induced upregulation of CD80, CD86, CD40, and IL-12 expression, 
as well as their allostimulatory activity in MLR, in murine [414]; and inhibits mouse 
plasmacytoid DC expression of IFNα, IL-12, and TNF-α [415]. In addition, TGF-β was also shown 
to inhibit the induction of inducible nitric-oxide synthase (iNOS) and the production of TNF-α 
and MMP-12 in macrophages [403,416], and to have an important role in the Treg-mediated 
induction of M2 macrophages in vivo, in mouse [417]. 
4.1.2. Role of transforming growth factor-β in mesenchymal stromal/stem cells 
immune suppressive function 
TGF-β is constitutively expressed by human BM-MSC and secreted at 
immunosuppressive concentrations; it is also upregulated after exposure to TNF-α or IFNγ 
[240,287]. Nevertheless, despite of the consistent description of the immunosuppressive 
functions of TGF-β in the literature, there are conflicting data in what concerns to its role in 
MSC-mediated immunosuppression. Using neutralizing antibodies directed against TGF-β1, Le 
Blanc and colleagues [234] demonstrated that the inhibition of PHA-stimulated T cell 
proliferation, observed in the presence of human BM-MSC, was not mediated by TGF-β. 
Conversely, the use of neutralizing anti-TGF-β antibodies restored human BM-MSC-derived 
inhibition of T cell proliferation in MLR [235]; and TGF-β derived from human BM-MSC has also 
been implicated in the downregulation of CD25, CD38, and CD69 expression by CD4+ and CD8+ 
T cells [84,181]. In the same line of evidence, and using the same strategy in peripheral blood 
or synovium CD4+ and CD8+ T cells from rheumatoid arthritis patients, stimulated with type II 
collagen, TGF-β was revealed to have an essential role in human BM-MSC-mediated inhibition 
of antigen-specific T cell proliferation and production of IFNγ and TNF-α, and in the induction 
of IL-4 production in T cells [181]. On the other hand, the inhibition of IFNγ and TNF-α 
production by T cells from mouse with CIA, and stimulated with type II collagen, in co-culture 
with human AT-MSC, was shown to be a process dependent of PGE2 and IL-10, rather than 
TGF-β [180]. 
In ragweed-induced asthma mouse model, intravenous infusion of BM-MSC alleviated 
asthma symptoms through the increased production of TGF-β, being reported that, under a 
Th2 environment, IL-4 and IL-13 upregulate TGF-β expression in MSC by activating STAT6 signal 
pathway [261]. Not surprisingly, it has been demonstrated that TGF-β is involved in the 
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induction of Treg cells by MSC, as this cytokine is known to have an essential role in FoxP3 
induction and maintenance [98,195,229,285-287,402]. 
Of all the inhibitory effects of human BM-MSC over NK cells (inhibition of NK cell 
proliferation, downregulation cytokines and activating receptors expression, and impairment 
of NK cell cytotoxicity), only the inhibition of cell proliferation induced by IL-15 is ascribed to 
TGF-β [327]; in turn, under IL-2 stimulation, TGF-β seems not to participate in the inhibition of 
proliferation [326]. Regardless, culture of peripheral blood NK cells with TGF-β1 results in the 
downregulation of the activating receptors NKG2D and 2B4, as well as in cell cycle arrest by 
the induction of the expression of p15INK4b [418]. As the abovementioned data on MSC/NK 
cell co-cultures was obtained using neutralizing antibodies against TGF-β, we may postulate 
that MSC have redundant mechanisms in what concerns to immune cell suppression and, 
therefore, the inhibition of one of the mechanisms may not necessarily conduct to the 
abolishment or mitigation of the immunoregulatory effect. 
Finally, TGF-β upregulates the expression of CD73 in CD4+ and CD8+ T cells, macrophages 
and DC [372,419]. CD73 is an ecto-enzyme that participates in the generation of adenosine, an 
immunosuppressive nucleoside, whose functions are explained in section 4.4 of this chapter. 
4.2. PROSTAGLANDIN E2 (PGE2) 
4.2.1. The effect of prostaglandin E2 on immune cells 
Prostaglandin (PG) E2 is an arachidonic acid-derived eicosanoid produced by 
cyclooxygenase (COX)-1 and COX-2 (whose activity yield PGH2), followed by the enzymatic 
action of PGE synthases. COX-1 is constitutively expressed in several cell types, whereas COX-2 
expression is inductive and rapidly upregulated under inflammatory conditions (such as in the 
presence of LPS, IFNγ, TNF-α, IL-1α, or IL-1β), where the conjugated action of both enzymes 
leads to the secretion of large amounts of PG, although is mainly the activity of COX-2 which 
regulates the amount of PGE2 produced. Though PGE2 can be produced by all cell types, in the 
context of an immune response, immune cells are the main source of this immune mediator, 
still epithelial cells and fibroblasts give an important contribute [420-423]. COX-2 expression is 
inhibited by the anti-inflammatory cytokines IL-4, IL-13, and IL-10; thus, these cytokines can 
regulate the synthesis of PG as well as of other arachidonic acid-derived lipid mediators 
(including leukotriene B4 and platelet-activating factor) [420]. 
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So far, four PGE2 receptors had been identified, the E prostanoid receptors (EP1-4), which 
differ in what concerns to PGE2 affinity – wherein EP3 and EP4 are high affinity receptors, while 
EP1 and EP2 display a lower affinity to the ligand – and trigger distinct signaling pathways – EP1 
activates phospholipase C (PLC); EP2 and EP4 are Gs-coupled receptors, which trigger adenyl 
cyclase activity and cAMP/PKA/CREB pathway; whereas the study of EP3 signaling is more 
complex because it possesses multiple isoforms generated by alternative splicing and can be 
coupled with either Gs or Gi, or regulate cell calcium levels. The four receptors also differ in 
terms of susceptibility to desensitization and duration of the signal, and EP4 was shown to be 
able to activate PI3K-dependent extracellular signal-regulated kinase (ERK)1/2 pathway as well 
[420-424]. Roughly, one can say that EP2 and EP4 receptors are functionally involved in the 
anti-inflammatory properties ascribed to PGE2 [421]; nevertheless, PGE2 ability to activate 
different signaling pathways depending on its own concentration and on the environmental 
conditions, helps to explain the complexity and, sometimes, apparent contradictions of PGE2 
biological functions. 
In fact, in the early phases of the inflammatory response, PGE2 induces vasodilatation 
and promotes the local infiltration and activation of neutrophils, macrophages, and mast cells 
(also promoting mast cell degranulation through EP1/EP3 receptors), whereas in later stages of 
inflammation, PGE2 inhibits the production of pro-inflammatory cytokines and induces IL-10 
expression in myeloid cells [423]. Concerning neutrophils, PGE2 is known to inhibit their 
activation and migration through EP2 signaling [421]; and to suppress the expression of TNF-α 
(via EP2 and EP4 receptors) and enhance IL-6 production (mediated by EP2 signaling) in mouse 
neutrophils [425]. Interestingly, despite being a chemoattractant to macrophages, PGE2 
ligation to EP2 at macrophage cell surface impairs its activation and phagocytosis [421,423]; 
PGE2 also decreases the production of ROS and induces the production of IL-10 by 
macrophages [421]. In mouse peritoneal macrophages, signaling through EP2 and EP4 reduces 
TNF-α and IL-12 expression in response to LPS (for both cytokines) or LPS plus IFNγ (for TNF-α) 
[426,427]. In human, EP2 and EP4 binding to PGE2 also decreases the pro-inflammatory 
cytokine production (namely TNF-α and IL-12) by monocytes and macrophages, and 
downregulates MHC-II expression [422,423,428]. Moreover, PGE2 is associated to the 
induction of IL-10 expression on tissue macrophages [423]. Noteworthy, this prostanoid has 
been shown to play an essential role in the development of tumor-associated suppressive 
macrophages and myeloid-derived suppressor cells [423]. 
Concerning NK cells, PGE2 suppresses NK cell activity in response to either IL-12 or IL-15, 
impairs the production of IFNγ, reduces the expression of receptors with an important role in 
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NK cell functions (CD94/NKG2C, DNAM-1, NKp80, 2B4 (CD244), and CD161), and decreases NK 
cytolytic activity against rat leukemic cells [421,423]. With respect to B cells, PGE2 was shown 
to inhibit both their proliferation and immunoglobulin production [429,430], or to induce Ig 
class switching and B cell differentiation into IgE-secreting plasma cells [422,424]. 
COX-2 and, subsequently, PGE2 expression is known to be upregulated by LPS and TNF-α 
in DC; and the DC-derived PGE2 can bind to EP2 and EP4 receptors on DC plasmatic membrane 
and autocrinally regulate their cellular functions [420]. Depending on the microenvironment 
and maturation stage, PGE2 may have opposite effects on DC function. Several studies pointed 
out that PGE2 impairs DC maturation, their MHC-II expression, and antigen presentation skills, 
while it upregulates IL-10 expression, through EP2 and EP4 ligation (although there are 
conflicting data concerning the IL-10 upregulation [431,432]); PGE2 treatment also results in 
the downregulation of IL-6, TNF-α, and IL-12 expression by DC [420,422,431,433-436], which is 
further enhanced and mediated by IL-10 [420,433,436] (the detailed anti-inflammatory 
properties of IL-10 are described later in this chapter, in section 4.6). In fact, PGE-driven IL-10 
production by DC amplifies the regulation of the inflammatory response [420]. Of note, when 
IL-10 action is blocked, PGE2 promotes IL-6 production; however, as PGE2 induces the 
expression of IL-10, which downregulates IL-6 expression, the direct effect of PGE2 on IL-6 
expression is masked by IL-10 action [420,433]. Interestingly, IL-10 prevents COX-2 expression 
by DC and monocytes (through the inhibition of NF-kB transcriptional activity and by 
accelerating the degradation of COX-2 mRNA), therefore, stopping the immune suppressive 
amplification loop [420]. Remarkably, these IL-10-producing DC have the ability to bias T cell 
differentiation toward Th2 phenotype and to suppress CTL response [421,423]. Besides IL-10, 
PGE2 is also described to upregulate the expression of the immune regulatory factors 
thrombospondin-1 and IDO in DC [423,437]. Conversely, when combined with TNF-α, PGE2 
stimulates DC and promotes IL-12 secretion [420,434]. 
Interestingly, monocyte treatment with PGE2 inhibits the differentiation into DC 
[53,437], IL-12 production, and the ability to induce T cell proliferation in MLR [53]; while 
upregulates the expression of IDO, IL-10, NOS2, and IL-4Rα, generating a phenotype which 
overlaps with that of myeloid-derived suppressor cells [437]. These cells also express the 
suppressive factors ILT2, ILT3, ILT4, and PDL-1, and have the capability to inhibit CD8+ T cell 
proliferation and granzyme B expression [437]. Notwithstanding, the action of PGE2 through 
EP2 and EP4 was also shown to induce maturation in human monocyte-derived DC and to 
enhance the expression of CD80, CD86, CD83, MHC-I, HLA-DR, CD40, and adhesion molecules 
(CD44, CD54, and CD58), principally when in the presence of pro-inflammatory cytokines (the 
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conditions tested correspond to TNF-α; TNF-α and IFNα; and TNF-α, IL-1β, and IL-6) 
[423,431,432,434,435]. Moreover, the presence of PGE2 during the maturation process of 
monocyte-derived DC was shown to reduce their secretion of IL-12p70, IL-6, and IL-10, and to 
condition DC to bias T cell response towards a Th2 profile [423,431,432,435]. 
PGE2 treatment, beyond increasing CCR7 expression, was also found to endow DC with 
the ability to migrate to secondary lymphoid organs (however, there are clues that this specific 
function of PGE2 can be also ensured by other factors in vivo [423]), in response to CCL19 and 
CCL21 (which are CCR7 ligands), and to CXCL12 (consistent with the observed PGE2-induced 
CXCR4 increase in DC); on the other hand, PGE2 decreases DC expression of CCL19, reducing 
the chance of naive T cell (which are CCR7+) to migrate into secondary lymphoid organs [421-
423,432,435,438-442]. Interestingly, once inside the lymph node, exposure of DC to PGE2 
decreases their activation status and ability to prime T cells [422]. In the same line, this 
prostanoid decreases CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), and CCL5 (RANTES) 
production by DC, reducing the immune cell infiltrate [421,422,436,442,443], as well as DC’s 
CCR5 expression [435,442]; whereas increases the expression of CCL17 (or thymus and 
activation-regulated chemokine, TARC) and CCL22 (or macrophage-derived chemokine, MDC) 
by human monocyte-derived DC and peripheral blood myeloid DC (in an EP2/EP4 dependent-
manner), which specifically attract Th2 memory T cells [442,444]. PGE2-derived upregulation 
of CCR7 expression is also observed on human monocytes, whereas during monocyte 
differentiation into macrophages, PGE2 cannot prevent the naturally occurring CCR7 
downregulation [445]. 
In the context of acute inflammation, bacterial products or tissue damage signals, 
complement split products, PGE2 (e.g. secreted upon tissue mast cell degranulation in 
response to complement anaphylatoxins), among others, will attract neutrophils, and these 
cells will release chemotactic factors that attract macrophages to the site of injury [230]. The 
presence of PGE2 in the early phase of the inflammatory response will, per se, attract new 
mast cells and stimulate their production of CCL2 (MCP-1) [423], increasing the number of 
infiltrating macrophages, and induce IL-8 secretion [423], which enable the recruitment of 
more neutrophils to the site of inflammation, overall amplifying the PGE2 and histamine 
release, vasodilatation, and infiltration of immune cells in the inflammatory site. Reported data 
suggest the ability of PGE2 to recruit macrophages is limited in time, as this prostanoid also 
induces the downregulation of CCR5 and Mac-1 on monocytes and macrophages (reducing 
their ability to migrate), as well as the reduction of CCL5 (RANTES) and of all three CXCR3 
ligands – CXCL9 (MIG), CXCL10 (IP10), and CXCL11 (ITAC) – limiting the recruitment of the 
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effector cells of a Th1 immune response: Th1 cells, CTL, NK cells (all of them described as 
CCR5+CXCR3+), and pro-inflammatory macrophages [423,444,446]. In turn, by promoting the 
expression of CCL17 (TARC) and CCL22 (MDC), PGE2 contribute to the recruitment of Th2 and 
Treg cells [423,444], and by upregulating CXCL12 (SDF-1) expression, it attracts myeloid-
derived suppressor cells, supporting tissue repair and the termination of the inflammatory 
response [423,437].  
PGE2 inhibits T cell proliferation [422,424], dampens IL-2 production by T cells and IL-2 
signaling [423]; it also skews T cells towards a Th2 phenotype, inhibiting IFNγ expression by 
CD4+ T cells [423,424], along with Ig class switching in B cells to IgE, the immunoglobulin class 
typically associated to a Th2 immune response [424]. The fostering of Th2 differentiation is 
further supported by the effect of PGE2 in inhibiting IL-12 production by DC and monocytes 
and, therefore, preventing the development of a Th1 immune response. In the same line, PGE2 
also inhibits the cytotoxic functions of CTL [423]. Interestingly, it was reported that the 
treatment of purified CD4+CD25- or CD4+CD25+ T cells with PGE2, induced the de novo 
generation of CD4+FoxP3+ Treg cells, for the former cell population, while increased the 
regulatory properties and upregulates FoxP3 expression in the latter [7,287,447]. Regardless, 
there are contradictory data published reporting that EP4 stimulation on T cells or DC supports 
Th1 differentiation, while EP2 and EP4 signaling promotes Th17 differentiation 
[423,439,448,449]. Furthermore, the addition of exogenous PGE2 to in vitro activated γ9δ2 T 
cells prevents their proliferation, production of TNF-α and IFNγ, and impairs their cytolytic 
activity [294].  
Not surprisingly, several bacteria [421] and tumor cells [423,437] make use of PGE2 
immunosuppressive properties, by stimulating its production and/or inhibiting its degradation 
(by suppressing the activity of the PGE2 degrading enzyme 15-hydroxyprostaglandin 
dehydrogenase, 15-PGDH) in order to escape from immune surveillance. 
4.2.2. Role of prostaglandin E2 in mesenchymal stromal/stem cells immune 
suppressive function 
Human BM-MSC constitutively express both COX-1 and COX-2, and constitutively 
produce PGE2, whose secretion augments upon PBMC, monocyte, mature myeloid DC, or T 
cell co-culture, after exposure to TNF-α and/or IFNγ, or in the presence of LPS 
[9,26,31,53,236,240,286,287,294]; as well as after MSC co-culture with NK cells, independently 
of IFN-γ secretion [326]. Likewise, human AT-MSC and UCM-MSC constitutively express PGE2 
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as well [26,31,248], and the former upregulate its expression in response to LPS, PBMC, or 
mature myeloid DC co-culture [31], while UCM-MSC augment PGE2 secretion upon PBMC co-
culture [26,248] or after IL-1β treatment [45,385]. 
The impairment of monocyte allostimulatory ability by human UCM-MSC is partially due 
to PGE2 action [248]. Indeed, it was reported that PGE2 secreted by human BM-MSC impairs 
monocyte differentiation into DC, suppresses IL-12 production and their ability to elicit T cell 
proliferation in MLR assays [53]; whereas mouse BM-MSC-derived PGE2 upregulates the 
expression of IL-10 by macrophages [286,287,377]. Similarly, in human, PGE2 was shown to 
mediate the BM-MSC-driven suppression of TNF-α secretion by DC [236], as well as the BM- 
and AT-MSC-derived induction of IL-10 production by pDC [31]. In the same line, synovial cells 
from mice with CIA stimulated in vitro with type II collagen, display a reduction of IFNγ and 
TNF-α protein expression when co-cultured with human AT-MSC, a process mediated by PGE2 
and IL-10 [180]. 
Furthermore, PGE2 was demonstrated to mediate the human BM-MSC-driven 
suppression of Vδ2+ γδ T cells [104,294] and Vα24+Vβ11+ iNKT cells [104] proliferation through 
EP2 and EP4 receptors (which are highly expressed at the γ9δ2 T cell surface) [104,294]. PGE2 is 
also involved in human BM-MSC-mediated inhibition of NK cell proliferation and cytotoxicity 
upon stimulation with IL-15 [327] or IL-2 [326]; in the latter condition, PGE2 and IDO have a 
synergistic suppressive effect over NK cell proliferation and cytotoxic abilities [326]. 
PGE2 secreted by human BM-MSC [26,31,236,240,243], AT-MSC [26,31], UC-MSC 
[26,248], and induced pluripotent stem cells (iPSC) [249] is required for modulation of cell 
proliferation in MLR and PHA-stimulated PBMC; likewise, PGE2 secreted by mouse BM-MSC 
[182] also mediates the inhibition of T cell proliferation. Accordingly, PGE2 was shown to 
reduce mRNA levels of CDK2 and other genes involved in cell proliferation [31]. PGE2 synthesis 
inhibitor reverses human BM-MSC-mediated suppression of IFNγ production by T cells [236], a 
mechanism shared with human UCM-MSC [385], although there are contradictory data 
concerning the influence of PGE2 over IFNγ suppression [31]. Remarkably, PGE2 was shown to 
be one of the factors underlying human BM- and AT-MSC induction of IL-10 expression on T 
cells [31] and also on fully differentiated Th17 cells [9]. In the same line of evidence, porcine 
BM-MSC was shown to induce CD4+IL-10+IFNγ+ T cells in MLR assays, in an IDO- and PGE2-
dependent manner; and those MSC-induced CD4+IL-10+IFNγ+ T cells were demonstrated to 
possess the ability to suppress PBMC proliferation in MLR assays through IL-10 secretion [266].  
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Regarding the role of PGE2 in the influence of MSC over T cell differentiation, it is 
described that both human BM- and AT-MSC can suppress the expression T-bet, STAT1, and 
STAT4 (involved in Th1 differentiation), and GATA-3, STAT6, and c-Maf (implicated in Th2 
differentiation), at mRNA level [31]. Interestingly, Yañez and colleagues [31] demonstrated 
that, for AT-MSC, PGE2 mediates this effect; conversely, inhibition of PGE2 synthesis by BM-
MSC did not restore the mRNA expression of the abovementioned factors. Concerning the 
effect of MSC-derived PGE2 over the differentiation towards Th17 phenotype, the studies 
carried out apparently yield conflicting data, because the distinct protocols used may explain 
the differences in the results obtained. In the one hand, the inhibition of PGE2 synthesis was 
shown not to reverse RORc downregulation mediated by either human BM- or AT-MSC co-
cultured with PBMC activated with PHA [31]. On the other hand, PGE2 derived from BM-MSC 
was demonstrated to inhibit Th17 differentiation from mouse [275,276] and human naive T 
cells (identified as CD4+CD45RA+) [9], activated by CD3/CD28 under Th17 differentiation 
conditions; as well as the expression of IL-17A, IL-22, IFNγ, and TNF-α by fully differentiated 
mouse [275] and human [9] Th17 cells. Finally, English and colleagues [286] demonstrated that 
PGE2 is also involved in the generation of Treg cells by human BM-MSC. 
Of note, porcine BM-MSC-derived PGE2 induces the expression of IDO in PBMC [266], 
whose immunosuppressive is detailed in the next section (section 4.3 of this chapter). 
4.3. INDOLEAMINE 2,3-DIOXYGENASE 
4.3.1. The effect of indoleamine 2,3-dioxygenase on immune cells 
Indoleamine 2,3-dioxygenase (IDO) is an intracellular tryptophan degrading enzyme, 
ubiquitously expressed in mammalian tissues; of note, the immune system express 
preferentially IDO1, in relation to IDO2. IDO catalyzes the rate-limiting step of tryptophan 
catabolism: the conversion of tryptophan in N-formylkynurenine. N-formylkynurenine is 
further degraded in kynurenine which is ultimately catabolized to the terminal metabolites 
picolinic acid or quinolinic acid. Thus, the action of IDO leads to tryptophan starvation and to 
the production of tryptophan metabolites [450,451]. The ability to degrade the essential 
amino acid tryptophan acts not only as a defense mechanism against viruses and intracellular 
pathogens, but also as an immunoregulatory mechanism to prevent overreactive inflammatory 
responses [451]. IDO expression on DC is upregulated by CD80/CD86 binding to CTLA-4, type I 
IFN, IFNγ and other cytokines, as well as TLR4, TLR7/8, and TLR9 ligands, which makes sense in 
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the context of the immunoregulatory function of IDO in limiting the duration and magnitude of 
the inflammatory response [451-453]. Conversely, IL-6 promotes IDO inhibition through 
proteosomal degradation, in a suppressor of cytokine synthesis (SOCS)3 dependent-manner, 
thus preventing the establishment of immune tolerance whenever dangerous signals are 
received [451]. 
The immunosuppressant effect of IDO relies not only on tryptophan depletion, but also 
on the increasing concentration of tryptophan metabolites with immunomodulatory functions. 
Noteworthy, IDO activity can hamper T cell responses directly, by affecting T cell 
activation/differentiation, or indirectly, by modulating the function of antigen-presenting cells. 
Indeed, in the presence of TGF-β, IDO is phosphorylated and assumes functions of a signaling 
molecule which induces a tolerogenic phenotype in pDC [451]; in the same line, the 
intermediate tryptophan metabolite 3-hydroxyanthranilic acid (3-HAA) impairs IL-12, IL-6, and 
TNF-α production by BM-derived DC stimulated with LPS, as well as the upregulation of CD40, 
CD80, CD86, and I-A, decreasing the ability of DC to induce T cell activation both in vitro and in 
vivo [454]. On the other hand, the inhibition of IDO activity in human monocyte-derived DC 
hampers the upregulation of CD80, CD86, HLA-DR, CD83, and CD40, induced by LPS, TNF-α, or 
CD40L treatment, and decreases the expression of CXCR4 [455]. 
Concerning the direct effects of IDO activity on T cells, the tryptophan metabolites 
kynurenine, picolinic acid, and quinolinic acid were shown to suppress the proliferation of 
human CD4+ T cells, CD8+ T cells, and NK cells, upon PHA activation or in MLR [240,450]. 
Likewise, IDO activity in both pDC and monocyte-derived DC was proven to induce the 
generation and/or expansion of CD4+FoxP3+ Treg cells by a mechanism dependent of IDO and 
CD80/CD86 binding to CD4+ T cells [456,457]. In fact, both tryptophan depletion and 
kynurenine-mediated activation of aryl hydrocarbon receptor, a transcription factor expressed 
by naive T cells, bias T cells towards a FoxP3+ Treg phenotype [451]. Of note, there are other 
enzymes beyond IDO that catabolyze other essential amino acids and whose action leads not 
only to the inhibition of T cell proliferation by amino acid starvation, but also to the expansion 
of Treg cell population [451]. 
In vivo, IDO is implicated in materno-fetal tolerance and in tumor escape from the 
immune system. Of note, increased IDO expression is associated to a poor clinical outcome for 
both solid tumors and hematological malignancies [451,452,456,458]. 
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4.3.2. Role of indoleamine 2,3-dioxygenase in mesenchymal stromal/stem cells 
immune suppressive function 
Although not constitutively expressed, upon IFNγ, TLR3, or TLR4 stimulation, IDO1 and 
IDO2 are induced in human BM-MSC [45,88,240,247]. Accordingly, it is described that, in 
human, the IDO gene promoter possesses response elements for IFNγ [240]. 
In fact, IDO enzymatic activity in human BM-MSC prevents T cell proliferation upon 
PBMC stimulation with anti-CD3/CD28 [52]. Likewise, either the inhibition of IDO activity, by 
using the chemical antagonist 1 methyl l-tryptophan [75,240], or the addition of tryptophan 
[247] to human BM-MSC/MLR co-cultures reverse the human BM-MSC-mediated inhibition of 
T cell proliferation in MLR. Interestingly, the same result is achieved by the addition of 
kynurenine to MLR which, together with the observation that kynurenine levels are 
augmented in MLR in co-culture with MSC, supports that, regardless of tryptophan depletion, 
kynurenine accumulation participates in the inhibition of T cell proliferation mediated by MSC 
[240]. Similarly, impairment of T cell proliferation by human AT-MSC is also mediated by IDO 
[459]. Conversely, IDO does not participate in the human BM-MSC-driven inhibition of IL-17, IL-
22, TNF-α, and IFNγ production by Th17 [9], but contributes to the inhibition of Th17 
differentiation mediated by mouse MSC [276]. 
In addition, it was demonstrated that IDO and PGE2 derived from human BM-MSC have 
a synergistic effect over the inhibition of IL-2-stimulated NK cell proliferation and cytotoxicity 
[326]; as well as that IDO participates in the induction of IL-10 expression by monocytes, driven 
by human BM-MSC [52]. Likewise, porcine BM-MSC was shown to induce CD4+IL-10+IFNγ+ T 
cells in MLR assays, which was mediated by PGE2 and IDO. These CD4+IL-10+IFNγ+ T cells are 
capable of suppressing PBMC proliferation in MLR assays, in an IL-10-dependent manner [266].  
In a mouse renal allograft model, MSC treatment was shown to augment the serum 
levels kynurenine, indicative of an increased IDO enzymatic activity, which were correlated to 
higher percentages of CD4+CD25++FoxP3+ Treg cells in both the spleen and the allograft. 
Moreover, the use of IDO-knockout MSC or IDO inhibitor leaded to the loss of graft tolerance 
[287]. 
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4.4. ADENOSINE/CD39-CD73 
4.4.1. The effect of adenosine on immune cells 
The extracellular nucleotides and nucleosides comprise a group of bioactive molecules 
whose levels are tightly regulated by ecto-enzymes. Extracellular adenosine triphosphate (ATP) 
has the ability to induce a pro-inflammatory response by monocytes and lymphocytes, while 
its derivative nucleoside, adenosine, possesses an immunosuppressive function mainly 
mediated by the A2A adenosine receptor (ADORA2A) and A3 adenosine receptor [372,460,461]. 
Adenosine is generated after the hydrolysis of extracellular ATP or ADP into AMP, by the ecto-
nucleotidase CD39, and sequential dephosphorylation by ecto-5’-nucleotidase (CD73); the 
extracellular levels (and function) of adenosine are, in turn, regulated by adenosine deaminase 
(ADA), which converts adenosine into inosine [460,461]. 
Though CD39 was firstly described as a B cell activation marker, it was later shown to be 
also expressed on subsets of activated T cells, CD4+CD25++FoxP3+ Treg cells, NK cells, NKT cells, 
monocytes, macrophages, DC, and neutrophils [372,460]. In fact, CD4+CD25++FoxP3+ Treg cells 
express both CD39 (at the plasmatic membrane) and CD73 (mostly located in the cell 
cytoplasm) and use adenosine to suppress T cell responses [372,419,461]. Furthermore, CD73 
expression in CD4+ and CD8+ T cells, macrophages, and DC is upregulated by TGF-β [372,419], 
and the expression of ADORA2A is upregulated in T cells upon activation, which increases their 
susceptibility to adenosine-mediated regulation [461,462]. Previous studies demonstrated that 
adenosine inhibits proliferation, decreases the expression of CD25 and CD28, and the 
production of IL-2, IFNγ, granzyme B, perforin, FasL, and TRAIL by mouse T cells [461-464]; 
treatment with ADORA2A agonist inhibits fully-differentiated mouse Th1 cells’ proliferation 
and IFNγ production, with no effect on Th2 cell proliferation [460]. In human, adenosine was 
found to inhibit CD4+ T cell proliferation and the expression of IL-2, TNF-α, IFNγ, and several 
chemokines in CD8+ T cells and CD4+ Th1 cells, as well as the priming and cytotoxic activity of 
CTL [465,466], and to impair the adhesion of activated T cells to tumor cells [461]. These 
suppressive effects over T cell function are achieved by interfering with T cell receptor 
(TCR)/CD3 signaling, specifically by inhibiting the phosphorylation, and subsequent activation, 
of Lck and zeta-chain-associated protein kinase of 70 kDa (ZAP-70) tyrosine kinases; and by 
impairing the signal transduction mediated by IL-2, as a result of the inhibition STAT5 activity 
[461]. 
105 
Beyond this massive inhibitory effect over T cells, wherein adenosine interferes with the 
three activation signals of T cells (provided by TCR/CD3, CD28 and IL-2), this 
immunosuppressive molecule also modulates the function of antigen-presenting cells. 
Specifically, it impairs the oxidative burst in monocytes and macrophages, decreasing the 
production of nitric oxide and superoxide; and inhibits monocyte maturation and 
differentiation into macrophages [467,468]. In the same line, adenosine downregulates the 
expression of MIP-1α, IL-12 and TNF-α and induces the expression of IL-10 in monocytes and 
macrophages, shifting macrophage pro-inflammatory phenotype to anti-inflammatory 
phenotype [461,467-469]; while in human DC, adenosine impairs the production of IL-12 and 
TNF-α, and induces the secretion of IL-10 which, altogether, will impair the development of a 
Th1 immune response [461,469,470]. Macrophage’s expression of A2A receptors is 
upregulated by HO-1 (section 4.12 of this chapter) [468]. Besides, a decreased expression of 
the costimulatory molecules CD80, CD86, and CD40 is also observed in mouse B cells under the 
influence of adenosine [461]. 
Concerning NK cells, adenosine was shown to diminish their proliferation rate, reduce 
the expression of TNF-α and IFNγ, induce defective granule exocytosis, and impair cytotoxic 
activity, in both mouse [461,471] and human [330,461,465]. Similarly, NKT cells produce lower 
levels of IFNγ under the influence of adenosine [469]. In neutrophils, the activation of A2A 
receptors suppresses the production of ROS and of the pro-inflammatory cytokines TNF-α, 
CCL3 (MIP-1α), CCL4 (MIP-1β), CXCL2 (MIP-2α), and CCL20 (MIP-3α); adenosine also 
downregulates the expression of adhesion molecules, interfering with neutrophil ability to 
adhere to the vascular endothelium [469]. Conversely, activation of A1 receptor activation 
promote neutrophil migration and adhesion to the endothelium [469]. 
4.4.2. Role of adenosine in mesenchymal stromal/stem cells immune 
suppressive function 
A proportion of human BM-MSC co-expresses CD39 and CD73, however, though the 
percentage of BM-MSC expressing CD73 is consensual (≈90%), the frequency of CD39+ human 
BM-MSC is not, being described to be ≈15-35% [400] and ≈80% [281]. The presence of 
activated T cells was shown to induce an increased production of adenosine by BM-MSC, 
which is accompanied by an increased percentage of BM-MSC expressing CD39 on their 
plasmatic membrane and of CD73+ T cells [400]. Interestingly, a remarkable increase of the 
percentage of CD39+CD73+ Treg cells and CD39+CD73+ BM-MSC [400], as well as an increased 
CD39 and CD73 mRNA levels in Th17 cells [281], is also observed in co-cultures of BM-MSC 
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with activated T cells, further increasing the enzymatic machinery responsible for adenosine 
production and ATP degradation. In addition, under these conditions, it is observed the 
upregulation of ADORA2A mRNA and the decreased expression of ADA mRNA in T cells [400], 
contributing to enhance the immunosuppressive effect mediated by adenosine. Similarly, an 
increased CD73 expression is verified in NK cells in co-culture with UC-MSC [329].  
The important role of adenosine in the context of MSC-mediated T cell inhibition was 
established by demonstrating that the blockage of ADORA2A signaling reverts the inhibitory 
effect of human BM-MSC over T cell proliferation, in co-cultures of BM-MSC with T cells [400]. 
Besides, anti-CD39 treatment of human-BM-MSC and Th17 cells co-cultures, abrogates MSC-
mediated inhibition of Th17 proliferation and reduction of IL-17 and IFNγ production by Th17 
cells [281]. Adenosine was also demonstrated to mediate the murine BM-MSC-derived 
inhibition of T cells proliferation [472].  
4.5. SEMAPHORIN-3A, GALECTIN-1, GALECTIN-3, AND GALECTIN-9 
4.5.1. Semaphorin-3A and galectin-1 
Neuropilin-1 is a receptor, present on T cells and DC, with the ability to bind to 
semaphorin-3A, galectin-1, and neuropilin-1 (homotypic interaction), among others. While the 
homotypic interaction plays an important role in intercellular interactions (e.g. contributes to T 
cell/DC interaction, or facilitates the cluster of T cells and tumor cells, in the context of an 
immune response), binding to semaphorin-3A or galectin-1 delivers inhibitory signals to T cells 
[473,474]. 
Catalano and colleagues [473] demonstrated that the soluble molecule semaphorin-3A 
inhibits T cell-mediated immune response, namely T cell proliferation, cytokine production, 
and cytotoxicity. The inhibition of proliferation of T cells stimulated with anti-CD3/CD28 
(though no inhibitory effect was observed over PMA-stimulated T cells) was associated with an 
increase of p27KIP1 expression and to the decreased secretion of IL-2 by T cells [473]. In turn, 
the impairment of IL-2, IL-4, IL-10, and IFNγ production is attributed to semaphorin-3A 
blockage of CD3/CD28-mediated activation of c-Jun, c-Fos, nuclear factor of activated T-cells 
(NF-AT), NF-kB, and ERK1/2, which disable IL-2 induction. Of note, semaphorin-3A increases 
the expression of Rap-1, which sequestrates Raf-1, impairing the activation of MEK and the 
downstream ERK1/2 [473]. Remarkably, semaphorin-3A is also used as a mechanism of tumor 
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evasion from the immune system, which is achieved either by the direct inhibitory effect over 
T cells or by the blockage of the homotypic interaction among neuropilin-1 expressed on T cells 
and tumor cells (as semaphorin-3A will compete for neuropilin-1 ligation) [473].  
In turn, galectins, an evolutionarily conserved family of β-galactoside-binding proteins, 
have been intensively studied in the recent years due to their role in materno-fetal tolerance 
[475]. They are widely express in human, being present in both lymphoid and non-lymphoid 
tissues; moreover their expression is upregulated in activated T cells, B cells, Treg cells, and 
inflammatory macrophages [475]. Galectin-1 has an inhibitory effect over T cell activation, 
which is mediated by binding to CD45, CD43, and CD7, or neuropilin-1, and includes 
impairment of proliferation, induction of apoptosis on Th1 cells, and bias of the immune 
response from Th1 towards a Th2 profile; notwithstanding, it promotes the survival of naive T 
cells and induces tolerogenic DC [474-476]. This inhibitory molecule is also involved in the 
suppressive mechanisms of Treg cells and in the malignant cells escape from the immune 
system [475,476]. 
Interestingly, human BM-MSC express both semaphorin-3A [474] and galectin-1 
[59,475,477], being reported that these factors contribute to MSC-mediated inhibition of T cell 
proliferation. Of note, galectin-1 is constitutively expressed by human BM-MSC and its 
expression is upregulated under inflammatory conditions [59,477]; it can be detected in 
human BM-MSC intracellularly, at the cell surface, and also secreted as a soluble molecule to 
the extracellular milieu, though membrane-bound galectin-1 is more effective than its soluble 
form [475-477]. Besides the anti-proliferative effect over both CD4+ and CD8+ T cells, galectin-1 
is also responsible for the reduction of TNF-α, IFNγ, IL-5, and IL-12 production by PBMC 
stimulated with either IL-2/OKT3 or CD28/OKT3, whereas its regulatory effect over IL-4 and IL-
10 depends on the type of stimulus given [475]. 
4.5.2. Galectin-3 and galectin-9 
Galectin-3 is also a negative regulator of T cells, able to induce T cell apoptosis through 
binding to CD7 and CD29, and which contributes to cancer immune escape [477-479]. Similarly 
to galectin-1, galectin-3 is also constitutively expressed on human BM-MSC and human UC-
MSC; it localizes intracellularly, at the cell surface, or is secreted into the extracellular 
environment; and its expression is upregulated upon TLR2 stimulation [477,478,480]. Galectin-
3 was also shown to be involved in the suppressive activity of  human BM- and UC-MSC over T 
cell proliferation [477,478,480]. 
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Concerning galectin-9, it is expressed by immune cells, endothelial cells, and fibroblasts 
[312]. It can bind to different receptors, including the glycoreceptor TIM-3 (T-cell 
immunoglobulin domain and mucin domain-3), expressed on terminally differentiated Th1 
cells, Th17 cells, and CTL, being reported that galectin-9/TIM-3 binding induces death of 
effector Th1 and Th17 cells, and impairs cytokine production by the former cell population 
[74,479]. Moreover, galectin-9 induces Treg cells from naive CD4+ T cells and inhibits Th17 
differentiation by mechanisms either dependent or independent of TIM-3 [74]. This inhibitory 
molecule is also expressed by tumor cells [479]. In human BM-MSC, the expression of galectin-
9 is induced by pro-inflammatory conditions – e.g. upon co-culture with activated PBMC, T 
cells, or B cells; and/or after treatment with IFNγ, TNFα, IL-1α, IL-1β, PGE2; or by TLR2, TLR3, or 
TLR4 stimulation [74,312] – and it plays an active role in MSC-mediated suppression of T cell 
proliferation [74,312], B cell proliferation, and IgG secretion by B cells [312]. 
4.6. INTERLEUKIN-10 
4.6.1. The effect of interleukin-10 on immune cells 
Interleukin-10 (IL-10) cytokine family includes IL-19, IL-20, IL-22, IL-24, and IL-26 
cytokines [481,482]. IL-10, originally described as the cytokine synthesis inhibitory factor 
(CSIF), is a pleiotropic cytokine with a predominant anti-inflammatory function though, 
depending on the microenvironmental conditions, it can display immunostimulatory activity as 
well; IL-10 is mainly produced by macrophages, but monocytes, specific T cell subsets, and 
specific B cell subsets can also secrete this cytokine [304,420,481,483]. Interestingly, IL-10 
expression is induced in monocytes/macrophages upon LPS stimulation, which suggest this 
cytokine acts to control the inflammatory response triggered by LPS; notwithstanding, it is also 
induced by PGE2 (chapter 1, section 4.2), in monocytes, DC, and T cells, wherein IL-10 
mediates and improves PGE2’s immunosuppressive effect [420,433]. In turn, IL-10 will 
subsequently inhibit COX-2 (and consequently PGE2) expression in DC and 
monocytes/macrophages [420], preventing the perpetuation of an immune suppressive 
environment. 
IL-10 receptor is a heterodimer constituted by an α (IL-10Rα) and a β chain, and its 
engagement with IL-10 in monocytes leads to the phosphorylation of JAK1 and Tyk2, with 
subsequent activation of STAT3 (mainly), but also STAT1 and STAT5, depending on the 
microenvironment; and to the induction of de novo synthesis of SOCS3. Roughly, STAT3 
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activation mediates the anti-inflammatory effects of IL-10 in myeloid cells; interestingly, in 
macrophages pre-exposed to IFNγ, IL-10 is modulated to preferentially activate STAT1, instead 
of STAT3, which ultimately results in a pro-inflammatory effect [483].  
The biological effects of IL-10 comprise the reduction of the expression of pro-
inflammatory cytokines (TNF-α and IL-1β) and chemokines in neutrophils, presenting similar 
effects on eosinophils and mast cells [481]. In monocytes/macrophages, IL-10 also inhibits the 
production of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, IL-12, G-CSF, GM-CSF, and TNF-α) 
induced by IFN-γ or endotoxin, a process associated with the induction of SOCS3 expression. 
Notwithstanding, IL-10 upregulates the expression of anti-inflammatory mediators, such as IL-
1 receptor antagonist (IL-1Ra) and soluble TNF-α receptors, and decreases the expression of 
MHC-II, CD86, and cell adhesion molecules, hampering antigen-presentation capability of 
monocytes/macrophages. Finally, it inhibits monocyte differentiation into DC, and 
downregulates the expression of CD86, IL-6, IL-12, TNF-α, and leukotriene B4 by DC 
[413,420,433,481,482,484]. IL-10 promotes increased phagocytic activity in 
monocytes/macrophages, associated to the increased expression of IgG-Fc receptors (CD16, 
CD32, and CD64) and scavenger receptors (CD163 and CD14) [481]. In macrophages, IL-10 
signaling through its receptor not only inhibits NF-kB p65/p50 translocation to the nucleus (by 
inhibiting IKK activity), but also blocks the DNA-binding of NF-kB already located in the cell 
nucleus; it also drives to the accumulation of the suppressive p50/p50 NF-kB homodimer in the 
nucleus, thus impeding the transcription of pro-inflammatory cytokines [481]. Besides, IL-10 
inhibits STAT1 phosphorylation induced by IFNα and IFNγ, decreasing the expression of IFN-
induced genes [481,483]. 
Due to the decrease of pro-inflammatory cytokines produced by monocytes and 
macrophages, particularly IL-12, IL-10 indirectly hampers Th1 immune response. Nevertheless, 
this anti-inflammatory cytokine also exerts direct effects on T cells, leading to the reduction of 
IL-2, IFNγ, IL-4 and IL-5 expression and preventing T cell proliferation, albeit these effects are 
more pronounced in naive T cells than in activated or memory T cells, probably because IL-
10Rα is downregulated upon T cell activation [481]. Noteworthy, the presence of IL-10 in the 
course of T cell activation induces a regulatory phenotype, characterized by the production of 
IL-10 by T cells [481]. On the contrary, no inhibitory effect over CD8+ T cells has been described 
so far for IL-10 [481]. 
Conversely, on NK cells, IL-10 presents a stimulatory effect, enhancing their proliferation 
and cytokine production (IFNγ, TNF-α, and GM-CSF), as well as the proliferation of CD56bright NK 
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cell subpopulation, induced by IL-2 [481]. Likewise, a discreet stimulatory effect on B cells is 
also observed: IL-10 prevents apoptosis, and enhances proliferation and differentiation into 
plasma cells [481]. 
Animal models underscore the biological importance of IL-10 in controlling exacerbated 
inflammatory states in vivo, such as those found in autoimmune diseases. Likewise, 
deregulation of IL-10 expression has been described in human autoimmune diseases, whereas 
IL-10 overexpression has been associated to several human malignant diseases and to a poorer 
outcome [481]. In the same line, viruses use IL-10 to escape from the immune system, either 
by stimulating IL-10 secretion by host immune cells, or by producing IL-10 homologs [481].  
4.6.2. Role of interleukin-10 in mesenchymal stromal/stem cells immune 
suppressive function 
Given the broad spectrum of immune cells whose function is regulated by IL-10, the role 
of this anti-inflammatory cytokine in the MSC-driven immunosuppression is being increasingly 
investigated. Interestingly, MSC avail themselves of IL-10 to regulate immune cells, not only by 
secreting the cytokine, but also by inducing its production in a wide range of immune cells 
[246,264,359,375]. 
Rat BM-MSC-derived IL-10 inhibits DC maturation and IL-12 secretion, while stimulates 
IL-10 production by DC [359]. These inhibitory effects were dependent on the activation of 
JAK1/STAT3 pathway induced by IL-10 in DC. In fact, JAK1/STAT3 activation was demonstrated 
to be necessary for IL-10 production by DC [359]. Likewise, mouse BM-MSC conditioned 
medium stimulates mouse splenocytes to produce IL-10, which will, in turn, prevent T cell 
proliferation in MLR [246]; mouse AT-MSC have the ability to impair the production of IFNγ 
and TNF-α by synovial cells from mice with CIA, stimulated with type II collagen, in a IL-10- and 
PGE2-dependent manner [180]. In turn, IL-10 secreted by mouse BM-MSC has the ability to 
impair Th17 cell differentiation, as well as IL-17A and IL-17F production, as demonstrated by 
silencing IL-10 gene in MSC by RNA interference technique [278]. In mouse T cells, IL-10 
inhibits STAT3 activation (in opposition to what had been described for monocytes and DC 
[359,481,482]), a transcription factor activated by IL-6 or IL-23 during Th17 differentiation and 
responsible by inducing the expression of RORγt and IL-17 [232,233,278]. Interestingly, IL-10 
activates STAT5 in T cells which, in turn, activates SOCS3, a suppressor of IL-6/STAT3 signaling 
pathway; in fact, IL-10 reduces STAT3 binding to promoter regions of RORγt, IL-17A, and IL-17F 
genes, disabling RORγt expression and Th17 differentiation [278]. 
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Human BM-MSC constitutively express IL-10 at immunosuppressive concentrations 
[240] and can also induce human monocytes and T cells to produce IL-10 [375,485]. In human 
MLR, IL-10 mediates the inhibitory effect of BM-MSC on T cell proliferation [239], though it is 
not involved in the downregulation of CD25, CD38, and CD69 expression in both CD4+ and CD8+ 
T cells, driven by human BM-MSC [84]. 
Of note, IL-10 induces the expression of HO-1, an enzyme with anti-inflammatory 
properties (detailed in section 4.12 of this chapter), in human DC [486] and mouse 
macrophages [481]; IL-10 also upregulates the expression of HLA-G (chapter 1, section 4.15) in 
human BM-MSC and monocytes [239]. 
4.7. INTERLEUKIN-6 AND LEUKEMIA INHIBITORY FACTOR  
4.7.1. The effect of interleukin-6 and leukemia inhibitory factor on immune cells 
Leukemia inhibitory factor (LIF) and IL-6 belong to the same cytokine family. Beyond the 
sequence homology and structure similarity between these cytokines, they share a common 
receptor and signal transducer subunit, gp130, and display overlapping functions, such as the 
induction of acute phase proteins in vivo [487,488]. Under different conditions these cytokines 
can either promote or inhibit inflammation, albeit they possess other important functions not 
related to the immune system (such as embryo implantation, maintenance of the pluripotency 
of mice embryonic stem cells, differentiation/maturation and survival of neurons and 
oligodendrocytes, bone metabolism, proliferation of muscle satellite cells and cardiomyocytes, 
for LIF; and epithelial regeneration, regulation of fat and bone metabolism, as well as several 
neural functions, for IL-6) [487-490]. 
In what concerns to the immunologic function of IL-6, their anti-inflammatory properties 
have been attributed to signaling through membrane-bound IL-6 receptor (IL-6R), designated 
by classic signaling, whereas pro-inflammatory function is associated with signaling mediated 
by soluble IL-6R (sIL-6R), or trans-signaling [491]. Distinct lines of evidence highlight the role of 
IL-6 in the transition between the innate and acquired immune response, and between the 
acute inflammation and the inflammation resolution [488]. In an initial phase of an insult, IL-6, 
along with other pro-inflammatory factors, leads to neutrophil infiltration into the injury site. 
The proteolytic cleavage of IL-6R expressed on neutrophils will amplify IL-6 trans-signaling, 
leading to the expression of monocyte-attractive chemokines and upregulating adhesion 
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molecules expression on endothelial cells and  lymphocytes, leading to the monocyte and 
lymphocyte infiltration in the site of injury, and enabling an acquired immune response [488]. 
IL-6 was shown to skew T cell differentiation towards Th17 or Th2, being recognized that it is 
necessary for Th17 differentiation and maintenance; also, it represses FoxP3 transcription, 
consequently suppressing Treg differentiation [488,492]. In contrast, LIF has the ability to 
inhibit Th17 differentiation, while supporting the expansion of Treg cell population in vivo 
[492-494]. Importantly, the role of LIF and IL-6 in cancer immune escape was proved by 
demonstrating that these cytokines induce monocyte polarization toward a M2 macrophage 
phenotype, both in vitro and in tumor-associated macrophages. These cells express high levels 
of IL-10 and low levels of IL-12, and can induce FoxP3+ Treg cells; along with these anti-
inflammatory properties, M2 macrophages also participate actively in tissue regeneration, 
contributing to the inflammation resolution [373,374].  
4.7.2. Role of interleukin-6 and leukemia inhibitory factor in mesenchymal 
stromal/stem cells immune suppressive function 
Recently, Melief and colleagues [375] demonstrated that IL-6, present in supernatant of 
human BM-MSC and monocytes co-cultures, skewed monocyte differentiation toward an IL-
10-producing M2 macrophage phenotype and inhibited their differentiation into immature DC, 
resulting in a negative regulation of the inflammation and antigen presentation. IL-6 is 
secreted by both BM-MSC and monocytes, and is further upregulated when the cells are in co-
culture; BM-MSC secrete higher amounts of the cytokine, compared to monocytes [375]. Of 
note, BM-MSC constitutively express IL-6 [79,375], a feature shared with human AT-MSC [292]. 
Interestingly, Najar and colleagues [60] reported that, at low doses, MSC support T cell 
proliferation, including Treg cell expansion, in a IL-6-dependent manner. In contrast, Melief 
and colleagues [285] demonstrated that IL-6 was not necessary for MSC-driven Treg cell 
expansion, perhaps due to the presence of other factors in the culture medium that were 
proven to possess the ability to induce Treg cells: TGF-β1 and HO-1 (produced by MSC), and 
CCL18 (derived from M2 monocytes). Finally, it was also reported that IL-6 produced by human 
fetal BM-derived MSC can increase the percentage of Th17 cells, with no effect in the number 
of Treg cells [252], demonstrating this cytokine can have opposite effects under different 
conditions. 
Concerning to LIF, it is expressed by human AT- and UCM-MSC and upregulated in the 
presence of activated PBMC; it also mediates MSC-derived inhibition of T cell proliferation and 
induction/expansion of Treg cell population [38,495]. 
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4.8. HEPATOCYTE GROWTH FACTOR 
4.8.1. The effect of hepatocyte growth factor on immune cells 
Hepatocyte growth factor (HGF) is a pleiotropic cytokine involved in liver regeneration, 
that plays an essential role in the regulation of cell proliferation, survival, and differentiation in 
a variety of organs, and also has a prominent role in the resolution of inflammation following 
an acute phase response, due to its anti-inflammatory activity [496-498]. As explained above 
(section 4.7), IL-6 is an acute phase cytokine produced after TLR4 stimulation (in an NF-kB-
dependent manner), which intervenes both in the inflammatory phase and in the 
inflammation resolution of the acute phase response, through the induction of HGF expression 
and other mechanisms [496]. 
In fact, HGF acts as a switch from a pro-inflammatory to an anti-inflammatory response. 
The signaling cascade activated after HGF binding to its receptor, c-Met, leads to PI3K/Akt 
activation and subsequent phosphorylation and inactivation of glycogen synthase kinase-3 
beta (GSK3β), a kinase with important functions in glycogen metabolism and in the regulation 
of cytokine expression [496,497]. GSK3β inactivation, in mouse macrophages [496] and human 
proximal tubular epithelial cells [497-499], is associated with an increased interaction between 
the co-activator protein (CBP) and phospho-CREB, making CBP/p300 less available to interact 
with NF-kB; also, in the presence of HGF, it is observed a reduced phosphorylation of the NF-kB 
p65; altogether leading to the decline of NF-kB transcriptional activity. Therefore, HGF 
switches off the transduction of NF-kB-dependent pro-inflammatory cytokines, such as IL-6 
production by mouse macrophages [496], IL-6 and CCL5 expression by human proximal tubular 
epithelial cells [497,499], while induces the production of IL-10 by mouse macrophages [496]. 
In vivo, in mouse chronic renal injury models, HGF inhibits the renal infiltration of T cells 
and monocyte/macrophage, by suppressing the NF-kB-induced CCL5 and CCL2 expression, and 
blocks Th1 polarization [497,499,500]. In addition, HGF was also shown to ameliorate GvHD 
mouse model, by reducing donor T cell infiltration in the liver, consequently preventing hepatic 
lesions, and by decreasing the serum levels of IL-12, and IFNγ and TNF-α mRNA expression in 
the liver and small intestine [501]. Moreover, HGF reduces allergic airway inflammation and 
regulate eosinophil functions [502]. 
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4.8.2. Role of hepatocyte growth factor in mesenchymal stromal/stem cells 
immune suppressive function 
Human BM-, AT-, and UCM-MSC constitutively express HGF at immunosuppressive 
concentrations [26,240], which is further upregulated in BM-MSC, in the presence of IFNγ 
[240] or in co-culture with T cells [26]. Nevertheless, the demonstration that HGF is an 
important soluble factor that mediates the inhibition of T cell proliferation in MLR, by human 
BM-MSC, was revealed by the use of neutralizing antibodies directed against HGF [235]; 
likewise, HGF derived from human placental MSC also inhibit CD3/CD28-induced T cell 
proliferation [503]. In opposition, HGF seems not to be involved in the suppression of PHA-
induced T cell proliferation by human BM-, UCM-, or AT-MSC [26,234]. As T cells do not 
express c-Met, the action of HGF on T cells is likely to be indirect and mediated by HGF-
induced IL-10 upregulation in monocytes [503]. 
4.9. INSULIN-LIKE GROWTH FACTOR 
Insulin-like growth factor (IGF)-1 and IGF-2 are pleiotropic growth factors, which can 
bind to either type 1 IGF receptor or insulin receptor, to promote cell proliferation and 
differentiation, also having an important role in the regulation of metabolism, behavior, and 
hematopoiesis [504]. Furthermore, there are six insulin-like growth factor-binding proteins 
(IGFBP), whose function ranges from blocking the biological effect of IGF, by impeding its 
interaction with the respective receptors, to acting as carrier proteins, facilitating IGF transport 
in the circulation and avoiding its proteolytic degradation [504,505]. 
From the immunologic point of view, both pro and anti-inflammatory actions had been 
ascribed to IGF [505,506]. Specifically, it has been reported the ability of IGF-2 to inhibit TNF-α-
dependent activation of JNK in oligodendrocytes; in turn, IGF-1 was shown to enhance IkB 
dephosphorylation in astrocytes, consequently preventing NF-kB nuclear translocation, and to 
impair TNF-α-mediated NF-kB activation in human colonic adenocarcinoma cells; moreover, 
IGF-1 was also shown to induce IL-10 expression by T cells [504,505]. Interestingly, the 
expression of IGFBP2 and IGFBP3 by human BM-MSC was shown to be involved in the 
suppression of PBMC proliferation [507]. 
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4.10. TNF-α STIMULATED GENE/PROTEIN 6 
4.10.1. The effect of TNF-α stimulated gene/protein 6 on immune cells 
Despite the anti-inflammatory properties of TNF-α stimulated gene/protein 6 (TSG-6) 
are recognized for a long time, only recently their modulatory actions over the cells of the 
innate and adaptive immune system have been demonstrated. In fact, TSG-6 has the ability to 
decrease human neutrophil and monocyte/macrophage infiltration at the site of injury, being 
demonstrated that TSG-6 binds to IL-8, impeding not only the chemokine transport across an 
endothelial monolayer but also its interaction with its receptor (CXCR2) expressed on 
neutrophils [380,508]. TSG-6 also inhibits TNF-α and IL-1α production by mouse macrophages 
[380]; to induce tolerogenic DC (with decreased expression of IL-12, CD40, CD80, and CD86, 
and higher production of IL-10 and TGF-β), capable of generating CD4+FoxP3+ Treg cells [509]; 
and to suppress T cell proliferation and IFNγ production, which was associated to TSG-6-
dependent repression of ZAP-70, linker for activation of T cells (LAT), and p42 mitogen-
activated protein kinase (MAPK) phosphorylation [509].  
 
4.10.2. Role of TNF-α stimulated gene/protein 6 in mesenchymal stromal/stem 
cells immune suppressive function 
The relevance of TSG-6 in MSC-mediated immunosuppression was demonstrated in 
several in vivo animal models (myocardial infarction, cornea injury, autoimmune diabetes, and 
peritonitis) [380,509-511]. In fact, human BM-MSC express TSG-6 [512] and its expression is 
upregulated after stimulation with TNF-α and other pro-inflammatory cytokines [380]. Human 
MSC-derived TSG-6 relies on different mechanisms to inhibit inflammation, and affects distinct 
immune cells. 
It was demonstrated in vivo that human MSC-derived TSG-6 mediates the inhibition of 
neutrophil and monocyte/macrophage infiltration, in a rat cornea injury model and mouse 
peritonitis model, respectively [380,510,511]. Human BM-MSC-derived TSG-6 also suppresses 
TLR2-induced TNF-α and IL-1α expression by mouse macrophages. It was demonstrated, in 
mouse macrophages, that TSG-6 – bounded or not to hyaluronic acid – interacts with CD44 
and, consequently, induces CD44/TLR2 dissociation, resulting in the inhibition of TLR2/NF-kB 
signaling pathway [380,511,513]. Similarly to human, TSG-6 produced by mouse BM-MSC 
inhibits DC maturation and function, apparently by interfering with MAPK and NF-kB signaling. 
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This inhibitory effect includes the suppression of CD80, CD86, MHC-II, and IL-12 expression, as 
well as the impairment of DC-induced T cell proliferation and IFNγ secretion in MLR [514]. 
Finally, human MSC-derived TSG-6 inhibits T cell proliferation and IFNγ production by mouse 
splenocytes, in vitro [509]. 
4.11. NOTCH SIGNALING 
4.11.1. The effect of Notch signaling on immune cells 
The Notch receptor family includes four trans-membrane proteins members (Notch-1-
4). Their binding to their ligands (Delta-like 1, 3, 4, or Jagged 1, 2) triggers the cleavage of 
Notch intracellular domain (NICD), which translocates to the nucleus, where it activates gene 
transcription; this corresponds to the canonical Notch signaling pathway. The remaining 
modes of activation of Notch signaling are collectively designated as non-canonical Notch 
signaling and, interestingly, those are the ones which seem to be involved in pathological 
conditions, thus, a therapeutic intervention that specifically inhibits non-canonical signaling 
would allow to improve the pathological condition without interfering with the normal 
physiologic processes mediated by Notch [515].  
The Notch signaling pathways are involved in morphogenesis, HSC self-renewal, cell 
growth, differentiation, and survival. In immune cells, Notch is involved in T cell development, 
regulation of T cell activity and effector cell differentiation, being demonstrated that Jagged 2 
induces Th2 differentiation, but also that Notch signaling is important in Treg,Th1 and Th17 cell 
differentiation, as well as for CTL. Notch also mediates the differentiation of marginal zone B 
cells versus follicular B cell fate in the spleen; the differentiation of DC (induced by Notch-1 and 
Delta-like 1); and the development of megakaryocytes [515-517]. 
Regardless, Notch signaling is also involved in immune suppression, either directly, or 
indirectly, by its essential role in Treg cell generation and maintenance [518]. In macrophages, 
Notch-1 signaling inhibits the expression of TLR4-induced TNF-α and IL-6 (by suppressing the 
activating phosphorylation of ERK1/2 and, consequently, hampering NF-kB activity), while 
induces the production of IL-10 [519]; likewise, non-canonical activation of Notch in DC, results 
in PI3K activation and induction of IL-10 expression [515]. In what concerns to mouse T cells, 
Delta-like 1 and Jagged 1 induce the inhibition of the expression of early activation markers 
(CD69 and CD25) and of T cell proliferation, whereas Delta-like 4 enhances T cell activation and 
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proliferation [520]; similarly, Notch-1 agonist inhibits CD3/CD28-induced mouse CD4+ T cell 
activation, proliferation and production of IL-2, TNF-α, and IFNγ [521]. 
4.11.2. Role of Notch signaling in mesenchymal stromal/stem cells immune 
suppressive function 
It is widely known that MSC induce tolerogenic DC, with low capability to stimulate T cell 
proliferation in MLR. In mouse, this attribute is partially dependent of Jagged 2 expression by 
DC, which is upregulated after contact with mouse BM-MSC [361]. 
As human BM-MSC express the Notch-1 ligands Jagged 1, Jagged 2, and Delta-Like 1, 3, 
and 4 [7,522], there is an active research to investigate whether human MSC suppress the 
immune system by activating Notch signaling pathways in immune cells. In fact, it is already 
proved that Jagged 1 expressed by human AT-MSC and BM-MSC mediates the inhibition of T 
cell proliferation, and the reduction of IL-2 and IFNγ production, which is associated to the 
inhibition of NF-kB activity [90,523]. Furthermore, the activation of Notch-1 on CD4+ T cells by 
Jagged 1 expressed on human BM-MSC was proved to mediate the induction of Treg cells by 
MSC [522]. 
Interestingly, TLR3 and TLR4 stimulation of MSC induces the downregulation of Jagged 1 
in these cells and, consequently, reduces MSC ability to suppress T cell proliferation [90]. 
4.12. HEME OXYGENASE-1 
4.12.1. The effect of heme oxygenase-1 on immune cells 
Heme oxygenase-1 (HO-1) is an ubiquitously expressed enzyme which catalyzes the 
heme degradation into biliverdin, carbon monoxide (CO), and free iron. Its expression is 
induced in most cell types under oxidative stress conditions, in which this enzyme displays 
important anti-oxidant and cytoprotective functions, but also under inflammatory 
environments, wherein HO-1 contributes to the regulation of the immune response. This 
enzyme plays also an important role in trophoblast survival and pregnancy success 
[267,524,525]. The HO-1-derived CO stimulates monocyte differentiation into macrophages, 
and an increased HO-1 expression is associated with the decreased expression of pro-
inflammatory cytokines and increased production of anti-inflammatory cytokines in 
macrophages [524]; in the same line, HO-1 was recently shown to be involved in macrophage 
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polarization to the M2 phenotype [526]. Moreover, HO-1 and its metabolites are also involved 
in hampering the activation of basophils and the pro-inflammatory function of mast cells [524]; 
in preventing the production of pro-inflammatory cytokines (IL-12p70, IL-6, and TNF-α) and 
inducing a tolerogenic phenotype on DC [486,524,526]; in impairing T cell proliferation by 
preventing IL-2 expression [525]; and in the regulation of CD4+ and CD8+ Treg cell function 
[524]. In fact, human CD4+ Treg cells constitutively express HO-1 and this enzyme was 
demonstrated to mediate Treg suppressive functions [525]. 
 Regarding in vivo animal models, HO-1-knockout mice develop chronic inflammation 
and possess defective immune regulation mechanisms; additionally, HO-1 and CO were also 
shown to decrease EAE disease activity, to promote allograft survival and to reduce neutrophil 
and eosinophil infiltration to sites of inflammation [524]. 
4.12.2. Role of heme oxygenase-1 in mesenchymal stromal/stem cells immune 
suppressive function 
Human BM-MSC express HO-1, but the protein expression levels of this enzyme display a 
great interindividual variability [267,527]. Noteworthy, rat BM-MSC were also shown to 
express HO-1, but its expression declines with the passage number [527]. HO-1 was shown to 
be involved in human BM-MSC-mediated inhibition of T cell proliferation in MLR [527]. In 
addition, human BM-MSC induce Treg cells and enhance their expression of IL-10 and TGF-β by 
mechanisms partially dependent on HO-1 [267,285,528]. The translation of the importance of 
HO-1 in MSC-based therapies was demonstrated by Chabannes and colleagues [527], in a rat 
model of cardiac allotransplantation, wherein the inhibition of HO-1 prevented the protective 
effect of rat BM-MSC infusion in graft rejection. 
4.13. MATRIX METALLOPROTEINASE-1-CLEAVED CCL2 
The recognition that some post-translational modifications naturally occurring in 
chemokines can alter their biologic activity and produce isoforms with antagonistic effects has 
been explored for many years, with the intent to exploit them as a therapeutic approach. This 
is the case of CCL2 (MCP-1), whose N-terminal proteolytic cleavage converts its agonist form 
into an antagonist form [529]. Remarkably, MSC-derived MMP-1 is able to cleave CCL2 yielding 
a CCL2 variant with antagonistic activity, which mediates the inhibitory effect over Ig 
production exerted by mouse BM-MSC [320]. In fact, MMP-1-processed CCL2 leads to Akt and 
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STAT3 inactivation in plasma cells, and the activity of STAT3 is essential for the induction of 
BLIMP-1 expression which, in turn, is necessary for Ig production (see section 3.3.1 of this 
chapter) [320]. Actually, the study carried out by Rafei and colleagues [320] suggests that 
MMP-1-cleaved CCL2 decreases Ig production by inducing the dedifferentiation of plasma cells 
into plasmablasts, which is supported by the decreased BLIMP-1 expression and increased 
levels of PAX5, as well as the increased proliferative activity, observed in plasma cells after 
treatment with MSC-conditioned medium or MMP-1-cleaved CCL2. Furthermore, MMP-1-
cleaved CCL2 also upregulates the expression of PD-L1 (an immunosuppressive molecule 
whose function is detailed in chapter 1, section 4.17.2) and inhibits STAT3 phosphorylation 
(and activation) on CD4+ T cells from EAE mice, thus inhibiting the secretion of IL-17 [530]. 
Likewise, in vivo, MSC also demonstrated the ability to reduce anti-hFVIII IgG titers in 
hemophilic mice [320], and to ameliorate the symptomatic neuroinflammation in EAE mice 
[530], through MMP-1-processed CCL2 binding to CCR2. 
4.14. ERYTHROPOIETIN-PRODUCING HEPATOCELLULAR B2 AND EPHRIN-B2 
Erythropoietin-producing hepatocellular (Eph) receptors embrace a large family of 
membrane-bound receptors with tyrosine kinase activity which, together with their ligands, 
ephrins, is involved in a multitude of biological processes, comprising axon development, 
angiogenesis, regulation of MSC migration and differentiation, and regulation of the immune 
response, including T cell development and function [531]. Despite the controversy concerning 
the effect of Eph receptors and ephrins on T cells, ephrin-A1 was demonstrated to inhibit CD4+ 
T cell proliferation, suppress Th2 cell activation and Th2 cytokines production, and prevent 
activation-induced cell death; in turn, EphB6/ephrin-B2 interaction enhances T cell response to 
antigen, whereas ephrin-B2 and ephrin-B3 are involved in T cell co-stimulatory signaling. 
Remarkably, there are evidences that the final effect of Eph/ephrin is dose-dependent, which 
may explain the contradictory data [531]. 
Recently, Nguyen and colleagues [531] demonstrated that human BM-MSC express 
EphB2 and ephrin-B2, whose ligands, ephrin-B1 and EphB4, respectively, are highly expressed 
on human T cells. They also reported that both EphB2 and ephrin-B2 were implicated in MSC-
induced inhibition of T cell proliferation in MLR. Moreover, EphB2 and ephrin-B2 hampered 
the mRNA expression of IL-2, IL-17, TNF-α, and IFNγ by T cells. Interestingly, EphB4 stimulation 
increases the expression of TGF-β1 by human BM-MSC [531]. 
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4.15. HUMAN LEUKOCYTE ANTIGEN G1 AND HUMAN LEUKOCYTE ANTIGEN G5 
4.15.1. The effect of human leukocyte antigen G on immune cells 
The human leukocyte antigen (HLA)-G is a non-classical HLA class I molecule with 
important immune suppressive functions. It was firstly identified in first-trimester 
trophoblasts, in the fetal-maternal interface, where it was demonstrated to have a decisive 
contribution in materno-fetal tolerance. Alternative splicing of HLA-G primary transcript gives 
rise to seven different isoforms, four of which correspond to membrane-bound proteins (HLA-
G1-4), and the remaining three to soluble proteins (HLA-G5-7); of note, a soluble HLA-G1 
isoform is generated after the proteolytic cleavage of membrane HLA-G1 (shed HLA-G1) 
[239,532]. HLA-G binds to killer immunoglobulin-like receptor (KIR2DL4 or CD158d), leukocyte 
immunoglobulin-like receptor (ILT-2, LILRB1, or CD85j), and ILT-4 (also known as LILRB2, or 
CD85d). KIR2DL4 is expressed on NK cells, ILT-4 is specific from the myeloid lineage, whereas 
ILT-2 is expressed by monocytes, DC, T cells, B cells, and NK cells [239]. 
The immune regulatory functions of HLA-G include inhibition of TNF-α and IFNγ 
production by PBMC [533], and suppression of IFNγ secretion by γδ T cells [532]; induction of 
tolerogenic DC, with impaired ability to prime T cells and increased expression of IL-10 and IL-6 
[239,532,534]; inhibition of B cell proliferation, differentiation, and Ig secretion [532]; 
reduction of the cytolytic activity of CTL, γδ T cells, and NK cells [239,532]; suppression of αβ T 
and γδ T cell proliferation [239] and reduction of the migratory abilities of activated CD4+ T 
cells, by reducing their expression of CCR2, CXCR3, and CXCR4 chemokine receptors [532]; and 
induction of Treg cells [534]. 
4.15.2. Role of human leukocyte antigen-G in mesenchymal stromal/stem cells 
immune suppressive function 
In 2007, Nasef and colleagues [67] reported for the first time the expression HLA-G in 
adult MSC, specifically in human BM-MSC. Subsequent studies showed that human BM-MSC 
express HLA-G1 and HLA-G5 [30,239], however, the data published about the expressed 
isoforms are contradictory. Of note, the expression of HLA-G isoforms was also detected in 
human fetal liver-derived MSC [30]. 
Remarkably, HLA-G5 produced by human BM-MSC was shown to impair NK cell cytolytic 
activity and IFNγ production, to induce IL-10 secretion by peripheral blood lymphocytes, and to 
expand CD4+CD25+FoxP3+ Treg cell population [239]. In turn, human MSC-derived HLA-G1 has 
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a role in MSC-induced decrease of IFNγ and increase IL-10 production by T cells [30]. Finally, 
MSC-driven suppression of T cell proliferation in MLR was shown to be mediated by both HLA-
G1 and HLA-G5, being demonstrated that, at molecular level, HLA-G1 upregulates the 
expression of p27KIP, while downregulates the expression of cyclin D1 and cyclin A, and 
decreases the levels of phosphorylated-Rb in T cells [30,239]. HLA-G1 and G5 expression by 
human BM-MSC is upregulated by cell contact with activated T cells, moreover, HLA-G5 
secretion is also enhanced after exposure to IL-10 [30,239]. 
4.16. CD200 
CD200 (or OX-2) is a membrane glycoprotein that belongs to the immunoglobulin 
superfamily. It has a broad distribution, including hematopoietic and non-hematopoietic cells 
(neurons, cardiomyocytes, endothelial cells, among others), and its expression is upregulated 
upon inflammation [41,401]; CD200 is also expressed on human BM-MSC [41,535], human 
UCM-MSC [41], but not detected on human UCB-MSC [42], though its expression was reported 
to be heterogeneous among the BM-MSC population and to display a great inter-individual 
variation [42]. In turn, CD200 receptor (CD200R) is restricted to the lymphoid (including T, B, 
NK, and NKT cells) and myeloid (DC, mast cells, eosinophils, basophils, neutrophils, and 
macrophages, especially regulatory M2 macrophages) lineages [42,401]. 
The use of knock-out mice lacking CD200 and blocking antibodies against CD200R, 
demonstrated the importance of CD200/CD200R axis in controlling autoimmunity and in graft 
survival, being also described that some viruses express CD200 homologues to escape from the 
immune system [401]. In fact, signal imparted by CD200/CD200R interaction inhibits Ras, 
MAPK, and NF-kB activity. As result, there is a decreased production of TNF-α and IL-6 by 
mouse macrophages activated with IFNγ or IL-17 (with no inhibitory effect over macrophages 
stimulated with LPS) [536], inhibition of IL-5, IL-13, IL-8, CXCL9, and CXCL10 protein expression 
by human monocytes [536], and decrease of mast cell degranulation, TNF-α and IL-13 
production [401,536]. Besides the inhibitory effect of CD200R signaling over the synthesis of 
several pro-inflammatory cytokines (TNF-α, IFNγ, IL-1, IL-6, and IL-17), it is reported an induced 
expression of the anti-inflammatory IL-10 and TGF-β [401]. Moreover, there are evidences 
showing that differentiation of monocytes into DC in the presence of CD200R agonists leads to 
the induction of tolerogenic DC, able to induce Treg cells in a IL-10- and TGF-β-dependent 
manner [537]; CD200R agonists also induces Treg cells from thymocytes [537]; and, finally, 
122 
CD200 binding to CD200R expressed on T cells induce their differentiation towards either a 
Treg or Tr1 cells expressing IL-10 and TGF-β [401]. 
Human BM-MSC-derived CD200 was shown to mediate the inhibition of TNF-α 
production by macrophages stimulated with IFNγ [42]. 
4.17. B7 FAMILY: ICOS/ICOSL, PD-1/PD-L1 AND B7-H4 
4.17.1. Inducible T-cell costimulator ligand (ICOSL) or CD275 
The inducible T-cell costimulator (ICOS or CD278) molecule is promptly induced after T 
cell activation (in both CD4+ and CD8+ T cells) and markedly enhanced after CD28 ligation, 
being therefore absent in naive T cells [538]. This molecule delivers a strong second signal of T 
cell activation upon binding to its ligand (ICOSL, or CD275, or B7h), which is constitutively 
expressed on antigen-presenting cells and in several non-hematopoietic tissues [538,539]. 
ICOS signaling promotes the expression of CD40L (by stabilizing CD40L mRNA) and, in general, 
also promotes the production of IL-4, IL-5, IL-10, TNF-α, IFNγ, and GM-CSF [538,540,541]. 
Moreover, this costimulatory signal is involved in Th17 cell differentiation and IL-17 
production, perhaps by inducing IL-21 expression by T cells [538,540,542]. Although, according 
to the reports publish so far, ICOS displays contradictory functions, which is suggestive of a 
complex role in the immune regulation, the final result of ICOS signaling depends on the 
microenvironment conditions. Nevertheless, it is reported that ICOS signaling preferentially 
favors Th2 polarization, function and humoral immune response (including the production of 
IL-4, IL-10, and IL-13), wherein the downstream activation of PI3K leads to the upregulation of 
NF-ATc1 which, in turn, enhances c-Maf expression and ultimately regulates IL-4 production 
[538-540]. 
In the same line of evidence, the crucial role of ICOS/ICOSL axis on B cell responses to T-
dependent antigen, arose from the observation that ICOS-/- deficient mice were unable to 
form germinal centers and to undergo immunoglobulin isotype switching. In fact, it was 
demonstrated that stimulation of T cells via ICOS, by DC bearing ICOSL, within the T cell zone 
of secondary lymphoid organs, upregulates the expression of Bcl-6 and changes their 
expression pattern of adhesion molecules and chemokine receptors, including CXCR5 
upregulation, that will ultimately drive T cell migration into the B cell follicles, following the 
CXCL13 gradient [301] (see section 3.3.1 of this chapter). Once within the B cell follicle, ICOSL 
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expressed on B cells will be essential for Tfh cells development within the germinal center 
(though the need of ICOS signaling seems to be overcome in high antigen concentration 
conditions) [301]. Then, fully differentiated Tfh cells provide stimuli to B cells – through CD40L, 
IL-21, and PD-1, among others – supporting B cell proliferation and affinity maturation within 
the germinal center; other cytokines produced by Tfh will control immunoglobulin isotype 
switching [301,540]. Of note, ICOS signaling enhances IL-21 expression in Tfh cells, a process 
mediated by the transcription factor c-Maf [301]. 
Besides, ICOS/ICOSL interaction is also essential for Treg cell expansion, maintenance, 
and function, though there is no direct evidence that ICOS signaling induce Treg differentiation 
[538,540,543]. ICOS is highly expressed in a subset of CD4+FoxP3+ Treg that produce IL-10; 
moreover, ICOS signaling induces production of IL-10 by CD4+ effector T cells and regulatory 
FoxP3- Tr1 cells [540,543]. NK and NKT cells also express ICOS, but its function on these cells 
remains to be elucidated [538]. 
The active role of ICOS/ICOSL signaling in in vivo immunosuppression was evidenced in 
breast cancer, being demonstrated that tumor-associated pDC induce the expansion of Treg 
cells and the secretion of IL-10 by CD4+ memory T cells within the tumor tissue, a process 
mediated by ICOSL. Further evidence of the ICOS/ICOSL immunosuppressive activity in vivo 
comes from the fact that a higher frequency of ICOS+ cells in the tumor tissue correlates with a 
poorer prognosis in breast cancer [541]. 
Concerning MSC, ICOSL mRNA expression was recently detected by Yi and colleagues 
[544] and our group [79,244] in human BM-MSC, whose expression was enhanced in the 
presence of TNF-α, IFNγ [544], PMA plus ionomycin [244], and LPS plus IFNγ [79]. However, up 
to now, ICOSL expression in MSC at protein level has never been assessed, and the role of 
MSC-derived ICOSL in the modulation of the immune system hasn’t yet been demonstrated. 
4.17.2. Programmed death-ligand 1 (PD-L1) or B7-H1 or CD274  
Programmed death-1 (PD-1, or CD279) receptor is expressed at low levels on resting T 
cells, B cells, NK cells, NKT cells, and myeloid cells; but its expression increases upon cell 
activation, and is further upregulated on T cells (a process mediated by NF-ATc1) under 
conditions of persistent antigen exposure and chronic inflammation, consequently being highly 
expressed on non-functional, exhausted T cells, that appear in the course of chronic viral 
infection [540,545,546]. PD-1 is a negative regulator of T cell activation, being involved in 
peripheral immune tolerance in both CD4+ and CD8+ T cells, upon binding to their ligands: 
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programmed death-ligand 1 (PD-L1, CD274, or B7-H1) or PD-L2 (or CD273, or B7-DC) [540]. In 
fact, it was demonstrated that binding of PD-L1 or PD-L2 to PD-1 inhibits TCR signaling and T 
cell activation, even in naive T cells, wherein PD-1 is modestly expressed [545]. PD-L1 is 
present in activated T cells, B cells, DC, monocytes/macrophages, BM-derived mast cells, as 
well as in a number of non-hematopoietic tissues; while PD-L2 expression can be induced on 
DC, macrophages, B cells, and mast cells from BM [539,546]. Both PD-L1 and PD-L2 expression 
is regulated by cytokines [546]. Of note, PD-L2 presents higher affinity for PD-1 as compared to 
PD-L1 but, interestingly, PD-L1 is also able to bind to CD80 [546,547]. 
PD-1/PD-L1 interaction results in the inhibition of the activating phosphorylation of CD3ζ 
chain and ZAP-70, which are activated downstream TCR binding to MHC/antigen complex by 
the kinases Fyn and Lck; it also hampers PI3K activation, that occurs in consequence of CD28 
signaling in T cells [230,546,547]. The enzymatic activity of PI3K leads to the activation of the 
downstream signal molecule Akt, which has the ability to upregulate the expression of glucose 
transporters and the glycolytic enzyme activity, fuelling the proliferation of activated T cells 
[546,547]. Beyond glucose metabolism, Akt is also involved in other important metabolic 
processes, including protein synthesis, cell survival, and cell proliferation [548]. Interestingly, it 
is known that CTLA-4 activation results in the inhibition of Akt activity, interfering with the 
same signaling pathway as PD-L1, but at a downstream level; noteworthy, PD-L1-mediated T 
cell inhibition is more effective than that of CTLA-4 [547]. Likewise, PD-L1 binding to PD-1 
expressed on B cells impedes the activating phosphorylation of Akt, p38, and ERK, involved in 
the three signaling pathways triggered after a productive BCR stimulation [175]. 
PD-L1 ligation to PD-1 hampers T cell proliferation, which is overcome by excessive anti-
CD3/CD28 stimulation, and modulates cytokine production (namely, decreases IFNγ and 
increases IL-10 secretion) [539,549]. According to the data collected so far, it seems that, while 
in naive T cells PD-1 impedes T cell activation, in non-naive T cells PD-1 signaling leads to the 
loss of effector functions and to T cell exhaustion [547]. Importantly, PD-1 signaling also 
induces the generation of de novo CD4+FoxP3+ Treg cells from naive CD4+ T cells (in the 
presence of TGF-β), in mice [546,550,551]. Treg induction by PD-1 is dependent from 
Akt/mTOR cascade inhibition and PTEN upregulation [546]. Besides, PD-1 augments the 
suppressive effect of pre-existent Treg cells [546]. In the same line, PD-1 signaling pathway 
also inhibits the macrophage and DC response to TLR stimuli, and decreases IL-6 and TNF-α 
expression in macrophages [546,549]. 
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This inhibitory molecule was shown to be one of the mechanisms of tumor escape from 
the immune system: in a melanoma mouse model, PD-1/PD-L1 interaction in tumor infiltrating 
CD4+ T cells contributes to their conversion in CD4+FoxP3+ Treg cells [550]; whereas in human, 
a higher expression of PD-L1 is associated to a poorer prognosis in both solid tumors (for 
instance pancreatic, esophageal, and ovarian cancer, melanoma, and renal cell carcinoma) and 
B-chronic lymphocytic leukemia [539,552]. Increased expression of PD-1 or PD-L1 has also 
been observed in other human B and T cell malignancies, in which the malignant cells showed 
to be resistant to specific cytolysis by T cells, in vitro [539]. 
In addition, PD-1 pathway was also shown to be involved in the immunosuppressive 
effect of MSC over T and B cells. Different studies demonstrated that co-culture of BM-MSC 
with immune cells induces the expression PD-L1 and PD-L2 in the former cell population 
[78,263,306,316], an effect shared with TNF-α, IFNγ, IL-6, or IL-17 [78,175,263]. PD-1 pathway 
is involved in human BM-MSC inhibition of B cell proliferation [306] and T cell production of 
IFNγ [78], whereas for human decidual stromal cells, it mediates the inhibition of TNF-α, IFNγ, 
and IL-2 production by CD4+ T cells [553]. In mice, PD-1 signaling participates in BM-MSC-
mediated inhibition of T and B cell proliferation [175,316], as well as in the suppression of the 
proliferation and IL-17 production by fully differentiated Th17 cells [263,530]. 
4.17.3. B7-H4 
B7-H4 is an inhibitory member of the B7 family. In human, B7-H4 surface protein 
expression can be induced on T cells, B cells, monocytes, and DC, after in vitro stimulation; this 
molecule is also present in non-immune cells; and tumor tissues were shown to express this 
inhibitory protein constitutively, including tumor-associated macrophages [539,540,545,548]. 
Remarkably, Treg cells can also induce B7-H4 expression in antigen-presenting cells, in an IL-
10-dependent manner [540]. However, the receptor for B7-H4 hasn’t been identified yet [545]. 
In mice, B7-H4 has the capability to impair CD4+ and CD8+ T cell proliferation, and its 
inhibitory effect affects both naive and pre-activated T cells, however naive T cells are more 
sensitive to B7-H4. This inhibitory molecule also impairs IL-2 production by T cells, inhibits the 
upregulation of CD25 and CD69 induced by T cell activation with anti-CD3/CD28, and hampers 
CD8+ T cell cytotoxic activity [540,548,554]. In humans, B7-H4 was shown to inhibit CD4+ and 
CD8+ T cell proliferation by inducing G0/G1 cell cycle arrest and apoptosis on activated T cells, 
along with the impairment of IFNγ expression by PBMC [548,555]. Wang and colleagues [548] 
have recently demonstrated that, on the basis of T cell inhibition by B7-H4, was the 
interference with the signaling pathways triggered by CD28, namely the inhibition of the 
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activation of Akt (and, consequently, also impairs the activity of the Akt’s substrate GSK3), 
ERK1/2, p38, and JNK (and its substrate Jun) [548,554]. Whereas Akt is involved in the 
regulation of the cellular uptake and metabolism of glucose, cell survival, and cell proliferation, 
ERK1/2 and JNK have a pivotal role in inducing IL-2 expression [546,548]. Conversely, B7-H4 did 
not affect the activity status of neither Lck nor ZAP-70, upon T cell stimulation with anti-
CD3/CD28, indicating that B7-H4 only acts over signal molecules localized at a downstream 
level of TCR and CD28 pathways [548]. Remarkably, the addition of exogenous IL-2 can 
overcome the inhibitory effect of PD-L1 and B7-H4, apparently because IL-2 leads to STAT5 
activation which, in turn, is able to activate Akt [546-548]. 
It was recently demonstrated that human BM-MSC express B7-H4 [556]. This molecule 
was shown to mediate BM-MSC inhibition of T cell activation and proliferation, by inducing cell 
cycle arrest, and impede NF-kB translocation to the nucleus [556,557]. 
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5. OBJECTIVES 
Since the report of Le Blanc and colleagues [198], in 2004, with first evidence of the 
clinical benefit of MSC-based therapy in humans, in one patient with treatment-resistant grade 
IV acute GvHD, an increasing body of evidence further confirmed the utility of MSC in the 
treatment of a wide range of diseases. However, distinct outcomes are not rarely reported 
when using MSC in clinical trials, in vivo animal models, or even in vitro assays. To explain 
these different end results, scientists have postulated that MSC arisen from distinct sources 
may have distinct abilities, concerning both the immunosuppression and production of growth 
factors. In this line, a significant number of studies have recently showed important 
differences among MSC isolated from different human tissues using in vitro assays. 
Notwithstanding, it is recognized that the activation/maturation/differentiation state of 
immune cells is different for distinct pathologies and, considering the same disorder, different 
patients may display distinct features regarding the distribution and function of the immune 
cells comprised in the aforementioned compartments. Furthermore, it is recognized that the 
differences found in those immune cell compartments can be associated to a distinct clinical 
course or may have prognostic value. Nevertheless, despite the growing knowledge on the 
influence of human MSC over the main immune cell populations, the information on specific 
(and less represented) immune cell subpopulations/compartments is scarce. Noteworthy, the 
few studies published so far in this field consistently described that the suppressive effect of 
MSC is distinct among the subpopulations defined within the main immune cell populations 
(e.g. naive versus memory T cells; fully differentiated effector T cells versus T cells undergoing 
differentiation into effector cells). 
Based on the above background, the main objective of this study aimed at gaining 
insight on the differences among human MSC derived from different tissues, concerning their 
immunosuppressive potential; and, as bone marrow-derived MSC are the most used in human 
immune-therapy protocols, we sought to investigate the influence of human BM-MSC in 
naturally occurring peripheral blood human monocyte subpopulations, mDC, and T cell 
functional compartments. 
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In order to accomplish this goal, we addressed the following specific objectives: 
 
1. To investigate and compare the effect of human MSC derived from BM, AT, and UCM 
on PHA-induced activation and proliferation of peripheral blood lymphocyte subpopulations, 
and on the mRNA expression of molecules with an important immune function for T cells and 
NK cells. 
2. To evaluate the influence of human BM-MSC on cell activation and cytokine 
production by peripheral blood monocyte subsets and mDC, upon stimulation with LPS plus 
IFNγ. 
3. To investigate how human BM-MSC modulate PMA plus ionomycin-induced cytokine 
production by each naturally occurring functional compartment of peripheral blood CD4+ and 
CD8+ T cells. 
4. In order to better understand how the stimulating agents used in our in vitro models 
for T cells (PMA plus ionomycin) and monocytes/DC (LPS plus IFNγ) stimulation influence 
human BM-MSC, we analyzed the phenotype and mRNA expression in non-stimulated BM-
MSC and after stimulation with either PMA plus ionomycin, or LPS plus IFNγ. 
 
The following chapters of this doctoral thesis thoroughly describe the studies carried on 
to accomplish the proposed specific objectives. The materials and methods used and the 
results obtained for each study are presented and discussed separately. 
 
 
 
  
129 
 
CHAPTER 2 | 
MESENCHYMAL STEM CELLS FROM UMBILICAL 
CORD MATRIX, ADIPOSE TISSUE AND BONE 
MARROW EXHIBIT DIFFERENT CAPABILITY TO 
SUPPRESS PERIPHERAL BLOOD B, NATURAL 
KILLER AND T CELLS 
 
 
 
130 
  
131 
1. ABSTRACT 
Introduction: The ability to self-renew, be easily expanded in vitro and differentiate into 
different mesenchymal tissues, soon render mesenchymal stem cells (MSC) an attractive 
therapeutic method for degenerative diseases. The subsequently discovery of their 
immunosuppressive ability, encouraged clinical trials in graft-versus-host disease and auto-
immune diseases. Despite of sharing several immunophenotypic characteristics and functional 
capabilities, the differences between MSC arising from different tissues still unclear and the 
published data are conflicting. 
Methods: Here, we evaluate the influence of human MSC derived from umbilical cord 
matrix (UCM), bone marrow (BM) and adipose tissue (AT), co-cultured with PHA-stimulated 
peripheral blood MNC, on T, B and NK cell activation; T and B cells’ ability to acquire 
lymphoblast characteristics; mRNA expression of IL-2, FoxP3, T-bet and GATA3, on purified T 
cells, and TNF-α, perforin and granzyme B on purified NK cells. 
Results: MSC arisen from all the three tissues were able to prevent CD4+ and CD8+ T cell 
activation and acquisition of lymphoblast characteristics and CD56dim NK cell activation, 
wherein AT-MSC showed a stronger inhibitory effect. Moreover, AT-MSC blocked T cell 
activation process in an earlier phase than BM- or UCM-MSC, yielding a great proportion of T 
cells in non-activated state. Concerning B cells and CD56brigh NK cells, UCM-MSC did not 
influence neither their activation kinetics nor PHA-induced lymphoblast characteristics, 
conversely to BM- and AT-MSC which displayed an inhibitory effect. Besides, when co-cultured 
with PHA-stimulated MNC, MSC seem to promote Treg and Th1 polarization, estimated by the 
increased expression of FoxP3 and T-bet mRNA within purified activated T cells, and to reduce 
TNF-α and perforin production by activated NK cells. 
Conclusions: Overall, UCM-, BM- and AT-derived MSC hamper T cell, B cell and NK cell 
mediated immune response by preventing their acquisition of lymphoblast characteristics, 
activation and changing the expression profile of proteins with an important role in immune 
function, except for UCM-MSC showing no inhibitory effect on B cells under these 
experimental conditions. Despite of the similarities between the three types of MSC evaluated, 
we detect important differences that should be taken into account when choosing the MSC 
source for research or therapeutic purposes. 
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2. INTRODUCTION 
Mesenchymal stem cells (MSC) are multipotential non-hematopoietic stem cells that 
possess the ability to self-renew and to differentiate in response to chemical, hormonal or 
structural stimuli into different lineages of mesenchymal tissues, such as osteocytes, 
chondrocytes, neurocytes and adipocytes [192,558-563]. MSC can be isolated from adult 
tissues, such as bone marrow, adipose tissue, endometrial polyps, menstrual blood, etc [559], 
and from fetal tissues, such as placenta, umbilical cord blood and matrix [34,564]. Their ability 
to differentiate into different tissues is variable according to their tissue of origin [560]. Bone 
marrow is the traditional source of human MSC, however there, they represent a rare 
population of approximately 0.001% to 0.01% of total nucleated cells and their frequency 
tends to decline with increasing age [1,4,34,565]. Although adult MSC have the ability to 
expand in culture whilst retaining their growth and multilineage potential [566], compared 
with MSC from fetal sources, they undergo less cell divisions before they reach senescence 
[560]. 
All MSC seem to share a significant number of characteristics, even if isolated from 
different sources: they are plastic adherent, exhibit a fibroblast-like morphology, express 
certain cell-surface markers (CD90, CD73 and CD105) and are distinguished from HPC and 
leukocytes by lacking CD34, CD45, CD14 and HLA-DR expression [14,192,560,567]. MSC secrete 
several cytokines, growth factors and extracellular matrix molecules that play an important 
role in the regulation of hematopoiesis, angiogenesis and in immune and inflammatory 
response [564]. Other interesting characteristics are that MSC can migrate and home to tissues 
and organs in response to growth factors, cytokines, chemokines or adhesion molecules and, 
therein, mediate immunomodulatory actions [14,565,568-570]. Moreover, due to their 
multipotency, MSC are a very attractive choice for clinical applications in several immune 
disorders such as arthritis, encephalomyelitis, systemic lupus erythematosus and in 
regenerative diseases, including diabetes and skin grafting [564-566,568,571]. Their low 
immunogenicity, immunomodulatory capacity and ability to differentiate into cells that 
regenerate damaged tissues, had already allowed the use of MSC in clinical trials for cellular 
and gene therapy [14,565,566,572-574]. MSC are able to inhibit the proliferation and function 
of T, B and natural killer (NK) cells, the cytolytic effects of antigen-primed cytotoxic T cells (CTL) 
by the induction of regulatory T cells (Treg) [14,568,572,574]. The immune modulation by MSC 
seems to be mediated by secretion of soluble factors, creating an immunosuppressive 
microenvironment. This niche also protects MSC from environmental insults, including 
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cytotoxic chemotherapy and pathogenic immunity [192,575]. Beyond that, there are studies 
reporting that a separation of MSC and mononuclear cells (MNC) by a semi-permeable 
membrane does not abrogate the inhibition of lymphocyte proliferation [316,572,576-579]. 
Different studies affirm that different molecules expressed by MSC are responsible for, 
or could contribute to, suppression of lymphocyte proliferation [14,565,572,580-582]. MSC 
have also been demonstrated to interfere with dendritic cells (DC) differentiation, maturation 
and function, by soluble factors. Consequently, this interference can be involved in 
suppression of T cells proliferation, as well as in the induction of regulatory antigen-presenting 
cells [565,570,572,581,583,584]. Moreover, MSC seem to differently modulate the function of 
the various T cell subsets, what is explained in detail in the review of Duffy et al [231]. 
In this study, we performed co-cultures of PHA-stimulated MNC with MSC from different 
sources (umbilical cord matrix, adipose tissue and bone marrow), for four days, to evaluate the 
immunomodulatory effects of MSC on the acquisition of lymphoblast characteristics, by T and 
B lymphocytes, and on immune cell activation, which has been assessed by the expression of 
CD69, CD25 and HLA-DR on CD4+ and CD8+ T cells, B cells and NK cells. After cell sorting of the 
different compartments of activated T cells, we have measured transcripts for T-bet, GATA3 
and FoxP3, to infer about T cell polarization to Th1, Th2 or Treg, respectively; the expression of 
mRNA for IL-2 was also quantified. In addition, the different compartments of activated NK 
cells were purified and mRNA expression of TNF-α, perforin and granzyme B was measured to 
evaluate the effect of MSC on these proteins with an important role in NK cell function. 
This study shows that MSC derived from different tissues possess different 
immunosuppression capabilities and their action varies with the immune cell type. 
3. METHODS 
3.1. MSC isolation, purification and co-culture with peripheral blood 
mononuclear cells  
Co-cultures were carried out in 6 well tissue culture plates (Falcon, Becton Dickinson 
Biosciences, BD, San Jose, CA, USA) with peripheral blood mononuclear cells (MNC) from 
healthy donors and allogeneic human MSC from the 3 different sources, bone marrow (BM), 
adipose tissue (AT) and umbilical cord matrix (UCM, also known as wharton’s jelly MSC), in the 
presence or absence of phytohemagglutinin (PHA, Irvine Scientific, Santa Ana, CA, USA), as 
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mitogenic stimulus. Biological samples were obtained from healthy donors, with informed 
consent, and the study was approved by the Ethics Committees of Instituto Português de 
Oncologia de Lisboa Francisco Gentil (Laws n.º 97/95, nº 46/2004) and Maternidade de Bissaya 
Barreto (ref. 356/Sec). MSC were isolated from at least 2 different healthy donors for each cell 
source and appropriately cultured and purified to homogeneity, as previously described 
[65,585,586]. 
In short, MNC from BM aspirates were plated at a density of 2x105 cells/cm2 on T-175 
flasks (Falcon BD) in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal 
bovine serum, streptomycin (0.025 µg/ml), penicillin (0.025 U/ml) (Gibco, Life Technologies, 
Paisley, UK), at 37ºC and 5% CO2 in a humidified atmosphere. Medium was changed twice a 
week. BM-MSC were isolated based on adherence to plastic, and near cell confluence (70-80%) 
exhausted medium was removed from the flasks, cells were washed with phosphate buffered 
saline (PBS, Gibco) and detached from the flask by adding Accutase solution (Sigma, St. Louis, 
MO, USA) for 7 minutes at 37ºC. Isolated BM-MSC expressed their characteristic 
immunophenotype being CD73, CD90 and CD105 positive and negative for CD31, CD34, CD45 
and CD80. Cell number and viability were also determined using the Trypan Blue (Gibco) 
exclusion method [65]. 
For AT-MSC isolation, AT samples were collected into a conical tube containing PBS 
supplemented with 20 mg/mL of human serum albumine, washed extensively with PBS and 
then digested with a 0.1% (w/v) Collagenase Type II (Sigma) solution for 30 minutes at 37ºC. 
After neutralizing the enzymatic activity of Collagenase with DMEM 10% fetal bovine serum, 
1% (v/v) penicillin (10000 U/mL)/streptomycin (10000 g/mL) (Gibco) and 0.1 % (v/v) Fungizone 
(Gibco), the adipose tissue was centrifuged at 2500 rpm for 10 minutes, in order to obtain a 
high density stromal vascular fraction. The contaminating red blood cells were lysed by 
ressuspending the pellet in 160 mM NH4Cl solution for 10 min at room temperature. Once 
again, the reaction was stopped with DMEM 10% fetal bovine serum, followed by 
centrifugation. Then, the suspension was filtered though a nylon mesh of 100 μm to eliminate 
the cellular debris and a cell count was performed. After plating and incubating overnight at 
37ºC, 5% CO2, the cells were washed with PBS in order to remove non-adherent cells. The cells 
were maintained at 37ºC, 5% CO2, in a fully humidified atmosphere in DMEM 10% fetal bovine 
serum and the medium changed every 3-4 days. When cells reached near 80% confluence, 
cells were harvested using Accutase and plated into new T-flasks (3000 cells/cm2). The number 
of cells and cellular viability were also determined [586]. 
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For UCM-MSC isolation, umbilical cords were rinsed with PBS (Gibco), arteries and veins 
were dissected and the remaining tissue fragments were digested with 0.1% collagenase type 
II (Sigma) for 4 hours at 37ºC. The solution was filtered and washed with Iscove’s Modified 
Dulbecco’s Media (IMDM, Gibco) supplemented with streptomycin (0.025 μg/mL) and 
penicillin (0.025 U/mL) (Gibco). Cell number was determined using the Trypan Blue (Gibco) 
exclusion method. Cells were plated in T-flasks at an initial density of 10 000 cells/cm2 using 
DMEM supplemented with 10% fetal bovine serum, StemPRO® MSC Serum-Free Medium, or 
StemPRO® MSC SFM XenoFree (all from Gibco) culture media and kept at 37ºC and 5% CO2 in a 
humidified atmosphere. When using StemPRO® MSC SFM/StemPRO® MSC SFM XenoFree cell 
culture, surfaces were pre-coated with CELLstartTM CTSTM (Invitrogen, Life Technologies, 
Paisley, UK) following the manufacturer’s instructions. After 48 hours of culture, the 
nonadherent cells were removed and cells were maintained by renewing the medium every 3-
4 days. Cultures were monitored by microscopy (Olympus CK40 optical microscope, Central 
Valley, PA, USA) in order to assess cell morphology and spreading [585]. 
All assays were performed using MSC between passage 3 and 5 and, prior to cell 
cultures, MSC identity was confirmed by immunophenotypic analysis: 5x105 cells were 
harvested to perform flow cytometry analysis for the MSC markers CD105, CD73 and CD90. 
MNC were purified from heparinized peripheral blood by density-gradient centrifugation 
(Lymphoprep, Axis-Shield PoC AS, Oslo, Norway) at 1310 x g, for 20 minutes. Cell cultures were 
maintained in RPMI 1640 with GlutaMax medium (Invitrogen) supplemented with 10% fetal 
bovine serum (Gibco) and antibiotic-antimycotic (Gibco). Control cultures consisted on MNC in 
the absence of MSC, with or without PHA stimulation (17 replicates for each condition). With 
this strategy, different sets of co-cultures were generated: MNC+BM-MSC and MNC+PHA+BM-
MSC (5 replicates for each condition); MNC+UCM-MSC, and MNC+PHA+UCM-MSC (7 replicates 
for each condition); MNC+AT-MSC and MNC+PHA+AT-MSC (5 replicates for each condition). A 
total of 300 000 MNC were added to each well and, in the conditions where the cells were 
activated by PHA, a concentration of 10 µg/mL of the mitogen was used; in each well where 
MSC were included, we added 30 000 cells, establishing a ratio of 10:1 (MNC:MSC). These 
plates were kept in culture for four days at 37°C, in 5% CO2 and 90% humidity. After four days 
under each condition, the cultured cells were washed with PBS 1X, pH7.4 (Gibco) and 
centrifuged at 540 x g for 5 minutes. 
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3.2. Identification and quantification of the different compartments of 
activated T, B and NK cells 
3.2.1. Immunofluorescent staining: 
Each cell culture was used for two purposes: (1) phenotypic study by flow cytometry, to 
evaluate the acquisition of lymphoblast characteristics by T and B cells and the activation 
kinetic of lymphocytes and (2) cell sorting and purification of the compartments of activation 
of lymphocytes, for gene expression analysis on T and NK cells. In order to identify different 
lymphocyte subtypes, we used monoclonal antibodies (mAb) conjugated with the following 
fluorochromes: fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll 
protein (PerCP), phycoerythrin cyanin 7 (PE-Cy7 or PC7), allophycocyanin (APC), 
allophycocyanin hillite 7 (APC-H7), pacific blue (PB) and amcyan (AC). T cells were identified by 
CD3 PB (clone UCHT1, BD Pharmingen, San Diego, CA, USA) expression and, among this cell 
population, CD4+ T and CD8+ T cells were identified based on CD4 FITC (clone 13B8.2, Beckman 
Coulter, Brea, CA, USA) and CD8 AC (clone SK1, BD) expression, respectively; CD19 FITC (clone 
SJ25C1, BD) or CD19 PC7 (clone J4.119, Beckman Coulter) were used to identify B cells, and 
CD56 PC7 (clone N901, Beckman Coulter) positivity, in the absence of CD3 expression, for NK 
cells; finally, we used CD90 APC (clone 5E10, BD Pharmingen) to identify and exclude MSC. To 
define the different stages of lymphocyte activation, we used mAb against CD69 PE (clone 
TP1.56.3, Beckman Coulter), CD25 APC-H7 (clone M-A251, BD Pharmingen) and HLA-DR PerCP 
(clone G46-6, BD Pharmingen). 
3.2.2. Flow cytometry data acquisition and analysis: 
Cells were acquired on a FACS CantoTM II (BD) using FACSDiva software (BD), and 100 
000 events were analyzed using Infinicyt 1.5 software (Cytognos, Salamanca, Spain). Through 
multi-parametric flow cytometry analysis, we identified four different subpopulations of CD4+ 
and CD8+ T cells: non-activated CD69-CD25-HLA-DR-; earlier activated CD69+CD25-HLA-DR-; 
intermediate activated CD69+CD25+HLA-DR-; and later activated CD69+CD25+HLA-DR+. In B 
cells, CD56dim NK and CD56bright NK cells, only three subpopulations were quantified: non-
activated CD69-CD25-, earlier activated CD69+CD25- and activated CD69+CD25+. 
3.3. Cell sorting of the activation compartments of T and NK cells 
Cultured lymphocytes were purified by fluorescence-activated cell sorting, using 
FACSAria flow cytometer (BD). Each compartment of activated lymphocytes were sorted 
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according to their typical phenotype: CD69-CD25-HLA-DR-, CD69+CD25-HLA-DR-, 
CD69+CD25+HLA-DR- and CD69+CD25+HLA-DR+ for T cells; and CD69-CD25-, CD69+CD25- and 
CD69+CD25+ for NK cells. 
3.4. Gene expression analysis 
The cell sorted subsets were centrifuged for 5 minutes at 300 x g and the pellet 
resuspended in 350L of RLT Lysis Buffer (Qiagen, Hilden, Germany) and total RNA extraction 
performed with the RNeasy Mini kit (Qiagen) according to the supplier’s instructions. Total 
RNA was eluted in a 50µl volume of RNase-free water. In order to quantify the amount of total 
RNA extracted and to verify RNA integrity, samples were analyzed using a 6000 Nano Chip kit, 
in an Agilent 2100 bioanalyzer (Agilent Technologies, Walbronn, Germany) and 2100 expert 
software, according to the manufacturer’s instructions. RNA was reverse transcribed with 
SuperScript III First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen), according to the 
manufacturer’s instructions. Relative quantification of gene expression by real-time PCR was 
performed in the LightCycler 480 II (Roche Diagnostics, Rotkreuz, Switzerland). Real-time PCR 
reactions were carried out using 1× QuantiTect SYBR Green PCR Master Mix (Qiagen), 1 X 
QuantiTect Primer Assay (TNFα: QT01079561; FoxP3: QT00048286; IL2: QT00015435; Tbet: 
QT00042217; Gata3: QT00095501; Granzime B: QT01001875; Perforin: QT00199955) (Qiagen) 
and 20ng of cDNA sample, in a total volume of 10 l. The reactions were performed using the 
following thermal profile: 15 min at 95°C, and 40 cycles of 15 sec at 94°C, 30 sec at 55°C and 30 
sec at 72°C. All samples were run in duplicate. Melting point analysis was done to ensure the 
amplification of the specific product. Real-time PCR results were analyzed with the LightCycler 
software (Roche Diagnostics). GeNorm Reference Gene Selection kit (PrimerDesign Ltd., 
Southampton, England) in conjunction with the geNorm software (PrimerDesign Ltd.) were 
used to select the reference genes to normalize data. The reference genes used for gene 
expression analysis, in T cells, were the splicing factor 3a, subunit 1 (SF3A1) and the 
topoisomerase (DNA) I (TOP1) and, in NK cells, were the ubiquitin C (UBC) and the 18S rRNA. 
The normalized expression levels of the genes of interest were calculated by using the delta-Ct 
method. 
3.5. Statistical analysis 
To determine the statistic significance of the differences observed between different 
culture conditions, non-parametric Mann-Whitney test and Wilcoxon paired-sample test were 
performed, using Statistical Package for Social Sciences (IBM SPSS, version 17.0, Armonk, NY, 
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USA). Data were expressed as mean percentage ± standard deviation. Statistically significance 
differences were considered when p value was lower than 0.05. 
4. RESULTS 
4.1. MSC prevent T and B cells’ acquisition of lymphoblast characteristics, 
except for UCM-MSC that are unable to inhibit this process in B 
Lymphocytes undergo multiple rounds of clonal division after mitogenic stimulation. 
Consequently, in the presence of PHA, lymphocytes start to proliferate and the cells acquire a 
lymphoblast morphology, which can be observed by flow cytometry as an increased forward 
scatter (FSC, corresponding to an increase in cell size) and side scatter (SSC, corresponding to 
an increased granularity) light dispersion properties, as shown in figure 2. A prior analysis of 
FSC-Area vs FSC-Height dot plot allowed an easy identification and exclusion of doublets.   
 
Figure 2. Cells displaying increased FSC and SSC light dispersion properties correspond to 
proliferating cells. Left: Bivariate dot plot histogram illustrating mononuclear cell (MNC) culture after 
PHA stimulation, displaying two distinct cell populations: (A) MNC with low forward scatter (FSC) and 
side scatter (SSC) light dispersion properties and (B) MNC with increased FSC and SSC properties. Right: 
Density histogram illustrating the DNA content of MNC from population A (green) and B (red), 
measured after propidium iodide staining, and proving that cells with increased FSC and SSC are 
actively proliferating. 
MNC were co-cultured with BM-, UCM- and AT-MSC at the ratio of 10:1, in the presence 
of PHA. When compared with the MNC+PHA control assay, in the presence of MSC, the 
frequency of CD4+ and CD8+ T cells with increased FSC and SSC properties was lower, as shown 
in table 1 (p <0.05 for BM-, UCM- and AT-MSC). Although only 18% of B cells acquired 
lymphoblast characteristics in control assay, a marked and statistically significant decrease of  
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the percentage of B cells with increased FSC and SSC properties occurred in the presence of 
BM- and AT-MSC, whereas UCM-MSC did not influence this process on B cells under these 
experimental conditions (Table 1). 
Table 1. Percentage of cells displaying increased FSC and SSC light dispersion properties 
% of cells with  
increased FSC and SSC 
MNC + PHA MNC + PHA + BM-MSC MNC + PHA + UCM-MSC MNC + PHA + AT-MSC 
n = 17 n = 5 n = 7 n = 5 
Total mononuclear cells 51 ± 3 31 ± 4 
a; d
 41 ± 15
d 
21 ± 10 
a; c; d
 
Total T cells 56 ± 2 31 ± 6 
a; d
 47 ± 19
d 
19 ± 13 
a; c; d
 
CD4
+
 T cells 54 ± 4 26 ± 3  
a; d
 47 ± 22
d 
15 ± 11 
a; c; d
 
CD8
+
 T cells 59 ± 4 38 ± 11 
a; d
 49 ± 16
d 
21 ± 7 
a; b; c; d
 
B cells 18 ± 3 9 ± 1 
a
 18 ± 9 
b
 7 ± 4 
a; c; d
 
Percentage (mean ± standard deviation) of cells with increased forward scatter and side scatter light dispersion 
characteristics after PHA stimulation, in the absence or in the presence of MSC from different sources, within the 
total MNC in culture and within the following cell populations: total T cells, CD4
+
 T cells, CD8
+
 T cells and B cells.  
Results are expressed as mean percentage ± standard deviation. Statistically significant differences were considered 
when p <0.05 for Mann-Whitney test: 
a
comparing with MNC+PHA; 
b
comparing with MNC+PHA+BM-MSC; 
c
comparing with MNC+PHA+UCM-MSC. Statistically significant differences were considered when p <0.05 for 
Wilcoxon paired-sample test: 
d
comparing with MNC+PHA. 
FSC, forward scatter ; SSC, side scatter; MNC, mononuclear cells; PHA, phytohemagglutinin; BM, bone marrow; 
UCM, umbilical cord matrix; AT, adipose tissue; MSC, mesenchymal stromal/stem cells. 
 
4.2. MSC derived from different tissues influence differentially the distribution 
of T, B and NK lymphocytes among non-activated and activated compartments 
To investigate the kinetics of lymphocyte activation, in the presence or absence of PHA 
and MSC arisen from different tissues, we analyzed four subpopulations of both CD4+ and CD8+ 
T cells, phenotypically defined as: CD69-CD25-HLA-DR- (non-activated), CD69+CD25-HLA-DR- 
(earlier activated), CD69+CD25+HLA-DR- (intermediate activated) and CD69+CD25+HLA-DR+ 
(later activated), in different culture conditions. Likewise, we identified three subpopulations 
of B cells, CD56dim and CD56bright NK cells: CD69-CD25- (non-activated), CD69+CD25- (earlier 
activated) and CD69+CD25+ (activated). 
As expected, lymphocytes from MNC cultures undergo activation only after exposure to 
PHA (Table 2). In these culture conditions, we observe that the co-culture of MSC from 
different sources presents a different effect in the inhibition of the activation. 
Analyzing CD4+ and CD8+ T cells from MNC culture, in the presence of PHA and absence 
of MSC, after 4 days of culture, we observe that the largest proportion of cells displays an 
intermediate activated phenotype (Table 2); the presence of either BM- or UCM-MSC in the 
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cell culture increases the frequency of earlier activated cells (p <0.05 for both MSC types and 
for both T cell subpopulations); whereas the presence of AT-MSC is associated to a significant 
increase of cells within the non-activated compartment (p <0.05) and, to a lesser extent, in 
earlier activated compartment (p <0.05) and, consequently, is observed an important decrease 
in intermediate activated compartment (p <0.05), for both CD4+ and CD8+ T cells (Table 2). 
In what concerns to B cells, when stimulated with PHA in the absence of MSC, the earlier 
activated compartment is the most representative. As consequence of BM and AT-MSC, B cells 
are partially inhibited to proceed to the earlier activated stage, as a result, the frequency of 
cells in that compartment is diminished, and this decrease has statistic significance only for 
both MSC types (Table 2). Conversely, UCM-MSC seem to be unable to inhibit the 
development of B cell activated phenotype (Table 2). 
Finally, co-cultures of MSC with MNC in the presence of PHA, present similar results for 
CD56dim NK cells, regardless the MSC nature and consisting in an augment of the non-activated 
compartment (p <0.05 for all MSC, comparing with MNC+PHA), at the expenses of the earlier 
activated compartment (Table 2). However, a distinct behavior is observed in CD56brigh NK 
cells, whose presence of PHA has a significantly smaller effect, comparing to the other 
lymphocyte’s populations considered in this study (Table 2). Despite this fact, we are able to 
observe a decreased percentage of CD56bright NK cells undergoing activation, when co-cultured 
with BM- or AT-MSC (p <0.05 for both); conversely, UCM-MSC have no effect on the kinetic of 
CD56bright NK cells activation (Table 2). 
4.3. MSC differentially influence mRNA expression of FoxP3, T-bet, Gata3 and 
IL-2 on T cells 
The analysis of gene expression levels of transcription factors and IL-2, among the 
different T cell activation compartments, previously sorted and purified, was performed in 
order to better understand the immunomodulatory mechanisms underlying MSC. 
In control assay (MNC+PHA), FoxP3 mRNA levels increase along with the progress of T 
cell activation; notably, the presence of AT-MSC strongly increases FoxP3 transcripts (p <0.05; 
Figure 3A). Attending to T-bet, whose mRNA expression increases in the earlier activated stage 
of the control assay, an increase that is not maintained in intermediate and later activation 
stages, it is observed that MSC further increase and maintain its expression along the 
activation process (p <0.05; Figure 3B). Conversely, GATA3 mRNA is not induced by PHA 
stimulation and the presence of MSC does not increase GATA3 mRNA levels (Figure 3C). 
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Table 2. Distribution of T, B and NK cells among the respective activation compartments 
Cell population MNC 
MNC + 
BM-MSC 
MNC + 
UCM-MSC 
MNC + 
AT-MSC 
MNC + 
PHA 
MNC + PHA + 
BM-MSC 
MNC + PHA + 
UCM-MSC 
MNC + PHA + 
AT-MSC 
 
n = 17 n = 5 n = 7 n = 5 n = 17 n = 5 n = 7 n = 5 
Total T cells 82 ± 5 80 ± 11 80 ± 7 86 ± 5 86 ± 3 79 ± 8 71 ± 17 86 ± 5 
CD 4
+
 T cells 81 ± 5 81 ± 9 77 ± 9 84 ± 3 77 ± 3 84 ± 7 67 ± 8 76 ± 10 
CD69
-
CD25
-
HLA-DR
-
 100 ± 0 100 ± 0 99 ± 2 100 ± 0 25 ± 7 23 ± 8 18 ± 9 43 ± 17 
a; b; c; d
 
CD69
+
CD25
-
HLA-DR
-
 0 ± 0 0 ± 0 1 ± 2 0 ± 0 6 ± 1 14 ± 4 
a; d
 15 ± 8 
a; d
 13 ± 1 
a; d
 
CD69
+
CD25
+
HLA-DR
-
 0 ± 0 0 ± 0 0 ± 0 0 ± 0 67 ± 7 58 ± 6 
a
 66 ± 17 43 ± 18 
a; d
 
CD69
+
CD25
+
HLA-DR
+
 0 ± 0 0 ± 0 0 ± 0 0 ± 0 3 ± 2 4 ± 2 2 ± 2 1 ± 0 
CD 8
+
 T cells 19 ± 5 19 ± 9 23 ± 9 14 ± 3 23 ± 3 16 ± 7 33 ± 8 24 ± 10 
CD69
-
CD25
-
HLA-DR
-
 99 ± 0 99 ± 2 98 ± 3 100 ± 1 18 ± 10 22 ± 3 12 ± 1 
b
 41 ± 12 
a; b; c; d
 
CD69
+
CD25
-
HLA-DR
-
 1 ± 0 1 ± 2 2 ± 2 0 ± 1 9 ± 1 16 ± 4 
a; d
 18 ± 9 
a; d
 14 ± 2 
a
 
CD69
+
CD25
+
HLA-DR
-
 0 ± 0 0 ± 0 0 ± 0 0 ± 0 68 ± 11 59 ± 6 
a
 67 ± 10 45 ± 14 
a; b; c; d
 
CD69
+
CD25
+
HLA-DR
+
 0 ± 0 0 ± 0 0 ± 0 0 ± 0 4 ± 2 2 ± 3 
d 
2 ± 2 1 ± 1 
B cells 2 ± 0 2 ± 1 4 ± 4 3 ± 2 3 ± 1 4 ± 1 4 ± 3 3 ± 2 
CD69
-
CD25
-
 98 ± 1 95 ± 4 97 ± 3 98 ± 1 40 ± 6 63 ± 23 37 ± 9 72 ± 15 
a; d
 
CD69
+
CD25
-
 2 ± 1 5 ± 4 3 ± 3 2 ± 1 56 ± 7 32 ± 15 
d 
60 ± 6 
b
 27 ± 14 
a; d
 
CD69
+
CD25
+
 0 ± 0 0 ± 0 0 ± 0 0 ± 0 4 ± 3 5 ± 10 4 ± 4 1 ± 1 
Total NK cells 16 ± 5 19 ± 10 16 ± 5 12 ± 5 12 ± 2 20 ± 9 20 ± 9 11 ± 5 
CD56
bright
 NK cells 3 ± 1 2 ± 1 3 ± 2 4 ± 3 8 ± 0 6 ± 3 6 ± 5 8 ± 4 
CD69
-
CD25
-
 99 ± 0 99 ± 1 99 ± 3 100 ± 1 82 ± 2 94 ± 2 
a; d
 80 ± 20 97 ± 1 
a; b; d
 
CD69
+
CD25
-
 1 ± 0 1 ± 1 1 ± 3 0 ± 1 17 ± 2 6 ± 2 
a; d
 18 ± 17 3 ± 1 
a; b; d
 
CD69
+
CD25
+
 0 ± 0 0 ± 0 0 ± 0 0 ± 0 1 ± 0 1 ± 0 2 ± 3 1 ± 0 
CD56
dim
 NK cells 97 ± 1 98 ± 1 97 ± 2 96 ± 3 92 ± 0 94 ± 3 94 ± 3 92 ± 4 
CD69
-
CD25
-
 97 ± 2 96 ± 7 97 ± 4 99 ± 1 29 ± 3 73 ± 18 
a; d
 74 ± 6 
a; d
 79 ± 19 
a; d
 
CD69
+
CD25
-
 3 ± 2 4 ± 7 3 ± 4 1 ± 1 68 ± 2 25 ± 17 
a; d
 25 ± 6 
a; d
 20 ± 19 
a; d
 
CD69
+
CD25
+
 0 ± 0 0 ± 0 0 ± 0 0 ± 0 3 ± 0 1 ± 1 1 ± 1 1 ± 0 
Distribution (mean ± standard deviation) of total T cells, CD4
+
 and CD8
+
 T cells, B cells, total NK cells, and CD56
dim
 
and CD56
bright
 NK cells in the MNC culture and among the following activation stages: non-activated CD69
-
CD25
-
HLA-DR
-
, earlier activated CD69
+
CD25
-
HLA-DR
-
, intermediate activated CD69
+
CD25
+
HLA-DR
-
, and later activated 
CD69
+
CD25
+
HLA-DR
+
, for T cell subpopulations; and non-activated CD69
-
CD25
-
, earlier activated CD69
+
CD25
-
 and 
activated CD69
+
CD25
+
, for B cells and NK cell subpopulations. MNC were subjected to different culture conditions: 
absence or presence of PHA and absence or presence of MSC from different sources. 
Results are expressed as mean percentage ± standard deviation. Statistically significant differences were considered 
when p <0.05 for Mann-Whitney test: 
a
comparing with MNC+PHA; 
b
comparing with MNC+PHA+BM-MSC; 
c
comparing with MNC+PHA+UCM-MSC. Statistically significant differences were considered when p <0.05 for 
Wilcoxon paired-sample test: 
d
comparing with MNC+PHA. 
MNC, mononuclear cells; PHA, phytohemagglutinin; BM, bone marrow; UCM, umbilical cord matrix; AT, adipose 
tissue; MSC, mesenchymal stromal/stem cells. 
 
Finally, in control assays, the maximal expression of IL-2 mRNA is observed in earlier activated 
stage, wherein the presence of MSC of any source under study leads to a reduction, which is 
more notable for AT-MSC (p <0.05 for BM- and AT-MSC), as depicted in figure 3D. 
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4.4. MSC differentially influence mRNA expression of perforin, granzyme B and 
TNF-α on NK cells 
Our data show that, on earlier activated and activated NK cells, both TNF-α and perforin 
mRNA expression is suppressed by all of the three types of MSC tested (Figure 4A and 4B, 
respectively). Concerning granzyme B mRNA expression, we observed that UCM-MSC induce 
an increased expression of this cytotoxic protein on activated NK cells, whereas BM- and AT-
MSC slightly reduce it (Figure 4C). 
5. DISCUSSION 
To assess the influence of MSC from different sources in the induction of lymphoblast 
characteristics on T and B cells, ability of T, B and NK cells to progress along the activation 
process and mRNA expression of genes related to T cell polarization and NK cytotoxic activity, 
MNC cultures, in the absence/presence of PHA and in the absence/presence of MSC, were 
carried out. 
PHA is a lectin with the ability to bind and crosslink different cell membrane 
glycoproteins, leading to the polyclonal activation of lymphocytes [587]. Although TCR, CD3 
and CD2 crosslinking by PHA mimics the T cells’ first signal of activation, leading to PKC 
activation and increasing the cytoplasmatic calcium levels, it is not sufficient to promote T cell 
activation, being required accessory signals given by antigen-presenting cells, which are also 
essential for IL-2 expression by T cells and, consequently, for their proliferation [587-590]. The 
early activation marker CD69 is expressed on NK, B and T cell surface 4 hours after activation 
and is implicated on the transcription of IL-2 and TNF-α; 12-24 hours after cell activation, the α 
subunit of IL-2 receptor (CD25) expression is upregulated, allowing the assembling of the high-
affinity IL-2 receptor on T cell plasmatic membrane; finally, between 48-60 hours, T cells 
initiate HLA-DR expression [591-594]. 
According to our data, both BM- and AT-MSC, when co-cultured with PHA-stimulated 
MNC, inhibit B cell acquisition of lymphoblast characteristics and progression from non-
activated to earlier activated stage, wherein AT-MSC display the strongest inhibitory capability, 
which corroborates with the results published by Bochev et al [318], who showed that AT-MSC 
had a stronger ability to inhibit immunoglobulin (Ig) production by B cells than BM-MSC.  
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Figure 3. mRNA expression of FoxP3, Tbet, GATA3 and IL-2 among the different T cells’ activation 
compartments. Semi-quantitative analysis of FoxP3 (A), T-bet (B) GATA3 (C), and IL-2 (D) mRNA 
expression for each activation stage phenotypically identified on T cells: non-activated (CD69
-
CD25
-
HLA-DR
-
), earlier activated (CD69
+
CD25
-
HLA-DR
-
), intermediate activated (CD69
+
CD25
+
HLA-DR
-
) and 
later activated (CD69
+
CD25
+
HLA-DR
+
). *Differences statistically significant (p <0.05, Mann-Whitney and 
Wilcoxon paired-sample test). MNC, mononuclear cells; PHA, phytohemagglutinin; BM, bone marrow; 
UCM, umbilical cord matrix; AT, adipose tissue; MSC, mesenchymal stromal/stem cells. 
Conversely, UCM-MSC do not influence neither B cells’ ability to acquire lymphoblast 
characteristics nor the distribution among the activation compartments. 
Several studies describe the inhibitory effect of MSC on B cell proliferation, activation, 
ability to differentiate to plasma cells and/or produce Ig [55,305,315,316,318,321], 
demonstrating that human BM-MSC block stimulated B lymphocytes on G0/G1 phases of the 
cell cycle and interfere with the phosphorylation status of ERK1/2 and p38 MAPK [315]. 
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Figure 4. mRNA expression of perforin, granzyme B and TNF-α among the different NK cells’ 
activation compartments. Semi-quantitative analysis of TNF-α (A), perforin (B), and granzyme B (C) 
gene expression for each cell activation stage phenotypically identified on NK cells: non-activated 
(CD69
-
CD25
-
), earlier activated (CD69
+
CD25
-
) and activated (CD69
+
CD25
+
). *Differences statistically 
significant (p <0.05, Mann-Whitney and Wilcoxon paired-sample test). MNC, mononuclear cells; PHA, 
phytohemagglutinin; BM, bone marrow; UCM, umbilical cord matrix; AT, adipose tissue; MSC, 
mesenchymal stromal/stem cells. 
Conversely to T cells, where a number of studies have been done to unveil the 
mechanisms beneath MSC suppression of the immune response, there are few studies 
concerning this matter on B cells. Based on the results yielded by previous studies on T cells, it 
is hypothesized that programmed cell death 1 ligand 1 (PD-L1), alternatively cleaved CCL2, 
prostaglandin E2 (PGE2), transforming growth factor-β (TGF-β), indoleamine 2,3-dioxygenase 
(IDO) and hepatocyte growth factor (HGF), whose constitutive or induced expression on MSC 
had already been demonstrated, might be the effector molecules supporting B cell inhibition. 
On mouse and murine models, PD-L1 [107,175,316] and alternatively cleaved CCL2 [107,320] 
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were demonstrated to mediate MSC inhibition of B cells; in contrast, TGF-β and IDO were not 
involved in this process [175,321]. PGE2 is known to be capable of inhibit human B cell 
function [429,430], but its relevance on MSC-induced B cell inhibition is still unknown. 
In our experimental design, MSC can act directly on B cells, but it should be also taken 
into account their suppressive effect on the other MNC in culture which, in turn, will condition 
B cell activation and proliferation. Indeed, by preventing T cell activation, cytokine production 
and downregulating BAFF expression on DC [595], MSC can indirectly and efficiently hamper B 
cell activation, proliferation and function. Likewise, there are growing evidences that the 
microenvironment conditions, such as type of stimulus, presence of other cell types and MSC:B 
cell ratio are determinant for the effect of MSC on B cells [98,175,305,315,319,596]. In fact, 
under appropriate conditions, MSC can enhance B cell proliferation, differentiation and Ig 
production [107,276,315,319]. 
Here we describe, for the first time, that the origin of MSC is essential in determining B 
cell fate, demonstrating that AT- and BM-MSC inhibit B cell activation and acquisition of 
lymphoblast characteristics, whereas UCM-MSC do not, under the same culture conditions. 
All the three types of MSC tested, when co-cultured with MNC in the presence of PHA, 
inhibit the acquisition of lymphoblast characteristics by CD4+ and CD8+ T lymphocytes, more 
marked for AT-MSC, followed by BM-MSC and, finally, UCM-MSC. Similarly, all MSC from 
different tissues displayed the ability to suppress the activation of CD4+ and CD8+ T cells. 
Remarkably, whereas UCM- and BM-MSC block the cell activation after the upregulation of 
CD69 (at the earlier activated stage), AT-MSC strongly inhibit the passage from non-activated 
to earlier activated stage, yielding a great proportion of non-activated T cells after mitogenic 
stimulus. Again, the effect of UCM-MSC is milder, as the percentage of cells achieving the 
intermediate activated stage does not differ from that observed in the absence of MSC. 
Likewise, the three types of MSC inhibit IL-2 mRNA expression on T cells, more evident in 
earlier-activated stage, in which UCM-MSC display a more moderate effect. In sum, MSC 
suppress T cell immune response by reducing their proliferation and blocking their activation, 
what is in part consequence of IL-2 reduction, a cytokine essential for T cell proliferation and 
differentiation, being described that the addition of exogenous IL-2 partially reverts MSC-
mediated inhibition [129]. 
MSC ability to inhibit T cell proliferation, activation and IL-2 expression is extensively 
described in the literature [39,45,58,61,234,248,596,597], as well as the capability to modulate 
the expression of other cytokines and diminish CTL cytolytic function. These capabilities are, at 
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least in part, mediated by soluble factors produced by MSC [45,400], namely TGF-β [286], 
PGE2 [26,31,424,596], IDO [52,596,598], leukemia inhibitory factor (LIF) [38], HLA-G5 
[67,239,246,596], galectin [59,246,474,475,478], Jagged-1 [90], adenosine [461,465] and 
semaphorin-3A [473,474], and/or cellular contact and interaction between the MSC surface 
proteins HLA-G1 [30,67], PD-L1 [316], CD200 [41,401] and B7-H4 [548,556,557], and the 
respective receptors on T cells.  
T cell proliferation is inhibited by LIF [38], TGF-β [286], Jagged-1 [90], PGE2 
[26,31,424,596], IDO [52,596,598], galectin-1 and -3 [59,474,475,478], HLA-G5 and HLA-G1 
[67,239,246,596], PD-L1 [316], B7-H4 [548,556,557], semaphorin-3A [45,90,473,474] and 
adenosine [461]. Both semaphorin-3A and adenosine prevent T cell proliferation by 
antagonizing signaling pathways downstream TCR and CD28; adenosine is also involved in the 
inhibition of IL-2, CD25, IFN-γ and TNFα expression and decreases cytolytic ability of CTL 
[461,465,473]. The negative costimulatory molecule B7-H4 prevents T cell activation, 
proliferation and production of IL-2 and other cytokines, by inhibiting NF-kB, ERK1/2 and JNK; 
B7-H4 also downregulates CD69 and CD25 expression on T cells [548,556,557]. 
Besides the effect exerted directly on T cells, indirect suppression also occurs by 
inhibition of DC maturation, as demonstrated for BM-MSC, consisting on the reduction of 
endocytosis and antigen processing capability, decreased expression of costimulatory 
molecules, chemokine receptors and cytokines essential for T cell activation (such as IL-12) 
and, consequently, diminishing DC capability to prime T cells, whereas stimulating IL-10 
expression and, therefore, inducing tolerogenic DC able to expand CD4+ Treg 
[31,45,98,107,238,360]. 
As previously described by our group [599] and others [600], MNC stimulation with PHA 
induces the expression of IFN-γ and IL-2, which activate antigen-presenting cells, contributing 
to the increased expression of IL-1, -6, -12 and TNF-α described on PHA-stimulated MNC [600-
602], and creating the conditions for Th1 polarization (IFN-γ plus IL-12), characterized by T-bet 
expression. In fact, we observe an increased T-bet mRNA expression in all the three T cell 
activation compartments sorted and purified from MNC stimulated with PHA and the presence 
of MSC seems to potentiate and preserve T-bet expression along the activation stages. When 
FoxP3 mRNA expression is concerned, we observe an augment in intermediate and later 
activated T cells from PHA-stimulated MNC cultures, more pronounced in the presence of 
MSC, specially AT-MSC. Thus, our data show that, using this experimental design, MSC favor T 
cell differentiation toward Th1 and Treg, but we have to be aware that this effect is exerted on 
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a small number of cells, since, in the presence of MSC, the percentage of T cells undergoing 
activation is very limited. 
 In opposition to the results obtained for T-bet mRNA expression, MSC support to Treg 
(CD4+FoxP3+) induction and expansion is widely described in the literature, contributing for this 
occurrence PGE2, TGF-β, HLA-G5, IDO, LIF, IL-10 and CD200, whose expression increases after 
MSC exposure to proinflammatory factors [9,38,45,52,98,195,229,231,236,239,249,270,286, 
287,401,596]. 
Although the increased T-bet expression on T cells may apparently be contradictory to 
previous works affirming that MSC inhibit Th1 polarization [182,231,236,251,252], it is worth 
to mention that, in the present work, it was measured T-bet mRNA expression within each one 
of the four purified T cells’ activation compartments, while in the aforementioned studies the 
sense of T cell polarization was inferred by the pattern of cytokines expressed, specifically by 
the decreased IFN-γ levels. As our data clearly demonstrate, the presence of MSC reduce the 
number of T cells undergoing activation, which conditions an overall reduction of IFN-γ levels 
on culture supernatant, even assuming the polarization is skewed toward Th1. In fact, it hasn’t 
already been described a direct mechanism by which MSC inhibit Th1 polarization, being 
hypothesized that it is an indirect effect of both the impairment of DC capability to prime naive 
T cells and the induction of Treg expansion [231]. Furthermore, MSC decrease IFN-γ expression 
in human mixed lymphocyte reaction [45], human MNC cultures [61,475], human T cell 
cultures [236] and mouse differentiated Th1 cells [251,263], which will bias the conclusions of 
those who use IFN-γ levels to infer about Th1 polarization. Of note, recent studies yielded 
contradictory data, showing that, under specific conditions, MSC may increase the levels of 
IFN-γ and IL-10 in the culture supernatants [61,249], which suggests that MSC influence on 
IFN-γ expression will depend on different factors, such as type of stimulation, type of 
hematopoietic cells present in cell culture and presence of cytokines on the milieu. Finally, a 
recently described T-bet+ Th1 cell subpopulation co-expressing IFN-γ and IL-10 [265] was 
demonstrated to be induced and expanded by MSC [485]. These T cells arise from Th1 
polarized cells that start producing IL-10, assuming regulatory activity [485]. Likewise, TGF-β, 
known to be produced by MSC, promotes IL-10 production by Th1 cells which, in turn, reduces 
IFN-γ expression by the same cells [406]. 
Thus, focusing our experimental design, MSC may act directly on T cells present in MNC 
fraction or, posteriorly, on PHA-mediated Th1-polarizing cells, since MSC immunomodulatory 
ability increases after their contact with proinflammatory cytokines, whose concentration in 
148 
culture medium raises after PHA-induced MNC activation. Namely, IFN-γ and/or TNF-α 
augment TGF-β expression by MSC [286,287], which induce IL-10 expression by Th1 cells and, 
consequently, reduces their IFN-γ production. Additionally, MSC downregulate IFN-γR 
expression on T cells surface [485], rendering them less prone to respond to IFN-γ. Also, we 
should not discard MSC effect on the DC present in the cell culture that may as well influence T 
cell function. 
The increased mRNA expression of T-bet promoted by MSC, observed along all the T cell 
activation process and within each activation compartment, make us think that MSC are able 
to suppress T cell-mediated inflammatory response by reducing the proportion of T cells that 
undergo activation but, once initiated the activation process, MSC will not alter T cell 
differentiation sense in PHA-stimulated MNC, thus, T cells will continue to differentiate 
towards Th1. Nevertheless, as MSC also decrease IL-2 mRNA expression on T cells undergoing 
activation, we may expect a limited clonal expansion of the activated lymphocytes that will 
further reduce the final number of effector T cells. Finally, there are several evidences 
supporting that, after the conclusion of the differentiation process, MSC are able to inhibit Th1 
effector functions. Altogether, MSC may inhibit Th1 immune response not by altering the 
sense of T cell polarization but, instead, by reducing the number of Th1 effector cells and by 
inhibiting the effector functions of differentiated Th1 cells. 
In relation to GATA-3, although some studies confirm that MSC modulate cytokine 
production by T lymphocytes toward a Th2 pattern, there are no evidences pointing to Th2 
differentiation mediated by MSC [182,231]; accordingly, our data show no influence of MSC on 
GATA-3 mRNA expression. This finding is in agreement with the MSC-mediated inhibition of B 
cell activation and acquisition of lymphoblast characteristics, observed in the present study. 
In what concerns to NK cells, PHA-induced activation is prevented for all the three types 
of MSC tested, except for UCM-MSC that are unable to inhibit the activation of CD56bright NK 
cell subset. Once again, AT-MSC exhibit the most pronounced inhibitory effect. 
In agreement with our results, previous studies described the downregulation of CD69 
expression on NK cells under the influence of BM-MSC [102,328]. Indeed, all the effects of MSC 
already described in the literature are consistent with the inhibition of NK cell activation: MSC 
prevent NK cell proliferation [238,326,327,596]; induce downregulation of functional NK 
receptors [33,43,102,326,327,596]; inhibit the expression of proinflammatory cytokines (such 
as IFN-γ and TNF-α) [33,45,98,102,326,327,596] and granzyme A [33] and prevent NK cell 
degranulation [33]. As a result of all the effects aforementioned, MSC hamper NK cell cytolytic 
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activity [43,326,327,596]. Different evidences point to an important role of PGE2, TGF-β, IDO, 
HLA-G5, HLA-G1 and adenosine on NK cell inhibition, despite of some conflicting results on this 
matter [45,67,98,102,195,239,326,327,461,465,596]. Moreover, the differences between MSC 
from different sources still unclear, with studies yielding contradictory data for BM-MSC 
inhibitory ability [43,102,326]. 
According to our data, after PHA stimulation, NK cells express perforin and TNF-α mRNA, 
which is downregulated by all the three types of MSC. This fact is in agreement with previous 
studies concerning TNF-α [45,327], but diverges from the results recently published by 
DelaRosa et al showing that perforin production remains unchanged in the presence of either 
BM- and AT-MSC co-cultured with purified NK cells [33]. Similarly, we observed that AT- and 
BM-MSC induce a slight reduction of granzyme B mRNA expression in the later activated stage 
of NK cells, whereas DelaRosa et al show that BM- and AT-MSC had no effect on NK cells’ 
granzyme B expression [33]. It is worth to remind that DelaRosa’s approach differs from ours, 
as in our study MSC were co-cultured with MNC, and the presence of other immune cells in 
the culture may influence NK cell behavior. Finally, Yen et al concluded that human embryonic 
stem cell-derived mesenchymal progenitors present a stronger ability to inhibit NK cell 
function compared to BM-MSC, by reducing the expression of NK-activating receptors and NK 
cell cytotoxic activity [43]; here, we observe that both BM- and UCM-MSC present a similar 
ability to inhibit CD56dim NK cell activation and TNF-α and perforin mRNA expression. 
In fact, it is difficult to compare results from studies concerning the MSC 
immunomodulatory ability because MSC are highly sensitive to the microenvironment and 
modulate their function according to the external conditions. Their function will vary 
depending on the ratio MSC:immune cells, the immune cells present in the cell culture, the 
immune cell activation status and the cytokines levels in the milieu [26,58-61,578], wherein 
proinflammatory cytokines, namely IFN-γ and TNF-α, increase MSC expression of IDO 
[39,45,52], galectin-1 [59], PGE2 [39,45,286,287], CD200 [41], TGF-β [286,287], IL-10 [286] and 
PD-L1 [263], although there are conflicting results [603]. On the whole, these evidences point 
to the improvement of immunomodulatory ability of MSC whenever they are in an 
environment resembling a chronic inflammation condition. Conversely, TLR3 or TLR4 
stimulation, mimicking an acute inflammation state, will reduce MSC immunomodulatory 
ability and decrease Jagged-1 and galectin-1 expression on MSC, similarly to that observed on 
Treg [45,59,90,248]. Thus, MSC will adapt their function according to the actual conditions and 
requirements of the organism. 
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With respect to the differences observed among the different types of MSC in the 
present study, the inhibitory ability of AT-MSC is stronger than that of BM- and UCM-MSC, 
what is in agreement with other published studies [26,39]. Although a few studies attempted 
to unravel the functional differences among AT-, BM- and UCM-MSC [31,36,603], recent works 
shed light on this subject, showing that AT-MSC express an higher level of COX-1 and PGE2 [26] 
and UCM-MSC display a lower expression of PGE2 and IDO compared to BM-MSC [39]. 
6. CONCLUSION 
Overall, UCM-, BM- and AT-MSC inhibit both acquisition of lymphoblast characteristics 
and activation of T cells, wherein AT-MSC display a more pronounced effect and UCM-MSC a 
milder effect. Of note, AT-MSC strongly impede T cells to proceed from non-activated to 
earlier activated stage, yielding a large proportion of T cells that remain non-activated, 
whereas with UCM-MSC, despite of the accumulation of T cells in earlier-activated stage, the 
proportion of T cells achieving the intermediate-activated state after 4 days of culture is equal 
to that observed in the absence of MSC. Nevertheless, MSC induce mRNA expression of the 
master transcriptional regulators of Treg and Th1 polarization on the T cells that proceed on 
the activation process. Thus, MSC may inhibit Th1 immune response not by altering the sense 
of T cell polarization but, instead, by reducing the final number of Th1 effector cells (both by 
preventing T cells to undergo activation and by hampering IL-2 production by activated T cells) 
and by inhibiting the effector functions of differentiated Th1 cells. 
Concerning B cells, our work showed that AT- and BM-MSC are capable of inhibit their 
activation and acquisition of lymphoblast characteristics, whereas UCM-MSC are not. To the 
best of our knowledge, this is the first report showing that UCM-MSC are unable to prevent 
activation of B cells from MNC cultures stimulated with PHA and display a behavior completely 
different from their counterparts arising from other tissues, clearly showing that MSC from 
different tissues may imply different immunomodulatory properties. 
Finally, all the three sources of MSC tested revealed a strong inhibitory capability over 
CD56dim NK cell activation, as well as over the production of TNF-α and perforin, whereas the 
activation of CD56bright NK cells was only inhibited by BM- and AT-MSC.  
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CHAPTER 3 | 
HUMAN BONE MARROW-DERIVED 
MESENCHYMAL STROMAL CELLS 
DIFFERENTIALLY INHIBIT CYTOKINE 
PRODUCTION BY PERIPHERAL BLOOD 
MONOCYTE SUBPOPULATIONS AND MYELOID 
DENDRITIC CELLS 
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1. ABSTRACT 
Introduction: The immunosuppressive properties of mesenchymal stromal/stem cells 
(MSC) rendered them an attractive therapeutic approach for immune disorders and an 
increasing body of evidence demonstrated their clinical value. However, the influence of MSC 
on the function of specific immune cell populations, namely monocyte subpopulations, is not 
well elucidated. 
Aim: Here, we investigated the influence of human bone marrow MSC on the cytokine 
and chemokine expression by peripheral blood classical, intermediate and non-classical 
monocytes and myeloid dendritic cells (mDC), stimulated with lipopolysaccharide plus 
interferon (IFN)γ. 
Results: We found that MSC effectively inhibit tumor necrosis factor (TNF)-α and 
macrophage inflammatory protein (MIP)-1β protein expression in monocytes and mDC, 
without suppressing CCR7 and CD83 protein expression. Interestingly, mDC exhibited the 
highest degree of inhibition, for both TNF-α and MIP-1β, whereas the reduction of TNF-α 
expression was less marked for non-classical monocytes. Similarly, MSC decreased mRNA 
levels of interleukin (IL)-1β and IL-6 in classical monocytes, CCL3, CCL5, CXCL9 and CXCL10 in 
classical and non-classical monocytes and IL-1β and CXCL10 in mDC. 
Conclusions: MSC do not impair the expression of maturation markers in monocytes and 
mDC under our experimental conditions, nevertheless they hamper the pro-inflammatory 
function of monocytes and mDC, which may impede the development of inflammatory 
immune responses. 
2. INTRODUCTION 
Mesenchymal stromal/stem cells (MSC) correspond to undifferentiated cells capable of 
self-renewal and to differentiate along different cell lineages [1]. The detailed study of their 
immunophenotypic characteristics facilitated MSC identification, quantification and isolation 
from different human adult tissues, such as bone marrow, adipose tissue, muscle, among 
others [1,13,34,46]. In turn, the discovery of their immunosuppressive potential, converted 
them into an attractive therapeutic approach for autoimmune diseases and pathological 
conditions where the activation of the immune system entails deleterious effects. 
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In the recent years, an increasing number of studies have reported the inhibitory effect 
of MSC over immune cells, wherein the majority of them focused on T lymphocytes [98,231]. 
However, even concerning T cells, only a limited number of studies analyzed and compared the 
influence of MSC over distinct functional T cell subsets, and demonstrated that functional T 
cells subsets are in fact differentially regulated by MSC [46,231,244,251,263,275,291]. In turn, 
as antigen-presenting cells have a pivotal role in T cell activation, differentiation and in 
directing their polarization [604], the study of MSC influence over monocytes and dendritic 
cells (DC) became an active field of research. Nevertheless, the number of studies performed 
in natural occurring DC is scarce [236,333], as the majority of them was carried out in 
monocyte-derived DC differentiated in vitro with GM-CSF and IL-4. Furthermore, to the best of 
our knowledge, no study investigated and compared the influence of MSC over the recently 
identified peripheral blood classical, intermediate and non-classical monocyte subpopulations 
[332].  
In 2010, Ziegler and colleagues [332] identified three distinct subpopulations within 
peripheral blood monocytes, which are phenotypically and functionally characterized as 
follows: classical monocytes are phenotypically characterized as CD14++CD16- [332,369]; 
intermediate monocytes, identified by CD14++CD16+ phenotype, display the highest expression 
of class II  major histocompatibility complex (MHC), compared to the remaining peripheral 
blood monocyte subpopulations, together with an increased ability to present antigens to T 
cells and to induce antigen-specific secretion of interleukin (IL)-12 and interferon (IFN)γ, 
besides, when challenged with zymosan or lipopolysaccharide (LPS), this cell subset presents 
the highest expression level of IL-10 [332,369]; finally, non-classical monocytes, phenotypically 
characterized as CD14+CD16++, are the most predisposed to differentiate into DC and induce 
the highest rates of T cell proliferation, however, after stimulation with LPS and IFNγ, they are 
less efficient in producing IL-1β, IL-6, IL-12 and tumor necrosis factor (TNF)-α compared to 
classical monocytes and myeloid dendritic cells (mDC) [332,369,605,606]. Of note, 
macrophages derived from CD16+ monocytes possess higher phagocytic activity than those 
generated from classical monocytes [369]. 
mDC correspond to a peripheral blood subset of DC, which are likely to be in transit 
from the bone marrow to tissues, where they will contact with foreign antigens and undergo 
maturation. Accordingly, peripheral blood mDC share some characteristics with immature DC, 
such as antigen uptake, processing and presentation activity, followed by T cell activation, the 
lack of CD83 and the production of IL-1β, IL-6, IL-12 and TNF-α after activation with LPS and 
IFNγ [332,604-609]. Of note, depending on the stimulus, mDC can acquire an anti-
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inflammatory expression profile, reducing IL-12 while increasing IL-10 expression, thus 
inducing a Th2 immune response [604,608]. It was recently described that peripheral blood 
mDC can be phenotypically distinguished in two subpopulations, CD1c (BDCA-1)+ and CD141 
(BDCA-3)+, with remarkable functional differences [332,608,609].  
In the present study, we investigated influence of human bone marrow-derived MSC on 
peripheral blood monocyte subpopulations (classical, intermediate and non-classical 
monocytes) and mDC, stimulated with LPS and IFNγ, in a co-culture system. With this aim, we 
proceeded to the quantification, by flow cytometry, of TNF-α, CCL4 (macrophage inflammatory 
protein (MIP)-1β), CCR7, CD83 and HLA-DR in the abovementioned immune cell populations. 
mRNA expression of IL-1β, IL-6, CCL3 (MIP-1α), CCL5 (regulated on activation, normal T cell 
expressed and secreted; RANTES), CXCL9 (monokine induced by gamma interferon; MIG) and 
CXCL-10 (interferon-gamma-inducible protein (IP)-10) was evaluated in previously purified 
classical and non-classical monocytes, as well as IL-1β and CXCL10 in purified mDC by. Besides, 
we assessed protein and mRNA expression of immune mediators and adhesion molecules in 
non-stimulated MSC or after LPS and/or IFNγ treatment. 
3. MATERIAL AND METHODS 
3.1. Collection and isolation of peripheral blood mononuclear cells and bone 
marrow mesenchymal stromal cells 
Peripheral blood samples from a total of six healthy donors (1 male and 5 females; mean 
age of 44±7 years, ranging from 22 to 51 years old), collected in heparin at the Blood and 
Transplantation Center of Coimbra (Portugal), and human BM samples from healthy donors 
(age ranging from 20 to 40 years old) were included in the present study. The use of these 
biological samples for research purpose was approved by Serviço de Transplantação de 
Progenitores Hematopoiéticos (UTM) do Instituto Português de Oncologia de Lisboa Francisco 
Gentil (laws 97/95 and 46/2004), and all participants gave written informed consent before 
entering in the study. 
Peripheral blood mononuclear cells (MNC) were isolated by Lymphoprep (Stemcell 
Technologies, Vancouver, Canada) gradient density centrifugation and then washed twice in 
Hank’s Balanced Salt Solution (HBSS, Gibco, Life Technologies, Paisley, UK). The MNC pellet 
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was resuspended in RPMI 1640 with GlutaMax medium (Invitrogen, Life Technologies) with 
antibiotic-antimycotic (Gibco), to the final concentration of 106 cells/500 μl. 
Peripheral blood MNC were subsequently analyzed for protein and mRNA expression in 
the following experimental conditions: 1) 106 MNC + 500 μl RPMI (negative control); 2) 106 
MNC + 0.5x106 MSC (negative control); 3) 106 MNC + LPS + IFNγ (positive control); 4) 106 MNC 
+ 0.5x106 MSC + LPS + IFNγ; 5) 106 MNC + 0.5x106 MSC, followed by MSC depletion and, then, 
stimulation with LPS+IFNγ. All the aforementioned cell cultures were carried out for 20 hours 
at 37°C, in a sterile environment with 5% CO2 and humidified atmosphere, plus an incubation 
period of 6 hours with the stimulator agents. The cell culture and stimulation protocols are 
detailed below, in “Immunophenotypic study of MSC and peripheral blood monocytes and 
mDC” section. 
For the isolation of human BM-MSC, MNC were isolated from BM samples by using a 
Sepax S-100 system (Biosafe, Eysins, Switzerland) in accordance with the instructions of the 
manufacturer. Cell number and viability were determined using the Trypan Blue (Gibco) 
exclusion method. 
BM MNC were plated at a density of 2x105 cells/cm2 in Dulbecco's Modified Eagle 
Medium (DMEM, Gibco) supplemented with 10% qualified fetal bovine serum (FBS, Sigma, 
Spain). After a 3-day incubation at 37ºC in humidified atmosphere containing 5% CO2, the non-
adherent cell fraction was discarded, and the adherent culture was maintained with a 
complete medium renewal every 3-4 days. After reaching a 70-80% confluency cells were 
detached using TrypLE (Life Technologies) for 7 minutes and then replated at an initial density 
of 3000 cells/cm2. For this study, MSC passages 3 and 5 were used. 
MSC identity was confirmed by performing fluorescent morphological analysis, 
mesodermal differentiation assays (osteogenic, adipogenic and chondrogenic) and 
immunophenotype characterization as described by Dominici et al. [2]. 
Subsequently, MSC were resuspended in RPMI 1640 with GlutaMax medium (Invitrogen) 
with antibiotic-antimycotic (Gibco) to the final concentration of 0.5x106 cells/500 μl. The 
protein and mRNA expression of MSC were studied in the following experimental conditions: 
1) 0.5x106 MSC + 500 μl RPMI (non-stimulated MSC); 2) 0.5x106 MSC + 500 μl RPMI + LPS; 3) 
0.5x106 MSC + 500 μl RPMI + IFNγ; and 4) 0.5x106 MSC + 500 μl RPMI + LPS + IFNγ. All the 
aforementioned cell cultures were carried out for 20 hours at 37°C, in a sterile environment 
with 5% CO2 and humidified atmosphere, plus an incubation period of 6 hours with the 
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stimulator agents. The cell culture and stimulation protocols are detailed below, in 
“Immunophenotypic study of MSC and peripheral blood monocytes and mDC” section. 
3.2. Immunophenotypic study of MSC and peripheral blood monocytes and 
mDC 
3.2.1. MSC stimulation with LPS, IFNγ and LPS plus IFNγ 
For the immunophenotypic study of MSC, we plated in 8 wells of tissue culture plates 
(Falcon, Becton Dickinson Biosciences, BD, San Jose, USA) 0.5x106 MSC in 1 ml of RPMI 1640 
with GlutaMax medium (Invitrogen) with antibiotic-antimycotic (Gibco). MSC were cultured for 
20 hours at 37°C, in a sterile environment with 5% CO2 and humidified atmosphere (to be in 
the same experimental conditions than those MSC co-cultured with MNC). Then, MSC were 
stimulated with LPS (100 ng/ml) from Escherichia coli (serotype 055:B5, Sigma), or IFNγ (100 
U/ml, Promega, Madison, USA), or LPS+IFNγ (100 ng/ml and 100 U/ml, respectively), in 
duplicate (to perform the immunophenotypic study and mRNA expression quantification), for 
6 hours at 37ºC in humidified atmosphere containing 5% CO2; in the remaining 2 wells, MSC 
were not stimulated. 
3.2.2. Immunophenotypic study of MSC 
For each experimental condition tested, cells were detached using TrypLE (Gibco); after 
incubating for 10 minutes at -20ºC, the content of each well was transferred to a 12x75 mm 
polystyrene cytometer tube, centrifuged for 5 minutes at 540xg and the supernatant was 
discarded. MSC immunophenotype was assessed using the 7-color monoclonal antibody (mAb) 
combination detailed in table 3 (tube 1). The cell pellet was incubated with the mAb for 10 
minutes in the darkness and washed with phosphate buffered saline (PBS). Finally, cells were 
resuspended in 500 μl of PBS and immediately acquired in a FACSCanto II (BD) flow cytometer. 
3.2.3. Co-culture of peripheral blood MNC and MSC and in vitro stimulation with LPS plus 
IFNγ 
In 6 wells of tissue culture plates (Falcon) 106 MNC were plated in 1 ml of RPMI 1640 
with GlutaMax medium (Invitrogen) with antibiotic-antimycotic (Gibco), and in 9 wells of tissue 
culture plates (Falcon) we plated 106 MNC + 0.5x106 MSC in a final volume of 1 ml, establishing 
a ratio of 2:1 (MNC:MSC). Cells were cultured for 20 hours at 37°C, in a sterile environment 
with 5% CO2 and humidified atmosphere. The content of 3 wells with co-cultured MNC+MSC 
was subjected to MSC depletion, using the EasySep Human CD271 Selection kit (Stemcell 
Technologies), according to the manufacturer’s instructions. 
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Table 3. Panel of mAb reagents (with clones and commercial source) used for the immunophenotypic 
characterization of classical, intermediate and non-classical monocytes, mDC and MSC 
Fluorochrome 
Tube PacB PacO FITC PE PerCPCy5.5 PECy7 APC APCH7 
1 
CD44 
clone IM7 
Biolegend 
CD45 
HI30 
Invitrogen 
CD106 
51-10C9 
BD Pharmingen 
CD73 
AD2 
BD Pharmingen 
CD184 
12G5 
BD 
CD13 
Immu103.44 
Beckman Coulter 
CD90 
5E10 
BD Pharmingen  
2 
CD16 
3G8 
BD Pharmingen 
CD45 
HI30 
Invitrogen 
CD83 
HB15a 
Beckman 
Coulter 
CCR7 
3D12 
BD Pharmingen 
CD14 
M5E2 
BD Pharmingen 
CD33 
D3HL60.251 
Beckman Coulter 
IREM-2 
UP-H2 
Immunostep SL 
HLA-DR 
L243 
BD 
3 
CD16 
3G8 
BD Pharmingen 
CD45 
HI30 
Invitrogen 
cyTNF-α 
MP6-XT22 
BD Pharmingen 
cyMIP-1β 
D21-1351 
BD Pharmingen 
CD14 
M5E2 
BD Pharmingen 
CD33 
D3HL60.251 
Beckman Coulter 
IREM-2 
UP-H2 
Immunostep SL 
HLA-DR 
L243 
BD 
4 
CD16 
3G8 
BD Pharmingen   
CD123 
SSDCL Y107D2 
Beckman Coulter 
CD14 
M5E2 
BD Pharmingen 
CD33 
D3HL60.251 
Beckman Coulter 
IREM-2 
UP-H2 
Immunostep SL 
HLA-DR 
L243 
BD 
Abbreviations: mAb, monoclonal antibody; mDC, myeloid dendritic cells; MSC, mesenchymal stromal/stem cells; 
PacB, pacific blue; PacO, pacific orange; FITC, fluorescein isothiocyanate; PE, phycoerythrin; PerCPCy5.5, peridinin 
chlorophyll protein-cyanine 5.5; PECy7, phycoerythrin-cyanine 7; APC, allophycocyanin; APCH7, allophycocyanin-
hilite 7. Commercial sources: Biolegend (San Diego, CA, USA); Invitrogen, Life Technologies (Carlsbad, CA, USA); BD 
Pharmingen (San Diego, CA, USA); BD (Becton Dickinson Biosciences, San Jose, CA, USA), Beckman Coulter (Miami, 
FL, USA); Immunostep S.L (Salamanca, Spain). 
 
Then, LPS+IFNγ (100 ng/ml and 100 U/ml, respectively), were added to 3 wells with 
MNC, 3 wells with co-cultured MNC+MSC and to the 3 wells with MNC+MSC where MSC had 
been depleted; and the cells in the remaining wells (3 with MNC and 3 with MNC+MSC) were 
not stimulated. To one of the wells in each experimental condition (MNC, MNC+MSC, 
MNC+LPS+IFNγ, MNC+MSC+LPS+IFNγ, MNC+MSC+Depetion+LPS+IFNγ), we added brefeldin A 
(10 μg/ml) from Penicillium brefeldiamun (Sigma), to prevent the release of de novo produced 
cytokines outside the cells. The samples were incubated at 37 °C, in a sterile environment with 
5% CO2 humidified atmosphere, for 6 hours. 
The samples with brefeldin A were used for the study of TNF-α and MIP-1β expression in 
monocytes and mDC, by flow cytometry, while the expression of CD83, CCR7 and HLA-DR, by 
flow cytometry, and the mRNA expression of cytokines, in monocytes and mDC, were 
performed in the samples without brefeldin A. All the aforementioned protein and mRNA 
expression studies were performed in all the different culture conditions: MNC, MNC+MSC, 
MNC+LPS+IFNγ, MNC+MSC+LPS+IFNγ, MNC+MSC+Depetion+LPS+IFNγ. 
3.2.4. Immunophenotypic study of peripheral blood monocytes and mDC 
For each experimental condition tested, cells were detached using TrypLE (Gibco); after 
incubating for 10 minutes at -20ºC, the content of each well was transferred to a 12x75 mm 
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polystyrene cytometer tube, centrifuged for 5 minutes at 540xg and the supernatant was 
discarded. Immunophenotypic analysis of peripheral blood monocytes and mDC, cultured in 
the presence/absence of LPS+IFNγ and in the presence/absence of MSC, was performed using 
8-color mAb combinations, detailed in table 3. For the study of CD83, CCR7 and HLA-DR 
expression (tube 2), cultured cells were incubated with the mAb for 10 minutes in the 
darkness, washed with PBS and, finally, resuspended in 500 μl of PBS and immediately 
acquired in a FACSCanto II (BD) flow cytometer. To study TNF-α and MIP-1β expression (tube 
3), cells were stained with the mAb for surface proteins antigens (CD16, CD45, CD33, CD14, 
IREM-2, HLA-DR) and, after an incubation period of 10 minutes in the darkness, washed with 
PBS. For intracellular staining, Fix&Perm (Caltag, Hamburg, Germany) reagent was used, 
according to the manufacturer’s instructions and in parallel with the mAb for TNF-α and MIP-
1β. After washing twice with PBS, the cell pellet was resuspended in 500 μl of PBS and 
immediately acquired. 
3.2.5. Data acquisition and analysis 
Data acquisition was performed in a FACSCanto II (BD) flow cytometer equipped with 
the FACSDiva software (v6.1.2; BD). For both MSC and MNC immunophenotypic studies, the 
whole sample from each tube was acquired and stored, corresponding to a number of events 
always above 0.1x106 or 0.5x106 events, respectively. For data analysis, the Infinicyt (version 
1.7) software (Cytognos SL, Salamanca, Spain) was used. 
3.2.6. Immunophenotypic identification of classical, intermediate and non-classical 
monocytes and mDC 
Attending to the markers used to analyze the expression of CCR7, CD83, HLA-DR, TNF-α 
and MIP-1β in classical, intermediate and non-classical monocytes and mDC, we used the 
following gate strategy to identify these four cell populations (Figure 5): classical monocytes 
express high levels of CD14 in the absence of CD16, together with high expression of CD33 and 
HLA-DR and being also positive for IREM-2 (CD300e); intermediate monocytes express high 
levels of CD14 as well, but display an increasing expression of CD16, associated to a slight 
decrease of CD33 expression, compared to classical monocytes; in turn, non-classical 
monocytes show CD16 positivity with a decreasing expression of CD14, they present the 
highest expression of CD45 along with the lowest expression of CD33 among the three 
monocyte subpopulations, and HLA-DR and IREM-2 expression is between that of classical and 
intermediate monocytes; mDC have lower side-scatter light dispersion properties and CD45 
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expression than monocytes, they present high expression of CD33 and HLA-DR in the absence 
of CD14, CD16 and IREM-2. 
3.3. Cell purification by fluorescence-activated cell sorting 
Monocytes and mDC cell populations from the cell cultures were purified by FACS, using 
FACSAria II flow cytometer (BD), according to their typical phenotype. Thus, the 6-color mAb 
combination used (Table 3, tube 4) allowed the identification of classical monocytes (HLA-
DR+CD33+IREM-2+CD14++CD16-), non-classical monocytes (HLA-DR+CD33+IREM-2+CD14+CD16+) 
and mDC (HLA-DR++CD33++IREM-2-CD14-CD16-). The purified cell populations were 
subsequently used for the quantification of mRNA expression. 
3.4. Analysis of mRNA expression in MSC and peripheral blood monocyte and 
mDC 
The content of each well of cultured MSC under the different experimental condition 
tested, or the purified mDC and monocyte subpopulations, was transferred to a 1.5 ml 
eppendorf tube, centrifuged for 5 minutes at 300xg and the pellet resuspended in 350 μl of 
RLT Lysis Buffer (Qiagen, Hilden, Germany). Total RNA was extracted with the RNeasy Micro kit 
(Qiagen), according to the supplier’s instructions. Then, total RNA was eluted in a 20 µl volume 
of RNase-free water RNA was reverse transcribed with Tetra cDNA Synthesis ® (Bioline, 
London, UK), according to the manufacturer’s instructions. Relative quantification of gene 
expression by real-time PCR was performed in the LightCycler 480 II (Roche Diagnostics, 
Rotkreuz, Switzerland). Real-time PCR reactions were carried out using 1x QuantiTect SYBR 
Green PCR Master Mix (Qiagen), 1x QuantiTect Primer Assay (for MSC: TNF3: QT01079561; IL-
10: QT00041685; IL-8: QT00000322; IL-6: QT00013461; ICOSL: QT00023660; IDO: QT00000504; 
TGFβ2: QT00025718; IL-1β: QT00021385; for purified classical and non-classical monocytes 
and mDC: IL-1β: QT00021385; IL-6: QT00083720; CCL3: QT01008063; CCL5: QT00090083; 
CXCL9: QT00013461; CXCL10: QT01003065) (Qiagen), in a final volume of 10 μl. The reactions 
were performed using the following thermal profile: 1 cycles of 10 min at 95°C, 50 cycles of 10 
sec at 95°C, 20 sec at 55°C and 30 sec at 72°C, 1 cycle of 5 sec at 95°C, 1 min at 65°C and 
continuo at 97°C, and 1 cycle of 10 sec at 21°C. All samples were run in duplicate. Real-time 
PCR results were analyzed with the LightCycler software (Roche Diagnostics). GeNorm 
software (PrimerDesign Ltd., Southampton, England) was used to select the reference genes to 
normalize data. The reference genes used for gene expression analysis were: cytochrome c1 
(CYC1) and splicing factor 3a subunit 1 (SF3A1) for MSC; glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and topoisomerase DNA I (TOP1) for classical monocytes; and GAPDH  
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Figure 5. Phenotypic characteristics of peripheral blood classical, intermediate, and non-classical monocytes, 
and mDC. Bivariate dot plot histograms illustrating the phenotypic strategy for the identification of the different 
monocyte subpopulations and myeloid dendritic cells (mDC) from peripheral blood. Classical monocytes (green 
events) express CD14 in the absence of CD16, they also show high reactivity for CD45, CD33, IREM-2, and HLA-
DR; intermediate monocytes (dark blue events) are characterized as CD14-positive displaying an increasing 
positivity to CD16, together with a high expression of IREM-2 and positivity for CD45, CD33 and HLA-DR; non-
classical monocytes (light blue events) are CD16-positive with a decreasing expression of CD14, they are highly 
positive to IREM-2 and CD45, while presenting the lowest CD33 expression among monocytes subpopulations; 
mDC (pink events) are phenotypically characterized as negative for CD14, CD16, and IREM-2, they present lower 
expression of CD45 and SSC properties, and higher expression of HLA-DR and CD33, compared to monocytes. 
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and beta-2 microglobulin (B2M) for non-classical monocytes and mDC. The normalized 
expression levels of the genes of interest were calculated by using the delta-Ct method. 
3.5. IDO detection by Western Blot 
Indoleamine-2,3-Dioxygenase (IDO) protein levels expression were determined by 
western blot in MSC without stimulation cultured in the presence or absence of MNC and in 
MSC stimulated with LPS, IFNγ or LPS+IFNγ, in the presence or absence of MNC. 
Cell lysates were prepared using RIPA buffer (Sigma) supplemented with complete 
protease inhibitor cocktail (Roche). After centrifugation at 10,000xg for 10 min at 4ºC, 
supernatants were collected. Seeblue Plus2 Prestained Protein Standard (Invitrogen) and 
Precision Plus Protein Standard (BioRad, Warszawa, Poland) were used as standard. SDS-
polyacrylamide gel electrophoresis was performed for separation of the proteins, and western 
blot were subsequently performed. For protein specific detection, the membranes were 
incubated with the primary mAb anti-IDO (clone 10.1, Merck Millipore, Darmstadt , Germany) 
diluted 1:5000. 
3.6. IL-6 production analysis 
IL-6 production was determined by enzyme-linked immunosorbent assay (ELISA), using a 
commercially available ELISA kit (RayBiotech, Norcross, USA), in the supernatant of MSC 
cultured in the presence/absence of MNC, with or without stimulation by LPS, IFNγ or 
LPS+IFNγ. The cultured cells were pelleted and the media was recovered to be tested by ELISA, 
performed according to the manufacturer’s instructions. 
3.7. Statistical analyses 
To determine the statistic significance of the differences observed between different 
culture conditions, non-parametric Friedman’s paired-sample test was performed, using 
Statistical Package for Social Sciences (IBM SPSS, version 17.0, Armonk, NY, USA). Data were 
expressed as mean percentage ± standard deviation. Statistically significant differences were 
considered when p value was lower than 0.05. 
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4. RESULTS 
In order to better understand how MSC regulate the immune function of the recently 
described monocyte subpopulations and mDC, we evaluated the expression of proteins 
involved in cell migration, activation/maturation, antigen presentation and the production of 
pro-inflammatory cytokines, in LPS plus IFNγ stimulated monocytes and mDC in the presence 
or absence of MSC. 
4.1. MSC inhibit TNF-α and MIP-1β protein expression in monocytes and mDC 
Considering TNF-α and MIP-1β expression, our results showed that MSC decreased both the 
percentage of cells producing TNF-α and MIP-1β (p <0.05, for all cell populations) as well as the 
amount of protein produced per cell (measured as mean fluorescence intensity, MFI, p <0.05 
for TNF-α-producing non-classical monocytes and mDC, and for MIP-1β-producing classical and 
intermediate monocytes and mDC), wherein MSC depletion prior to LPS+IFNγ stimulation 
resulted in a less effective reduction of the percentage of TNF-α producing monocytes (Figure 
6A). It is worth mentioning that MSC inhibition capability is different for distinct pro-
inflammatory proteins and for the different cell populations addressed in this study: MSC are 
less effective in regulating MIP-1β than TNF-α, and the expression of TNF-α in non-classical 
monocytes and of MIP-1β in classical monocytes is inhibited to a lesser extent than that of the 
remaining cell populations (Figure 6B). Furthermore, mDC exhibited the highest percentage of 
inhibition among all cell populations under study (Figure 6B). We found a similar behavior for 
MSC+MNC co-cultures stimulated solely with LPS (data not shown). Transwell assays 
demonstrated that the regulatory effect of MSC over TNF-α and MIP-1β was partially due to 
soluble factors (data not shown). 
4.2. MSC influence CCR7 and CD83 protein expression in monocytes and mDC 
In peripheral blood, classical, intermediate and non-classical monocytes and mDC from 
healthy individuals do not express CCR7 or CD83, however, 24 hours-culture of MNC in RPMI 
induced CCR7 and CD83 expression in a small percentage of intermediate monocytes and in an 
important percentage of mDC, further increased when co-cultured with MSC (Figure 7A-B). For 
classical and non-classical monocyte subpopulations, CCR7 and CD83 were only expressed 
after LPS+IFNγ stimulus. Of note, the simultaneous presence of MSC and LPS+IFNγ generated 
an even higher percentage of CCR7+ cells for classical and intermediate monocytes, and also of 
CD83+ cells for latter cell population. Interestingly, if MSC were depleted prior to LPS+IFNγ  
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Figure 6. MSC inhibition of TNF-α and MIP-1β protein expression in monocytes and mDC. (A) 
Percentage (mean ± standard deviation) of cells producing TNF-α and MIP-1β and amount of protein 
expressed per cell, measured as mean fluorescence intensity (MFI, mean ± standard deviation), for 
classical, intermediate and non-classical monocytes and mDC, under the following culture conditions: 
upon MNC stimulation with LPS+IFNγ (MNC+LPS+IFNγ), MNC co-cultured with MSC and stimulated with 
LPS+IFNγ in the presence of MSC (MNC+MSC+LPS+IFNγ), MNC co-cultured with MSC and stimulated 
with LPS+IFNγ immediately after depletion of MSC from the culture system 
(MNC+MSC+Depletion+LPS+IFNγ). Statistically significant differences were considered when p<0.05 (*) 
for Friedman’s paired-sample test. (B) Percentage (mean ± standard deviation) of inhibition by MSC 
(present in the culture system during LPS+IFNγ MNC activation, or depleted prior to activation) on the 
percentage of monocytes and mDC producing TNF-α and MIP-1β. Statistically significant differences 
were considered when p<0.05 for Friedman’s paired-sample test: 
a
 vs the same cell population in 
MNC+MSC+Depletion+LPS+IFNγ condition; 
b
 vs non-classical monocytes in the same culture conditions; 
c
 
vs mDC in the same culture conditions; 
d
 vs intermediate monocytes in the same culture conditions. 
MSC, mesenchymal stromal/stem cells; TNF-α, tumor necrosis factor-α; MIP-1β, macrophage 
inflammatory protein-1β; mDC, myeloid dendritic cells; LPS, lipopolysaccharide; IFNγ, interferon γ; MNC, 
mononuclear cells. 
stimulation, the percentage of CCR7+ cells was similar to that observed in MNC+LPS+IFNγ 
condition for both monocyte subpopulations (Figure 7A). We found no important alterations in 
the amount of CCR7 expressed per cell (MFI) among the different culture conditions, for all cell 
populations considered; however an increased CD83 MFI was observed in intermediate and 
non-classical monocytes and mDC in MNC+MSC+LPS+IFNγ culture condition (data not shown).  
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Figure 7. Influence of MSC on CCR7, CD83 and HLA-DR protein expression in monocytes and mDC. 
Percentage (mean ± standard deviation) of CCR7
+
 (A) and CD83
+
 (B) cells among classical, intermediate 
and non-classical monocytes and mDC, under the following culture conditions: non-stimulated MNC 
(MNC), non-stimulated MNC co-cultured with MSC (MNC+MSC), MNC stimulated with LPS+IFNγ 
(MNC+LPS+IFNγ), MNC co-cultured with MSC and stimulated with LPS+IFNγ in the presence of MSC 
(MNC+MSC+LPS+IFNγ), MNC co-cultured with MSC and stimulated with LPS+IFNγ immediately after 
depletion of MSC from the culture system (MNC+MSC+Depletion+LPS+IFNγ). Statistically significant 
differences were considered when p<0.05 for Friedman’s paired-sample test: 
a
 vs MNC; 
b
 vs MNC+MSC. 
(C) Expression of HLA-DR (measured as mean fluorescence intensity) among CCR7
+
 and CCR7
-
 monocyte 
subpopulations and mDC. Statistically significant differences were considered when p<0.05 (*) for 
Friedman’s paired-sample test. MSC, mesenchymal stromal/stem cells; mDC, myeloid dendritic cells; 
MNC, mononuclear cells; LPS, lipopolysaccharide; IFNγ, interferon γ. 
To further confirm that CCR7+ monocytes and mDC corresponded to cells undergoing 
maturation, we evaluated the amount of HLA-DR expressed per cell (MFI), because mature 
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monocytes and mDC express higher levels of HLA-DR. Accordingly, we found that HLA-DR 
expression (MFI) was higher for CCR7+ vs CCR7- cells, for classical and intermediate monocytes 
subpopulations and mDC, reaching statistical significance (Figure 7C). 
4.3. MSC differentially regulate cytokine and chemokine mRNA expression in 
mDC, classical and non-classical monocytes 
The regulation of IL-1β, IL-6, CCL3, CCL5, CXCL9 and CXCL10 mRNA expression by monocytes 
and mDC was also evaluated. MSC showed a high ability to reduce mRNA expression of all the 
cytokines and chemokines under study in classical monocytes (p <0.05 for CCL5 and CXCL10) 
(Figure 8); remarkably, the mRNA expression of IL-1β, IL-6, CCL3 and CCL5 was even lower for 
MSC+MNC co-culture in which MSC were depleted before MNC stimulation with LPS+IFNγ (p 
<0.05 for CCL5), except for CXCL9 (p <0.05). However, for non-classical monocytes, only the 
mRNA expression of chemokines was significantly downregulated (p <0.05 for CCL5, Figure 8); 
whereas, in mDC, IL-1β mRNA expression was downregulated (p <0.05) and CXCL10 remained 
unchanged under the influence of MSC (Figure 8). Remarkably, MSC depletion prior to 
LPS+IFNγ stimulation abrogated CCL3 and diminished CCL5 and CXCL10 mRNA regulation for 
non-classical monocytes, while decreasing CXCL10 mRNA expression in mDC (Figure 8). 
4.4. LPS and IFNγ modulate mRNA and protein expression in MSC 
To understand how the MNC stimulators used in this study affect MSC activity, we 
evaluated the expression of molecules with an important role in the immune function, at 
mRNA and protein level, in non-stimulated MSC and after LPS and/or IFNγ stimulation (Figure 
9). 
MSC showed constitutive expression of CD13, CD44, CD73, CD90, CD106, CD184 and IL-6 
proteins and IL-6, inducible costimulatory ligand (ICOSL) and transforming growth factor β 
(TGF-β1) mRNA transcripts (Figure 9). The variation of the expression of the proteins assessed 
by flow cytometry is expressed here as the ratio of the (MFI of MSC+stimulator)/(MFI of non-
stimulated MSC). The protein expression of CD73 and CD184 increased after LPS (ratio of 
1.47±1.10 and 1.28±0.55, respectively), IFNγ (ratio of 1.24±0.74 and 1.23±0.35, respectively) 
and LPS+IFNγ (ratio of 1.34 and 1.49, respectively); CD90 increased after treatment with LPS or 
LPS+IFNγ (ratio of 1.64±1.16 and 1.49±0.70, respectively); whereas only the stimulation of MSC 
with LPS+IFNγ increased the protein expression of CD44 and CD106 (ratio of 1.22±0.24 and 
1.30±0.47, respectively); finally, CD13 expression showed no alterations after treatment with 
the stimulator agents. None of the described results reached statistical significance. 
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Figure 8. MSC effect on cytokines and chemokines mRNA expression in monocytes and mDC. Semi-
quantitative analysis of IL-1β, IL-6, CCL3, CCL5, CXCL9 and CXCL10 mRNA expression in classical and non-
classical monocytes and mDC, under the following culture conditions: : MNC stimulated with LPS+IFNγ 
(MNC+LPS+IFNγ), MNC co-cultured with MSC and stimulated with LPS+IFNγ in the presence of MSC 
(MNC+MSC+LPS+IFNγ), MNC co-cultured with MSC and stimulated with LPS+IFNγ immediately after 
depletion of MSC from the culture system (MNC+MSC+Depletion+LPS+IFNγ). Statistically significant 
differences were considered when p<0.05 for Friedman’s paired-sample test: 
a
 vs MNC+LPS+IFNγ; 
b
 vs 
MNC+MSC+Depletion+LPS+IFNγ. MSC, mesenchymal stromal/stem cells; mDC, myeloid dendritic cells; 
IL, interleukin; MNC, mononuclear cells; LPS, lipopolysaccharide; IFNγ, interferon γ. 
At mRNA level, we verified that LPS+IFNγ stimulation induced upregulation of TNF-α, IL-
1β, IL-6, IL-8, IDO and ICOSL. Besides, MSC stimulation with LPS increased the mRNA 
expression of TNFα and IL-1β, while decreasing ICOSL; an upregulation of IL-8 mRNA was 
observed after stimulation with either LPS or IFNγ; and IDO mRNA levels increased in MSC 
stimulated with IFNγ (Figure 9). However, the analysis of the supernatant from MSC cultures 
by ELISA, showed that IL-6 was constitutively expressed by MSC and neither LPS nor IFNγ 
altered their expression at protein level. Additionally, IDO was not detected by western blot in 
MSC lysates (data not shown) and no alterations were found in TGF-β1 mRNA expression after 
MSC stimulation with LPS and/or IFNγ (Figure 9). None of the stimulators altered MSC 
morphology or differentiation capability; and though MSC stimulated with LPS showed a 
higher level of expansion, it occurred after the first passage and after culture day 10, thus not 
affecting our results (data not shown). 
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Figure 9. Modulation of mRNA expression of pro and anti-inflammatory proteins in MSC by LPS, IFNγ 
and LPS+IFNγ. Semi-quantitative analysis of TGF-β, ICOSL, IDO, IL-8, IL-6, IL-1β and TNF-α mRNA 
expression in MSC after stimulation with LPS, IFNγ, or LPS+IFNγ. Statistically significant differences were 
considered when p<0.05 for Friedman’s paired-sample test: 
a
 vs MNC; 
b
 vs MNC+LPS. MSC, 
mesenchymal stromal/stem cells; LPS, lipopolysaccharide; IFNγ, interferon γ; TGF-β, transforming 
growth factor β; ICOSL, inducible costimulatory ligand; IDO, indoleamine-2,3-dioxygenase; IL, 
interleukin; TNF-α, tumor necrosis factor-α; MNC, mononuclear cells. 
5. DISCUSSION 
The aim of the present work was to gain a deeper insight on the immunosuppressive 
effect of human bone marrow-derived MSC on the recently described peripheral blood 
monocyte subpopulations (classical CD14++CD16-, intermediate CD14++CD16+ and non-classical 
CD14+CD16++ monocytes) [332,369] and mDC. To the best of our knowledge, this is the first 
study reporting the effect of MSC on these specific cell populations. To accomplish this goal, 
the expression of TNF-α, CCL4 (MIP-1β), CCR7 and CD83 was evaluated by flow cytometry and 
the mRNA expression of IL-1β, IL-6, CCL3 (MIP-1α), CCL5 (RANTES), CXCL9 (MIG) and CXCL10 
(IP-10) was quantified in FACS-sorted and purified classical and non-classical monocytes, and 
IL-1β and CXCL10 mRNA levels were evaluated in mDC. 
Finally, we evaluated protein and mRNA expression in non-stimulated MSC and after LPS 
and/or IFNγ treatment, in order to understand how their regulatory function could be 
affected. As previously described, we found a slight increase in the mRNA of the pro-
inflammatory cytokines TNF-α and IL-6, along with a significant increase in the chemotactic IL-
8 [36,86,87,89,90,94,610] and the immunosuppressor IDO, ICOSL and CD73 [52,88,94], upon 
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stimulation with LPS+IFNγ. Of note, an increased expression of other immunoregulatory 
molecules, such as fibroblast growth factor 2 (FGF2), hepatocyte growth factor (HGF), 
cyclooxygenase 2 (COX2), prostaglandin E2 (PGE2), upon TLR4 stimulation had also been 
described in the literature [73,90,92,94]. Moreover, LPS+IFNγ promoted an increased protein 
expression of adhesion molecules in MSC: CD106 (VCAM-1), CD184 (CXCR4), CD54 (ICAM-1), 
CD90 (Thy-1) and CD44. These adhesion molecules are involved in cell-to-cell and cell-
extracellular matrix interaction and their upregulation had been reported to improve both 
MSC interaction with immune cells, namely T cells, and MSC migration [9,10,611,612]. Taken 
together these data suggest that, under an inflammatory microenvironment, MSC increase the 
expression of adhesion molecules that allow their close interaction with immune cells, 
contributing to increase the efficiency of paracrine mediators with immunosuppressive 
function produced by MSC. 
Our data showed that MSC efficiently inhibit TNF-α and MIP-1β production, in all the 
three monocytes subpopulations and mDC, by reducing both the percentage of producing cells 
and the amount of cytokine produced per cell, albeit our results suggested that MSC exert a 
more pronounced inhibitory effect over TNF-α expression than over MIP-1β. The partial 
inhibition observed in transwell assays suggests that both soluble factors and cell contact 
mechanisms are involved in this process. Interestingly, MSC exerted a higher inhibition over 
TNF-α production by intermediate monocytes and mDC (compared to classical and non-
classical monocytes), which correspond to the two cell populations more skilled for antigen 
presentation to T cells [369]. Furthermore, MSC impaired the mRNA expression of all the 
cytokines and chemokines under study in classical monocyte, as well as of the chemokines in 
non-classical monocytes and of IL-1β in mDC. Taken together, our data support that MSC 
inhibit the pro-inflammatory function of monocytes and mDC both by reducing the expression 
of pro-inflammatory cytokines (TNF-α, IL-1β and IL-6) and also by downregulating chemotactic 
factors that attract T cells and monocytes (CCL3, CCL4, CCL5, CXCL9 and CXCL10) and whose 
expression is induced by LPS plus IFNγ. 
In fact, LPS binding to TLR4 expressed on monocytes and mDC plasmatic membrane 
results in the downstream activation of MAPK (ERK1/2, JNK and p38), NF-kB and AP-1 [613], 
followed by the induction of the transcription of TNF-α, IL-1β, IL-6, MIP-1β (CCL4), CCL3, CCL5, 
CXCL9 and CXCL10 [614-621]. IFNγ signaling can also contribute to IL-1β, CXCL9 and CXCL10 
mRNA expression in human monocytes, macrophages and DC [616,622-624]. Despite the 
overlapping signaling molecules participating on TNF-α and MIP-1β gene expression induction 
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[614], MSC showed more efficiency in inhibiting TNF-α, suggesting differences between these 
two signaling pathways. 
Taking into account previous studies which investigated the mechanisms underlying the 
inhibition of cytokine and chemokine expression by MSC, we can point out the constitutively 
expressed IDO, Jagged-1, adenosine and/or PGE2 as possible candidates to the impairment of 
TNF-α production observed in the cells under study [90,236,420,422,428,454,519,625]; 
whereas PGE2 has also been described to reduce MIP-1β expression in monocyte-derived DC 
[439,626]. As, for the evaluation of protein expression by flow cytometry, we added brefeldin 
A to the cell culture together with LPS+IFNγ (which stopped the proteins synthesized de novo 
in the Golgi apparatus and prevented them to reach the extracellular medium), the inhibition 
of TNF-α and MIP-1β production can only be attributed to proteins constitutively expressed by 
MSC, or induced after their contact with peripheral blood MNC. 
Conversely, the assays made to evaluate mRNA expression were conducted in the 
absence of brefeldin A, so, for the final inhibitory effect accounted proteins constitutively 
expressed by MSC or induced by the contact with MNC, stimulator agents, or cytokines 
produced by MNC in response to LPS plus IFNγ activation. In fact, stimulation of MSC with LPS 
and/or IFNγ induces the expression of several immunosuppressor factors, such as HGF, nitric 
oxide (NO) and insulin-like growth factor (IGF) and increase Jagged-1, PGE2 and IDO expression 
[73,87,88,92,94]. In line with this, previous studies demonstrated that IL-6 expression might be 
inhibited by Jagged-1 and HGF in macrophages [519,627], or by IDO in DC [454], though IDO 
presents the opposite effect in human cancer cells [628]. In turn, PGE2 has the ability to impair 
the expression of CCL3, CCL5 and CXCL10 in human DC, macrophages [444,626,629], microglial 
cells and astrocyes [630] and of CXCL9 and CXCL10 in human breast cancer cells [623]; HGF and 
NO were demonstrated to inhibit CCL5 expression in human renal tubular epithelial cells and in 
mouse keratinocytes, respectively [497,498,631], while CXCL10 expression in melanoma cells is 
downregulated by NO [632]. The decreased expression of genes induced by TLR4 signaling 
pathway was shown to result from ERK1/2 inhibition by Jagged-1, and NF-kB inhibition by 
PGE2, HGF, IDO and adenosine [420,454,498,519,625,627,633]. 
In the present study, neither CCR7 nor CD83 protein expression was inhibited by the 
presence of MSC in the cell culture; furthermore, CCR7+ cells displayed a higher HLA-DR MFI 
than their CCR7- counterparts; altogether suggesting that MSC do not inhibit monocyte and 
mDC activation/maturation under our experimental conditions. Regarding the important role 
of CCR7 in monocyte and DC migration, it was demonstrated that solely the upregulation of 
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CCR7 expression does not necessarily corresponds to increased migration ability; however, it 
has been reported that PGE2 can upregulate the expression of CCR7, CD83 and HLA-DR in DC 
and of CCR7 in monocytes and, simultaneously, increase the cells’ migratory response to the 
lymph node-derived CCR7 ligands, CCL19 and CCL21 [422,431,434,438-440,445]. IFNγ share 
the ability to increase CCR7 expression in monocyte-derived DC and, if administrated with 
TLR4 agonist, to potentiate their CCR7-driven migration; in turn, NO and IGF-I can induce CD83 
expression in DC [506,624,634]. According to our data, MSC do not impede the expression of 
CD83 and CCR7 in LPS+IFNγ-activated monocyte and mDC, but impair their pro-inflammatory 
function by decreasing the expression of TNF-α, IL-1β and IL-6. In the same line, the reduction 
of chemokine expression induced by MSC may inhibit classical and non-classical monocytes’ 
ability to recruit T cells and monocytes, consequently hampering the interaction of these 
antigen-presenting cells with T cells. 
It was recently reported that macrophages and monocytes can assume 
immunoregulatory functions, induced by IL-6 and/or PGE2, and characterized by decreased 
TNF-α expression and increased IL-10 production [52,371,378,379,635], wherein MSC can 
actively participate [268,377]. Attending to the particular experimental conditions of the 
present study, as reported here and by others, MSC constitutively express IL-6 which is further 
upregulated upon stimulation with LPS [86,87,89,90,92,94] and this cytokine has the ability to 
downregulate TNF-α expression in monocytes [351,375]. Several studies reported MSC-derived 
inhibition of CD83, CD80, CD86, HLA-DR upregulation in DC differentiation assays 
[25,47,333,348-350,375] and impairment of their migratory ability, both in vitro and in vivo, 
toward CCL21 [346,636]. In opposition, van der Berk et al. reported that human UCB-MSC did 
not inhibit monocyte differentiation into immature DC and supported not only DC maturation 
but also the migration towards CCL21 [353]. It is worth to mention that we detected ICOSL 
mRNA in MSC, as recently described by Yii et al. [544], which was upregulated upon LPS+IFNγ 
stimulation. This finding opens new possibilities for the immunosupressive mechanisms of 
MSC, because ICOSL induces IL-10-producing regulatory T cells [604]. 
Here, we did not use a protocol to differentiate monocytes into DC, instead we analyzed 
the naturally occurring peripheral blood monocytes subpopulations and mDC (which 
corresponds to a more physiological condition) to assess the influence of MSC. Our results 
suggest that, upon MNC stimulation, MSC do not impede monocyte or mDC to express the 
activation/maturation markers CD83, CCR7 and HLA-DR. Conversely, MSC impair monocyte 
and mDC pro-inflammatory function, by decreasing the production of TNF-α, IL-1β and IL-6, 
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and reducing the monocytes’ ability to recruit T cells and other monocytes, by diminishing 
MIP-1β, CCL3, CCL5, CXCL9 and CXCL10 expression.  
As MSC are highly sensitive to the microenvironment, small differences in the 
experimental protocol may yield different results. In fact, concentration and time of exposure 
to LPS may conditioned MSC influence on immune cells [87,635,637]; also, the state of 
activation/maturation of DC will determine different responses to MSC regulatory factors 
[422]; all these variables difficult the comparison of the results obtained in different studies. 
6. CONCLUSIONS 
Altogether, our results showed that bone marrow-derived MSC inhibit TNF-α and MIP-
1β protein expression in activated classical, intermediate and non-classical monocytes, as well 
as in mDC. Remarkably, the inhibition observed was more pronounced for TNF-α expression 
than for MIP-1β and, regarding TNF-α, non-classical monocytes were more resistant to MSC-
induced suppression. Of note, mDC exhibited the highest degree of regulation for both TNF-α 
and MIP-1β. Similarly, MSC downregulate mRNA expression of pro-inflammatory cytokines and 
chemokines by monocytes and mDC. Conversely, the induction of activation/maturation 
markers (CD83, CCR7 and HLA-DR) by LPS plus IFNγ activation was not impaired by MSC. Thus, 
despite of not suppressing the activation/maturation of monocytes and mDC, MSC impair their 
pro-inflammatory function by reducing the expression of pro-inflammatory cytokines and 
chemotactic factors for monocytes and T cells, which may ultimately hamper the development 
of an inflammatory immune response. 
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1. ABSTRACT 
Introduction: The different distribution of T cells among activation/differentiation stages 
in immune disorders may condition the outcome of mesenchymal stromal cells (MSC)-based 
therapies. Indeed, the effect of MSC in the different functional compartments of T cells is not 
completely elucidated. 
Methods: We investigated the effect of human bone marrow MSC on naturally 
occurring peripheral blood functional compartments of CD4+ and CD8+ T cells: naive, central 
memory, effector memory and effector compartments. For that, mononuclear cells (MNC) 
stimulated with phorbol myristate acetate (PMA) plus ionomycin were cultured in the 
absence/presence of MSC. The percentage of cells expressing tumor necrosis factor (TNF)-α, 
interferon (IFN)γ, interleukin (IL)-2, IL-17, IL-9 and IL-6, and the amount of cytokine produced, 
was assessed by flow cytometry. mRNA levels of IL-4, IL-10, transforming growth factor (TGF)-β 
and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in purified CD4+ and CD8+ T cells, 
and phenotypic and mRNA expression changes induced by PMA+ionomycin stimulation in 
MSC, were also evaluated. 
Results: MSC induced the reduction of the percentage of CD4+ and CD8+ T cells 
producing TNF-α, IFNγ and IL-2 in all functional compartments, except for naive IFNγ+CD4+ T 
cells. This inhibitory effect differentially affected CD4+ and CD8+ T cells, as well as the T cell 
functional compartments; remarkably, different cytokines showed distinct patterns of 
inhibition regarding both the percentage of producing cells and the amount of cytokine 
produced. Likewise, the percentage of IL-17+, IL-17+TNF-α+ and IL-9+ within CD4+ and CD8+ T 
cells and of IL-6+CD4+ T cells was decreased in MNC-MSC co-cultures. MSC decreased IL-10 and 
increased IL-4 mRNA expression in stimulated CD4+ and CD8+ T cells, while TGF-β was reduced 
in CD8+ and augmented in CD4+ T cells; with no changes for CTLA-4. Finally, PMA+ionomycin 
stimulation didn’t induce significant alterations on MSC phenotype, but increased 
indoleamine-2,3-dioxygenase (IDO), inducible costimulatory ligand (ICOSL), IL-1β, IL-8 and TNF-
α mRNA expression. 
Conclusions: Overall, our study showed that MSC differentially regulate the functional 
compartments of CD4+ and CD8+ T cells, which may differentially impact their therapeutic 
effect in immune disorders. Furthermore, the influence of MSC on IL-9 expression can open 
new possibilities for MSC-based therapy in allergic diseases. 
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2. INTRODUCTION 
The discovery of the immunosuppressive potential of mesenchymal stromal cells (MSC) 
propelled a large number of studies in the past decade, mainly focusing on T cells. The 
suppressive effect of MSC over T cells comprises inhibition of T cell proliferation, activation, 
differentiation in effector cells and effector function, by altering their cytokine profile and 
impairing the cytolytic activity of cytotoxic T cells [231]. MSC-derived immunosuppression can 
be achieved by direct MSC-T cells interaction, through plasmatic membrane proteins or soluble 
factors produced by MSC, or indirectly by MSC-mediated suppression of antigen-presenting 
cells [45]. In fact, human bone marrow (BM) MSC impair dendritic cell maturation and 
decrease the expression of co-stimulatory molecules and interleukin (IL)-12, while increasing 
IL-10 expression, consequently hampering T cell activation [45,53,348,349,635]. A similar 
effect is observed in monocytes which, in the presence of human BM-MSC, develop an anti-
inflammatory phenotype with increased IL-10 expression [355,375,379]. 
However, it is well established that the behavior of MSC depend on numerous factors, 
such as the source of MSC, the type of immune cells present in the cell culture, the state of 
activation and differentiation of the T cells and the type of stimuli used [46,59,61,62,263]. In 
turn, the information available on the effect of MSC over T cells at different stages of 
activation/differentiation is scarce, and the data concerning the influence of MSC on the naive-
effector T cell differentiation process are contradictory. Most of the publications describe an 
inhibitory action over Th1 and Th17 differentiation, along with a decreased expression of the 
cytokines related to these effector phenotypes: interferon (IFN) γ, IL-2 and tumor necrosis 
factor (TNF)-α, for Th1; and IL-17A, IL-17F and IL-21, for Th17, both in vitro and in vivo 
[9,180,231,263,271,275,281]. Nevertheless, some studies reported that MSC promoted Th17 
differentiation and IL-17A production [231,251,252,254,280]. 
Different disorders of the immune system, and different stages of each immune disease, 
are characterized by distinctive distribution of T cells among activation/differentiation 
compartments, which is a reflection of the T cell subsets with a predominant role in the 
disease etiology. This highlights the importance of knowing the effect of MSC on each 
individual functional compartment, in order to predict and understand the outcome of MSC 
cell therapy. 
Here, we investigate the suppressive effect of human BM-MSC over peripheral blood 
CD4+ and CD8+ T cells distributed among the naturally occurring naive, central memory (CM), 
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effector memory (EM) and effector compartments. Peripheral blood mononuclear cells (MNC) 
were stimulated with phorbol myristate acetate (PMA) plus ionomycin in the 
absence/presence of MSC, and the expression of IL-2, TNF-α and IFNγ was evaluated by flow 
cytometry for CD4+ and CD8+ T cells distributed among the naive, CM, EM and effector 
compartments; the expression of IL-6, IL-9 and IL-17 was also evaluated in total CD4+ and CD8+ 
T cells.  In addition, IL-4, IL-10, TGF-β and CTLA-4 mRNA levels were assessed in FACS-purified 
CD4+ and CD8+ T cells. Finally, the protein expression of CD13, CD44, CD73, CD90, CD106, 
CD184 (CXCR4) and mRNA transcripts of IDO, ICOSL, TGF-β1, IL-1β, IL-8 and TNF-α were 
evaluated in non-stimulated MSC and after stimulation with PMA plus ionomycin. 
In this study, we report that the functional compartments of CD4+ and CD8+ T cells are 
differentially regulated by MSC, which may condition the outcome of MSC cell therapy in 
immune disorders with distinctive distribution of T cells among activation/differentiation 
compartments. Of note, MSC decrease the percentage of CD4+ and CD8+ T cells expressing 
TNF-α, IFNγ, IL-2, IL-6, IL-9 and IL-17, as well as the amount of TNF-α and IFNγ produced at a 
single-cell level. The influence of MSC on IL-9 can be a possible mechanism contributing to 
allergic inflammation amelioration by MSC. 
3. METHODS 
3.1. Collection and isolation of peripheral blood mononuclear cells and bone 
marrow MSC 
Peripheral blood samples from a total of 8 healthy donors (1 male and 7 females; mean 
age of 41±11 years, ranging from 21 to 50 years old), collected in heparin at the Blood and 
Transplantation Center of Coimbra (Portugal), and human BM samples from healthy donors 
(age ranging from 20 to 40 years old), were included in the present study. The use of these 
biological samples for research purpose was approved by the Ethics Committee of Instituto 
Português de Oncologia de Lisboa Francisco Gentil (Laws nº 97/95, nº 46/2004) and all 
participants gave written informed consent prior entering in the study. 
Peripheral blood mononuclear cells (MNC) were isolated by Lymphoprep (Stemcell 
Technologies, Vancouver, Canada) gradient density centrifugation and then washed twice in 
Hank’s Balanced Salt Solution (HBSS, Gibco, Life Technologies, Paisley, UK). The MNC pellet 
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was resuspended in RPMI 1640 with GlutaMax medium (Invitrogen, Life Technologies) with 
antibiotic-antimycotic (Gibco), to the final concentration of 106 cells/ml. 
Peripheral blood MNC were subsequently analyzed for protein and mRNA expression in 
the following experimental conditions: 1) 0.5x106 MNC + 500 μl RPMI (negative control); 2) 
0.5x106 MNC + 0.25x106 MSC (negative control); 3) 0.5x106 MNC + 500 μl RPMI + PMA + 
ionomycin (positive control); 4) 0.5x106 MNC + 0.25x106 MSC + PMA + ionomycin. All the 
aforementioned cell cultures were carried out for 20 hours at 37°C, in a sterile environment 
with 5% CO2 and humidified atmosphere, plus an incubation period of 4 hours with the 
stimulator agents. The cell culture and stimulation protocols are detailed below, in 
“Immunophenotypic study of MSC and peripheral blood T cells” section. 
For the isolation of human BM-MSC, MNC were isolated from BM samples using Sepax 
S-100 system (Biosafe, Switzerland), according to manufacturer’s instructions. Cell number and 
viability were determined using the Trypan Blue (Gibco) exclusion method. 
BM MNC were plated at a density of 2x105 cells/cm2 in Dulbecco's Modified Eagle 
Medium (DMEM, Gibco) supplemented with 10% qualified fetal bovine serum (FBS, Sigma, 
Spain). After a 3-day incubation at 37ºC in humidified atmosphere containing 5% CO2, the non-
adherent cell fraction was discarded, and the adherent culture was maintained with a 
complete medium renewal every 3-4 days. After reaching a 70-80% confluency cells were 
detached using TrypLE (Life Technologies) for 7 minutes and then replated at an initial density 
of 3000 cells/cm2. For this study, MSC passages 3 and 5 were used. 
MSC identity was confirmed by performing fluorescent morphological analysis, 
mesodermal differentiation assays (osteogenic, adipogenic and chondrogenic) and 
immunophenotype characterization as described by Dominici et al. [2]. 
Subsequently, MSC were resuspended in RPMI 1640 with GlutaMax medium (Invitrogen) 
with antibiotic-antimycotic (Gibco) to the final concentration of 0.5x106 cells/ml. The protein 
and mRNA expression of MSC was studied in the following experimental conditions: 1) 
0.25x106 MSC + 500 μl RPMI (non-stimulated MSC); 2) 0.25x106 MSC + 500 μl RPMI + PMA + 
ionomycin. All the aforementioned cell cultures were carried out for 20 hours at 37°C, in a 
sterile environment with 5% CO2 and humidified atmosphere, plus an incubation period of 4 
hours with the stimulator agents. The cell culture and stimulation protocols are detailed 
below, in “Immunophenotypic study of MSC and peripheral blood T cells’ section. 
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3.2. Immunophenotypic study of MSC and peripheral blood T cells 
3.2.1. MSC stimulation with PMA plus ionomycin 
For the immunophenotypic study of MSC, we plated in 4 wells of tissue culture plates 
(Falcon, Becton Dickinson Biosciences, BD, San Jose, USA) 0.25x106 MSC in 1 ml of RPMI 1640 
with GlutaMax medium (Invitrogen) with antibiotic-antimycotic (Gibco). MSC were cultured for 
20 hours at 37°C, in a sterile environment with 5% CO2 and humidified atmosphere (to be in 
the same experimental conditions than as those MSC co-cultured with MNC). Then, MSC from 
two of the four wells were stimulated with PMA (50ng/ml; Sigma) plus ionomycin (1µg/ml; 
Boehringer Mannheim, Germany), for 4 hours at 37ºC in humidified atmosphere containing 5% 
CO2; in the remaining 2 wells, MSC were not stimulated. The immunophenotypic study and 
mRNA expression quantification were performed in non-stimulated and PMA+ionomycin-
stimulated MSC. 
3.2.2. Immunophenotypic study of MSC 
For each experimental condition tested, cells were detached using TrypLE (Gibco); after 
incubating for 10 minutes at -20ºC, the content of each well was transferred to a 12x75 mm 
polystyrene cytometer tube, centrifuged for 5 minutes at 540xg and the supernatant was 
discarded. MSC immunophenotype was assessed using the 8-color monoclonal antibody (mAb) 
combination detailed in table 4, tube 1. The cell pellet was incubated with the mAb for 10 
minutes in the darkness and washed with PBS. Finally, cells were resuspended in 500 μl of PBS 
and immediately acquired in a FACSCanto II (BD) flow cytometer. 
3.2.3. Co-culture of peripheral blood MNC and MSC and in vitro stimulation with PMA 
plus ionomycin 
In 4 wells of tissue culture plates (Falcon) 0.5x106 MNC were plated in 1 ml of RPMI 1640 
with GlutaMax medium (Invitrogen) with antibiotic-antimycotic (Gibco), and in other 4 wells of 
tissue culture plates (Falcon) we plated 0.5x106 MNC + 0.25x106 MSC in a final volume of 1 ml, 
establishing a ratio of 2:1 (MNC:MSC). Cells were cultured for 20 hours at 37°C, in a sterile 
environment with 5% CO2 and humidified atmosphere. 
After the incubation period, PMA+ionomycin (50ng/ml and 1µg/ml, respectively) were 
added to 2 wells with MNC and 2 wells with co-cultured MNC+MSC; the cells in the remaining 
wells (2 with MNC and 2 with MNC+MSC) were not stimulated. Brefeldin A (10 μg/ml), from 
Penicillium brefeldiamun (Sigma), was added to 1 well of each experimental condition – 1) 
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MNC, 2) MNC+MSC, 3) MNC+PMA+ionomycin, and 4) MNC+MSC+PMA+ionomycin – to 
prevent the release of de novo produced cytokines outside the cells. Then, we proceeded to an 
incubation at 37 °C, in a sterile environment with 5% CO2 humidified atmosphere, for 4 hours. 
The samples with brefeldin A were used for the study of cytokine expression in T cells by 
flow cytometry, while the mRNA expression was performed in the samples without brefeldin 
A. All the aforementioned protein and mRNA expression studies were performed in all the 
different culture conditions: MNC, MNC+MSC, MNC+PMA+ionomycin, MNC+MSC+ 
PMA+ionomycin. 
3.2.4. Immunophenotypic study of peripheral blood T cells 
For each experimental condition tested, cells were detached using TrypLE (Gibco); after 
incubating for 10 minutes at -20ºC, the content of each well was transferred to a 12x75 mm 
polystyrene cytometer tube, centrifuged for 5 minutes at 540xg and the supernatant was 
discarded. Immunophenotypic analysis of peripheral blood T cells, cultured in the 
presence/absence of PMA+ionomycin and in the presence/absence of MSC, was performed 
using 7-color mAb combinations, detailed in table 4. In short, cells were stained with the mAb 
for surface proteins antigens (CD3, CD27, CD4, CD45RA and CD8) and, after an incubation 
period of 10 minutes in the darkness at room temperature, washed with PBS. For intracellular 
staining, Fix&Perm (Caltag, Hamburg, Germany) reagent was used, according to the 
manufacturer’s instructions and in parallel with the mAb for TNF-α and IL-17 (tube 2), IFNγ and 
IL-6 (tube 3), or IL-2 and IL-9 (tube 4). After washing twice with PBS, the cell pellet was 
resuspended in 500 μl of PBS and immediately acquired. 
3.2.5. Data acquisition and analysis 
Data acquisition was performed in a FACSCanto II (BD) flow cytometer equipped with 
the FACSDiva software (v6.1.2; BD). For both MSC and MNC immunophenotypic studies, the 
whole sample from each tube was acquired and stored, corresponding to a number of events 
always above 0.1x106 or 0.5x106 events, respectively. For data analysis, the Infinicyt (version 
1.7) software (Cytognos SL, Salamanca, Spain) was used. 
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Table 4. Panel of mAb reagents (with clones and commercial source) used for the immunophenotypic 
characterization of MSC and peripheral blood T cells. 
Fluorochrome 
Tube PacB PacO FITC PE 
PerCPCy5.5 
or PECy5 
PECy7 APC APCH7 
1 
CD44 
clone IM7 
Biolegend 
CD45 
HI30 
Invitrogen 
CD106 
51-10C9 
BD Pharmingen 
CD73 
AD2 
BD Pharmingen 
CD184 
12G5 
BD 
CD13 
Immu103.44 
Beckman Coulter 
CD90 
5E10 
BD Pharmingen  
2 
CD3 
UCHT1 
BD Pharmingen  
cyTNF-α 
MP6-XT22 
BD Pharmingen 
cyIL-17 
SCPL1362 
BD Pharmingen 
CD27 
14CD27 
Beckman Coulter 
CD4 
SFCI12T4D11 
Beckman Coulter 
CD45RA 
HI100 
BD 
CD8 
SK1 
BD 
3 
CD3 
UCHT1 
BD Pharmingen  
cyIFNγ 
4S.B3 
BD Pharmingen 
cyIL-6 
MQ2-6A3 
BD Pharmingen 
CD27 
14CD27 
Beckman Coulter 
CD4 
SFCI12T4D11 
Beckman Coulter 
CD45RA 
HI100 
BD 
CD8 
SK1 
BD 
4 
CD3 
UCHT1 
BD Pharmingen  
cyIL-2 
MQ1-17H12 
BD 
cyIL-9 
MH9A3 
BD Pharmingen 
CD27 
14CD27 
Beckman Coulter 
CD4 
SFCI12T4D11 
Beckman Coulter 
CD45RA 
HI100 
BD 
CD8 
SK1 
BD 
5 
CD4 
RPA-T4 
BD Pharmingen  
CD25 
M-A251 
BD Pharmingen 
CD127 
R34.34 
Beckman Coulter  
TCRγδ 
11F2 
BD Pharmingen 
CD8 
B9.11 
Beckman Coulter 
CD3 
SK7 
BD Pharmingen 
Abbreviations: mAb, monoclonal antibody; MSC, mesenchymal stroma/steml cells; PacB, pacific blue; PacO, pacific orange; 
FITC, fluorescein isothiocyanate; PE, phycoerythrin; PerCPCy5.5, peridinin chlorophyll protein-cyanine 5.5; PECy5, 
phycoerythrin-cyanine 5; PECy7, phycoerythrin-cyanine 7; APC, allophycocyanin; APCH7, allophycocyanin-hilite 7. 
Commercial sources: Biolegend (San Diego, CA, USA); Invitrogen, Life Technologies (Carlsbad, CA, USA); BD Pharmingen (San 
Diego, CA, USA); BD (Becton Dickinson Biosciences, San Jose, CA, USA), Beckman Coulter (Miami, FL, USA). 
 
3.2.6. Immunophenotypic identification of T cells within the different functional 
compartments 
The identification and quantification of the four T cell functional compartments, was 
carried out after the exclusion of cell debris (which corresponded to events with very low 
forward scatter (FSC) and heterogeneous side scatter (SSC) light dispersion properties) and 
doublets (identified by their FSC-area and FSC-height characteristics). Then, T cells were 
identified based on CD3 positivity and intermediate FSC and SSC properties (Figure 10). Within 
this cell population, the functional compartments of CD4+ and CD8+ T cells (phenotypically 
characterized as CD3+CD4+CD8- and CD3+CD4-CD8+, respectively) were identified according to 
their differential expression of CD45RA and CD27, as follows: naive T cells are characterized by 
CD45RA+CD27+ expression, CM T cells are CD45RA-CD27+, EM and effector T cells display 
CD45RA-CD27- and CD45RA+CD27- immunophenotype, respectively (Figure 10). 
3.3. Cell purification by fluorescence-activated cell sorting 
CD4+ and CD8+ T cell populations from the cell cultures were purified by fluorescence-
activated cell sorting (FACS), using FACSAria II flow cytometer (BD), according to their typical  
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Figure 10. Gating strategy for identifying CD4
+
 and CD8
+
 T cells’ functional compartments and 
cytokine expression among each T cell compartment. Bivariate dot plot histograms illustrating (A-C) 
overall T cells in the cell culture and (C) CD4
+
 (blue events) and CD8
+
 (pink events) T cells. The 
identification of T cells’ functional compartments were made within CD8
+
 (D) and CD4
+
 (E) T cell 
subpopulations, based on CD45RA and CD27 expression, as follows: CD45RA
+
CD27
+
 phenotype 
corresponds to naive (N) T cells, CD45RA
-
CD27
+
 corresponds to central memory (CM), effector memory 
(EM) T cells are CD45RA
-
CD27
-
, and effector T cells display CD45RA
+
CD27
-
 phenotype. The expression of 
cytokines (illustrated in panel (F) for CD8
+
 T cells and in (G) for CD4
+
 T cells) was evaluated within each 
CD4
+
 and CD8
+
 T cell functional compartments. 
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phenotype. Thus, the 6-color mAb combination used (Table 4, tube 5) allowed the 
identification of CD4+ T cells (CD3+CD4+CD8-TCRγδ-) and CD8+ T cells (CD3+CD4-CD8+TCRγδ-). 
The remaining mAb found in the panel were used to exclude γδ T cells (which correspond to 
CD3+TCRγδ+ events) and regulatory T cells (which are CD25++CD127-/dim). The purified cell 
populations were subsequently used for the quantification of mRNA expression. 
3.4. Analysis of mRNA expression in MSC and purified CD4+ and CD8+ T cells  
The content of each well of cultured MSC under the different experimental condition tested, 
or the purified CD4+ and CD8+ T cell populations, were transferred to a 1.5 ml eppendorf tube, 
centrifuged for 5 minutes at 300xg and the pellet resuspended in 350 μl of RLT Lysis Buffer 
(Qiagen, Hilden, Germany). Total RNA was extracted with the RNeasy Micro kit (Qiagen), 
according to the supplier’s instructions. Then, total RNA was eluted in a 20 µl volume of RNase-
free water. RNA was reverse transcribed with Tetra cDNA Synthesis ® (Bioline, London, UK), 
according to the manufacturer’s instructions. Relative quantification of gene expression by 
real-time PCR was performed in the LightCycler 480 II (Roche Diagnostics, Rotkreuz, 
Switzerland). Real-time PCR reactions were carried out using 1x QuantiTect SYBR Green PCR 
Master Mix (Qiagen), 1x QuantiTect Primer Assay (for MSC: TNF3: QT01079561; IL-8: 
QT00000322; IL-1β: QT00021385; TGF-β1: QT00025718; ICOSL: QT00023660; IDO: 
QT00000504; for purified CD4+ and CD8+ T cells: IL-10: QT00041685; IL-2: QT00015435; IL-4: 
QT00012565; TGF-β: QT00000728; CTLA-4: QT01670550) (Qiagen), in a final volume of 10 μl. 
The reactions were performed using the following thermal profile: 1 cycles of 10 min at 95°C, 
50 cycles of 10 sec at 95°C, 20 sec at 55°C and 30 sec at 72°C, 1 cycle of 5 sec at 95°C, 1 min at 
65°C and continuo at 97°C, and 1 cycle of 10 sec at 21°C. All samples were run in duplicate. 
Real-time PCR results were analyzed with the LightCycler software (Roche Diagnostics). 
GeNorm software (PrimerDesign Ltd., Southampton, England) was used to select the reference 
genes to normalize data. The reference genes used for gene expression analysis were: 
cytochrome c1 (CYC1) and splicing factor 3a subunit 1 (SF3A1) for MSC; beta-2 microglobulin 
(B2M) and tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta 
(YWHAZ) for CD4+ and CD8+ T cells. The normalized expression levels of the genes of interest 
were calculated by using the delta-Ct method. 
3.5. Statistical analysis 
To determine the statistic significance of the differences observed between different 
culture conditions, non-parametric Wilcoxon and Friedman’s paired-sample tests were 
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performed, using Statistical Package for Social Sciences (IBM SPSS, version 17.0, Armonk, NY, 
USA). Data were expressed as mean percentage ± standard deviation. Statistically significant 
differences were considered when p value was lower than 0.05. 
4. RESULTS 
To investigate MSC ability to regulate cytokine protein expression in CD4+ and CD8+ T 
cells and how the influence of MSC varies among the different T cell functional compartments 
– naive, central memory (CM), effector memory (EM) and effector compartment – non-
stimulated or PMA+ionomycin-stimulated MNC were cultured in the absence or presence of 
MSC. We used 8-color flow cytometry to identify the four abovementioned compartments 
among CD4+ and CD8+ T cells and analyze the protein expression of TNF-α, IFNγ and IL-2 within 
each cell compartment, and of IL-17, IL-6 and IL-9 in total CD4+ and/or CD8+ T cells. Besides, 
mRNA expression of IL-4, IL-10, TGF-β and CTLA-4 in purified CD4+ and CD8+ T cells was also 
assessed. Finally, MSC were stimulated with PMA plus ionomycin and the protein expression of 
CD13, CD44, CD73, CD90, CD106, CD184 (CXCR4) and mRNA levels of IDO, ICOSL, TGF-β, IL-1β, 
IL-8 and TNF-α were evaluated and compared to that of non-stimulated MSC. 
4.1. MSC decrease the frequency of T cells producing TNF-α, IFNγ and IL-2, as 
well as the protein expression at single cell level, and regulate differentially the 
distinct T cell functional compartments 
Co-culture of MSC with PMA+ionomycin-stimulated MNC decreased the percentage of 
both CD4+ and CD8+ T cells expressing TNF-α (p <0.05) – observed in all individuals enrolled in 
this study – as well as the amount of protein produced per cell (p <0.05), measured as mean 
fluorescence intensity (MFI), in all cell compartments analyzed, except for TNF-α MFI in naive 
CD4+ T cells, where MSC did not induce changes (Figure 11). Of note, the effect of MSC over 
the frequency of TNF-α+ cells was more pronounced in CD4+ T cells, compared to CD8+ T cells, 
and in naive and CM compartments for both CD4+ and CD8+ T cells (Figure 11). 
Concerning IFNγ and IL-2, we observed an overall reduction of the frequency of both 
CD4+ and CD8+ T cells producing these cytokines in MSC+MNC+PMA+ionomycin co-cultures (p 
<0.05 for all functional compartments of CD8+ T cells producing IFNγ and for effector CD4+ T 
cells producing IL-2), as illustrated in figure 12 and 13. Of note, MSC decreased the percentage 
of IFNγ-producing CD4+ and CD8+ T cells in 63% and 88% of the individuals under study, 
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Figure 11. Percentage of CD4
+
 and CD8
+ 
T cells expressing TNF-α. Upper panels: Percentage (mean ± 
standard deviation) of CD4
+
 and CD8
+
 T cells, distributed among their functional compartments, 
producing TNF-α (within the correspondent functional compartment of CD4
+
 or CD8
+
 T cells, 
respectively) and amount of protein expressed per cell, measured as mean fluorescence intensity (MFI, 
mean ± standard deviation), after MNC stimulation with PMA plus ionomycin in the absence of MSC 
(MNC+PMA+ionomycin) or in co-culture with MSC (MSC+MNC+PMA+ionomycin). The lower panel 
represents the percentage of inhibition induced by MSC on the percentage of CD4
+
 and CD8
+
 T cells 
expressing TNF-α. Statistically significant differences were considered when p<0.05 for Wilcoxon 
paired-sample test: * vs. MSC+MNC+PMA+ionomycin; ** p<0.05 for the groups indicated in the figure. 
TNF-α, tumor necrosis factor-α; MNC, mononuclear cells; PMA, phorbol myristate acetate; MSC, 
mesenchymal stromal/stem cells; CM, central memory; EM, effector memory. 
respectively; and in 75% and 63% of the individuals for CD4+ and CD8+ T cells expressing IL-2, 
respectively. This decrease affected all T cell compartments, though it was less pronounced in 
naive T cells and not visible for naive CD4+ T cells producing IFNγ (Figures 12 and 13). MSC 
diminished   the   amount   of  IFNγ  produced  by  T cells  (MFI),  primarily  in  EM  and  effector  
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Figure 12. Percentage of CD4
+
 and CD8
+ 
T cells expressing IFNγ. Upper panels: Percentage (mean ± 
standard deviation) of CD4
+
 and CD8
+
 T cells, distributed among their functional compartments, 
producing IFNγ (within the correspondent functional compartment of CD4
+
 or CD8
+
 T cells, respectively) 
and amount of protein expressed per cell, measured as mean fluorescence intensity (MFI, mean ± 
standard deviation), after MNC stimulation with PMA plus ionomycin in the absence of MSC 
(MNC+PMA+ionomycin) or in co-culture with MSC (MSC+MNC+PMA+ionomycin). The lower panel 
represents the percentage of inhibition induced by MSC on the percentage of CD4
+
 and CD8
+
 T cells 
expressing IFNγ. Statistically significant differences were considered when p<0.05  for Wilcoxon paired-
sample test: * vs. MSC+MNC+PMA+ionomycin; ** p<0.05 for the groups indicated in the figure. IFNγ, 
interferon γ; MNC, mononuclear cells; PMA, phorbol myristate acetate; MSC, mesenchymal 
stromal/stem cells; CM, central memory; EM, effector memory. 
compartments (p <0.05 for EM CD4+ T cells, EM CD8+ T cells and effector CD8+ T cells); an 
effect more pronounced among CD8+ than CD4+ T cells (Figure 12).In turn, concerning the 
amount of IL-2 produced, effector CD4+ T cells from MSC+MNC+PMA+ionomycin co-cultures 
displayed a lower IL-2 MFI compared to those from stimulated MNC cultures (p <0.05), 
whereas no differences were found in the remaining T cell compartments (Figure 13). 
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Figure 13. Percentage of CD4
+
 and CD8
+ 
T cells expressing IL-2. Upper panels: Percentage (mean ± 
standard deviation) of CD4
+
 and CD8
+
 T cells, distributed among their functional compartments, 
producing IL-2 (within the correspondent functional compartment of CD4
+
 or CD8
+
 T cells, respectively) 
and amount of protein expressed per cell, measured as mean fluorescence intensity (MFI, mean ± 
standard deviation), after MNC stimulation with PMA plus ionomycin in the absence of MSC 
(MNC+PMA+ionomycin) or in co-culture with MSC (MSC+MNC+PMA+ionomycin). The lower panel 
represents the percentage of inhibition induced by MSC on the percentage of CD4
+
 and CD8
+
 T cells 
expressing IL-2. Statistically significant differences were considered when p<0.05 for Wilcoxon paired-
sample test: * vs. MSC+MNC+PMA+ionomycin; ** p<0.05 for the groups indicated in the figure. IL-2, 
interleukin-2; MNC, mononuclear cells; PMA, phorbol myristate acetate; MSC, mesenchymal 
stromal/stem cells; CM, central memory; EM, effector memory. 
We observed neither CD4+ nor CD8+ T cells produce cytokines in non-stimulated MNC 
and non-stimulated MNC+MSC cultures. 
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4.2. MSC decrease the frequency of T cells producing IL-17, IL-6 and IL-9 
The presence of MSC in the stimulated-MNC culture resulted in a decreased percentage 
of both Th17 and Tc17 cells (p <0.05), verified in all individuals studied, without alteration of 
the amount of IL-17 produced per cell, measured as MFI (Figure 4). Similarly, MSC reduced the 
frequency IL-17+TNF-α+CD4+ and IL-17+TNF-α+CD8+ T cells (p <0.05), which was observed in all 
individuals under study. In these T cell populations, IL-17 MFI remained constant, while a lower 
TNF-α MFI was detected in both cell populations for MSC+MNC+PMA+ionomycin co-cultures 
(p <0.05 for CD8+ T cells; Figure 14).  
The frequency of CD4+ and CD8+ T cells expressing IL-6 or IL-9 was lower in the presence 
of MSC (p <0.05 for IL-9+CD4+ T cells and IL-9+ CD8+ T cells); 88% of individuals showed 
decreased percentage of CD4+ T cells expressing IL-6, while in 75% and 100% of the individuals 
MSC reduced CD4+ and CD8+ T cells producing IL-9, respectively (Figure 15). 
We observed no cytokine production by CD4+ or CD8+ T cells in non-stimulated MNC and 
non-stimulated MNC+MSC cultures. 
4.3. mRNA expression of IL-4, IL-10, TGF-β and CTLA-4 in purified CD4+ and 
CD8+ T cells from MNC cultured in the absence/presence of MSC 
Overall, MSC decreased IL-10 and increased IL-4 mRNA expression in stimulated CD4+ 
and CD8+ T cells; while TGF-β mRNA levels were reduced in CD8+ and augmented in CD4+ T 
cells, and CTLA-4 remained constant regardless of MSC presence in the MNC culture (Figure 
16). Of note, a high inter-individual variability in mRNA levels of all molecules studied was 
observed. 
4.4. Protein and mRNA expression in PMA plus ionomycin stimulated vs non-
stimulated MSC 
The analysis of the protein expression of CD13, CD44, CD73, CD90, CD106, CD184 
(CXCR4) by flow cytometry showed no differences with biological significance for these 
molecules (data not shown), albeit there were significant statistical differences for CD106 (MFI 
of 2499±861 and 2713±869 for non-stimulated and stimulated MSC, respectively) and CD184 
(MFI of 7103±2059 and 8116±2224 for non-stimulated and stimulated MSC, respectively). In 
turn, MSC stimulation with PMA plus ionomycin induced the increase of IDO, ICOSL, IL-1β, IL-8 
and TNF-α mRNA levels (p <0.05 for IL-1β, IL-8 and TNF-α) and showed a tendency to decrease 
TGF-β mRNA (not statistically significant), as illustrated in figure 17. 
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Figure 14. Percentage of CD4
+
 and CD8
+ 
T cells expressing IL-17. Left upper panels: Percentage (mean 
± standard deviation) of CD4
+
 and CD8
+
 T cells producing IL-17 (within total CD4
+
 T cells and total CD8
+
 T 
cells, respectively) and amount of protein expressed per cell, measured as mean fluorescence intensity 
(MFI, mean ± standard deviation), after MNC stimulation with PMA plus ionomycin in the absence of 
MSC (MNC+PMA+ionomycin) or in co-culture with MSC (MSC+MNC+PMA+ionomycin). Right upper 
panels: Percentage (mean ± standard deviation) of CD4
+
 and CD8
+
 T cells producing simultaneously IL-
17 and TNF-α (within IL-17
+
CD4
+
 T cells and IL-17
+
CD8
+
 T cells, respectively) and amount of protein 
expressed per cell, measured as mean fluorescence intensity (MFI, mean ± standard deviation), after 
MNC stimulation with PMA plus ionomycin in the absence of MSC (MNC+PMA+ionomycin) or in co-
culture with MSC (MSC+MNC+PMA+ionomycin). The lower panel represents the percentage of 
inhibition induced by MSC on the percentage of CD4
+
 and CD8
+
 T cells expressing IL-17 or IL-17 and 
TNF-α. Statistically significant differences were considered when p<0.05 for Wilcoxon paired-sample 
test: * vs. MSC+MNC+PMA+ionomycin. IL-17, interleukin-17; MNC, mononuclear cells; PMA, phorbol 
myristate acetate; MSC, mesenchymal stromal/stem cells; TNF-α, tumor necrosis factor-α; CM, central 
memory; EM, effector memory. 
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Figure 15. Percentage of CD4
+
 and CD8
+ 
T cells expressing IL-6 or IL-9. Upper panel: Percentage (mean 
± standard deviation) of CD4
+
 T cells expressing IL-6 (within total CD4
+
 T cells) and of total, CD4
+
 and 
CD8
+
 T cells producing IL-9 (within total T cells, CD4
+
 T cells and total CD8
+
 T cells, respectively), after 
MNC stimulation with PMA plus ionomycin in the absence of MSC (MNC+PMA+ionomycin) or in co-
culture with MSC (MSC+MNC+PMA+ionomycin). Lower panel: Percentage of inhibition induced by MSC 
on the percentage of total, CD4
+
 and/or CD8
+
 T cells expressing IL-6 or IL-9. Statistically significant 
differences were considered when p<0.05 for Wilcoxon paired-sample test: * vs. 
MSC+MNC+PMA+ionomycin. IL-6, interleukin-6; IL-9, interleukin-9; MNC, mononuclear cells; PMA, 
phorbol myristate acetate; MSC, mesenchymal stromal/stem cells. 
5. DISCUSSION 
Despite of the increasing number of studies on MSC-derived immunosuppression of T 
cells, those which investigated whether MSC action differed among T cell functional 
compartments are scarce. As the immune system disorders candidates to MSC cell therapy 
comprise a heterogeneous group concerning the distribution of T cells among their functional 
compartments and the effector T cells underlying the disease, it becomes urgent to 
understand how MSC regulate the distinct T cell functional compartments. 
Thus, in the present study, the influence of MSC in the cytokine expression profile of 
naive, CM, EM and effector compartments of CD4+ and CD8+ T cells was evaluated directly in 
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these subsets naturally occurring in the peripheral blood of healthy individuals. The 
abovementioned functional compartments were identified within CD4+ and CD8+ T cell 
populations by flow cytometry, based on their differential expression of CD45RA and CD27. 
The production of IL-2, TNF-α and IFNγ was further evaluated within each cell compartment. 
To the best of our knowledge, this is the first study reporting the effect of MSC on the cytokine 
expression by T cells that analyzed simultaneously all the four functional compartments of 
CD4+ and CD8+ T cells naturally occurring in the peripheral blood. 
Our results showed that, in a co-culture system with MNC stimulated with 
PMA+ionomycin, MSC downregulate TNF-α, IFNγ and IL-2 protein expression in both CD4+ and 
CD8+ T cells, which corroborates with previous studies reporting that MSC induce the decrease 
of this cytokines detected in the co-culture medium [129,181,236,237,250,252,475], at mRNA 
level [46,252,254], or the percentage of T cells producing cytokines [181,245,251,263,291] in in 
vitro experiments and in vivo animal experimental models [180,271,272]. 
The analysis of the expression of those pro-inflammatory cytokines within each T cell 
functional compartment revealed that MSC has the ability to modulate the function of T cells 
included in naive, CM, EM and effector compartments, however to a different extent. 
Interestingly, effector CD8+ T cells, which present the highest percentage of TNF-α-producing 
cells among CD4+ and CD8+ T cell functional compartments, correspond to those which are less 
sensitive to MSC-mediated TNF-α downregulation. Therefore, as TNF-α constitute an 
important effector mechanism of CD8+ T cell-mediate immune response, with a pivotal role in 
the pathophysiology of several autoimmune disorders and GvHD, we may postulate that MSC 
present a milder inhibition on cells with a higher degree of differentiation. Conversely, IL-2 
expression is highly inhibited in CM, EM and effector CD4+ T cells. MSC-mediated IL-2 
downregulation had already been described for CD4+ or total T cells and is correlated to MSC 
ability to impair T cell proliferation [46,129,254]. Similarly to Aggarwal et al. [236], that 
reported MSC-mediated inhibition of IFNγ in human CD45RA+ T cells, we observed a decreased 
frequency of naive T cells producing IFNγ, but only among CD8+ T cells, while no inhibitory 
effect was detected over naive CD4+ T cells. Besides, a more pronounced inhibitory effect was 
observed among the CM, EM and effector compartments, compared to naive cells, for CD4+ 
and CD8+ T cells; similarly, Krampera et al. [291] found a stronger inhibitory effect over mouse 
memory T cells, compared to naive T cells. In the same line, more recent studies showed that 
MSC induced human memory T cells, whose identification was based on CD45RO expression, 
to express IL-17, which did not occur in the naive compartment [254,280]. 
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Figure 16. mRNA expression of IL-10, TGF-β, IL-2, IL-4 and CTLA-4 in CD4
+
 and CD8
+
 T cells. Semi-
quantitative analysis of IL-10, TGF-β, IL-2, IL-4 and CTLA-4 mRNA expression in FACS-purified CD4
+
 and 
CD8
+
 T cells from the following culture conditions: non-stimulatred MNC (MNC); non-stimulated MNC 
co-cultured with MSC (MNC+MSC); MNC stimulated with PMA plus ionomycin (MNC+PMA+ionomycin); 
MNC stimulated with PMA plus ionomycin in co-culture with MSC (MNC+MSC+PMA+ionomycin). 
Statistically significant differences were considered when p<0.05 for Wilcoxon paired-sample test, 
comparing MNC+PMA+ionomycin vs. MNC+MSC+PMA+ionomycin. IL, interleukin; TGF-β, transforming 
growth factor β; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; MNC, mononuclear cells; PMA, 
phorbol myristate acetate; MSC, mesenchymal stromal cells. 
At this point, our results and previously published data support the idea that MSC differently 
regulate the distinct T cell functional compartments, which can impact the outcome of MSC 
cell therapy. 
Concerning other pro-inflammatory cytokines, MSC induced a decreased percentage of 
CD4+ and CD8+ T cells expressing IL-17 and IL-9, and of CD4+ T cells producing IL-6. Conversely, 
at mRNA level, we observed a tendency to an increase of the anti-inflammatory IL-4 and TGF-β 
in CD4+ T cells, as described by others [180,181,231,236]. It has been attributed to MSC the 
ability   to  inhibit  Th17  differentiation,  from  mouse  and  human  T  cells,  and  decrease  the  
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Figure 17. mRNA expression of TNF-α, IL-8, IL-1 β, TGF-β, ICOSL and IDO in MSC. Semi-quantitative 
analysis of TNF-α, IL-8, IL-1 β, TGF-β, ICOSL, IDO mRNA expression in non-stimulated MSC (MSC) and in 
MSC stimulated with PMA plus ionomycin (MSC+PMA+ionomycin). Statistically significant differences 
were considered when p<0.05 for Wilcoxon paired-sample test, comparing MSC vs. 
MSC+PMA+ionomycin. TNF-α, tumor necrosis factor-α; IL, interleukin; TGF-β, transforming growth 
factor β; ICOSL, inducible costimulatory ligand; IDO, indoleamine-2,3-dioxygenase; MSC, mesenchymal 
stromal cells, PMA, phorbol myristate acetate. 
expression of IL-17 in differentiated Th17, an effect assigned to prostaglandin E2  
[9,263,271,272,275,277]; however, the effect of MSC on T cells expressing IL-17 is 
controversial and some studied show that Th17 function can be enhanced by MSC 
[251,252,254,263,280]. Nevertheless, the different experimental approaches used may explain 
the conflicting data. 
Beyond the direct impairment of Th1 and Th17 immune responses, by reducing the 
expression of their typical effector cytokines (TNF-α, IFNγ, IL-2 and IL-17), MSC can also induce 
the expression of the anti-inflammatory cytokine IL-10 in both Th1 and Th17 cells [9,264]. 
IL-6 is a cytokine with recognized pro- and anti-inflammatory properties. Roughly, anti-
inflammatory biological effects can be ascribed to IL-6 classic signaling via membrane IL-6 
receptor (IL-6R), while pro-inflammatory function is associated to trans-signaling mediated by 
soluble IL-6R (sIL-6R) [491]. The essential role of this cytokine in inflammation was confirmed 
by several animal models of autoimmune inflammatory diseases, where the blockage of IL-6 
trans-signaling prevented the inflammatory process. As an inflammatory state contribute to 
proteolytic cleavage of IL-6R, resulting in the release of sIL-6R, trans-signaling is likely to be 
enhanced under this condition; besides, IL-6 is necessary for Th17 differentiation and 
maintenance [488]. MSC-mediated reduction of IL-6 expression in CD4+ T cells is in agreement 
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with the decreased expression of the other pro-inflammatory cytokines evaluated in the 
present study, namely the percentage of T cells producing IL-17. 
The biological effects of IL-9 still poorly described. This cytokine is produced by Th9, Th2, 
Treg and Th17 cell subsets and plays an important role in the immune response against 
helminthes and in allergic inflammation [638-640]. Despite promoting Th2 cytokine 
production, enhancing the regulatory function of Treg and suppressing the expression of the 
pro-inflammatory cytokines TNF-α, IL-12 and IFNγ under certain experimental conditions; IL-9 
is also able to expand Th17 cell population and to promote inflammation, as the adoptive 
transfer of Th9-polarized cells induces experimental autoimmune encephalomyelitis and 
experimental autoimmune uveitis [638,641]. Recent works showed that in vivo systemic 
administration of MSC is beneficial in allergic airways inflammation mouse models, by 
increasing IL-10 and decreasing IL-4, IL-5 and IL-13 cytokine secretion [249,259-261]. To the 
best of our knowledge, IL-9 had never been evaluated in in vivo MSC-mediated suppression of 
allergic inflammation in animal models; also, this is the first study reporting the inhibition of IL-
9-producing CD4+ and CD8+ T cells by MSC, opening new possibilities in the investigation of 
MSC in allergic inflammation. 
6. CONCLUSIONS 
MSC constitute a possible therapeutic approach for immune-mediated disorders, 
however these pathologies are very heterogeneous in what concerns to the effector T cell 
subset involved and to the distribution of T cells among their functional compartments. Thus, a 
detailed knowledge of the effect of MSC over each individual functional compartment of CD4+ 
and CD8+ T cells became essential to predict and understand their outcome as cell therapy. 
Here, we investigated whether human BM-MSC altered the expression of pro-inflammatory 
cytokines among the CD4+ and CD8+ T cell functional compartments naturally occurring in the 
peripheral blood. 
Overall, our results showed that MSC inhibits TNF-α, IFNγ and IL-2 protein expression in 
all CD4+ and CD8+ T cell functional compartments, except for IFNγ expression in naive CD4+ T 
cells, where MSC had no suppressive effect. Interestingly, MSC-derived inhibition was stronger 
for CD4+ than CD8+ T cells, concerning IL-2 and TNF-α, whereas it was more pronounced in 
CD8+ T cells for IFNγ. 
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It is noteworthy that MSC showed distinct inhibitory patterns for the different functional 
compartments of T cells. MSC-derived inhibition of TNF-α expression was more marked among 
naive, CM and EM T cells, for both CD4+ and CD8+ T cell subsets; CM CD4+ T cells and effector 
and EM CD8+ T cells were the functional compartments displaying a higher degree of 
suppression of IFNγ expression; and the inhibition of IL-2 production was more pronounced 
among effector, EM and CM CD4+ T cells and CM CD8+ T cells.  
Finally, we verified that, under our experimental conditions, MSC co-culture reduced the 
percentage of both CD4+ and CD8+ T cells expressing IL-17, IL-9 and of CD4+ T cells producing IL-
6. The influence of MSC on IL-9 can open new possibilities of research regarding the clinical use 
of MSC in allergic inflammation. 
In the present study, we showed that MSC differentially regulate the functional 
compartments of T cells. Also, the pattern of inhibition of the functional compartments of 
CD4+ T cells differed from that observed in CD8+ T cells. Our data revealed that the distinctive 
distribution of T cells among activation/differentiation compartments of immune system 
disorders will condition the therapeutic effect of MSC. 
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OVERALL DISCUSSION 
1. DIFFERENCES AMONG THE IMMUNOSUPPRESSIVE ABILITIES OF HUMAN MSC 
DERIVED FROM BONE MARROW, ADIPOSE TISSUE, AND UMBILICAL CORD MATRIX – 
OBJECTIVE 1 
Because the differences of the immune suppressive capabilities of human MSC arising 
from different tissues were a theme of debate, we investigated how MSC derived from BM, AT, 
and UCM influenced T, B, and NK cell activation and proliferation; mRNA expression of 
molecules with an important role in the immune function (IL-2 in T cells, and TNF-α, granzyme 
B, and perforin in NK cells); and mRNA expression of the master transcription factors for T cell 
differentiation into Th1, Th2, and Treg cells (T-bet, GATA3, and FoxP3, respectively), within 
each T cell activation compartment. This study is described in chapter 2. 
 
1.1. Human MSC derived from BM, AT, and UCM differentially inhibit 
lymphocyte activation and proliferation 
To explore whether MSC isolated from BM, AT, and UCM have distinct inhibitory abilities 
over mitogen-induced lymphocytes’ activation and proliferation, we co-cultured PHA-
stimulated PBMC with either, BM, AT, or UCM-derived MSC. We found striking differences 
among MSC arisen from the three sources: AT-MSC displayed a stronger inhibitory effect over 
B cell, CD4+ T cell, and CD8+ T cell proliferation and activation, and over CD56dim and CD56bright 
NK cell activation; whereas UCM-MSC had a milder inhibitory action. Of note, UCM-MSC 
influenced neither B cell proliferation and activation, nor CD56bright NK cell activation, under 
our experimental conditions. Remarkably, in the presence of AT-MSC the proportion of CD4+ 
and CD8+ T cells in non-activated stage (CD69-CD25-HLA-DR-) was higher than that observed for 
BM and UCM-MSC, which may be perceived as an ability to block T cell activation in an early 
phase of the activation process. 
In contrast to our results, Prasanna and colleagues reported that UCM-MSC displayed a 
stronger inhibitor effect than BM-MSC over T cell proliferation induced upon PHA or MLR 
stimulation of PBMC [39]; likewise, Bárcia et al. described that UCM-MSC inhibited T cell 
proliferation in CD3/CD28 plus IL-2-stimulated PBMC to a greater extent than BM-MSC [37]; in 
turn, Najar et al. didn’t find significant differences among the suppressive effect of UCM-MSC 
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and BM-MSC over T cell proliferation induced by MLR or PHA plus IL-2 stimulation of purified T 
cells [26]. 
Considering cell activation, our data pointed out that UCM-MSC had the lowest ability to 
suppress activation of CD4+ T cells, CD8+ T cells (measured by CD69, CD25, and HLA-DR 
expression), and CD56dim NK cells (measured by CD69 and CD25 expression), upon PHA 
stimulation of PBMC, in comparison to BM-MSC and AT-MST; besides, UCM-MSC were unable 
to inhibit activation of B cells and CD56bright NK cells. In the same line, Prasanna and colleagues 
showed that, in PHA-stimulated PBMC, BM-MSC were able to inhibit IFNγ secretion and CD28 
expression by T cells to a greater extent than UCM-MSC; remarkably, UCM-MSC induced 
higher levels of CTLA-4 on T cell surface than BM-MSC [39]. On the other hand, Najar et al. 
showed that, upon stimulation of purified T cells with PHA plus IL-2, UCM-MSC inhibited T cell 
activation (measured by CD38 expression) to a greater extent than their BM counterparts [26]. 
Notwithstanding, the studies comparing AT-MSC and BM-MSC are more consistent, 
indicating that AT-MSC display a higher immunosuppressive capacity. Indeed, AT-MSC 
exhibited a stronger inhibitory effect over the proliferation of CD4+ and CD8+ T cells, either for 
PBMC stimulated with PHA (in our study), for PHA plus IL-2-stimulated purified T cells, or MLR 
[26]. In the same line, AT-MSC possess a stronger suppressive effect over PHA-induced CD4+ 
and CD8+ T cell activation, compared to BM-MSC, evaluated by our group based on the 
expression of CD69, CD25, and HLA-DR, and by others [26] by CD38 expression. 
Similarly, in our study, AT-MSC were more effective in suppressing PHA-induced 
activation (measured by CD69 and CD25 expression) and proliferation of B cells than BM-MSC. 
In the same line, a superior inhibitory activity of human AT-MSC, compared to BM-MSC, over Ig 
production by B cells had been demonstrated by Bochev et al [318]; whereas other studies 
corroborate the inhibitory ability of human MSC over B cell proliferation [305,306,312-315], as 
detailed in chapter 1, section 3.3.2.1, showing this inhibitory effect is achieved by an arrest in 
G0/G1 phase of the cell cycle induced by BM-MSC [305,315]. Human MSC were also shown to 
impair B cell function as Ig-producing cells [55,305,306,312,314,318,319] and differentiation 
into plasma cells [306,309,314,315], which can be a consequence of the defective B cell 
activation observed in the presence of MSC. These subjects are thoroughly described in 
chapter 1, sections 3.3.2.2 and 3.3.2.3. 
Similarly, to what was observed for T and B cells, AT-MSC were more effective in 
suppressing PHA-induced activation of CD56dim NK cells, and CD56bright NK cells (measured by 
CD69 and CD25 expression) than BM-MSC, under our experimental conditions. Inhibition of 
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CD69 upregulation was also described by others for IL-2-activated NK cells [102], though other 
studies obtained contradictory results [33,326]. Corroborating with MSC-derived suppression 
of NK activation, there are numerous studies describing the suppressive effect of human MSC 
over NK cell function, described in detail in section 3.4.2.2 of the 1st chapter. 
Our results demonstrated that human MSC from different sources possess important 
differences concerning their immunosuppressive ability, which may influence the final 
outcome obtained in in vitro assays or in clinical applications. 
 
1.2. The influence of human MSC derived from BM, AT, and UCM over IL-2 
mRNA expression within each one of the distinct activation compartments of T cells 
According to our results, all the three types of MSC studied were able to efficiently 
inhibit IL-2 mRNA expression in earlier activated T cells (which corresponds to the activation 
compartment with higher IL-2 mRNA expression after PHA stimulation). Remarkably, BM-MSC 
are more efficient in inhibiting IL-2 mRNA expression in T cells, as compared to AT or UCM-
MSC. Accordingly, a previous study had shown that human BM-MSC were more efficient in 
inhibiting IL-2 secretion (IL-2 protein level measured in the culture supernatant) than UCM-
MSC, when co-cultured with PHA-stimulated PBMC [39]. The impairment of IL-2 production 
may contribute to the inhibitory activity displayed by MSC over T cell proliferation. However, 
studying the overall IL-2 mRNA levels within purified T cell subsets, or the protein levels in the 
culture supernatant, give an incomplete information. If in the one hand mRNA translation to 
protein is a complex process which can be further regulated and, therefore, may not reflect 
the cytokine protein levels, on the other hand, knowing the total mRNA or total protein levels 
isn’t informative about what is happening at single-cell level. In fact, these approaches give no 
information about whether MSC exert an equal inhibitory effect over all T cells, or if their 
inhibitory function is specially focused on specific T cells subsets, which equally will lead to the 
reduction of total IL-2 mRNA or protein levels. The study described on chapter 4 sought to 
overcome that shortcoming. 
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1.3. The influence of human MSC derived from BM, AT, and UCM on TNF-α, 
granzyme B, and perforin mRNA expression within the distinct activation 
compartments of NK cells 
Attending to NK cells, our study showed that MSC derived from BM, AT, and UCM 
suppress TNF-α and perforin expression at mRNA level, which is in agreement with other 
studies describing a reduced protein levels of TNF-α [327], IFNγ [75,76,102,236,326,327,329], 
granzyme A [33], and granzyme B [102], though was also described that BM and AT-MSC have 
no inhibitory effect over granzyme B expression by IL-2-activated NK cells [33]. Of note, we 
found no effect of MSC over perforin mRNA expression in NK cells, which was verified as well 
by others at protein level [33]. Moreover, human MSC possess the ability to suppress other 
effector molecules which participate in NK cell immune function and, consequently, impair NK 
cell cytolytic activity, as detailed in section 3.4.2 of the 1st chapter. 
 
1.4. Regulation of T-bet, FoxP3, and GATA3 mRNA expression within the 
distinct activation compartments of T cells, by human MSC derived from BM, AT, and 
UCM 
Concerning the master transcription regulators of T cell differentiation, we verified that 
MSC did not alter mRNA of GATA3, but increased the mRNA expression of T-bet and FoxP3 in 
activated T cell compartments. Of note, FoxP3 mRNA upregulation was more pronounced in 
the presence of AT-MSC, compared to BM and UCM-MSC. 
Despite a great number of studies described MSC promote Treg cell generation and 
expansion, both in vitro and in vivo (detailed in chapter 1, section 3.1.2.5), only recently the 
potential of human MSC derived from different tissues to induce Treg cells was tested, being 
demonstrated that BM-MSC and UCM-MSC possess equal ability to generate Treg cells when in 
co-culture with anti-CD3/CD28 plus IL-2-stimulated T cells [37]. 
Concerning the increased T-bet mRNA expression we observed in the purified T cell 
activation compartments, it is apparently in opposition to several studies describing that 
human and mouse MSC inhibit Th1 cell differentiation and function 
[129,231,236,251,262,263], as detailed in chapter 1, section 3.1.2.3. Nevertheless, all these 
studies inferred that MSC inhibited Th1 cell differentiation and function based on the 
decreased levels of IFNγ in the culture supernatant or on the decreased percentage of IFNγ-
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producing CD4+ T cells, not by investigating T-bet expression on T cells. Recently, our group 
showed that human BM-MSC decreased the amount of IFNγ produced per cell (measured as 
MFI) [244], which is consistent with the hypothesis that a decreased IFNγ level in the culture 
supernatant may be a consequence of a reduced ability of Th1 cells to produce this cytokine, 
rather than a direct deleterious effect of MSC over T-bet expression by T cells. 
Recently, Pianta and colleagues [255] reported a reduction on the percentage of CD4+T-
bet+ T cells, in MLR, in the presence of conditioned medium derived from human amniotic-
MSC. However, we had demonstrated that when only the activated compartments of T cells 
are analyzed, human MSC derived from the BM, AT, and UCM induce an increase in T-bet 
mRNA expression in PHA-stimulated T cells. As the proportion of activated T cells is highly 
reduced under the influence of MSC, it is expectable that, even if the augment of T-bet mRNA 
was reflected at protein level in activated T cells, the percentage of CD4+T-bet+ T cells and of 
IFNγ-producing cells among total CD4+ T cells would be reduced. 
 Altogether, it seems that human MSC are able to hamper Th1 immune response by 
different mechanisms, depending on the microenvironmental conditions: MSC can either 
inhibit Th1 cell differentiation, perhaps by reducing the number of Th1 cells generated upon 
stimulation, as consequence of the impairment of T cell proliferation and activation, but 
without interfering with the sense of T cell proliferation (further studies assessing T-bet 
protein expression within the T cell activation compartments will be need to elucidate this 
point); or can directly inhibit the effector functions of fully differentiated Th1 cells [251]. 
 
2. IMMUNOSUPPRESSIVE EFFECT OF HUMAN BM-MSC ON PERIPHERAL BLOOD 
MONOCYTE SUBSETS AND mDC – OBJECTIVE 2 
There are an increasing number of studies describing the suppressive effect of human 
MSC over T cells, being demonstrated that T cell suppression is achieved not only by a direct 
inhibitory effect of MSC over T cells (described in section 3.1 of the 1st chapter), but also 
indirectly, by MSC modulation of antigen-presenting cell function, biasing these cells toward a 
tolerogenic phenotype (detailed in chapter 1, section 3.5 and 3.6). Nevertheless, regarding this 
field of research, we found limited data concerning the effect of human MSC over freshly 
isolated peripheral blood DC, as the majority of the published data refers to in vitro generated 
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monocyte-derived DC; and concerning monocytes, the influence of human MSC on the 
recently described peripheral blood monocyte subsets (classical, intermediated, and non-
classical monocytes) had never been assessed. The study described in the chapter 3 intended 
to clarify the effect of human BM-MSC over the naturally occurring peripheral blood mDC and 
to explore whether BM-MSC differentially affected the function of the distinct subsets of 
peripheral blood monocyte subsets. 
 
2.1. Human BM-MSC differentially inhibit TNF-α and CCL4 (MIP-1β) protein 
expression in the distinct monocytes subsets and mDC 
Our results showed that MSC efficiently inhibited TNF-α and CCL4 (MIP-1β) production 
by monocytes and mDC, both by decreasing the percentage of producing cells and by reducing 
the amount of cytokine produced per cell (measured as MFI). mDC were more susceptible to 
MSC-driven suppression than monocytes and, among the distinct monocyte subsets, the 
lowest degree of inhibition was observed in classical and non-classical monocytes for CCL4 and 
TNF-α, respectively. 
According to our results, upon LPS plus IFNγ stimulation a percentage above 80% of TNF-
α producing cells is observed among all monocytes subsets; nevertheless, when analyzing the 
amount of cytokine produced per cell (measured as MFI), non-classical monocytes appear as 
the main producers of TNF-α; interestingly, this cell subset is the most resistant to MSC-
derived suppression. Accordingly, previous studies showed the deleterious effect of BM-MSC 
on monocyte pro-inflammatory function by reducing TNF-α and IL-12 expression, and their 
allostimulatory abilities [236,248,355], while increasing the expression of IL-10 [52,285,375]; 
altogether hampering the development of Th1 immune response. 
Consistently with our observations, human MSC derived from the BM, AT, and amniotic 
tissue also inhibit LPS-induced TNF-α expression, as well as IFNγ and IL-12 production, by 
monocyte-derived immature mDC [31,351]; likewise, naturally occurring peripheral blood 
slanDC [333] and mDC [236] also experienced a decreased TNF-α expression when co-cultured 
with human BM-MSC. Interestingly, BM-MSC co-culture with peripheral blood DC also resulted 
in the impairment of IL-12 production and induction of IL-10, ILT3, and ILT4 expression 
[236,333]. Moreover, MSC-treated slanDC fail to trigger a Th1 immune response [333]. Overall, 
the published data support that MSC impair the pro-inflammatory functions of DC while 
promote the development of a tolerogenic phenotype. 
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CCL4 is the CCR5 ligand, and has an important role in the chemoattraction of T cells and 
monocytes [642], therefore, by suppressing the expression of this chemokine, BM-MSC hinder 
monocyte and mDC interaction with T cells. The strong inhibition observed for mDC assumes 
great biological significance given their important role as antigen-presenting cells. In the same 
line, CCL4 expression is also strongly inhibited in intermediate and non-classical monocytes. 
The intermediate monocytes have been described to have the highest ability to present 
antigens to T cells, among all peripheral blood monocyte subsets [369], whereas non-classical 
monocytes were shown to express the highest levels of HLA-DR and CD86, which is predictive 
of antigen presentation abilities, and include the slanDC, with recognized antigen-presenting 
cell activity [332,335,368]. These data suggest that MSC impair T cell chemoattraction toward 
the cell subsets that have the capability to stimulate them most efficiently. 
 
2.2. Effect of human BM-MSC on CCR7 and CD83 protein expression in 
monocytes and mDC 
Under our experimental conditions, neither CCR7 nor CD83 were inhibited by MSC in 
monocytes and mDC. The observed augmented HLA-DR expression in CCR7+ versus CCR7- cells 
further confirm the activated state of the cells bearing CCR7 at the cell surface. 
In opposition to our study, wherein no biologically significant alterations on HLA-DR 
expression were observed for LPS plus IFNγ-activated monocytes subsets and mDC in the 
presence of BM-MSC, previous studies demonstrated that human BM-MSC, AT-MSC, UCM-
MSC, and UCB-MSC hamper HLA-DR upregulation in monocytes [248,268,355]. Concerning the 
influence of MSC on CD83 upregulation after DC stimulation, there are contradictory data in 
the literature, being reported that MSC hinder CD83 upregulation [25,31], but also that they 
do not affect CD83 upregulation [53], or further upregulate CD83 and CCR7 expression upon 
monocyte-derived immature DC stimulation with LPS or a pro-inflammatory cytokine cocktail 
[353,354]. Thus, it seems that MSC regulation of the expression of activation markers by DC is 
a complex process probably influenced by several factors. 
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2.3. Human BM-MSC differentially regulate cytokine and chemokine mRNA 
expression in mDC, classical and non-classical monocytes 
MSC decreased mRNA expression of IL-1β and IL-6 in classical monocytes, but not in 
non-classical monocytes; in addition, MSC also reduced mRNA transcripts of CCL3, CCL5, 
CXCL9, and CXCL10 in classical and non-classical monocytes, and IL-1β and CXCL10 in mDC. 
The decreased mRNA expression of IL-1β and IL-6 in classical monocytes, and IL-1β in 
mDC, is consistent with the described suppression of other pro-inflammatory cytokines 
mediated by human BM-MSC, such as TNF-α, IL-6, and IL-12, in monocytes and DC 
[236,333,355]. The decreased mRNA expression of CCL3, CCL5, CXCL9, and CXCL10, if reflected 
at protein levels, may impair T cells (attracted by CCL3 and CCL5, which binds to CCR1 and 
CCR5 receptors) and, more specifically, Th1 cells (expressing CXCR3, the receptor for CXCL9 
and CXCL10) chemotaxis toward monocytes and mDC [642], which is in the same line than 
MSC-driven CCL4 suppression observed in this study at protein level. Of note, CCL5 also binds 
to CCR3 receptor, expressed by eosinophils, basophils, mast cells, and Th2 cells [642], 
suggesting that MSC can also difficult the development of a Th2 immune response. 
 
3. IMMUNOSUPPRESSIVE EFFECT OF HUMAN BM-MSC ON NATURALLY OCCURRING 
PERIPHERAL BLOOD T CELL FUNCTIONAL COMPARTMENTS, AND ON PERIPHERAL 
BLOOD T CELLS PRODUCING IL-17, IL-9 AND IL-6 – OBJECTIVE 3 
Though the inhibitory effect of human MSC over IL-2, IFNγ, and TNF-α had previously 
been described in the literature, an experimental approach that analyzed MSC suppressive 
effect within each individual T cell functional compartment (naive, central memory (CM), 
effector memory (EM), and effector) was missing. The description of MSC-driven IL-2, IFNγ, 
and TNF-α suppression in overall CD4+ and CD8+ T cells gives no information about the effect of 
MSC at a single cell level, and don’t allow to distinguish whether the suppressive action 
embraces all T cells or is more focused on specific T cell subsets. T cells included in distinct 
functional/differentiation compartments have differential activities. This subject assumes 
great relevance when considering the clinical use of MSC in disorders of immune etiology, 
wherein T cells’ distribution among the activation, differentiation, or functional compartments 
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is commonly disturbed. In this setting, to get insight of how MSC influence the function of each 
specific T cell functional compartment may help to predict the clinical benefit of MSC therapy 
in the distinct diseases, or even in distinct patients. The influence of human BM-MSC on the 
distinct functional compartments of CD4+ and CD8+ T cells was the subject of the study 
described in chapter 4. 
 
3.1. Immunosuppressive effect of human BM-MSC on IL-2, IFNγ, and TNF-α 
expression by naturally occurring peripheral blood naive, central memory, effector 
memory, and effector T cells 
Our results showed that co-culture with BM-MSC decreased the percentage of PMA plus 
ionomycin-stimulated T cells producing IL-2, IFNγ, and TNF-α, as well as IFNγ and TNF-α MFI, 
among CD4+ and CD8+ T cells from all the functional compartments studied, except for IL-2 and 
IFNγ in naive CD4+ T cells, and IL-2 in naive CD8+ T cells, because only a residual percentage of 
cells expressed the mentioned cytokines. 
The suppressive effect of human BM-MSC over T cell cytokine production was previously 
described in the supernatant protein levels of IL-2 [39,237,243] and IFNγ [236,237]; in 
agreement, MSC-induced reduction of IL-2, IFNγ, and TNF-α T cell expression was also found in 
mouse [129,231,251,263], and is detailed in chapter 1, section 3.1.2. 
According to our results, the degree of inhibition for TNF-α and IL-2 was higher for CD4+ 
T cells than for CD8+ T cells, and the opposite was verified for IFNγ. Analyzing the suppressive 
effect among the distinct functional compartments of CD4+ T cells, we observed that effector 
and EM CD4+ T cell subsets were more resistant to MSC-induced inhibition of TNF-α 
production; whereas the degree of inhibition for IL-2 and IFNγ was equivalent among all the 
functional compartments, except for naive CD4+ T cells, wherein only a residual percentage of 
cells expressed the abovementioned cytokines. Therefore, the CD4+ T cell subsets that produce 
higher levels of TNF-α (both by having a higher percentage of TNF-α-producing cells and higher 
MFI) were the less inhibited. 
Concerning CD8+ T cells’ functional compartments, we observed that effector and EM 
CD8+ T cell subsets presented the highest degree of inhibition on IFNγ production, and the 
lowest degree of inhibition on TNF-α and IL-2 production (once again, only a residual 
percentage of naive CD8+ T cells produce the aforementioned cytokines). Accordingly, mouse 
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BM-MSC also display a more marked inhibition on IFNγ-producing memory CD8+ T cells, 
compared to naive CD8+ T cells [291]. And, similar to what was observed for CD4+ T cells, the 
CD8+ T cell subsets that produce higher levels of TNF-α (both by having a higher percentage of 
TNF-α-producing cells and higher TNF-α MFI) were the less inhibited, in our study. 
The inhibition of IL-2 production by T cells is likely to contribute to MSC-driven 
suppression of T cell proliferation. IL-2 produced by CD4+ T cells is essential to induce both 
CD4+ T cell (acting autocrinally) and CD8+ T cell proliferation, and IL-2 produced by CD4+ T cells 
was inhibited by MSC to a greater extent than that produced by CD8+ T cells. Besides the 
promotion of T cell clonal expansion, IL-2 also contributes to T cell differentiation into effector 
cells and activates NK cells [230]. The importance of the suppression of IL-2 secretion in MSC-
derived impairment of T cell proliferation is notorious in the studies in mouse and baboons 
demonstrating that the addition of exogenous IL-2 to immune cells and MSC co-culture restore 
T cell proliferation [129,242].  
The higher inhibitory degree exerted by MSC over the CD8+ T cell subsets that produce 
the highest levels of IFNγ (EM and effector compartments) shows a clear inhibitory action of 
MSC over the Th1 immune response. In fact, IFNγ contributes to Th1 cell differentiation and 
exert other important roles in the context of a Th1 immune response, such as the activation 
and differentiation of CTL; activation of NK cells, DC, and macrophages; increase of 
macrophage’s phagocytic and anti-microbial activity; upregulation of MHC-I, MHC-II, and IL-12 
expression, and increase of the antigen-presentation skills of antigen-presenting cells; 
moreover, IFNγ also induces Ig class switching in B cells to IgG [230]. 
Finally, the milder action of MSC over the T cell subsets producing the highest amounts 
of TNF-α (EM and effector compartments) is consistent with the lower MSC suppressive action 
over the cytotoxic activity of fully differentiated effector CD8+ T cells reported in MLR [62]. In 
fact, TNF-α is an important effector molecule with cytotoxic functions, capable of induce 
apoptosis after binding to the receptor TNFR1 in the target cells. Its pro-inflammatory activity 
includes the upregulation of chemokine and adhesion molecules expression, contributing to 
the formation of the immune cell infiltrate in sites of inflammation; and the increase of the 
phagocytic and anti-microbial activity by macrophages [230,643]. Accordingly, our results and 
the previously published data suggest that the immunosuppressive action of MSC over 
immune effector mechanisms is more moderate over cells with a higher degree of 
differentiation. 
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3.2. Immunosuppressive effect of human BM-MSC on naturally occurring 
peripheral blood T cells expressing IL-17, IL-9, and IL-6  
We found that MSC decreased the percentage of CD4+ and CD8+ T cells producing IL-9, 
IL-17, and co-expressing IL-17 and TNF-α; as well as the percentage of CD4+IL-6+ T cells. 
MSC-mediated impairment of Th17 cell differentiation [9,251,263,275-279] and the 
suppression of IL-17 secretion by fully differentiated Th17 [9,263,275,278,281] had already 
been demonstrated for human and mouse, though there are studies reporting the 
enhancement of Th17 differentiation [252,254,280] or function [251,262] under the influence 
of MSC, as detailed in chapter 1, section 3.1.2.4. Here, we reported that MSC exerted an 
inhibitory effect over the naturally occurring Th17 and Tc17 cells from healthy individuals 
peripheral blood, by decreasing the percentage cells producing IL-17, alone or in combination 
with TNF-α, and the amount of TNF-α produced per cell (measured as MFI) which, overall, is 
consistent with the MSC role in the regulation of the inflammatory response. 
Despite an increasing knowledge on the anti and pro-inflammatory functions of IL-6, 
their role in Th17 differentiation and B cell Ig production, the function of Th6 still elusive 
[233,488,491,644]. We verified a decreased percentage of Th6 cells induced by MSC, which is 
consistent with their suppressive effect over IL-6 produced by mDC [333], human mast cells 
[399], mouse macrophages [381], and the decreased IL-6 serum levels detected among MSC-
treated CIA mice [182]. 
The observation that MSC decreased percentage of CD4+ and CD8+ T cells expressing IL-
9, is in agreement with a recent work showing that T cells cultured with conditioned medium 
derived from human amniotic-MSC displayed a reduced IL-9 protein levels in the culture 
supernatant [255]. IL-9 is involved in the response against helminthes and in allergic 
inflammation; promotes the expansion and activity of mast cells (including the upregulation of 
IL-5 and IL-13 secretion by mast cells); and both anti-inflammatory and pro-inflammatory 
effects had been ascribed to this cytokine [638,641]. These new findings may broaden the 
research field concerning the MSC influence on allergic inflammation. 
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CONCLUDING REMARKS 
 
Overall, we found that human MSC derived from different tissues (BM, AT, and UCM) 
displayed a distinct suppressive ability over T, B, and NK cell activation and/or proliferation. 
Those differences were more relevant for B cell and CD56bright NK cell activation, in which UCM-
MSC did not present an inhibitory effect, in opposition to MSC derived from the other tissues. 
Among the three types of MSC tested, AT-MSC presented the highest suppressive activity. We 
also found that MSC hindered PHA-induced T cell activation, but didn’t affected their sense of 
polarization, inferred by the mRNA expression of T-bet which was not inhibited under the 
influence of MSC. 
We described an inhibitory effect induced by BM-MSC on the protein and mRNA 
expression of pro-inflammatory cytokines and chemokines by peripheral blood mDC and 
peripheral blood monocyte subpopulations (classical, intermediate, and non-classical 
monocytes); remarkably, the influence of BM-MSC was distinct for the different monocyte 
subsets. The inhibition of cytokine and chemokine expression was not accompanied by the 
inhibition of activation/maturation markers expression. Thus, despite displaying an 
activated/mature phenotype, mDC and monocytes presented a hampered pro-inflammatory 
function which may hinder the development of inflammatory immune responses. 
Likewise, human BM-MSC were also shown to inhibit pro-inflammatory cytokine 
production by all CD4+ and CD8+ T cell functional compartments; notwithstanding, the distinct 
T cell functional compartments displayed a different pattern of cytokine inhibition. This may 
impact the therapeutic outcome of MSC-based therapies for diseases with a different 
distribution of T cells among the functional compartments. Furthermore, the description of the 
inhibitory effect of BM-MSC on Th9 and Tc9 cells may bring new insights in the beneficial 
therapeutic effect of MSC in allergic inflammation animal models. 
Thus, though the immunosuppressive activity of human MSC is unequivocal, it is 
important to have in mind that their tissue of origin influences their suppressive effect, and 
these differences have different manifestations in the distinct main lymphocytes 
subpopulations (CD4+ and CD8+ T cells, B cells, and CD56dim and CD56brigth NK cells). When 
focusing our attention on particular antigen-presenting cell subsets (mDC, and classical, 
intermediate, and non-classical monocytes) and specific CD4+ and CD8+ T cell functional 
compartments (naive, central memory, effector memory, and effector compartments), it 
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becomes obvious that they are not evenly affected by the suppressive action of human BM-
MSC. 
All these factors are likely to affect the clinical outcome of MSC-based therapies and, 
therefore, according to our results, the choice of the MSC source, the representativeness of 
each monocyte subpopulation, and the profile of T cell distribution among the functional 
compartments should be taken into account in in vivo assays, to further understand how they 
actually impact the clinical outcome of MSC-based therapies and, perhaps, to explain some 
incongruities observed among different diseases or different subjects with the same diagnosis. 
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